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Abstract 
AIM: To conduct a systematic literature review on the existing literature on the prevalence of 
medication errors across the medicines management system in primary care; To explore the 
systems of error management in primary care; to investigate the prevalence and nature of 
medication errors in children, 0-12 years, and in older patients, ≥65 years, in primary care; 
and to explore community pharmacists’ interventions on medicines-related problems. 
METHODS: 1) Systematic literature review; 2) Questionnaire survey of Primary Care Trusts 
(PCTs), Clinical Commissioning Groups (CCGs) and NHS Area Teams; 3) Retrospective 
review of the electronic medical records of a random sample of older patients, ≥65 years old, 
and children 0-12 years old, from 2 general practices in Luton and Bedford CCGs, England; 
4) Prospective observation of community pharmacists’ interventions on medicines-related 
problems and prescribing errors from 3 community pharmacies in Luton and Bedford CCGs 
in England. 
DATA ANALYSIS: Quantitative data from records review were analysed using Microsoft 
Excel on data extracted from an Access database. Statistical tests of significance were 
performed as necessary. Descriptive statistics were conducted on quantitative data from the 
studies and inductive qualitative analyses were conducted on aspects of the questionnaire 
survey. 
RESULTS:  
 The systematic literature review demonstrated that medication errors are common, and 
occur at every stage of the medication management system in primary care, with error 
rates between ≤1% and ≥90%, depending on the part of the system studied and the 
definitions and methods used. There is some evidence that the prescribing stage is the 
most susceptible, and that the elderly (over 65 years) and children (under 18 years) are 
more likely to experience significant errors, although very little research has focussed 
on these age groups.  
 The questionnaire survey of PCTS, CCGs and NHSE demonstrated that national and 
local systems for managing medication errors appeared chaotic, and need to be better 
integrated to improve error learning and prevention in general practice 
 The retrospective review of patients’ medical records in general practices demonstrated 
that prescribing and monitoring errors are common in older patients and in children. 
2739 unique prescription items for 364 older patients ≥65 years old were reviewed, 
with prescribing and monitoring errors detected for 1 in 3 patients involving about 1 in 
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12 prescriptions. The factors associated with increased risk of errors were: number of 
unique medications prescribed, being ≥75 years old, being prescribed medications 
requiring monitoring, and medications from these therapeutic areas: corticosteroid, 
NSAID, diuretic, thyroid and antithyroid hormones, statins and ACE-I/ARB. 755 
unique prescription items for 524 younger patients 0-12 years old were examined, with 
approximately 1 in 10 prescriptions and 1 in 5 patients being exposed to a prescribing 
error. Factors associated with increased risk of prescribing errors in younger patients 
were: being aged ≤10 years old, being prescribed three or more medications, and from 
similar therapeutic areas as above. Majority of the errors were of mild to moderate 
severity.  
 Community pharmacists performed critical interventions as the last healthcare 
professional defense within the medicines management system in primary care. 
However, this role is challenged by other dispensary duties including the physical 
aspects of dispensing and other administrative roles.  
CONCLUSION Prescribing and monitoring errors in general practice, and older patients and 
children may be more at risk compared to the rest of the population, though most errors 
detected were less severe. Factors associated with increased risk for errors in these age 
groups were multifaceted. The systems for periodic laboratory monitoring for routinely 
prescribed drugs, particularly in older patients, need to be reviewed and strengthened to 
reduce preventable hospital admissions.  Antibiotic dosing in children in general practice 
needs to be regularly reviewed through continued professional developments and other 
avenues. As guidance on local arrangements for error reporting and learning systems are less 
standardised across primary care organisations, pertinent data from adverse prescribing 
events and near misses may be lost. Interventions for reducing errors should therefore explore 
how to strengthen local arrangements for error learning and clinical governance. Community 
pharmacists and/or primary care pharmacists provide an important defence within the 
medicines management system in primary care. Policy discussions and review around the 
role of the pharmacist in primary care are necessary to strengthen this defence, and harness 
the potential thereof.
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Glossary 
 
Monitoring error  A monitoring error occurs when a prescribed medicine is not 
monitored in the way, which would be considered acceptable 
in routine general practice. In this study, it is the absence of 
relevant laboratory tests, for specific drugs, being carried out 
at the frequency listed in the criteria, with tolerance of 
+50%. If a patient refused to give consent for a test, then this 
would not constitute an error.  
Prescribing error  A prescribing error occurs when, as a result of a prescribing 
decision or prescription-writing process, there is an 
unintentional, significant: reduction in the probability of 
treatment being timely and effective, or increase in the risk 
of harm when compared to generally accepted practice.  
ScriptSwitch®  Prescribing decision support software (with specific features 
to help general practices control their prescribing costs).  
SystmOne®  A type of GP clinical computer system supplied by the 
company, TPP.  
TPP  Type of GP computer system supplier.  
 17 
List of abbreviations 
ACEI  Angiotensin Converting Enzyme Inhibitor  
ADR Adverse Drug Reaction 
BD  Twice Daily  
BNF  British National Formulary  
CHD  Coronary Heart Disease  
CI  Confidence Interval  
CNS  Central Nervous System  
Comm. Pharm  Community Pharmacist  
CP Community Pharmacy 
CPCF Community Pharmacy Contractual Framework 
CVD Cardiovascular Disease 
DH Department of Health 
DRP Drug Related Problem 
GIT Gastro-Intestinal Tract 
GMC General Medical Council 
GPhC General Pharmaceutical Council 
ENT  Ear, Nose and Throat  
GP  General Practitioner  
HCP Healthcare Professional 
ID  Identification Code  
INR  International Normalized Ratio  
IHD Ischaemic Heart Disease 
IHI Institute for Healthcare Improvement 
IMD Indices of Multiple Deprivation 
IoM Institute of Medicine 
MPharm Master of Pharmacy Programme 
IQR  Inter Quartile Range  
MR  Modified Release  
MRP Medicine Related Problems 
MUR Medicines Use Review 
NHS  National Health Service  
NICE  National Institute for Health and Clinical Excellence  
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NMS New Medicine Service 
NPSA  National Patient Safety Agency  
NSF National Service Framework 
NRLS  National Reporting and Learning System  
NSAID  Non-Steroidal Anti-Inflammatory Drug  
OTC Over-The-Counter 
P  P-value  
PCNE Pharmaceutical Care Network Europe 
PCT  Primary Care Trust  
PSNC Pharmaceutical Services Negotiating Committee 
PRACtISE Prevalence And Causes of Prescribing errors in general practice study 
QOF Quality of Outcomes Framework 
REC Research Ethics Committee 
Rx Prescription 
RPS Royal Pharmaceutical Society 
TDS Three times daily 
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Thesis structure 
This thesis is structured as outlined below. 
 Chapter 1 of this thesis sets out the context of the background to research in patient 
safety. This introduction discusses the nature of the problem of medical and medication 
errors, history of medical and medication errors, the relationship between medication 
errors and adverse drug reactions, the medicines use process, medication errors in 
secondary and primary care, and in older and younger patient populations, identification 
of medication errors, and reporting medication errors.  
 Chapter 2 outlines the theoretical and philosophical framework underpinning this research 
with respect to quantitative approaches to the evaluations of prescribing and monitoring 
errors. 
 Chapter 3 outlines the overall methods applied in this research and comments on the 
feasibility study.  
 Chapter 4 – Phase 1, Study 1 – outlines the systematic search and review of the existing 
literature on medication errors in primary care.  
 Chapter 5 – Phase 1, Study 2 – describes the research process for characterization of the 
systems used by Primary Care Trusts (PCT) and Clinical Commissioning Groups (CCG) 
for the identification, recording and reporting of medication errors in a before-and-after 
study.  
 Chapter 6 to Chapter 8 – Phase 2, Study 3 – reports on the retrospective review of 
medical records of older patients and children in general practice to identify potential 
prescribing and monitoring errors. Chapter six provides background information on the 
study’s aim and objectives and describes the study setting. Chapter seven provides 
information on the characteristics of older patients ≥65 years old reviewed and the results 
of the investigations. Chapter eight provides information on the characteristics of younger 
patients 0-12 years old and the results of the investigations. Chapter 9 provides 
discussions on chapters 6 to 8 
 Chapter 10 – Phase 2, Study 4 – reports on the prospective observation of community 
pharmacists’ interventions on prescribing errors and medicines-related problems in 
primary care.  
 Chapter 11 – Phase 3 – provides a general discussion on the implications of the research 
findings and recommendations and pulls together the results and conclusions from the 
entire research process, with the limitations of the research.  
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Chapter 1. Introduction/background to the study  
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1.0 Introduction on Patient Safety 
Within the last decade, medical error and patient safety have been the subjects of discussions 
for government bodies, healthcare organizations, and researchers, the media, and patients. 
The American Institute of Medicine (IOM) report, ‘To Err is Human’, highlighted the 
harmful, common, expensive, and more importantly, the preventable nature of medical errors 
(Kohn et al., 1999). A United Kingdom (UK) Department of Health, DH report ‘An 
Organization with a Memory: Learning from Adverse Events in the NHS,’ emphasised the 
importance of reporting and learning from errors across the UK National Health Service, 
NHS (Department of Health, 2000). These government reports established the need for a 
paradigm shift in safety culture within healthcare organisations and their teams, teamwork, 
active reporting and learning from adverse events. The reports further emphasised the role of 
active reporting and error learning between the various departments of healthcare systems 
based on the preventable and reoccurring nature of medical errors. Therefore, much emphasis 
has been placed on the need to adopt a non-punitive attitude towards healthcare professionals 
who make errors, as although they are direct results of human failures (Reason, 2000), errors 
are products of the systems that produce them (Leape et al., 1995). 
The increased awareness on errors in medical practice has sparked much research into the 
health service dimensions of patient safety. Albeit, studies and interventions to prevent error 
occurrence presently lack standardization and uniformity, making the whole system appear 
chaotic (Vincent, 2010). Comparing results or outcomes of interventions has been difficult to 
achieve. Nevertheless, in spite of the large variations in data seen in different settings, there is 
enough evidence of the high rates of medical error, and its burdensome harm to patients 
(Vincent, 2010), and ironically, the increasingly-pressured healthcare service.
 1.1 A historical perspective on medical harm and the evolution of patient 
safety 
Although medicine is increasingly moving towards acknowledging and understanding 
medical harm and prevention, medical harm and attempts to prevent them date back to 
Hippocrates classic maxim to “abstain from harming or wronging any man” (Vincent, 2010). 
Modern medicine still has the potential for substantial harm, possibly greater now than the 
past, due to so much advances and complexities in practice and therapy. Charles Vincent’s 
account on the history of medical harm and the evolution of patient safety provides an 
interesting perspective provided below (Vincent, 2010). 
 
Heroic medicine dominated the early 19th century when medical interventions were more 
focussed on saving lives, irrespective of the costs of doing so, leading to much suffering by 
patients. Treatments were very dramatic and crude e.g. treatment of ‘morbid excitement’ such 
as yellow fever may have involved draining over half the total blood volume of the patient by 
heroic physicians, who in turn demonstrated heroism. On the other end of the spectrum were 
practitioners who believed absolutely in natural healing, and therefore viewed heroic 
medicine as lethal. A more practical position developed over time however, and physicians 
moved to a rational view where the risk-benefit ratio of medical interventions was assessed 
prior to treatment. This risk-benefit ratio clearly underpins orthodox medical practice today – 
patient health outcomes have taken centre-stage with a subsequent increase in the healthcare 
professional’s responsibility to them, including the avoidance of discomfort and pain from 
both the disease and its treatment. 
Defining what constitutes harm was not any greyer then than today, however. For the heroic 
healers, the most important outcome was to avoid death, and any measure taken to achieve 
these would have been justified.  On the other hand, the proprietors of natural healing 
avoided any form of human suffering in medical intervention. The middle or rational position 
attempts to maintain a balance between beneficial interventions and undue suffering. As such, 
a complete state of medical safety may be non-existent even in the face of a very rational and 
balanced healthcare system today. Therefore, safety in healthcare needs to be understood, 
viewed, and promoted by stakeholders in the light of other specific treatment outcomes and 
objectives. 
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Irrational medical interventions were one category of harm. Hospital-acquired infections 
were another source of harm that dominated the earlier practice of medicine. Sepsis was 
common, and gangrene readily encountered that “those entering hospital for surgery were 
‘exposed to more chance of death than the English soldier on the field of Waterloo’” (Porter, 
1999 in Vincent 2010). Not all physicians at the time agreed with the school of thought. 
However, following empirical research and publication, by the end of the 19th century, 
disease transfer was eased by infection control, sterilisation, and the use of gloves, masks etc. 
Today, hospital-acquired (nosocomial) infection is still a problem due to the interplay of 
many factors including insufficient hand washing among healthcare professionals, 
comparable to what was seen over a century ago. 
The pioneering work of Ernest Codman, a Boston surgeon of the early 20th century in 
analysing surgical outcomes and reviewing them is partly relevant for the history of error 
classification or categorisation. Codman acknowledged his errors in surgery, made them 
public, and challenged his colleagues to show the effectiveness of their procedures (Vincent, 
2010). Through his actions, Codman received opposition from his colleagues. However, part 
his proposals were eventually adopted by the American Surgical Society. His principles and 
views led to the formation of the Joint Commission on Accreditation of Healthcare 
Organizations (JCAHO), which is the largest accrediting body in the US (Sharpe and Faden, 
1998 as cited in Vincent, 2010). 
Earlier on, harm from medical intervention was not a subject for discussion when medical 
practice achieved relatively small outcomes. During the 1920’s however, terminologies such 
as ‘iatrogenic disease’ meant that medical harm was increasingly being recognised, although 
the term initially referred to a nervous problem experienced by a patient that was associated 
with diagnosis. There was a clear divide between practitioners who viewed medical harm an 
inevitable by-product of advancements in medical practice and those who thought more 
stringent practices could avoid some forms of patient harm, following increase in medical 
interventions in the mid 1950’s. 
Systematic evaluations of adverse events resulting from hospitalisation mishaps commenced 
in the 1960s, when reports started to be collated and reviewed, although initial reports 
suggested that harm due to staff errors were left out. Drug treatment was identified as a major 
factor leading to adverse events following further investigation by researchers; the most 
hazardous drugs being nitrates, digoxin, Lidocaine, aminophylline and heparin (Vincent, 
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2010). Procedures, which became associated with the most problems, included intravenous 
interventions and catheterisation; falls were also implicated. Some of these processes, for 
instance, fall in the elderly due to therapeutic interventions, are challenging sources of harm 
even today.  
Illich’s controversial identification and documentation of ‘social iatrogenesis’ and ‘cultural 
iatrogenesis,’ described excessive reliance on medicine to solve normal problems of living, 
and people’s inability to manage ill health respectively, further contributing to the growing 
literature of medical harm in the 1970’s (Vincent, 2010). Illich’s emphasis was on the need 
for people to take responsibility for their health, avoid too much dependence on medical 
interventions, based on his belief that medical harm was not going to be avoided by 
technological and pharmacological innovations. Government papers towards the end of the 
20th century reiterated his claims. 
Although the concept of medical error and harm has been around for a very long time, more 
than ever before, healthcare professionals are increasingly acknowledging and evaluating 
patient harm from medical error. Pioneering research and researchers, and other factors, 
including a mission to improve the quality of healthcare, evaluations of the characteristics of 
error, high profile cases, learning from psychology and high risk industries, litigation and 
compensation, and government and public influences, have greatly influenced the evolution 
of patient safety (Vincent, 2010) 
Patient safety came forward on the back of the understanding and practice of quality 
improvement. The birth of quality improvement programs in the early 20th century, such as 
maternal morbidity and mortality reviews by the British Ministry of Health in 1928, exposed 
the complexities of issues around patient safety. Quality of care issues were inferred from 
geographical variations in medical interventions and outcomes, and efforts were made to 
improve healthcare processes and administration by following quality assurance procedures 
in manufacturing industries, such as continuous quality improvement, total quality 
management, business process re-engineering and quality circles. These quality management 
approaches relied on both evaluation of systematic data and optimisation of personnel 
contributions to improve outcomes. By the 1990’s, healthcare stakeholders became 
increasingly aware of the place of systematic quality improvement programmes. 
Another concept, which evolved in the 20th century, is learning from error, following a call 
for clinicians to deliberately identify and learn from them, based Sir Karl Popper’s 
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philosophy of Science, which surmises that scientific knowledge is never final, but that 
advancement in science relies on identifying limitations in exiting theories. The concept of 
the fallibility of medical practice and professionals, and what to do with inevitable system 
and personnel failures was introduced. 
High-profile cases of medical errors, for example, the death of Betsy Lehman from a drug 
overdose during chemotherapy, wrong leg amputation of Willie King, and the death of Ben 
Kolb during a minor injury from a drug error, the UK Bristol Royal Infirmary infant 
morbidity and mortality following cardiac surgeries, etc. showed that the healthcare system 
was not fail-safe (Vincent, 2010). The Bristol Inquiry, published following the events of 
infant morbidity and mortality from cardiac surgery, adopted a systems approach to error 
analysis, and brought about change from tragedy. Bristol demonstrated that interplay between 
system and personnel factors were ultimately responsible for widespread quality issues 
throughout the NHS, and its recommendations were relevant to the entire health system. 
High-risk industries such as aviation, chemical and nuclear industries, with high stakes on 
safety, have influenced patient safety researchers tremendously, and studies of major mishaps 
in these industries have shaped the theory of medical error. Subsequently, research and 
practice evaluations, first in anaesthesia and obstetrics resulted in broader systematic 
evaluations of healthcare and interventions to reduce harm. The work and publication of 
Leape in 1994 challenged the then prevalent blame-culture in medicine, and promoted the 
place of the discipline of psychology and human factors, and learning from other industries, 
to solve the problem of medical error (Leape, 1994; Vincent, 2010)  
Litigation, although a direct deterrent to reporting, has also influenced patient safety by 
leading to the evolution of clinical risk management to reduce patient harm (Vincent, 2010). 
 
1.1.1 Professional and government reports 
Professional and government reports also influenced patient safety. The US Institute of 
Medicine report ‘To Err is Human’ pleaded for action on improving patient safety across the 
healthcare strata following the review of many studies of error and harm (Kohn et al., 1999) 
as cited in (Vincent, 2010). It became a very important milestone in the development of 
patient safety, by establishing it as a fundamental requirement of medical practice. It 
achieved what could be described as a professional and political awakening to the deep issues 
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of patient safety and quality in healthcare, and recommended actions on patient safety across 
US healthcare strata: establishment of a Centre for Patient Safety, and robust systems for 
reporting of adverse events and errors, and promotion of the development of safety initiatives 
by healthcare organisations, their regulatory and professional bodies.  
The IoM report spurred many other government and professional reports on patient safety, 
including the UK’s ‘An Organisation with a Memory: Learning from Adverse Events in the 
NHS’, which placed much emphasis on error learning (Department of Health, 2000; Vincent, 
2010). The report reviewed the systems of learning, and similar to the work of Leape and 
Cooper, drew parallel to learning from high-risk industries, and the need for culture change 
and teamwork within the NHS (Department of Health, 2000; Vincent, 2010). 
 
The psychology of error has underpinned analysis of errors. According to Reason, errors are 
divided into two broad categories namely slips and lapses, which are associated with actions, 
and mistakes, which are associated with knowledge. Slips and lapses are associated with 
using the wrong action to achieve the right plan: slips are external actions while lapses are 
internal events. Mistakes are associated with using the wrong plan in the first place to achieve 
the right action. Mistakes may be rule-based or knowledge-based. Violations, on the other 
hand are intentional deviations from standards or rules. These concepts describe the active 
failures by those people at the ‘sharp end’ of the system who are working the system, in 
healthcare, the providers and users of the system. It is the interaction between the ‘active and 
latent failures,’ which lead to errors as shown in the below. 
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Figure 1: Reason's "Swiss Cheese" Model (image with permission from 
www.patientsafety.duhs.duke.edu
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1.2 Incorporating safety with quality 
The section above has provided a synopsis on the history of medical harm and the emergence 
of patient safety. This section will discuss the relationship between the quality of care and 
safety, drawing on Donabedian’s framework for quality and Vincent’s definition of safety in 
healthcare (Donabedian, 1986; Vincent, 2010). As Vincent surmised, it is important to 
understand that safety is not the principal priority in healthcare, as often mentioned by 
government ministers, hospital and care executives, conference speakers and even the front 
staff delivering healthcare. The priority of healthcare is to make people feel better, by 
providing good quality healthcare. Safety really becomes a priority where it comes into 
conflict with other ‘legitimate’ objectives of healthcare. 
Patient safety should be one of many objectives of healthcare – a chief executive for example, 
has to balance costs, safety, effectiveness, patient access to care and satisfaction with service, 
amongst others; a general practitioner attempts to prescribe in a cost-effective manner; 
patients also have to balance safety against other objectives. However, because safety is a 
concept, and is less tangible and less readily measurable than other quality indicators, it is 
quite easily ignored and forgotten in the press of events. Within the past decade, there have 
been many initiatives with a call to actively pursue and promote safety, as opposed to 
ordinarily avoiding damage; the need to actively reduce errors and promote the evolvement 
of a reliable and high quality healthcare has been underscored. 
Patient safety has been defined as ‘the avoidance, prevention and amelioration of adverse 
outcomes or injuries stemming from the process of healthcare (Vincent, 2006). This 
definition acknowledges the inherent harm in healthcare, and the need to support the 
recipients of harm when it becomes unavoidable (Vincent, 2010). The focus of this definition 
of patient safety is very instructive – to avoid, prevent and ameliorate adverse outcomes or 
harm. Harm reduction is thus pivotal to a system such as healthcare with safety as one of its 
objectives. Harm reduction is not synonymous with error reduction as patient harm is not 
always due to errors. For instance, patient harm from the use of medicines may not 
necessarily be caused by an error in the medication-handling system. Although many errors 
do not lead to harm, identification of errors and their prevention is an important step in 
learning, in maintaining safety, and overall, improving the quality of care. 
Donabedian has described the quality of care as being related to its capacity to achieve 
desired improvements in health and well being, in conditions acceptable to both the recipient 
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of care and the wider society (Donabedian, 1986). Quality, in this definition, will comprise of 
four aspects namely the technical management of health and illness, management of the 
relationship between healthcare providers and their clients, facilities of care and the 
principles that rule the affairs in general and the healthcare system in particular. Quality of 
care therefore defines the gap between what is achievable and what actually exists – when 
this gap is minimal, quality is good; the converse is true (Vincent, 2010) . Donabedian has 
also described the difference between the structure, process and outcome of healthcare to 
promote the understanding that quality relies on the interactions between difference 
components of care, which are all amenable to evaluation both by providers and their clients. 
(Donabedian, 1986). Other renowned expert identified six measures of quality, which map 
well onto Donabedian’s four aspects mentioned above – technical excellence, social 
acceptability, humanity, cost, equity and relevance to need (Donabedian, 1986; Maxwell, 
1984). As Vincent noted, safety was not expressed as one these dimensions of quality then, 
even though the concept of safety in healthcare is already interlaced between other measures, 
such as Maxwell’s technical excellence and acceptability and Donabedian’s principles that 
govern the affairs of healthcare and the healthcare system (Vincent, 2010). The US Institute 
of Medicine (IoM) report, “To Err is Human,” initially, and subsequently, the British 
Department of Health (DH) report, “An Organisation with a Memory,” have put safety in 
healthcare in the lead (Department of Health, 2000; Kohn et al., 1999; Vincent, 2010). More 
recently, the US IoM have highlighted six aims for healthcare improvement: safety, 
effectiveness, patient-centred, timely, efficiency and equitable (Institute of Medicine (U.S.). 
Committee on Quality of Health Care in America., 2001).  
Summarily, Safety is established as one of the indicators of quality. When harm is caused due 
to lapses in the process of care, then a safety issue exists. The concept of patient safety had 
updated the quality of care: it shows that healthcare could be harmful to patients; brings 
important attention to the impact and results of error and harm; enables medicine to face-up 
to errors in healthcare, and address the nature and causes of error; helps healthcare to learn 
from other high risk industries; generates new systems and tools to healthcare improvement 
etc. Therefore, true quality assurance in healthcare will access the safety dimension of the 
quality of care. 
 
 
 30 
1.3 Medication error 
1.3.1 Background/introduction 
A medical error may occur at any stage in a patient’s interaction with healthcare, which could 
include investigation, diagnosis, laboratory testing, surgery, therapeutic and non-therapeutic 
management, patient education, compliance and concordance. Each of these stages is 
associated with different types of errors. Of these, medication errors have been shown to be 
one of the most common, resulting in unprecedented levels of patient morbidity and mortality 
(Aronson, 2009b; Department of Health, 2008; Garfield et al., 2009; Vincent, 2010). The 
USA, UK, World Health Organization and many developed countries have identified that 
priority needs to be given to improving patient outcomes and medication safety in healthcare 
(Britt et al., 1997; Department of Health, 2000, 2004; Thomsen et al., 2007; World Health 
Organisation, 2002). 
Medication errors (and the Adverse Drug Reactions, ADRs, which result from them) form 
part of a much global problem known as medicines-related problems (MRPs). An MRP is an 
event that involves drug treatment or therapy, which potentially or actually interferes with the 
patient experiencing an optimum outcome of care (Hepler & Strand, 1990). MRPs are a 
growing source of concern, especially with an ageing population and an increase in chronic 
diseases, co-morbidities and polypharmacy. 
One way of reviewing the processes of care and determining if specified standards are being 
met is to study the errors associated with these processes (Vincent, 2010).  The use of 
medication or therapeutic management is the most common form of intervention in medical 
practice. As such, medication error is the most extensively studied area of medical errors, and 
could occur at any point within the medicines management or handling system, which 
includes prescribing, preparation or dispensing, and patient administration. A medication 
error may be described broadly as any mistake in drug use or therapeutic management. Types 
of medication errors include wrong decision in the choice of drug, omitting to give the drug, 
incorrect or suboptimal dose, overdose, formulation error, wrong route, etc. (Dean et al., 
2000; Vincent, 2010). Studies on medication errors vary in scope – some evaluate the whole 
system of medication handling, while others focus on a specific point within the system, and 
have a different objective to studies on adverse drug events (ADE), which are directed 
towards the outcome of care (Vincent, 2010). 
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Research and practice have varying interpretations of what should be classed as a medication 
error; this has implications for data collection and interpretation (Ferner, 2014). The issues 
around definition and classification of errors will be discussed further on. Firstly, an 
understanding of the concept of medication error is imperative, and a methodological 
approach as described by Morimoto et al is useful. An incident is an umbrella term to 
describe any misdeed in the medication use process, which may be an adverse drug event or 
reaction (ADE or ADR), potential ADE, medication error, or even none of these. Some ADEs 
are due to medication errors, and all potential ADEs are medication errors, as their 
identification often indicates error interception. Minor errors, which have small or no 
potential for harm are not grouped as potential ADEs but are also classed as medication 
errors. Should the incident however have the potential to harm a patient, it is considered both 
a medication error and a potential ADE i.e. a potential ADE is a medication error with the 
potential to cause injury but which does not actually result in an injury due to circumstances, 
chance or because it was intercepted and corrected. A preventable ADE is an injury that is the 
result of an error occurring at any stage in medication use. A non-preventable ADE is an 
injury due to a medication but which is not due to an error. Therefore, studies of errors differ 
from studies of non-preventable ADE. An ameliorable ADE is an injury of which the severity 
or duration may have been significantly reduced if different actions had been taken. A non-
ameliorable ADE is an injury in which there is no existing way to reduce its severity or 
duration. (Morimoto et al., 2004). These concepts overlap and are not mutually exclusive as 
shown in Figure 2 below. 
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Figure 2: Relationship between adverse drug events (ADEs), potential ADEs, and medication 
errors (Morimoto et al., 2004)
Ameliorable 
ADEs 
Preventable 
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1.3.2 Prevalence and harm from medication errors 
Although the specific rates and frequencies of medication errors are not known (Ferner, 
2014), most errors in medication go unnoticed. Of those that are identified, very few 
culminate in ADEs or ADRs (Campbell & Cantrill, 2001). For instance, in a UK hospital 
study, about 1.5% of prescribing errors was detected in 36,200 medication orders, with just 
over half (54%) being associated with the choice of dose, and 0.4% of orders were potentially 
serious (Dean et al., 2002). In the recently-published PRACtiSE Study, 4.9% prescriptions 
contained a prescribing or monitoring error from a retrospective review of 1,200 patient 
electronic medical records in 15 general practices in the UK; of these, 1 in 550 (0.18%) were 
judged to contain a ‘severe’ error (Avery, Barber, et al., 2012). In a UK study of 55 care 
homes, although 69.5% of all residents had one or more errors the mean potential harm for 
prescribing, monitoring, administration and dispensing errors was 2.6, 3.7, 2.1, and 2.0 
(0=harm; 10=death) respectively (Barber et al., 2009). In the USA, a study demonstrated 
about 1.7% errors in prescriptions dispensed from community pharmacies (Flynn et al., 2003) 
as cited in (Campbell & Cantrill, 2001). Another study in Hull in the UK found 0.48% near 
misses and 0.08% dispensing errors in 51, 357 items (Edmondson et al., 2003) as cited in 
(Dean Franklin & O'Grady, 2007). Other researchers found 0.04% dispensing errors in 
125,395 dispensed items (Ashcroft, Quinlan, et al., 2005). Franklin and O’Grady found an 
overall dispensing error rate of 3% in 2859 dispensed items at the final check stage of the 
dispensing process prior to patient collection (Dean Franklin & O'Grady, 2007). However, 
the impact of these relatively low level of harm from medication errors is better understood 
when interpreted in terms of the high volumes of medication items used daily – in England, 
the number of prescription items dispensed in the community per year went over one billion 
for the first time in 2012 - equating to 2.7million a day, or over 1,900 a minute (Prescribing 
and Primary Care Services, 2013).  Furthermore, the emotional, physical, financial and 
healthcare costs of patient morbidity and mortality are simply unquantifiable (Vincent, 2010).  
The place of medication error research cannot be overemphasised. There are many 
opportunities for errors, considering the many small but individual steps from prescribing a 
drug to receipt and use by the patient. Medication error studies have evaluated the whole 
system of drug handling or focussed on a specific point within the system, the latter being 
more commonplace (Vincent, 2010). A few studies have indicated that patient safety 
incidents in hospitals take their roots from primary care management. In the UK for instance, 
6.5% hospital admissions were related to ADRs in a study of 18,820 inpatients (Pirmohamed 
 34 
et al., 2004). In the US, researchers reviewed 661 patients in ambulatory care through the use 
of record reviews and telephone interviews, and found that approximately 25% had an ADE, 
with 11% of events being preventable (Gandhi et al., 2003). Winterstein et al (2002) found 
that 4.3% of all hospital admissions were drug-related, many of which were preventable 
(Winterstein et al., 2002). Furthermore, healthcare systems must evaluate medication errors 
because, like other medical errors, they are products of the systems that produce them, and a 
system susceptible to a ‘minor’ error can produce a ‘severe’ error if system failures and error-
producing conditions are not reviewed and addressed (Leape, 1994). Medication error 
research is also important for identifying and implementing system changes that improve 
patient safety and population health outcomes. In a study evaluating the impact of 
computerised prescribing on outpatient prescribing errors, although a small number of 
prescriptions were found to lead to actual harm, a large number had even greater potential to 
cause serious harm (Gandhi et al., 2005). Paediatric patients or the elderly may be the most 
vulnerable in these situations (Vincent, 2010). Developing interventions in both primary and 
secondary care, implementing and evaluating their impacts on measurable outcomes to ensure 
safer medicines management is therefore a key priority. Another reason to study medication 
errors is the evidence that the annual number of deaths resulting from medication errors had 
increased, from 20 in 1990 to below 200 in 2000 (Department of Health, 2000). In addition, 
the high cost of litigation arising from medication errors against a limited healthcare budget 
cannot be overlooked.  
Interventions to reduce medication error occurrence have been researched, implemented and 
evaluated in secondary and primary care. In the United States, and a few other countries, 
computerized provider order entry (CPOE) systems have greatly reduced some error 
categories because they provide important warnings and flags on contraindications and 
potential allergies to prescribers while using them (Abramson, Barrón, et al., 2011). In the 
UK, concepts like robotic dispensing, and the use of patients’ own medication while on 
admission have also reduced the incidence of medication errors in secondary care (Dean 
Franklin et al., 2008). In UK community practice, government healthcare initiatives like the 
National Reporting and Learning System (NRLS), medicines management, Quality of 
Outcomes Framework (QOF), Older Patients Framework, and other Clinical Commissioning 
Group (CCG) and NHS initiatives have influenced medication safety recently. However, the 
problem of medication error is not over because any one intervention is insufficient to 
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prevent all error types and new types or categories of errors are increasingly uncovered as 
errors are often the products of the system that produces them. 
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1.3.3 Where, why and how medication errors occur 
Medication error studies evaluate whether a medication was correctly handled within the 
medicines management process (prescribing, transcribing, dispensing, administration and 
monitoring), usually without actual or potential harm to the patient (Vincent, 2010). Other 
researchers have included repeat dispensing, and the education and training of patients and 
healthcare professionals in the medicines management process (Avery et al., 2002). Adverse 
drug events (ADEs) on the other hand, focus on the harm, which may or may not have been 
caused by a medication error (Vincent, 2010). Examples of ADE include excessive doses of 
antihypertensives, which results in bradycardia or hypotension, prescribing drugs to patients 
who have known allergies to those drugs, inadequate monitoring of warfarin etc. (Vincent, 
2010). Other consequences of error may be social, which also pose as sources of unnecessary 
sufferings to patients, and result in waste of healthcare resources.  
Researchers in psychology and patient safety have provided important insights into why and 
how human error occurs as discussed below. 
 
1.3.4 Accident causation model 
Preventable ADEs result from one or more failures in the medicines management process. 
Researchers used an illustrated case to demonstrate how a series of staged failures eventually 
lead to an ADE (Avery et al., 2002). In the model, the patient suffered the adverse event 
following underlying sources of systems failure such as problems with computerised warning 
systems, inter-service communication, and dissemination of therapeutic knowledge, staff 
training, organisation and workload distribution (Avery et al., 2002). These failures in the 
systems lead to other problems (e.g. slips and memory lapses, lack of standardised protocol 
for prescribing for patients discharged from hospital, lack of patient information, lack of drug 
knowledge etc.) that directly contribute to the event. These systems failures and the problems 
they create, if not intercepted at stages within the medicines management process 
(prescribing, dispensing, patient education and medication monitoring) where errors should 
otherwise be prevented, eventually lead to an adverse event. The researchers compared their 
model with that of Leape, concluding that a better understanding of system failures would 
provide suggestions on how the system could be made better and safer (Leape et al., 1995).  
The work of Reason has also been widely used to understand why human error occur and 
highlight management strategies (Reason, 1990, 2000). The Swiss cheese model identifies 
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that errors occur as a result of a series of breakdown of safety guards. An error may be 
intercepted at many points within a system (for example, in medicines management, an error 
may be intercepted at the final check stage of a prescription before handing out to the patient 
(in which case it is classed as a ‘near-miss’), or may actually miss detection through many 
safety gates within the medicines management system to reach the patient (when it is then 
classed as an ADE due to a medication error). These models provide an insight into how 
errors may be prevented by improvements at the stages of the medicines management 
process. While these models provide important insight into why errors occur, they may be 
difficult to apply in all clinical and real scenarios, and could be time-consuming. 
Furthermore, parts of systems’ visible failures are a direct result of an ever-increasing 
squeeze on limited healthcare budgets across economies as more people are now living 
longer with increasing co-morbidities.  
 
1.3.5 Secondary and primary care 
As the medication handling process differs between secondary and primary care, potential for 
medication errors also varies. For instance, in secondary care, there is close co-working 
amongst healthcare professionals, and trained healthcare professionals often do medication 
administration with supervision. In primary care however, patients are in touch with various 
health care professionals (physicians, pharmacists, dentists, nurses, others) at various sites 
and mostly self-administer their own medicines. In addition, monitoring may be more 
organised in secondary care because patients are usually resident within an institution and are 
in regular contact with healthcare professionals without the added responsibility of having to 
organise and book their own appointments unlike in primary care. The nature of medication 
errors observed at the different stages of medication handling would therefore vary widely 
between secondary and primary care. The most dangerous points in the medicines 
management process within primary care relate to the prescribing decision, administration 
and monitoring, emphasising the differences between secondary and primary care here 
outlined (Avery et al., 2002). 
 
1.3.6 Geriatrics vs. Paediatrics 
Older people use healthcare more. Patients over 65 years old, usually with multiple co-
morbidities account for approximately 60% of admissions, and 70% of bed days (Vincent, 
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2010). However, little research has focussed on patient safety in older people, even though 
they are more susceptible to healthcare error and harm. The evidence that older people 
experience more adverse events than their younger counterparts, most of which are typical of 
their age groups, such as falls, nosocomial infections, and drug errors, is non-debatable. The 
care of older people with multiple conditions is not adequately provided for by limited 
healthcare services and budget, while ironically, an interplay between physiological and 
social factors in the elderly makes therapeutic interventions complex (Vincent, 2010). Older 
people have contributory and risk factors, which lead to undesirable outcomes; however, if 
healthcare intervention is proactive and effective at managing these risks at an early stage, 
quick and desirable outcomes would be achievable (Long, 2010) in (Vincent, 2010). Vincent 
describes a range of ‘geriatric giants,’ or syndromes, which older people experience in 
concert when on hospital admission most of which complicate their therapeutic management 
and conditions leading to undesirable patient outcomes. With effective management within 
the hospital, a host of those syndromes could be readily overcome. In the community, the 
prognosis is more complex. Delirium, depression, incontinence, dehydration and 
malnutrition, which Vincent (2010) describes as geriatric syndromes, are much less 
noticeable when they set in. Adverse drug events due to medication errors including drug-
drug interaction, side effects leading to non-compliance, confusion, etc. can also interfere 
with therapeutic management of the elderly, which can lead to hospital admissions. The irony 
is that so much less research has focussed on medication safety in the elderly (Olaniyan et al., 
2014). 
Studies also suggest that paediatric patient safety needs more attention (Avery, Barber, et al., 
2012; Olaniyan et al., 2014; Vincent, 2010). Vincent (2010) surmises that factors contributing 
to this in hospital may include failure to be looked after by a paediatrician, failure of 
sufficient supervision of senior staff, and failure of staff to administer fluids adequately and 
correctly (Vincent, 2010). In community practice, these factors are mirrored to a large extent 
– lack of readily recognisable symptoms of worsening illness, incorrect dose determinations 
and administrations, etc. The young may be as frail as the elderly, and particular attention 
needs to be paid to these age groups who use healthcare more and are therefore more 
susceptible to harm (Ghaleb et al., 2010; Rees et al., 2015). 
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1.4 Defining a medication error 
With varying definitions used by different groups, the issue of defining a medication error 
has been debatable for some time. Clinicians, healthcare practitioners and researchers may 
define errors differently. Many terms have been used perhaps, incorrectly and 
interchangeably to describe medication errors (Ferner, 2014). Some of these include: 
medication error, failure, near miss, rule violation, deviation, preventable adverse drug event 
(ADE), potential ADE, ADRs, to name a few. Definitions and classifications of errors are 
however crucial to medication error research to estimate the rates of errors. Some studies 
seem to provide higher rates than others purely because of what was included in the 
definition and subsequently data collection. The first step to tackling the bigger problem of 
chaotic measurements and interpretations is to clearly define what constitutes a medication 
error.  
Lisby and colleagues sought to describe the extent and characteristics of medication error 
definitions in hospitals, their consequences for measuring the prevalence of medication 
errors, and to determine whether there were associations between definitions and prevalence. 
Their systematic review found that the reported prevalence was 2-75% from 45 studies 
(Lisby et al., 2010). They also found 26 different wordings for a generic definition of a 
medication error and concluded that definitions and methods of detection of medication 
errors were not reproducible but subject to researchers’ preferences. The study by Lisby et al 
(2010) was carried out on studies performed in Europe, the USA, Canada and Australia. 
Differences in healthcare systems across countries, and evolution of clinical knowledge over 
time may account for some of the reported variation in prevalence. 
Ashcroft et al (2005) found “lower” rates of dispensing errors in a study of dispensing errors 
in UK community pharmacies when compared to other similar small-scale studies but 
reiterated that the studies could not be directly compared and interpreted due to differences in 
study design and operational definitions (Ashcroft, Quinlan, et al., 2005). Interpretation of 
quantitative prescribing error studies was also problematic due to lack of clear definitions in 
the literature (Dean et al., 2000). The researchers described a lack of a generally accepted 
definition that would make quantification more meaningful and universal allowing for 
comparison of studies and use of error rates as a meaningful element of clinical governance. 
Some studies have included only errors that result in harm (adverse drug events), whereas 
others have added errors that have not reached the patient (near misses) giving a wide range 
of rates being described in the literature (Garfield et al., 2009; Lisby et al., 2010). Dean and 
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colleagues identified this problem of multiplicity of definitions over a decade ago, and 
proceeded to develop and validate an operational definition of a prescribing error for research 
use when they evaluated prescribing errors in a UK hospital which is now widely used (Dean 
et al, 2000), 
The problem of definition is also extended to error classification and severity grading. Where 
error classification is achieved by agreement between a doctor and a pharmacist, these are 
often largely based on the knowledge and views of individual practitioners, and may not be in 
agreement with other healthcare professionals or (Dean et al., 2000), or a different sector of 
healthcare. 
The National Coordinating Council for Medication Error Reporting and Prevention  (NCC 
MERP) and the National Patient Safety Agency (NPSA)’s definition and severity grading of 
medication error is now increasingly being adopted in many error studies and practice. This is 
a positive step towards standardisation of error management. The NCC MERP defines a 
medication error as “any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of health professional, 
patient or consumer”. This definition therefore covers the whole of the medicines 
management process, from prescribing through to medication monitoring (Department of 
Health, 2004). The NCC MERP index for categorising errors describes the categories in 
increasing severity from ordinary exposure to circumstances/events with capacity to cause 
error, A, to patient death, I. 
Any research into the prevalence or incidence of medication error types will require 
operational definitions to clarify what should be counted as an error or otherwise.  
 
1.4.1 Challenges of defining and classifying errors 
The discourse of definitions of errors is an important background for any medication error 
study as presented in this section. For example, defining the term ‘prescribing error’ may 
appear relatively simple. However, practitioners and researchers may disagree about what 
constitutes an error. As Charles Vincent noted, achieving agreement on a working definition 
of a prescribing error once required a full primary study and an outline of scenarios that 
should be included or excluded as prescribing errors, even with room for disagreement (Dean 
et al., 2000; Vincent, 2010). In the Investigating the prevalence and causes of prescribing 
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errors in general practice (PRACtISE) study, Avery and colleagues provided a detailed 
analysis of the issues around defining an error as examined below (Avery, Barber, et al., 
2012). 
Classifying an act as an error is a value judgement; it is subjective in that the training and 
experience of the person(s) making such judgement cannot be ignored and will always 
influence their decision. If an error judgement is based solely on scientific facts, such as 
drug-receptor interactions, it is expected to fail because, “as Aristotle pointed out, the worlds 
of facts and values are different” (Avery, Barber, et al., 2012). The researchers noted that the 
use of expressions, which suggest value judgments such as “’failure’, ‘inappropriate’, 
‘should’, etc.” should therefore be explained to reduce inconsistencies in their interpretation 
i.e. an error definition should not be so broad to give rise to different interpretations, 
nevertheless not so specific that it becomes useless or impractical. An error definition should 
be fairly widely applicable within and across healthcare systems if sufficient information is 
provided to extrapolate its rules to different situations. 
The researchers highlighted three important points in relation to error definitions:  
 The suitability of a definition for the purpose for which it is intended (differences 
between an error definition in practice for incident reporting versus the extent and 
detail of a definition used in quantitative research); 
 The need to separate definition, which comes first, from classification (which may 
include types of errors or potential outcome for example); and 
 The confusion generated by researchers when they use different words for similar 
purposes and/or similar words for different purposes in their publication. 
 
Senders and Moray suggested that an error should be interpreted as something done, which 
 A set of rules or external observer did not desire 
 Moved an outcome beyond acceptable limits; and 
 Was not intended by the actor (Senders et al., 1991) as cited in Vincent, 2010). 
 
These two schools of thought, and probably others, suggest that a set of criteria is required for 
defining an error. The requirements for an error to be workable therefore are the need for a 
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set of standards against which there must be some sort of failure, albeit without the intention 
of the actor to do so. What these criteria do not point out readily is that the divide between 
these principles in practice is very blurred as exemplified in the succeeding paragraphs 
(Vincent, 2010). 
Dean and colleagues used the Delphi technique to develop and validate an operational 
definition of a prescribing error for research use when they studied prescribing errors in a UK 
hospital: 
“A clinically meaningful prescribing error occurs when, as a result of a prescribing decision 
or prescription-writing process, there is an unintentional significant 
 Reduction in the probability of treatment being timely and effective, or  
 Increase in the risk of harm when compared with generally accepted practice.” 
This definition was developed following a Delphi process, which involved 34 judges: 
physicians, surgeons, pharmacists, nurses and risk managers. Lists of 27 scenarios, which 
should be included as prescribing errors, 8, which should not, and 7, for which judgement 
will depend on the individual situation, accompanied this definition. The scenarios included 
in the list were not meant to be comprehensive, but rather to explain a sample of potentially 
equivocal cases to facilitate decision on whether those scenarios should be classed as errors 
or not (Dean et al., 2000). 
The authors pointed out three important aspects of this definition: 
 “Unintentional” – this definition is based on theories of human error and would exclude 
any risk of harm due to deliberate acts 
 “Compared with generally accepted practice” – From the work of Bates et al (1995), a 
medication error is classified as a preventable adverse drug event (ADE) (Bates et al., 
1995). The reference to “generally accepted practice” is based upon the preventability of 
errors i.e. errors are not acceptable practices. Avery et al (2013) noted that some authors 
set very high standards for practice, which leads to incredibly high error rates with no 
acceptability to healthcare professionals (HCP) or policy makers. Using their example, all 
cases of penicillin allergy could be avoided by never using drugs with a penicillin 
structure in patients who have never used penicillin. However, the use of penicillin is 
acceptable, and as such, prescribing penicillin to a patient without a history of allergy 
 43 
would not lead to an error as long as it was suitable for them (Avery, Barber, et al., 2012; 
Avery et al., 2013). 
 “Significant” – the Delphi panel felt this word should be included for two reasons:  
o It was thought important to clarify between clinically-meaningful prescribing 
errors and those scenarios where it could not be judged that an error has occurred 
but where treatment optimization was possible 
o It was included to allow for rational errors in the prescribing process, which would 
not lead to adverse events for the patient. The word “significant” was therefore 
included to clarify that the definition is of a “clinically meaningful” prescribing 
error.  
Although this definition is now widely used, a small number of critiques of this definition 
have been published. Avery and colleagues (2012) have responded to critiques of their 
definition by Ferner and Aronson, who have suggested that developing definitions using 
consensus-based methods such as the Delphi technique is defective in that it is a definition by 
committee (Aronson, 2009a; Ferner, 2009; Ferner & Aronson, 2006). The authors of the 
definition have argued that credibility of research findings is important to practitioners if they 
are to consider them seriously and use findings meaningfully. They reason that consensus of 
healthcare professionals provide a validity element to the definition, and that the Delphi 
technique overcomes the problem of dominance by one or more individuals and eliminates 
peer pressure – issues commonly associated with committee-based decision-making. 
Furthermore, some authors have criticised the inclusion of only “clinically meaningful” 
prescribing errors based on the argument that when an error occurs, it may be a pointer to a 
weakness in the system, and that and that the risk of harm cannot be extrapolated from a 
single patient to the population(Ferner, 2009; Ferner & Aronson, 2006). However, the term 
“clinically meaningful” indicates that there is s category of “clinically insignificant” errors, or 
errors with minimal risk of harm to the patient, as such this definition does not appear to 
completely ignore clinically insignificant errors. Perhaps this may be an indication that 
reported error rates should include an element of severity assessment to increase their clinical 
relevance (Garfield et al., 2013). 
Ferner and Aronson have also suggested that an “attainable standard” should be used in place 
of “generally accepted practice” because “generally accepted practice” may be poor (Ferner 
& Aronson, 2006). Avery and colleagues (2012) have questioned what that attainable 
standard should be, and by who should such standards are set.  
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Attainable standards or generally accepted practice however both have something in 
common – the need to be measured against some form of “good” practice. Patients’ 
confidence in healthcare and use of medicines, especially at the healthcare professional end 
of the system, is directly related to how safe clinical practice is. Users of healthcare would 
expect that any principle and/or policy, which would contribute to the safety and integrity of 
healthcare and medication use would be attainable and acceptable. 
 
1.4.1.1 Classifying errors 
Error classification can be done in many ways. An error can be understood with respect to the 
behaviour involved, the underlying psychological processes, and in relation to the factors, 
which contributed to it: a classification such as ‘wrong drug’ describes behaviour of issuing 
the wrong drug. Such an error will be psychologically classed as a slip (Vincent, 2010). 
Classification schemes have been proposed in high-risk industries to aid the preparation of a 
safety case that outlines what errors might occur. The Predictive Human Error Analysis 
(PHEA) technique has been generally developed for use in high-risk industries where the 
actions of single person can be fairly outlined (Vincent, 2010). PHEA uses six main 
categories or errors: planning, operation, checking, retrieval, communication, and selection 
errors. Classifications of errors in healthcare can readily draw from schemes like PHEA. To 
be useful in practice, error classifications, like definitions should be clear. Clarifying 
classifications used is important to facilitate interpretation and usefulness of error data. Error 
data, which are intended to provide feedback to healthcare providers, need to be relevant to 
daily practice and facilitate or provide a basis for behaviour or cultural change. It is therefore 
not surprising that many UK studies sensibly classify errors using the behaviours involved 
(Avery, Barber, et al., 2012; Barber et al., 2009; Dean et al., 2000; Ghaleb et al., 2010). 
Though it may be useful to map such behavioural classifications onto other schemes, such as 
psychological processes or even a system like PHEA for comparison, this classification 
appear to communicate more relevantly with healthcare stakeholders. 
 
1.4.2 Error definition in practice 
Furthermore, Avery and colleagues surmised that the boundary of the system of detecting 
errors has to be considered and defined (Avery, Barber, et al., 2012). They gave the following 
example; would a community pharmacist who interprets a GP’s Latin abbreviations for the 
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patient be a part of the system, or have they received a prescribing error? This has 
implications for the interpretation and usefulness of study results by healthcare professionals 
across various healthcare systems – prescription-only-medicines, POMs can vary across 
healthcare systems, and in developing countries, a community pharmacist does not 
necessarily perform prescription transcription and dispensing. This is also relevant in other 
sectors within primary care such as residential or nursing homes where a pharmacist may not 
always undertake prescription transcription or dispensing. The researchers noted that as 
assumptions and expectations are unavoidable, these should be made as clear and standard as 
possible within a particular study. Such assumptions could also be clarified with case law. 
Specifically, in primary healthcare, the role of the community pharmacist (or dispenser in a 
dispensing practice) who assumedly would always be an intermediary to translate the 
instructions of a prescriber to a patient, has to be considered (Avery, Barber, et al., 2012). For 
example, a prescriber may issue a prescription for Levothyroxine with a daily dose of 
75micrograms daily, which requires three tablets of Levothyroxine 25micrograms or one 
each of Levothyroxine 25- and 50-micrograms each. Although a prescription of this nature 
may not be clear to a patient, it is fair to assume that the dispensing pharmacist will translate 
this as necessary. This rule applies to Latin abbreviations such as “OD” or “BD.” Avery and 
colleagues therefore decided not to include the prescription of brief or abbreviated 
instructions as errors in the PRACtISE study. In situations where the directions are produced 
directly on prescription labels such as with the Electronic Prescription Service Release, EPSR 
2, this parallel may not always be however. One of the complexities of community practice or 
primary care is that it is assumed a patient will always go to the same pharmacy to fill their 
prescription. In practice, this is not the case. As such prescriptions of both co-dydramol and 
Paracetamol for example, without a clear statement by the prescriber that they should not be 
taken together is recorded as a potential duplication error (Avery, Barber, et al., 2012).  
Also, a potential error could be date-specific as a result of developments in clinical 
knowledge. The researchers gave examples of prescribing a Cyclooxygenase II inhibitor 
(COX II) in a patient with a cardiovascular disease, which may not have been judged as an 
error a few years ago; and the out-dated need for an additional contraception if a broad-
spectrum antibiotic is prescribed while taking a combined oral contraceptive pill. The time-
dependent information relating to an error in what was initiated in the past is therefore 
relevant. 
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Avery and colleagues also noted that “a reduction in the probability of treatment being timely 
and effective” might be difficult to identify. Under-dosing of antimicrobial agents were 
included as an error in their study – the researchers argued that under-dosing may lead to a 
“treatment being less effective,” and an increase in the risk of antimicrobial resistance. 
In error studies, review of patient medical records has been found to be a more thorough 
approach than analysis of incident reports (Tam et al, 2008, Aronson, 2009, Avery et al, 
2012, Olaniyan et al, 2014). Successful retrospective review of prescriptions and medical 
records directly relates to documentation. For example, prescribing Phenoxymethylpenicillin 
to a penicillin-sensitive patient would only be picked up as an error if information on 
patients’ allergies were documented. If the lack of information makes it impossible to make a 
valid judgement on whether or not an error has occurred, no errors should be recorded 
(Avery, Barber, et al., 2012). 
 
1.4.3 Primary care-specific issues 
Avery and colleagues further considered how to handle prescription items left on a repeat 
prescription but not actually requested by the patient. The researchers decided not to include 
these cases as errors as they explained they were only looking at issued prescriptions. In 
practice however, items left on repeat can directly result in the “reduction in the probability 
of treatment being timely and effective,” if the ‘wrong item’ is issued. This may be relevant 
in a study of older patient groups who generally take more medication and who experience 
more changes in their dosage regimen. As such, if an item, which is recorded in the medical 
notes as being discontinued is left on a patient’s repeat, this would be recorded as an error 
based on the researcher’s experience of the chaos and waste observed in community 
pharmacy practice with issuing discontinued items.  
The present study also considered a patient’s most probably behaviour when specific 
information about dosage instructions and/or route of administration was missing (Avery, 
Barber, et al., 2012)– Avery et al gave this example – if an eye drop did not specify the eye 
being treated for a symptomatic condition, this was not recorded as an error as the patient was 
likely to know which was being treated; for asymptomatic conditions such as glaucoma 
however, this was recorded as an error. The risks associated with the drug were also taken 
into consideration with this judgement – potent topical corticosteroids, which did not have 
specific instructions about where to be applied, and how often were counted as errors. The 
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researchers did not record errors for medications that have detailed Patient Information 
Leaflets (PIF) or those with only one main indication or dosage schedule, or those available 
over-the-counter (OTC) for the relevant indication such as paediatric Paracetamol suspension 
since the information provided on the packaging may be sufficient to inform this patient. A 
patient may not however always be in receipt of an original container of a medication. For 
example, paediatric Paracetamol suspension may be dispensed from a stock of 2000Litres 
into dispensing bottles of the volume ordered by the doctor. For the present study therefore, 
each case was individually judged  – for example, a prescriber’s instruction may become a 
potential source of confusion to a patient even if the medication is available OTC. 
Furthermore, a patient may decide not to fill a prescription if is cheaper to obtain it as an 
OTC. High-risk drugs, and medications with a wide range of potential doses, such as oral 
steroids, were also judged as errors if dosage regimes were ambiguous (Avery, Barber, et al., 
2012).  
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1.5 Assessing the potential for harm: potential and actual errors 
Research has suggested that the severity of errors should be assessed in addition to the 
frequency of errors when measuring error rates (Garfield et al., 2013). The clinical relevance 
of study results may be increased when compared with studies presenting prevalence alone 
(Garfield et al., 2013). However, in their systematic review, Garfield and colleagues observed 
that a total of 40 different tools (including adaptations of other tools) were used in 60 
publications. The methods used in assessing severity of errors were disparate; however, most 
of the tools identified had some features in common. In addition, the researchers found that 
little information was available on development of the majority of the tools with respect to 
their validity, reliability, and whether they were developed to assess potential or actual harm. 
 
Tools based on actual patient outcomes may have limited use in practice if a researcher 
becomes aware of an error and are expected to intervene (Barber et al., 2009; Garfield et al., 
2013). In retrospective studies like the present study, it may be difficult to recognize clinical 
effects because of the time delay between the occurrence and identification of errors (Dean & 
Barber, 1999) and incomplete documentation of drug effects in patients’ medical records. 
These provide some advantage with using potential outcomes to assess severity because even 
when actual patient harm is unknown, judgements could be made about severity. However, 
assessing potential severity based on potential outcomes is likely to be a subjective 
judgement (Garfield et al., 2013). 
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1.6 Reporting and learning from error 
The importance of error reporting appears to have been underscored. However, Vincent, in 
his book, Patient Safety (second edition, chapter five), has provided a synopsis on the issue of 
error reporting while emphasising its most important relevance, learning (Vincent, 2010). 
Sadly, tragedies and accounts of failures in healthcare seem to have a very notorious way for 
re-occurrences considering more recent high-profile cases like Mid Staffordshire NHS Trusts 
failure. Medicine and science bear similarities from Popper’s philosophy of science, which 
states that scientific knowledge is anything but permanent, and that science progresses on the 
recognition of imperfections in accepted theories (Vincent, 2010). Popper’s position argues 
that the recognition of faults, or errors, or imperfections in existing theories actually grows 
knowledge in a process involving a case of throwing out the old for the new and ‘better;’ this 
view turns error from its very negative undertones to a theme of value, very resourceful, and 
clue to progress, both scientifically and clinically. However, healthcare has yet to embrace 
this position whole-heartedly. Healthcare professionals possess some idealised position of 
authority, which has been assumed by individual professionals or rather imposed upon them 
by their colleagues or patients, that is almost not questionable in spite of a decade-long 
campaign to learn from errors from their professional colleagues. Such a high view or 
position of authority can be misguided and hazardous where such authorities are not expected 
to make mistakes leading to further opportunities to hide errors. 
The quality of paediatric cardiac surgery by two surgeons began to raise concerns among 
clinical staff at the Bristol Royal Infirmary in the late 1980’s. There were suggestions that 
when compared with other specialist units, the results of paediatric cardiac surgery were not 
as good, and that mortality rates were significantly higher. The death of a child who was 
scheduled for surgery against the advice of anaesthetists, some surgeons, and the DH led to 
the launch of an external enquiry, and ultimately extensive local and national media 
coverage. The Secretary of State for Health subsequently launched an Inquiry into Bristol. 
The report made many recommendations to the Health Service (Teasdale & Council of the 
Society of British Neurological, 2002). The inquiry underscored the fact that healthcare could 
be dangerous when the standards slip, and established the need for openness in medical 
performance and health outcomes, and further emphasis was laid on the subject of medical 
error, system and human failure in the delivery of healthcare (Treasure, 1998). 
Many recommendations were made on the back of ‘Bristol,’ some of which included the vital 
role of teamwork, the monitoring of care, and role of regulation, among others. One of the 
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elements of the monitoring of care, and role of regulation is learning from error, which is 
often facilitated through error reporting, collating local and national information received and 
sharing best practices. Error reporting in healthcare is still however not yet standardised and 
may appear chaotic at the best of times; there may be lack of clear pathways for healthcare 
professionals on what, where and how they should be reporting, which can lead to duplication 
of efforts, increase in error-reporting systems within institutions and healthcare systems, and 
other related activities, which may be grouped together under the broad area reporting . 
Healthcare organisations use various kinds of reporting systems. In the UK, the yellow card 
system and the National Reporting and Learning System (NRLS) are used to capture adverse 
drug reactions and medical errors respectively. The UK’s yellow card system, which provides 
a system for early detection of trends in adverse drug reactions, was set up in 1964 following 
thalidomide poisoning. NRLS established by the National Patient Safety Agency, NPSA is 
one of the offshoots of increasing focus on patient safety following the DH call for a 
paradigm in safety culture within the NHS. As well as serving a learning function, local 
health authority systems also serve as information sources for impending complaints and 
litigation. However, as would be discussed in later, the risk management systems used by 
local authorities in the NHS are not properly developed and standardised.  
Aviation and the nuclear industry have provided a reference for healthcare with respect to 
safety and reporting systems. The Aviation Safety System comprise of interacting 
components, which are designed to detect, analyse, and act on real incidents and ‘near-
misses,’ while identifying other possible risks (Vincent, 2010). Although this has not always 
been, NASA’s safety system firmly establishes the principles, behaviours, and attitudes 
towards reporting, which need to be cultivated within healthcare for a functional system. 
Safety reporting systems may be voluntary or mandatory, the latter being more common with 
regulatory bodies, and may serve additional functions to error learning. However, 
effectiveness of the system requires peoples’ commitment to make it work. Healthcare is very 
far from the ideal, as reporting is still linked with ‘punishment.’ Ideally, reporting should not 
lead to punitive measures, but this uncertainty amongst healthcare professionals is one of the 
barriers to the potential usefulness of reporting. The usefulness and relevance of incident 
reports in healthcare depends on how complete enquiries made thereof are.  
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1.6.1 Healthcare Reporting Systems 
Reporting systems within healthcare are as varied and stratified as healthcare – systems could 
be generic, department- or speciality-specific, even nationally, regionally or locally 
functional – with their value and effectiveness being strongly related to their types and/or 
purposes (Vincent, 2010). Local incident reporting systems in hospitals, which serve as safety 
and quality improvement tools as well as resources for claims management, were developed 
following increase in awareness of risk management. Similar systems are used in primary 
care organisations in developed healthcare systems. The British NPSA Reporting and 
Learning System (RLS), launched in 2004, is potentially more practical as a national 
reporting and learning system when compared with USA, where the healthcare system 
comprise a diverse range of public and private sectors. The Australian Incident Monitoring 
System (AIMS) is a large scale reporting system, which is based on a standard form. It allows 
multiple sources of information and important analysis (Runciman et al., 2003). The British 
NPSA RLS like AIMS, can pull together rare events on its system to inform learning and 
action. However, the sheer volume of reports to those national systems may not support 
important local learning. Furthermore, Incident reporting systems, though very useful, are 
limited at detecting adverse events (Franklin et al., 2009; Tam et al., 2008). As such, local 
mechanisms for error learning should complement such large-scale error-reporting systems. 
 
 
1.7 Medication error reporting 
Medication error reporting is a very important process in managing errors (Sarvadikar et al., 
2010). Incident reporting improves prevention of future occurrences of medication incidents 
in a healthcare system: provision of valuable feedback to reporters and their colleagues, 
identification of system failures within the medication handling procedure, development of 
local and national risk management standards, identification of developing trends relating to 
patient and medication safety, and the impact of these on patient outcomes. 
The National Patient Safety Agency (NPSA) in the UK has set up the National Reporting and 
Learning System (NRLS) to make sure that lessons being learnt from ADEs due to 
medication errors in one area are learnt similarly across the whole healthcare system. As 
such, all healthcare providers are expected to report serious ADEs and ‘near misses’ in 
accordance with this national incident reporting scheme. A DOH report (2000) sought to 
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improve safety and patient outcomes through reporting, analysing and learning form Adverse 
Incidents in the National Health Service, NHS (Department of Health, 2000).  
In spite of all these benefits of incident reporting, routine reporting procedures have been 
estimated to report as low as 5% of adverse events that may be detected by case note reviews 
in secondary care (Sari et al, 2007 as cited in Sarvadikar et al., 2010). There are no reported 
figures for primary care where over 80% of prescriptions are written (Department of Health, 
2008). 
There have been a number of identified barriers to reporting medication errors, and efforts to 
improve these should be geared at overcoming these barriers rather than a blind call to report 
incidents occurring within healthcare system. These barriers may include shame (Davidoff, 
2002 as cited in Sarvadikar et al., 2010), fear of punitive measures against healthcare 
professionals who make errors (Evans et al, 2006 as cited in Sarvadikar et al., 2010), lack of 
simplified reporting systems (Maidment and Thorn, 2005 as cited in Sarvadikar et al., 2010), 
fear of litigation (Ashcroft et al., 2006), lack of support within healthcare organisations 
(Maidment and Thorn, 2005 as cited in Sarvadikar et al., 2010), or even lack of the necessary 
level of awareness of the importance of error reporting amongst different healthcare 
professionals or the systems available for error reporting. 
Sarvadikar and colleagues surveyed the attitudes of different healthcare professionals to error 
reporting. While nurses and pharmacists were more inclined to report incidents of all levels 
of severity despite their fear of being blamed or even punished for them, doctors were rather 
more inclined to report more serious errors than ‘less severe’ ones. However, the same level 
of responsibility to error reporting should be shared by all healthcare professionals if lessons 
are to be learned since “minor” errors always have potential to become more severe incidents, 
as they are more often a result of system failures. 
Although studying errors by reviewing routine error reports have been observed to grossly 
underestimate the true levels of error rates, it remains a practical approach to obtaining error 
data in secondary and primary care in the long term as it brings minimal interruptions to the 
healthcare system. Researchers surmised that reporting systems help in the identification of 
latent errors such as skill mix and staffing levels in community pharmacies which otherwise 
may not be evidently visible by observational methods (Ashcroft et al., 2006). 
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The attitude of healthcare professionals to reporting error incidents may be an indication of 
the safety culture and climate within the organisations.  
 As medication errors are generally caused by multiple factors (Department of Health, 2000), 
understanding these factors and the interactions between them is crucial to preventing their 
occurrences. According to Reason, the interactions of active failures of individuals and latent 
conditions within an organization are responsible for medication errors (Reason, 1990). Many 
studies have focussed on assessing error rates and types but understanding practitioners’ 
perceptions of issues affecting error occurrence and prevention is indeed valuable in creating 
and maintaining a safety culture in the outpatient setting (Teinilä et al., 2011). There is 
therefore a need to survey organizational and cultural items relating to medication safety in 
primary care – to explore the primary outpatient care practitioners’ perceptions of medication 
errors and error prevention. 
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1.8 Medication errors in primary care 
Attention to patient safety and medication error issues have been mostly directed at 
secondary care as this clearly indicates high-risk procedures such as surgery and blood 
transfusions, and an environment full of potential for risks such as nosocomial infections 
(Gaal et al., 2010; Harmsen et al., 2010). However, secondary care represents only a small 
percentage of a patient’s use of the healthcare services. 
In many countries, most patients receive most of their healthcare needs in primary (1°) care 
(Harmsen et al., 2010). In the UK, the DOH report, Building on strengths-delivering the 
future (2008) estimated that greater than 80% of prescriptions for medication are written in 
primary care, and about 71% of the medication budget is currently spent in primary care 
(Department of Health, 2008). Furthermore, over 600 million prescription items are 
dispensed in community pharmacies in England and Wales (Ashcroft, Quinlan, et al., 2005). 
In addition, a wide variety of drugs are prescribed and monitored in primary care (including 
the monitoring of some medications which are routinely initiated from secondary care), and 
primary care practitioners are progressively taking on more and more complex medication 
regimen and patient health responsibilities (Avery et al., 2002). 
A few studies have also showed that patient safety incidents in hospitals take their roots from 
primary care management. In the UK, 6.5% admissions to hospital were related to adverse 
drug reactions in a study of 18,820 patients that were admitted to hospital (Pirmohamed et al., 
2004). Similar studies have been conducted in the Netherlands, France, Germany and the 
USA (Harmsen et al., 2010). Kohn et al (1999) in the IOM report, 'To err is human', 
estimated that 1 in every 131 outpatient deaths is attributable to medication errors. Over a 
decade ago, Winterstein et al (2000) as cited in Avery et al, 2002, in a systematic review and 
meta-analysis of 15 studies found that about 7% of hospital admissions were drug-related and 
over half of them were preventable in the first instance. About 60% of the groups of 
medication that were found to lead to increases in ADEs then have now only being given due 
attention when first prescribed to a patient by the recently initiated New Medicines Service 
(NMS) in England and Wales. 
The dearth of information on medication errors in primary care may be attributable to many 
factors. Unlike secondary care, different health care professionals come in contact with 
patients at various locations; therefore, there is a requirement for multidisciplinary co-
working with great implications for transfer of information and communication (Harmsen et 
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al., 2010). A World Health Organization (WHO) body, World Alliance for Patient Safety, 
concluded that inadequate or inappropriate communication and coordination are major 
priorities for patient safety research in the developed countries (Kennedy et al., 2011). 
Prescribing errors in the primary care setting are sometimes due to a breakdown in 
communication between prescribers and community pharmacists e.g. ordering commercially 
unavailable medicines, omission of parts of prescriptions, or even writing the wrong aspects 
of a prescription such as patient’s name, address, age, medication, dosage or directions. 
Lack of ready availability of copies of prescriptions for review, coupled with the scenario that 
patients get their prescriptions dispensed at multiple pharmacies are some of the factors that 
contribute to inadequate data describing the frequency and impact of outpatient medication 
errors (Gandhi et al., 2005). Self-administration by patients further has great implications for 
monitoring (Gandhi et al., 2003). Administration errors themselves are however indicative of 
defects in the medicines management process. 
As contact with general practitioners occurs sparsely, communication about patient health 
problems is not (Gandhi et al., 2003). The researchers reiterated that lack of comprehensive 
documentation of patient care in the community might reduce the benefits of chart review, 
which is extensively employed in inpatient studies. 
There is increasing research into methods for improving medication safety in primary care. 
Changing prescribing behaviour through educational outreaches, increasing use of 
computerised prompts (although some problems exists with physicians overriding these), 
increased focus on medicines mostly implicated and pharmacists’ interventions are on the 
increase in many countries (Avery et al., 2009; Avery et al., 2002; Teinilä et al., 2011). In 
primary care, medication reviews and monitoring, repeat prescribing and the evolution of the 
expert patient are further ways in which the use of medication in primary care is increasingly 
made safer (Avery et al., 2002). 
Nevertheless, with an increase in the methods for improving medication management 
systems, the problems are far from being over because none of them are self-sufficient, and 
may only improve individual aspects of the system as discussed above. Improvements in the 
medication management process are therefore a continuum especially as newer trends of 
problems are increasingly uncovered. 
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1.9 Research questions 
The research questions that arise from the background above include the following: 
 What are the current issues on medication errors in primary care – error rates and 
prevalence and interventions implemented to prevent medication errors? Are specific 
patient categories more susceptible to errors? 
 What are the current systems for managing medication errors in UK primary care? 
How do these systems compare locally? What does primary healthcare safety culture 
look like? 
 What is prevalence of medication errors in primary healthcare? What types of 
medication errors occur the most in UK primary care organizations, especially within 
vulnerable patient groups identified? 
 What types of errors frequently occur in the primary healthcare setting? 
 What roles do community pharmacists play in intercepting medication errors in 
primary care? 
 
1.10 Aim and objectives 
The aim of the study was therefore to determine the prevalence and nature of prescribing 
errors in general practice in older patients ≥65 years old and children 0-12 years old, and to 
identify defences against error occurrence in primary care. 
 
The objectives were 
 To undertake a systematic review of medication errors across the entire medication 
management process in primary care 
 To describe the current systems and processes of medication error identification, 
recording and reporting in primary care organizations as pointers to their current culture 
of safety using postal questionnaires to Primary Care Trusts (PCTs), Clinical 
Commissioning Groups (CCGs) and NHS Area Teams 
 To investigate the prevalence and nature of prescribing errors in older patients ≥65 years 
old and in children in primary care through the retrospective review of patient medication 
records in participating general practices 
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 To investigate the prevalence and nature of monitoring errors in older patients ≥65 years 
old and in children in primary care through the retrospective review of patient medication 
records 
 To explore whether the prevalence and nature of errors vary with patient and prescription 
characteristics through analyses of data collected from the retrospective review of patient 
medication record 
 To explore error-producing conditions in general practice, particularly amongst 
vulnerable patient groups through interrogation of data collected from the retrospective 
record reviews 
 To explore community pharmacists’ roles and interventions on medicines related 
problems in primary care through direct observations in participating community 
pharmacies 
 To make recommendations for practice to reduce prescribing and monitoring errors in 
general practice from the findings of the systematic review, results from the retrospective 
review of patient medical records in participating general practices and observations in 
community pharmacies. 
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Chapter 2. Research context and theoretical framework  
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2.0 Introduction 
Research is the systematic and rigorous method of enquiry, which aims to describe 
phenomena and to develop and test descriptive concepts and theories; overall, the main aim 
of research is to contribute to a scientific body of knowledge, and in healthcare, to improve 
health systems, health services, and health outcomes (Bowling, 2014). Ann Bowling has 
provided a detailed synopsis on the principles of Health Service Research in her book, 
“Research Methods in Health: Investigating health and health services,” fourth edition. This 
has provided important insight for the current research as discussed in the following 
paragraphs. 
This chapter provides an outline of the range of research methods used in health and health 
services enquiries. These guided the researcher to choose suitable research methods and 
designs to address particular research questions. As Ann Bowling pointed out, it is not 
feasible to place research methods in order of superiority, as various methods are suitable for 
various research questions: a cross-sectional survey, for example, can be used to enquire 
about the health status of a population, an experimental method may be more suitable for 
investigating cause-and-effect, and qualitative methods including observations, in-depth 
interviews and focus groups may be more suited to an area of enquiry of which little is 
known. Triangulated research methods, which consist of complimentary, combined 
methodological approaches to enquire about the different aspects of a research question, is 
increasingly recommended as a way of ensuring the external validity of the research. This is 
even highly relevant in health research, as health is multi-dimensional and health research is 
multi-disciplinary in nature. There is close working relationship between healthcare 
professionals and the different disciplines investigating health and health services. This 
means a variety of valid research methods including quantitative and qualitative, descriptive 
and analytical research methods is available. 
 
2.1 Health research, health services and health systems research 
Health research is described as: 
“The process for obtaining systematic knowledge and technology, which can be used for the 
improvement of the health of individual groups. It provides the basic information on the state 
of health and disease of the population; it aims to develop tools to prevent and cure illness 
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and mitigate its effects and it attempts to devise better approaches to health care for the 
individual and the community,” (Davies, 1991 as cited in Bowling, 2014). Health research 
has a pivot role in providing the information required for the planning of services to achieve 
health. 
Health systems research is more broadly defined as “ultimately concerned with improving the 
health of a community, by enhancing the efficiency and effectiveness of the health system as 
an integrated part of the overall process of socio-economic development,” (Varkevisser et al, 
1991 as cited in (Bowling, 2014). In advanced healthcare systems like the UK and the USA, 
the focus is more on health services research rather than on health systems research, which is 
more narrowly explained in terms of the relationship between health service delivery and 
population health needs. The Medical Research Council provides an example of this 
relationship as the “identification of the health care needs of the population and the study of 
the provision, effectiveness and use of health services” (Clarke and Kurinczuk 1992 as cited 
in Bowling, 2014). Health services research is concerned with assessment of health services 
with respect to their appropriateness, effectiveness, and costs while health research refers to 
descriptive enquiries of the experience of illness and the population’s views of health and ill 
health. Importantly, these concepts overlap. However, to be useful, the findings of health 
services need to be converted into actions or interventions. 
Although they share the same concepts with respect to the evaluation of structure, process 
and outcome, health services research differs from audit and quality assurance in that it has 
evaluation at its heart, not monitoring. Evaluation describes assessment of the effectiveness 
of organisations, services and initiatives using scientific methods, and the rigorous and 
systematic research data collection (Shaw 1980 as cited in (Bowling, 2014)). Evaluation of 
health service, under which the present project falls under, comes under health services 
research. 
Furthermore, while clinical research focuses on biochemical indicators of health outcomes 
and more recently albeit limited, on the quality of life of patients, health services research 
evaluates the results of clinical interventions on social, psychological, physical and economic 
perspectives, and the health sector (Hunter and Long 1993 as cited in (Bowling, 2014). 
Health services research has three emphases: interaction between population health 
requirements and demand for health services, and the provision, use and appropriateness of 
health services; the processes and infrastructures, their efficiency and quality; and the 
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suitability and appropriateness of health service interventions with respect to their 
effectiveness and cost-effectiveness in addition to patients’ expected health outcomes 
The current research sits mostly within the second theme – the processes and infrastructures 
and their efficiency and quality, and to a lesser extent within the third theme or focus – 
suitability and appropriateness of interventions. Investigating the incidence and nature of 
medication errors in vulnerable patient populations including older and younger patients 
ultimately reviews the processes of medicines use – prescribing, transcribing, dispensing and 
administration, this time, the focus being on prescribing (and monitoring) errors. An example 
of “the suitability and appropriateness of interventions” will be a clinical pharmacist’s 
retrospective review of medical records to identify whether the current systems within 
general practices are preventing the most common errors in older patients and in children. 
 
2.1.1 Evaluation of the quality of care 
In a research on medication errors, it is imperative to define the evaluation of the quality of 
care. In evaluating healthcare, quality of care is defined in respect of its effectiveness with 
enhancing the population’s health status, and a measure of how professional and public 
standards about care are met (Donabedian, 1980 as cited in Bowling, 2014). In Donabedian’s 
model, systematic assessment of quality evaluate the structure of healthcare (including 
staffing and building); the process (including service delivery, organisation and use; for 
example, consultation rates and referrals, admission and discharge protocols, prescribing 
practices such as prescribing safety); output (including productivity, access, effectiveness); 
and outcome (health outcomes including disability, discomfort, dissatisfaction). There are 
other related definitions of quality of care. Higginson (1994) as cited in (Bowling, 2014), 
defined quality of care in relation to effectiveness, acceptability and humanity, equity and 
accessibility and efficiency. 
The aspect of health services research, which assesses the quality of care, involves the 
evaluation of structure, process and outcome of healthcare interventions such as prescribing 
in the current study. 
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2.2 The theoretical framework of assessment 
Theories about the conduct of research (the philosophy of science) are important because 
they have influenced the progression of the systematic and rigorous research practices and 
methods, and the selection of methods. Scientific research methods entail the methodical or 
systematic enquiry of the phenomena of interest through thorough investigation using the 
senses, usually sight and hearing, complimented by technical instruments, correct 
measurement, and finally, experimentation through the careful manipulation of an 
intervention in controlled conditions and investigation and determination of the outcome. An 
important characteristic of scientific research methods is that the practice systematic. This 
means that an established set of guidelines and methods, which are rigorously complied with, 
and against which the research may be assessed, form its basis. Overall, the goal of scientific 
research is that the influence of other factors – including the inquirer’s influence – on 
research findings is significantly reduced. 
In addition to being systematic, it is imperative for scientific research to be rigorously 
conducted to reduce contamination and improve the precision of research findings through 
the following processes: comprehensive documentation of the research processes, objective 
data collection or observation, systematic collection, analysis and interpretation of the data, 
thorough maintenance of comprehensive research records, validity checks using additional 
research methods, repeated measures of the phenomena of interest, and reliability – testing by 
a different trained investigator using the same methods, measurement and analyses tools, to 
generate the same outputs or results.  
The method of enquiry chosen depends on the investigator’s position or their perception of 
how society works. An investigation, which starts with an idea, followed by development of 
theories and hypotheses, which are in turn tested by data is termed deduction. If research 
however starts with data collection followed by constructing hypotheses for testing from 
them, this method is described as induction. Deductive and inductive analyses form a huge 
aspect of scientific research and knowledge.   
In the current study, both deductive and inductive analyses were relevant: the current 
literature suggests that medication errors are common in older patients and in children due to 
factors, which may include polypharmacy, diminishing pharmacokinetics and 
pharmacodynamics, co-morbidities, system failures, etc. in older patients, and the need for 
age- or weight-appropriate dose, etc. in children. From these findings, theories and 
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hypotheses are established, and data is collected to test these hypotheses. On the other hand, 
the systems of identifying, recording and reporting medication errors at Clinical 
Commissioning Groups, CCG (and formerly Primary Care Trusts, PCTs) level have not been 
previously characterised by primary research. The analyses of data generated from PCT/CCG 
surveys will guide the construction of hypotheses for testing in an inductive process. 
Theoretical perspectives or paradigms govern every aspect of a scientific research. Research 
questions are therefore based on collection of assumptions, called paradigms. Paradigms are 
essential because they guide the focus and provide frameworks for interpreting findings. The 
reformulation of theories or perspectives where existing paradigms are altered is in turn 
provided by research observations. Although an enquirer’s theoretical perspectives cannot be 
completely ignored throughout a research process, sources of bias, which undermine validity 
and reliability, should be consciously reduced through the rigorous and objective process of 
research. 
The philosophical framework of deductive logic formed the basis of scientific research 
previously. Francis Bacon and John Locke established empiricism or inductive methods 
based on the need for making observations as opposed to just theoretical statements. 
Following Karl Popper’s proposal that knowledge is gained by falsification of hypotheses, 
the hypothetico-deductive method was birthed, and forms the basis of modern scientific 
methods.  
In theory, scientific research methods consist of rules and systems, based on the hypothetico-
deductive method against which research can be evaluated. Practically however, scientific 
research is based on a less formal and somewhat haphazard mix of the rules of deductive and 
inductive or probabilistic paradigms – ‘a mixture of empirical conception and the certainties 
of deductive reasoning. 
The different types of paradigms, which can be used to inform and guide an investigator’s 
research, include the following: 
 Grounded theory: This is commonly employed in social science. The process of 
identifying theory from data that has been systematically collected and analyzed is 
referred to as grounded theory. Most of the hypotheses and concepts are worked out 
systematically from the data during the course of research to generate a theory from 
the data. It is a theory, which occurs inductively from the study of the interests it 
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represents. There is therefore a reciprocal relationship between data collection, 
analyses and theories.  
 Constructivist grounded theory: The Constructivist grounded theory underlines 
multiple individual realities (Charmaz, 2000 as cited in Bowling, 2014). It involves 
concurrent data collection and analyses, where analytic codes and categories are 
developed from the data as opposed to a priori hypotheses, establishing middle-range 
theories, not grand theories to describe processes, applies theoretical sampling as 
opposed to representative sampling to verify conceptual categories, and undertaking 
literature review after the analyses. There is controversy that this theory leads to 
artificial manipulation of data, which is contradictory to the original theory 
(Piddephatt, 2006 as cited in Bowling, 2014). 
 Positivism: The enquirer’s perception about society governs this method of 
investigation. It assumes an external reality, which guides the determination of facts 
 Functionalism: This is a positivist approach, which focuses on the social system. 
Illness is viewed in relation to its impact on the immediate social system, and the 
consequences thereof. Anything, which interferes with the social system and its 
values are described as dysfunctional, and those, which contribute to its functioning as 
functional. It is a system of holistic science. 
 Phenomenology: The phenomenological philosophy proposes that research 
observation should come before theory because ‘it initiates, reformulates, deflects and 
clarifies theory,’ (Merton 1968 as cited in (Bowling, 2014)). Phenomenology is based 
on the paradigm that knowledge is socially built through the interaction of 
individuals, and that this understanding is undermined with the tools of positivism. 
Phenomenology is based on individuals’ interaction between individuals in their 
natural existence. The tools are open-ended, unstructured, in-depth interview or 
participant observation. 
 
As Ann Bowling surmises, the question should not be about choosing between quantitative 
methods or positivism and phenomenology or qualitative methods, but about the 
identification of novel ways to combine both in studies as they can compliment each other 
and produce rich research outputs (Bowling, 2014). Qualitative techniques are useful in 
producing rich data, particularly in new research topics and complex phenomena. On the 
other hand, quantitative methods are useful when the research area is relatively 
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straightforward, responsive to valid and reliable investigation. The use of triangulated or 
multiple methods of enquiry, if anything increase accuracy, validity and provide usefulness of 
the quantitative data that has been collected. The current research uses a mixed method 
approach to investigate the prevalence and nature of prescribing and monitoring error in 
primary care. 
 
The deliberation in this thesis was to acknowledge and understand which paradigm was most 
appropriate to answer the research questions raised from the literature on medication errors in 
primary care. Methodological consideration was given to 
1. The nature and source of information 
2. Access to information and data collection 
3. Analyses and interpretation of research findings 
4. Implications of conclusions and contribution to existing scientific knowledge 
 
2.3 Positivism 
The principles of biomedicine are based on positivism. Positivism accentuates positive facts 
and aims to identify laws using quantitative methods. It describes a systematic observation 
and measurement of matter, which are believed to be free from the value judgement of the 
scientist due to the availability of objective systems of measurement. It is based on the 
premise that theories are examinable using the deductive principles of the scientific method, 
and is the central philosophy underlying quantitative scientific methods. In social sciences, 
Positivism assumes that external stimuli are necessary to alter human behaviour, and that it is 
possible to investigate social phenomena using the principles of the natural scientist. Surveys 
and experimental methods, and statistical techniques of analyses are the most popular 
positivism tools. Many of the methods used in health and healthcare research are based on the 
positivist belief. For example, structured interviews reduce the influence of the instrument 
and the enquirer on the respondent. Positivism is somewhat over dependent of experimental 
method and does not combine adequately, qualitative methods, which are believed to be able 
to provide understanding of human behaviour and social processes.  
In the current study, the rational principles of the hypothetico-deductive method of positivism 
was recognised as a theoretical framework for the production of knowledge on medication 
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errors in primary care based on the investigator’s assumption. The hypothetico-deductive 
method underlies modern scientific research. In this method, a hypothesis is developed from 
existing theory, and consequences deduced from that theory are tested against empirical data. 
If the hypothesis is false, the enquirer can develop a new one. If not, other tests or enquiries 
are used to attempt falsification. This means removing falsehood, rather than verifying 
theories brings about scientific progress. Operationalism, which states that the principles used 
in empirical research must be measured in terms of the indicators used to determine them 
influenced the challenge of accuracy inherent in the scientific hypothetico-deductive method. 
With respect to the current research, an operational definition of what constitutes a 
prescribing error in primary care is central to achieving objective measurements. A system of 
rules and procedures, which forms the basis of the research and following the principles of 
the hypothetico-deductive method, and against which the study can be evaluated constitutes 
the theory of the modern and rational scientific method. Research needs to be conducted 
systematically and rigorously while eliminating or reducing sources of bias. In practice 
however, the distinction between empiricism and deductive reasoning is less marked.  
A scientific objective approach to identifying medication errors through the retrospective 
review of medical records in older patients and in children, using operational definitions, 
forms and objective assessment of prescriptions, and the use of quantitative and statistical 
analyses to interrogate the data from these studies, are based on the principles of the scientific 
hypothetico-deductive or positivist theory based on hypotheses and estimates of predictions 
that prescribing errors affect these vulnerable patient groups more than the rest of the 
population.  
Although the multidisciplinary group of experts who judged the severity of errors followed 
established principles and rules of determination of prescribing error severity judging, their 
judgements were not completely value free as demonstrated by Williams and Ashcroft 
(Williams & Ashcroft, 2009). 
The current study did not seek to explore the meaning of prescribing errors from the patients’ 
or practitioners’ perspectives in a qualitative or phenomenological enquiry as this was 
recently studied through focus groups and interviews and published by Slight and colleagues 
(Slight et al., 2013). However, the findings of Slight and colleagues, and the hypotheses 
developed thereof, on the causes of prescribing and monitoring errors in primary care have 
influenced the current study. 
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The aspect of the study, which sought to characterise the PCT/CCG systems of managing 
medication errors in primary care combines a quantitative deductive and qualitative inductive 
methods of enquiry. The section below discusses previous studies, which have investigated 
medication errors and those that employed this strategy. 
 
2.4 Development of methodology 
Medication errors, notably prescribing errors have been investigated in previous studies using 
quantitative methods and, in a limited number of cases, a mixed method approach, which 
usually involves case note reviews and interviews of patients and healthcare professionals has 
been used (Avery, Barber, et al., 2012; Barber et al., 2009; Gandhi et al., 2003; Gandhi et al., 
2005; Kaushal et al., 2010). The purpose of the interviews conducted in most of these studies 
was mainly to verify descriptive information retrieved from medical records from patients, 
and in few cases, to conduct in-depth qualitative interviews on prescribers’ perception of the 
concept of prescribing errors, and observation (Avery, Barber, et al., 2012; Barber et al., 
2009). The quantitative methods approach used in these studies focused on deductive, 
scientific measurements or estimations of the prevalence and nature of medication errors, and 
identification of risk factors for medication errors, with the main goal of building up theories 
to compare groups and make extrapolations. Due to the fairly large sample sizes used, the 
results may be generalizable. Slight and colleagues (2013) used qualitative in-depth 
interviews to seek understanding of how prescribers ‘perceive the world’ in relation to 
prescribing errors. Barber and colleagues (2009) used direct observation and theoretically 
framed interviews. Although the research included a quantitative estimation of the prevalence 
and nature of prescribing errors in primary care, they also sought to understand what 
prescribing errors meant to practitioners. In the background of conducting research on 
prescribing errors, quantitative methods have therefore been used to investigate prevalence 
rates, nature and factors associated with prescribing errors. Qualitative research methods have 
been used to understand the social meaning of prescribing errors to individuals based on the 
paradigm of phenomenology that ‘reality’ is multi-faceted, and collectively interrogated 
through the interaction of individuals who “use symbols to interpret each other and assign 
meaning to perceptions and experience” (Bowling, 2014). The main purpose of the current 
research in this thesis is to quantitatively investigate the prevalence and nature of prescribing 
errors in older patients and in children using the hypothetico-deductive principles of 
positivism, though aspects of the study have some qualitative elements to it. 
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The mixed methodology research paradigm could be simultaneously or consecutively used 
during development of instruments of measurement, data collection, analyses and deductions. 
Both methods complement each other. In this study, qualitative methods were essential in the 
initial stages of developing the PCT/CCG survey questionnaire design, scale construction and 
analyses. Quantitative techniques are appropriate for unambiguous, valid and reliable 
estimates of the prevalence of prescribing and monitoring errors. 
 
2.5 Identification of potential prescribing errors 
The identification of a potential prescribing error in an older patient population may be 
challenging due to the prevalent need for co-prescribing effective medications for co-
morbidities. Understanding patient characteristics and care pathways during investigative 
enquiries can however aid detection. The literature on medication errors suggest that 
identifying potential prescribing errors is based on the set of rules or definitions applied to the 
enquiry (Dean et al., 2000). Previous studies have therefore acknowledged that the definition 
and method used when identifying potential prescribing errors can affect the error rate 
reported (Avery, Barber, et al., 2012; Lisby et al., 2010; Olaniyan et al., 2014).  
Methods used to capture error information have included retrospective and prospective 
medical records reviews, retrospective and prospective audit of electronic and paper 
prescriptions in general practices or those presented to community pharmacies, pharmacist-
led identifications, patient interviews, direct observations, review of discharge summaries, 
incident report reviews, retrospective review of national data archives, and practitioner 
interviews. Study objectives, study setting (country), study population, researcher’s 
preference and access to relevant information are some of the factors, which may determine 
the choice of method in investigating the rates of prescribing errors. Higher error rates were 
consistently reported in studies that retrospectively reviewed prescriptions and patients’ 
medical records when compared to reviews of incident reports and community pharmacist 
interventions. This is largely due to the limited information available without access to 
patients’ records.  
One of the challenges of retrospectively reviewing patients’ medical records is a potential for 
incomplete information. This is a major challenge where hand-written records or 
prescriptions are reviewed but is significantly reduced in healthcare systems where electronic 
medical records are in place, such as in the British NHS. It could however be argued that it 
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may be difficult to judge a prescriber’s intention by what they have written down without 
interviewing them. Although interviews can produce relevant information on potential errors, 
there is the possibility that interviewees may not recall the circumstances around incidents by 
the time of the interview takes place. Avery and colleagues mitigated against the problem of 
incomplete information by recording no error if lack of information made it impossible to 
make a valid judgement on whether or not an error had taken place (Avery, Barber, et al., 
2012). 
What constitutes a prescribing error in each study has been mainly influenced by researchers’ 
objectives and preferences. Some studies have included all rule violations including 
omission, commission, and integration errors leading to high error rates (Al Khaja et al., 
2007), whereas some have focused on specific subtypes of prescribing errors, such as drug 
interaction errors, leading to low rates (Chen, Avery, et al., 2005). The multiplicity of error 
definition has been identified, and researchers have attempted to develop definitions, which 
could be operationalized in research and practice (Alldred et al., 2008; Dean et al., 2000; 
Dean Franklin & O'Grady, 2007). While it may be useful to have a universally accepted 
definition, researchers need to state explicitly the definition they have used. An ideal 
definition should bridge the gap between research and practice to enable research to lead 
development. 
 
Consideration also needs to be given to how errors are expressed. In the systematic review 
underpinning this study, many denominators were used to express error rates (Olaniyan et al., 
2014). Barber and colleagues (2009) expressed error rates as a percentage of opportunities for 
errors; the rational was that to judge that an error has occurred, a chance for occurrence had 
to first of all be established. In the literature, error rates are mostly expressed as a percentage 
of items (prescriptions) or patient. Importantly, error rates need to be expressed in simple to 
interpret forms for busy healthcare professionals to make sense of the information. 
Potential prescribing errors have also been classified differently in studies depending on the 
objectives of the investigators. Most studies have classified prescribing errors by type such as 
drug interactions, wrong dose, wrong strength, etc., while a few have classified errors based 
on their characteristics such as being preventable, ameliorable, etc. (Gandhi et al., 2003). 
Some UK studies and elsewhere have also classified errors by the British National 
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Formulary, BNF chapters of the drugs affected, mainly to inform interventions or 
recommendations to stakeholders. 
Most studies on prescribing errors in primary care are usually multidisciplinary 
collaborations – physicians, nurses, pharmacists, psychologists, social scientists, and 
statisticians, among others. When specified, pharmacists have mostly been involved in the act 
of identifying potential prescribing errors (Al Khaja et al., 2005; Avery, Barber, et al., 2012; 
Barber et al., 2009; Chen, Avery, et al., 2005), though physicians and nurses have also been 
involved. (Avery, Barber, et al., 2012) and Barber et al (2009) justified the use of CCG 
(formerly PCT) pharmacists as their job roles already involved the review of medical records 
and patient medications. The higher involvement of pharmacists in this process may be 
justified owing to their training and skills in drug use, pharmaceutical care plans, medicines 
optimisation and medicines management. 
 
2.6 Classification of severity assessment of prescribing errors 
It has been established that prescribing errors are common in secondary care, and studies are 
increasingly suggesting that error rates may even be higher in primary care. A systematic 
review found a median medication error rate of 7% or 52 errors per 100 admissions when 65 
eligible studies were reviewed (Lewis et al., 2009). In primary care, the error rate ranged 
from ≤1% to ≥90 % when Olaniyan et al, 2014, reviewed 34 studies. Medication errors 
however range from those with severe consequences to those that result in little or no harm to 
the patient. It is argued that since errors are a result of the systems that produce them, it 
should not matter if they do result in severe consequences or not, as errors have a potential 
for reoccurrence, and similar shortfalls in them medication system produce both harmful and 
non-harmful errors, provide additional work pressures for already squeezed healthcare 
systems, and can impact negatively on patients’ confidence in their healthcare (Garfield et al., 
2013). Therefore, there is suggestion that to be truly useful, potential errors should not just be 
identified but should be assessed for severity to provide clinically relevant information and 
ensure adequate evaluation of interventions to reduce errors (Uzych, 1996). 
The methods used for assessing the severity of errors vary widely though many features in 
common. Although Garfield and colleagues’ systematic review (2013) identified 40 different 
tools used by 60 studies for assessing error severity, most used single-item classification 
systems for assessing error severity with associated definitions, and were mostly presented as 
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ordinal Likert scales (Garfield et al., 2013). One tool, Dean and Barber’s tool, was based on a 
visual analogue scale. Some of the tools were for assessing severity error as well as other 
types of assessment e.g. National Coordinating Council for Medication Error Reporting 
(NNC MERP) tool included a ‘not an error’ category. 
Most of the tools reviewed by Garfield and colleagues were developed for medication errors 
in general, while some were developed for studies of prescribing error. Some of the tools 
identified by the researchers to assess potential errors were based on other tools, which were 
originally designed to assess actual harm such as the NCC MERP index. The researchers 
noted that using tools based on actual outcome might be impractical in a research situation 
from an ethical point of view where the research is expected to intervene. Although using 
potential outcome is then beneficial in that judgements could still be made without 
knowledge of the actual outcome, judgements are more subjective. 
Garfield and colleagues  found that most tools ranged from potentially or actually lethal, to 
minor/mild error, or no harm. Some tools included the highest level of severity as ‘severe,’ or 
‘harmful,’ and others adapted existing tools by expanding the levels to suit their studies. The 
researchers found that a measure of reliability was established for 17 of the 40 tools and 
validity was reported for only 5 tools. Two of the 40 tools were identified with acceptable 
validity and reliability – the NCC MERP index tool as adapted by Forrey et al who collapsed 
the nine levels into six, and Dean and Barber’s tool. Garfield et al surmised that Dean and 
Barber’s tool might be relevant for research purposes because it has been tested on larger 
sample sizes and its continuous scale can improve statistical analyses (Garfield et al., 2013). 
Dean and Barber’s tool (Dean & Barber, 1999), which has been successfully used in UK 
primary- care studies such as those of (Avery, Barber, et al., 2012; Barber et al., 2009; Dean 
Franklin & O'Grady, 2007), used generalizability theory to establish reliability – to obtain an 
acceptable generalizability coefficient, four reviewers or expert panel were needed to assess 
error severity. Their mean scores were subsequently used as the index of severity. Although 
this tool may be potentially time-consuming, a multi-disciplinary panel may be best suited to 
evaluating data on errors. 
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2.7 Framework for thesis 
The research process reported in this thesis was guided by a mixed methods approach as 
outlined below. 
The positivist approach described above was used to guide the experimental aspects of the 
research process. Positivism aims to discover laws using hypothetico-deductive or 
quantitative methods of enquiry. In this approach, the researcher systematically observes and 
measures phenomena, and the results of these investigations are to a large extent undistorted 
by the value judgement of the enquirer due to the availability of objective systems of 
measurements. The most popular tools, which are used in positivism, are surveys and 
experimental methods and statistical techniques of analyses. 
Experimental methods are applied in this study to the retrospective review of medical records 
and the prospective observation of pharmacists’ intervention on prescription errors, to 
investigate the prevalence and nature of prescribing errors in primary care. The data obtained 
is subjected to statistical analyses to describe phenomena. Although the aspect of the study, 
which sought to characterise the systems used by PCTs/CCGs to manage medication errors 
was studied using structured questionnaires, inductive analysis was applied to relevant 
aspects to produce a rich and insightful result. 
The severity assessment of the prescribing errors identified in this study was based on 
potential outcome as opposed to actual outcome and as such, may be subjected to the value 
judgment of the assessors – different people may produce different judgements. To reduce 
this, ‘case laws’ compiled by Avery et al (2012) were applied to the current study. 
The hypothetico-deductive method is not free from criticism. As Brown (1977), as cited in 
Bowling (2014) argued, refutation of hypothesis is not a sure process as it relies on 
observations, which may not necessarily be correct due to the challenges of measurement. As 
Bowling pointed out, investigators are always faced with the issue of accuracy of 
measurement when using experimental methods. The approach used by positivists to deal 
with the question of accuracy of the experimental method, based on the positivist belief that 
laws govern phenomena, and that these can be measured by following the principles of the 
scientific method, is known as Operationalism. Operationalism argues that the principles used 
in empirical research must be defined relative to the indicators used to measure them e.g. 
identifying prescribing errors based on a working or operational definition. Some scientists 
however argue that operationalization may be inadequate and somewhat misleading, leading 
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to problem of validity (Blalock and Blalock 1977) as cited in Bowling (2014). Validity asks 
the question “is the measure measuring what it purports to?” e.g. is the definition of 
prescribing error actually identifying prescribing errors? As such, Operationalism only 
provides flexible guidance to the research process and does not claim that the concepts are 
synonymous with the indicators of measurement although the researcher is faced with the 
problem of relating empirical concepts to theoretical concepts. 
Bowling (2014) outlined the important steps, which should guide quantitative research: issues 
of sampling and sampling methods and the principles, which guide quantitative surveys and 
the experimental analytic method. Bowling described the place of internal and external 
validity to judge the quality of experimental enquiries. Where appropriate, the appropriate 
steps were taken to ensure internal validity. 
 
2.7.1 Reliability and validity 
The reproducibility and consistency of the instrument of measurement is referred to as 
reliability. It measures the extent to which the instrument of measurement is standardised and 
free from random error and produce internal consistency and repeatability. Bowling identifies 
parameters, which need to be reviewed before an instrument could be judged as reliable. 
These included test-retest, inter-rater reliability and internal consistency. Repeatability is 
measured by test-retest procedures, which involves the administration of the instrument at 
different time periods, where the test conditions have not changed; inter-rater reliability can 
be used to determine the extent to which the results obtained by two or more observers agree 
when observing the same phenomenon. 
 
2.7.1.1 Validity 
After it has been satisfactorily subjected to repeated tests in the populations for which it was 
designed, an instrument is assigned validity. This is known as internal validity. External 
validity refers to the extent of generalizability of the research findings to the wider population 
of interest. External validity recognises that generalising a study’s results to a wider 
population of interest depends on the context of the study. It has an implication for applying 
the research findings in practice. Content validity refers to judgements (usually made by a 
panel) about the length to which the content of the instrument appears logically to observe the 
characteristic or phenomenon it is intended for. 
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Data collection tools used in this current study were previously validated and used in a 
previous UK study, the PRACtISE Study by Avery and colleagues (Avery, Barber, et al., 
2012). In a validation process, one of the supervisors retrospectively reviewed a 5% and 10% 
random sample each of the records of older patients ≥65 years and younger patients 0-12 
years respectively, which had been reviewed by the principal investigator. No disparities 
were recorded between the supervisor and investigator’s observations; therefore a 100% 
agreement was achieved. 
 
2.7.1.2 Threats to reliability and validity 
Various sources of threats to the reliability and validity of an investigation have been 
documented. These threats, known as biases and errors in the conceptualisation of the 
research idea, the design, sampling and process of the study, have the potential to result in 
systematic deviations from the true value (Last, 1988 as cited in Bowling, 2014). Biases and 
error can affect the experimental or quantitative research as well as social research. As such, 
all forms of research constantly attempt to reduce sources of bias and errors. The sources of 
bias identified in this research include the following: design bias, interviewer bias, non-
response bias, random measurement error, sampling bias, and systematic bias. Steps were 
taken to reduce the influence of these sources of errors, and others, on the current research 
process, analyses and conclusions. 
This thesis has drawn from previous studies examining prescribing and monitoring errors in 
primary care to explore the various methods available, and to address the research questions 
outlined at the end of the introduction chapter above. This section has discussed the context, 
theoretical framework, and methods to establish the investigator’s assumptions or 
philosophical reasoning in relation to the gaps in the literature and how they could be 
answered.  
A summary of the research questions and methodology used are outlined below in Table 1. 
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Table 1: Summary of study research questions and methodology used 
Research questions Methodology Rationalisation/ Method Outcome measures 
 What are the reported rates of 
different types of medication 
errors across the entire 
medication use process in 
primary care – in the UK and 
elsewhere 
 What are the interventions, 
which have been adopted in 
primary care to prevent 
prescribing errors. What 
interventions may be suitable 
to preventing some of the 
prescribing errors identified in 
the present study 
 Quantitative  
 Literature review 
of interventions to 
prevent 
prescribing errors 
in primary care 
and 
recommendation 
of pragmatic 
interventions to be 
used to prevent the 
errors identified in 
the current study 
 Identification of 
published research 
findings on 
medication errors in 
primary care 
 Identification of 
previously effective 
interventions and 
recommendations 
based on these 
 Systematic 
literature review 
 Reflection on the 
types and nature of 
errors identified in 
the current study 
and how 
interventions may 
prevent them 
 Definitions and methods 
used in studies/comparisons 
 Countries and settings 
 Prevalence and rates of 
errors reported; comparison 
of error rates 
 Critical appraisal of the 
methods reported 
 Interventions implemented 
in general practices and 
community pharmacies to 
identify and prevent 
prescribing errors 
What are the current systems and 
processes of managing 
(identification, recording and 
reporting) medication errors 
locally in the UK primary care  
Mixed method: 
quantitative method 
using structured 
surveys with 
qualitative, inductive 
Characterisation of the 
systems of error 
management in primary 
care at PCT/CCG levels 
pre/post-CCG creation 
Semi-structured postal 
survey 
Description existing protocols 
for identification, recording and 
reporting of medication errors 
at local authority level 
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analyses of data 
What are the characteristics of 
older patients and children with 
prescribing errors in general 
practice: patient demographics 
and drug use in these patient 
groups 
Quantitative Description of the 
patient population 
studied with respect to 
their demographics and 
patterns of drug use 
Review of patient 
medical notes in 
general practice using 
standardized and 
validated methods and 
forms 
Age distribution of study 
sample, patterns of drug use, 
therapeutic and BNF chapter 
categorisation of drugs used 
What is the prevalence and nature 
of prescribing errors identified in  
 Older patients 
 And children, in general 
practice 
Quantitative  Identification of 
potential 
prescribing errors 
 Description of error 
categories and type; 
severity assessment 
of potential errors 
 Review of patient 
medical records in 
general practice 
 Assessment of 
potential errors by 
expert panel  
 Nature and types of 
potential prescribing errors 
 Prevalence of prescribing 
errors per item and per 
patient 
 Severity ratings or scores 
What is the prevalence of 
prescription and medicines-
related problems identified from 
community pharmacists’ 
intervention on prescription errors 
Quantitative Identification of 
pharmacists’ 
intervention on 
prescription error: rates 
and nature  
Prospective review of 
prescriptions 
presented to 
community 
pharmacies 
 Prevalence and nature of 
prescription problems and 
medicines related problems 
in community pharmacies 
 Severity classification of 
problems identified 
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The table above provided a summary of the research questions in the study. The overall framework for the PhD is shown below in Figure 3. 
 
 
 
 
 
 
 
 
 
 
This chapter has reviewed the theoretical framework underpinning this thesis and provided a description of the philosophical paradigm adopted. 
The structure of the thesis has been outlined. 
Phase 1 Phase 2 
Study 1 
Literature review: 
define problem 
and makes 
interpretation 
Study 2 
Characterization of the systems and 
processes for error identification, 
recording and reporting within PCTs, 
CCGs and NHSE Area Teams 
Study 3 
Investigation of the prevalence and nature of prescribing and 
monitoring errors in general practice 
Study 4 
Investigation of the prevalence and nature of prescribing 
errors and medicines-related problems intercepted by 
community pharmacists 
Phase 3:  
Discussion: implications and 
recommendations of interventions 
to reduce medication errors based 
on the study findings 
Figure 3: Overall framework for the research 
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Chapter 3. Methodology  
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3.0 Methodology 
This chapter provides an overview of the general methods used in each phase and study of 
this research as outlined in Figure 3 above. Each study chapter further provides a detailed 
methods section. 
 
3.1 General method 
This study was an in-depth, multi-phase, and multicentre study to explore the safety of 
medication use in primary care. The study used a mixed methodology and was conducted in 
three phases. Phase one comprised a systematic literature review, and characterisation of the 
existing systems of and processes for medication error identification, recording and reporting 
by primary care organisations, formerly Primary Care Trusts, PCTs and Clinical 
Commissioning Groups, CCGs. Phase Two comprised a review of the definitions of 
prescribing errors in primary care leading to the adoption of a pragmatic and widely-accepted 
definition of a prescribing error for the purposes of this study. Phase Two also comprised the 
retrospective review of the clinical records of older patients and children in general practices 
(GP) surgeries to identify potential prescribing errors. Phase Two also comprised the 
prospective observation of community pharmacists’ interventions on medicines-related 
problems and an audit of their daily activities. Based on the findings from Phases one and 
two, practical recommendations were made to prevent the occurrence of medication errors in 
primary care organisations.  
 
3.2 Support and ethics application and approval 
The study was conducted following ethical approval from relevant healthcare organisations 
and support from associated healthcare professionals mainly general practitioners, practice 
managers and community pharmacists. Written support were obtained from 
 Luton CCG 
 Bedfordshire CCG 
 Harrow PCT 
 NHS South West London Primary Care (comprising of Croydon, Kingston, Richmond, 
Sutton & Merton and Wandsworth CCGs) 
 Kingfisher Practice in Crawley Green, Luton CCG 
 80 
 Salisbury House Surgery in Leighton Buzzard, Bedford CCG 
 Lloyds Pharmacy, Hitchin Road, Stopsley, Luton CCG 
 Lloyds Pharmacy, Leighton Buzzard, Bedford CCG 
 Royal Pharmacy, Luton CCG (see appendices) 
 
Application for ethical approval was sought and obtained from the Health Research 
Authority’s (HRA) National Research Ethics (NRES) Committee East of England – 
Cambridge Central following a review meeting attended by the research degree student and 
supervisors on 11th May 2012. Provisional approval was obtained on the 29th of May 2012 
(Appendix 10) and a favourable opinion obtained on the 27th of September 2012 (see 
appendices for protocol approved by ethics).  
At the point of seeking approval from the individual Research and Development (R and D) 
departments of the then PCTs, the R and D departments of Luton CCG and NHS South 
London raised concerns on the intention of the study to access medical records without 
patient consent.  They then suggested to the study to either seek patient consent or apply to 
the then National Information Governance Board (NIGB) now the HRA Confidentiality 
Advisory Committee (HRA CAG), for section 251 support. 
Section 251 of the NHS Act 2006 re-enacted Section 60 of the Health and Social Care Act 
2001. The terms Section 60 and Section 251, when used in relation to use of patient 
information therefore refers to the same powers. These powers allow the Secretary of State 
for Health to make regulations to set aside the common law duty of confidentiality for 
medical purposes where it is not possible to use anonymized information and where seeking 
individual consent is not practicable. Under the Health and Social Care Act 2008, 
responsibility for administering these powers was transferred from the Patient Information 
Advisory Group to the HRA. Section 251 came about because it was recognised that there 
were essential activities of the NHS, and important medical research, that required use of 
identifiable patient information but because patient consent had not been obtained to use 
people's personal and confidential information for these other purposes, there was no secure 
basis in law for these uses.  
Due to the intended number of medical records that were going to be reviewed, it was 
impractical to seek patient consent. Moreover, the concept of medication error research may 
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be unnecessarily unnerving for patients and practitioners. Therefore, an application was made 
on the IRAS to the NIGB for ‘section 251 support,’ for exemption from seeking patient 
consent. Completing the IRAS forms for the NIGB application however, meant that sections 
of the REC form would be amended. As such, the REC, who had initially granted full 
approval to the study, changed the approval from final to provisional in December 2012 
pending the results of the NIGB application.  
Application was made to the NIGB in February 2013. Similar to the REC, NIGB meets about 
once in two months, and this schedule translated into delays. Approval was finally obtained 
on the 11th of June 2013 (Appendix 11). 
The normal time scale for ethics approvals was usually within three to five months. However, 
due to the extensive changes in the NHS primary care structure through the abolition of PCTs 
and formation of CCGs, full ethical approval from the HRA NRES, HRA CAG, PCTs/CCGs, 
and their respective R and D departments took over ten months. The HRA NRES does not 
support any data collection prior to full ethical approval. 
The research team had on-going communication and engagement meetings with the 
participating CCGs to establish links with the leads in the face of the transition of PCTs to 
CCGs. Discussions and presentations on study administration and strategies for recruitment 
of practices and pharmacies dominated those meetings. While waiting for the HRA CAG’s 
response, an audit protocol was developed as a back up plan and tested with Luton CCG. 
 
3.3 Study design 
3.3.1 Phase 1 Study 1: Systematic literature Review 
A systematic literature review and critical appraisal of studies on medication errors and 
interventions implemented in primary care to prevent errors was undertaken. The following 
databases were searched: PubMed, ISI Web of Knowledge (Web of Science), Scopus, 
Science Direct, Google Scholar, Medline, CINAHL (Cumulative Index to Nursing and Allied 
Health Database), International Pharmaceutical Abstracts, Embase, PsycINFO, PASCAL, 
COCHRANE. There was a preference for peer-reviewed journals. Relevant unpublished 
works, such as doctoral thesis were also searched for. The search terms comprised two 
themes namely medication errors and primary care, while secondary care was excluded. 
Inclusion and exclusion criteria are outlined below: 
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a) Search was limited to studies published in English Language 
b) Search was not be restricted to the UK to gain an international perspective 
c) “Medication error” was used as Medical Search Heading (MeSH) term and 
keyword 
d) Articles covered broad topics including definition of ME, incidence and 
prevalence, types, intervention and outcome measures 
e) The reference lists of relevant papers were reviewed to identify other articles 
f) The search identified publications of established authors in the field of medication 
safety 
g) Studies focusing on just a specific disease conditions or specific drugs were 
excluded 
h) Any study that mentioned the following were reviewed – definition, prevalence 
and incidence, interventions, safety climate and culture. 
Analysis: 
Summary of findings were presented in a table with headings including study aim and 
objectives, study population, definitions and methods used, and the findings. A discussion of 
the critical appraisal of the studies was produced. 
 
3.3.2 Phase 1 Study 2: Characterisation of PCTs, CCGs and NHS England systems for 
identification and learning from medication errors in primary care. 
The Heads of Medicine Management (HOMM) and Chief Pharmacists (CP) in each of 146 
PCTs, 108 CCG and 28 NHS England Areas were contacted by the research student to 
complete a postal questionnaire. A covering letter and a data collection pro-forma in the form 
of a questionnaire was sent out directly to the respondents with a pre-paid reply envelop to 
the research office. The covering letter provided a brief description of the study’s objectives, 
procedures, contact details of the researcher. The questionnaire contained the questions 
outlined in Appendix 12.  
Analysis: Quantitative data was entered onto the computer and analysed using Microsoft 
Excel. Qualitative data on the processes and protocols for error identification, reporting and 
interventions implemented to prevent errors were grouped and coded for inductive analysis. 
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3.3.3 Phase 2  
Study setting and recruitment of participants for Phase Two of the study are described below. 
3.3.3.1 Study Setting 
The study setting was purposively selected general practice surgeries and community 
pharmacies located within the geographical zones of conveniently sampled CCGs (formerly 
PCTS) namely Bedfordshire and Luton PCTs. When PCTs were abolished and CCGs created, 
further consent was sought from the new CCG structure. The study set out initially to recruit 
two general practices, one each of rural and urban settings with varying levels of deprivation, 
from three purposively selected CCGs (formerly PCTs) to represent general practices 
nationally. To achieve this, five Primary Care Trusts (PCTs) were approached. These 
included City and Hackney, Luton, Bedfordshire, Harrow PCTs, and NHS South West 
London. 
The CCGs were purposively selected based on the presence of a diversity of patient ethnicity 
and age groups within the communities. They represented a patient population diverse in 
socio-economic status (according to the National Statistics Socio-Economic Classification, 
NS-SEC, which provides an indication of socio economic indices based on occupation). The 
CCGs were selected because they include areas classified as most- and least-deprived Small 
Areas according to the English Indices of Multiple Deprivation (IMD), 2010. The sample size 
was selected within our available resources, and the presence of contacts known to the 
supervisory team. General practices and community pharmacies were recruited as outlined 
below. City and Hackney PCT declined participation citing conflicting on-going projects as 
the reason. NHS South West London, Bedfordshire and Luton CCGs gave their consents to 
participate, and the study was eventually conducted in Bedfordshire and Luton CCGs due to 
time constraints 
3.3.3.2 Recruitment of general practice (surgeries) 
Luton and Bedford CCG were approached to provide the research student with a full list of 
the general practices and community pharmacies within their wards. From the list obtained 
from Luton, all general practices in their geographical zones were invited to express their 
interest to participate in the study by sending out an invitation letter to each of them. As 
response was very low (only two general practices responded), the research team decided to 
recruit a convenient sample of general practices and community pharmacies in both CCGs. 
Invitation letters and practice information sheets provided a brief description of the aim and 
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objectives of the research, and how the study would contribute to their practices. 
Additionally, the information sheet gave a summary of how the study would affect the 
practices. Practices were selected based on the following inclusion and exclusion criteria: 
a) Up to two practices per PCT will be selected – one of a more “rural” location, and 
the other “urban” based on NS-SEC classification and IMD 2010. 
b) Practices who hold electronic patient medical records will be recruited 
c) Practices will be easy to access by public transport. 
d) Practices who do not keep electronic records of prescriptions will be excluded. 
e) Practices that do not have the space to enable the research student to review 
patient records for the purposes of the study will be excluded. 
 
3.3.3.3 Recruitment of community pharmacies 
Community pharmacies within a 2-mile radius of the recruited surgeries were conveniently 
sampled by direct approach to invite them to participate in the study. The 2-mile radius was 
set to allow the study to focus on small “cohorts” of surgeries and pharmacies who were very 
likely to work closely together to meet patients’ needs. In the UK, patients are more likely to 
fill their prescriptions at pharmacies within this distance of their surgeries, which are usually 
located close to their dwellings. Of six pharmacies, three each within Luton and Bedford 
CCGs, three gave their consent to participate. The invitation letter and Pharmacy Information 
sheets provided relevant information similar to those used to recruit general practices. 
Inclusion and exclusion criteria were similar to those of the general practices as outlined 
above. 
 
3.3.3.4 Definitions of prescribing and monitoring errors used in study 
3.3.3.4.1 Prescribing error 
One of the preliminary objectives of the present study was to develop a general practitioner 
and primary healthcare professional-led definition of a prescribing error, which would 
hopefully form a foundation for both research and practice. Due to limited funds, and time 
pressures placed on the project by the abolition of Primary Care Trusts, PCTs and creation of 
CCGs, this objective was reviewed. A secondary deterrent was the potential of increasing the 
plethora of definitions in the literature. Following a systematic review of medication safety in 
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primary care with an element that reviewed the error definitions used, the present study 
adopted the definition of a prescribing error developed and validated by (Dean et al., 2000), 
and of a monitoring error by (Alldred et al., 2008). Although the definition of Dean et al was 
developed with UK secondary care in mind, it is widely applicable in primary care in the UK. 
This definition has been used in the Department of Health, DH report “Building a safer NHS 
for patients – improving medication safety (Department of Health, 2004), and has been 
successfully adopted in other studies (Dean et al, 2000; Sagripanti et al, 2002; Donyai et al, 
2007 and Franklin et al, 2007 in (Alldred et al., 2008). Researchers have successfully used 
this definition when they investigated the prevalence and nature of prescribing errors in 
primary care (Avery, Barber, et al., 2012). Furthermore, this definition was used by 11 of 65 
studies (Kane-Gill & Devlin, 2006) as cited in (Avery, Barber, et al., 2012). The definitions 
used are stated below: 
“A clinically meaningful prescribing error occurs when, as a result of a prescribing decision 
or prescription-writing process, there is an unintentional significant 
 Reduction in the probability of treatment being timely and effective, or  
 Increase in the risk of harm when compared with generally accepted practice” (Dean 
et al., 2000). 
 
3.3.3.4.2 Monitoring errors 
Alldred et al (2008) had observed that the evidence regarding how often a particular medicine 
should be monitored was sparse and information from various sources were often conflicting. 
A definition of monitoring errors was therefore developed and validated by Alldred et al, 
when they conducted a UK study on Care Home Use of Medicines (CHUMS). Along with 
their definition, researchers, general practitioners and clinical pharmacists collated a set of 
criteria, which were meant to be both practical and easy to use. The list was not intended to 
be exhaustive but focussed on drugs, which were most likely to be prescribed and had the 
potential for harm. The drugs or groups of drugs, which were included in the list, were judged 
to require monitoring in the primary care setting (Appendix 16).  
 
The core definition of a monitoring error as agreed by the study is: 
“A monitoring error occurs when a prescribed medicine is not monitored in the way which 
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would be considered acceptable in routine general practice. It includes the absence of tests 
being carried out at the frequency listed in the criteria, with tolerance of +50%. This means, 
for example, that if a drug requires liver function tests at 3 monthly intervals, we would class 
as an error if a test has not been conducted within 18 weeks. If a patient refused to give 
consent for a test, then this would not constitute an error” (Barber et al., 2009). The 
researchers chose to allow at 50% tolerance in the timing of tests because they felt it is a 
pragmatic and generous limit. These definitions were adopted in the current study. 
In their study of the prevalence and nature of prescribing errors in UK general practice, 
Avery and colleagues reflected on defining errors in practice: they described an evolving list 
of what is termed “case law” as required in addition to definitions. This case law is founded 
on the published list of examples of scenarios or cases of what should, and should not, be 
included as an error. The researchers noted that additional case law is likely to be needed as a 
study moves on. In previous studies, an adjudication panel has been used to draw up case law 
(Alldred et al., 2008; Dean et al., 2000). Appendix 18 contains examples of judgements made 
by the error-judging panel on scenarios identified as part of their study. This has guided by 
the present study. 
3.3.3.5 Assessment of severity of potential prescribing and monitoring errors 
Dean and Barber developed a visual analogue tool to predict the harm that would result from 
errors when the real-life outcome is unknown as in the present study (see Chapter 6 below). 
They used generalizability theory to predict the harm that would result from medication 
administration errors, and validated it by the blind assessment of errors with known 
outcomes. The method involves assessment of the potential clinical significance of identified 
errors by a panel of five judges using a visual analogue scale, which is numbered from 0 to 
10, with 0 representing an error with no clinical effects on the patient, and 10 an incident that 
would result in death. Errors with an average score less than 3 are classed as minor, 3-7 
inclusive as moderate, and errors with an average score of greater than 7 are severe. The 
present study has adopted the use of Dean and Barber’s visual analogue scale (see below) to 
assess the potential harm or severity of the prescribing and monitoring errors identified in this 
study (Dean & Barber, 1999). 
The NPSA patient safety incident severity rating scale is conventionally used to assess the 
severity of errors reported to the NPSA. This scale has also been adapted for severity 
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assessment of the potential errors identified in the current study as shown below, mainly to 
facilitate provision of feedback to participating organizations. 
 
Table 2: NRLS patient safety incident severity rating scale 
Severity Description 
No harm Impact prevented: any patient safety incident that has the potential to 
cause harm but which may be prevented, resulting in no harm to people 
receiving NHS-funded care 
Impact not prevented: any patient safety incident that has the 
potential to run to completion but no potential to cause harm occurring 
to people receiving NHS-funded care 
Low Any patient safety incident that has the potential to require extra 
observation or minor treatment and cause minimal harm, to one or 
more persons receiving NHS-funded care 
Moderate Any patient safety incident that has the potential to result in a moderate 
increase in treatment and which may cause significant but not 
permanent harm, to one or more persons receiving NHS-funded care 
Severe Any patient safety incident that has the potential to result in permanent 
harm to one or more persons receiving 
NHS-funded care 
Death Any patient safety incident that has the potential to directly result in the 
death of one or more persons receiving NHS funded care 
 
 
3.3.4 Phase 2 Study 3: Determination of the prevalence and nature of prescribing 
errors in general practice in older patients 65 years and over, and children 0-12 
years 
Using the definitions outlined above, the researcher, a clinical pharmacist conducted 
thorough retrospective review of random samples of electronic patient medical records 
(PMR) on Vision and SystmOne GP clinical computer systems in the two general practices, 
using forms used in a previous study of the prevalence of prescribing errors in primary care 
(Avery, Barber, et al., 2012). These GP clinical computer systems are used to store patients’ 
notes electronically. The data stored include all details of a patient’s medical history, acute 
and repeat medication records and the results of blood and other investigations, including 
electronically transmitted information from secondary care such as discharge notes. 
Sample size determination: In the PRACtISE Study, a 4.9% prescribing error rate was found 
from the retrospective review of case notes from a random sample of 2% of practice 
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registered patients. The study reviewed a total of 1,777 PMRs. Of these, 1,200 records had 
received a prescription for at least one medication in the 12-month data collection period 
(Avery et al., 2013). The advice of a University of Hertfordshire medical statistician was 
sought on determining an appropriate sample size for the current study. The statistician 
advised that determining sample size from the PRACtISE study was not appropriate as the 
study was not limited to the same age groups as in the current study. Based on these, the 
current study aimed to review a practical percentage registered older patients and children in 
the general practices. Based on the number of these patient groups registered in both 
practices, at least 10% sample was selected for review. 
The research degree student carried out review of patient medication record in the 12 months 
to data collection for the purposes of identifying potential prescribing errors. Only the 
medical records of paediatric patients (aged 0-12 years) and older patients (aged 65 years and 
above) were reviewed. The selection of the study age groups was based on suggestions in the 
literature that these patients were more susceptible to higher error rates. Within these age 
groups, patients’ records were randomly selected using randomization table generated by the 
researcher from www.randomizer.org. 
The research data from the clinical retrospective review of patients’ electronic records was 
validated by one of the supervisors of the project. The supervisor selected a random sample 
of the records of older patients (2%) and children (10%), which were reviewed in each 
practice. The supervisor then reviewed these records. There were no disagreements with the 
research data collected by the research degree student. The data entered onto the Access 
database was reviewed against original data collection forms in a data cleansing process. 
Prescribing errors were assessed for potential harm by a panel of three pharmacists from 
clinical, community and academic pharmacy backgrounds using Dean and Barber’s tool for 
assessing the severity of prescribing errors.  
During their study of the Prevalence and Nature of Medication Errors in Primary Care, Avery 
et al (2012) developed a detailed list of “case law,” following discussions by a multi-
disciplinary error-judging panel. This list described what should, and should not, be included 
as an error, alongside rationale of these decisions. It was used throughout the study to ensure 
that judgements made by the researcher were reliable and appropriate (Appendix 18). This list 
of “case law” was also presented to the panel in the current study to provide some training in 
error-judging for the purposes of the study, and to ensure that their judgements were 
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comparable with the most recent study by Avery et al, which was commissioned and 
published by the General Medical Council (GMC) to improve prescribing practices in UK 
primary care. It was hoped that the media and professional attention given to the findings of 
the study would have influenced prescribing practices, and that the judgements in the current 
study were therefore reliable and appropriate.  
Some of the principles established in the development of the “case laws” were: each 
prescription could be associated with more than one error; an overdose associated with the 
addition of two or more items was considered one error; drug interactions were recorded 
against the second of the two drugs affected to avoid duplication; dosing and frequency errors 
were combined as one to dose/strength error; no error documented if incomplete information 
meant that a decision could not be reached as to whether an error had taken place or not 
(Avery, Barber, et al., 2012).  
Potential errors were compiled and presented in a questionnaire format and presented to the 
judges. The use of the two tools outlined above allowed comparison of results. 
Analysis: All error data were coded and entered onto an Access database, and exported to 
Microsoft Excel for descriptive analyses. The overall prevalence of prescriptions errors was 
calculated and presented along with 95% confidence interval (CI). The different types of 
errors detected were presented. Appendix 19 presents the analysis framework, which guided 
the study and Appendix 17 shows the typology of errors used. 
Limitations: the data was collected in two practices, which makes the findings difficult to 
generalise. 
 
3.3.5 Phase 2 Study 4: Observation of pharmacists’ interventions on prescriptions 
errors and MRPs in community pharmacies, and observation of pharmacists’ 
daily activities 
Prospective observation of community pharmacists’ interventions on prescription errors and 
medicines-related problems (MRPs) was conducted. Three MPharm (final year MSc 
Pharmacy students) collected the community pharmacy data. The research student coached 
MPharm final year students to audit the role and activities of the pharmacists in prescription 
reviews and queries, and other MRPs identified by the pharmacist using forms used in in 
previous MPharm projects. Direct observation of the pharmacists’ activities allowed the 
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collection of rich data unlikely to be recorded from spontaneous reports by pharmacists, 
particularly during dispensary busy hours. Information on patients’ demographics and 
detailed description of detected problems were recorded. Origin of the prescription, type, 
medication involved, pharmacist intervention and an estimate of the time it took to resolve 
the problem were recorded. The incidence rates reported from a previous observational audit 
of medicines-related problems in three pharmacies were 1.5% per prescriptions and 0.8% per 
items. Based on these figures, the current observation was not limited to paediatrics (0 to 12 
years) and older (65 years and over) patients though the analyses will involve reviewing the 
patient age groups susceptible to MRPs. 
Analysis: based on their training and experience, the community pharmacists and researcher 
supported MPharm students to classify MRPs as mild, moderate or severe. Incidence rates 
and their corresponding 95% CI were determined using standard methods. Items and 
prescriptions dispensed were used as denominations in determining error rates. 
3.4 Pilot study 
The purpose of the pilot study or preliminary fieldwork was to assess the feasibility of the 
methods outlined, and the practicality of the data collection instruments. The pilot studies in 
the general practices and community studies did not identify any need to review the data 
collection instruments. As such, the results of the pilot study were analysed with the main 
study. However, study arrangements were adjusted as summarised below: 
Study 2: PCT/CCG error management systems 
The study had intended to send the survey electronically via email. To obtain the email 
addresses of the relevant person, phone calls were made to about 30 PCTs initially. However, 
it proved difficult and near impossible to obtain the email addresses of potential respondents, 
the Clinical Governance Leads. It was therefore decided to send the questionnaire by post. 
Another challenge, which was encountered, was identifying the most relevant person or role 
to address the questionnaire to. Although the questionnaire was initially designed with 
“Clinical Governance Leads” as the potential respondents, following the telephone 
conversations to PCTs, it became apparent that various titles were used for similar roles 
between PCTs. Since the survey was therefore invariably aimed at any member of the PCT or 
CCG dealing with medication incidents, it was difficult to ascertain exactly who should be 
completing the questionnaire. It was therefore decided to mail the questionnaire to both the 
“Heads of Medicines Management” and “Chief Pharmacists” as these were the most relevant 
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titles. Each questionnaire was marked with a unique code to ensure that more than one 
questionnaire was not recorded for any organisation, although the study did not receive more 
than one response from any PCT/CCG eventually. 
Study 3: Retrospective review of the electronic clinical medical records of older patients and 
children in general practices 
No amendments were required for the data collection forms. As such, data from the pilot 
study was analysed with the main study. To analyse data from the pilot study, an Access 
database was created specifically for the current study. It was however not practical to use the 
database as forms were originally designed to be independent of each other. The researcher 
therefore decided to obtain permission from the authors of the PRACtISE study to use an 
erstwhile database. Consent was obtained, and the database was adapted to suit the current 
study.
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4.0 Systematic literature review: Safety of medication use in primary 
care 
4.1 Abstract 
4.1.1 Background 
Medication errors are one of the leading causes of harm in healthcare. Review and analysis of 
errors have often emphasized their preventable nature, and potential for re-occurrence. In the 
past decade, research has focussed on estimating the scale of medication errors and 
prevention. Much of this work has been in secondary care, which is associated with high-risk 
procedures and the use of high-risk medicines. However, patients receive most of their 
healthcare needs in primary care. Of the few error studies conducted in primary care to date, 
most have focussed on estimating the incidence, describing the nature of individual parts of 
the medicines management system, and evaluating individual error-prevention strategies. 
Studying individual parts of the system does not provide a complete perspective and may 
further weaken the evidence and undermine interventions. 
4.1.2 Aim and Objectives 
This study reviewed the existing literature on the incidence of medication errors in primary 
care across the entire medicines management system. The objectives were:  
1. To appraise studies addressing medication error rates in primary care 
a. To report error rates at each point of the system 
b. To appraise the methods used to identify errors in the studies 
c. To identify of the most susceptible points and patient groups 
d. To compare error rates between healthcare settings, and  
2. To identify studies on interventions to prevent medication errors in primary care. 
 
4.1.3 Methods 
A systematic search of the literature related to medication errors in primary care was 
performed in the following databases: PubMed (MEDLINE), International Pharmaceutical 
Abstracts (IPA), Embase, PsycINFO, PASCAL, Science Direct, Scopus, Web of Knowledge, 
and CINAHL PLUS from 1999 to November, 2012. Bibliographies of relevant publications 
were searched for additional studies. 
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4.1.4 Results 
Thirty-three studies estimating the incidence of medication errors, and thirty-six studies 
evaluating the impact of error-prevention interventions in primary care were identified and 
reviewed. Studies stating definitions and methods used, and those measuring the impact of 
interventions were included. This review demonstrated that medication errors are common, 
and occur at every stage of the process, with error rates between < 1% and >90%, depending 
on the part of the system studied and the definitions and methods used. The prescribing error 
rate in primary care in the UK was between 4.9% and 8.3%. It was difficult to directly 
compare error rates between studies due to differing units of measurement and sampling 
methods. There is some evidence that the prescribing stage is the most susceptible, and that 
the elderly (over 65 years), and children (under 18 years) are more likely to experience 
significant errors, although little research has focussed on these age groups. Individual 
interventions such as medication reconciliation or pharmacist-led interventions demonstrated 
marginal improvements in medication safety when implemented on their own but had more 
impact when jointly implemented. The overall safety and quality of the medication system 
could be improved by adopting a holistic approach to management and interventions. 
4.1.5 Conclusion 
Targeting the more susceptible population groups and the most dangerous aspects of the 
system may be a more effective approach to error management and prevention in primary 
care. Co-implementation of existing interventions at points within the system may offer time- 
and cost-effective options to improving medication safety in primary care. 
Keywords: Medication error (and related terms) and primary care (and related terms); not 
secondary care (and related terms). 
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4.2 Introduction 
Medical error and patient safety have been the subjects of discussions for government bodies, 
healthcare organizations, the media, researchers and patients in the past decade. The 
American Institute of Medicine (IOM) report, “To err is human”, describes the harmful, 
common, expensive and, importantly, the preventable nature of medical errors (Kohn et al., 
1999). A UK Department of Health (DH) report, “An organization with a memory: learning 
from adverse events in the NHS (National Health Service)” (Department of Health, 2000), 
emphasises the importance of learning from errors based on their potential for reoccurrence. 
These government reports underscore the need for a paradigm shift in safety culture within 
healthcare teams and organisations, the role of teamwork, and active reporting. The USA, 
UK, World Health Organization and many developed countries including Australia and 
Denmark, have identified that priority needs to be given to improving patient safety and 
outcome (Britt et al., 1997; Department of Health, 2000, 2004; Thomsen et al., 2007; World 
Health Organisation, 2002). 
Medication errors are one of the most common types of medical errors resulting in patient 
morbidity and mortality (Aronson, 2009b; Department of Health, 2008; Garfield et al., 2009; 
Vincent, 2010). Much of the research conducted on medication safety has focussed on the 
secondary care setting because of its associated high-risk procedures such as blood 
transfusion, surgery and the potential for hospital-acquired infections (Garfield et al., 2009). 
However, a few studies have indicated that patient safety incidents in hospitals take their 
roots from primary care management (Pirmohamed et al., 2004). 
The medicines management process differs between secondary and primary care owing to 
variations in practitioner, patient and process features with implications for error potential. 
For example, in secondary care, there is close co-working amongst healthcare professionals – 
doctors, nurses, pharmacists – and medication administrations and reviews occur in 
collaboration. In primary care however, patients come into contact with these health care 
professionals at different times and places, and mostly self-administer their own medicines. 
Patients may frequent multiple pharmacies in primary care presenting challenges for 
medicines reconciliation (Gandhi et al., 2005). Medication monitoring in primary care is 
further complicated by relying on the patient to organise and book follow-up appointments 
(Gandhi et al., 2002). A World Health Organization (WHO) body, World Alliance for Patient 
Safety, concludes that inadequate or inappropriate communication and coordination are major 
priorities for patient safety research in developed countries (Kennedy et al., 2011).  
 96 
Medication error studies evaluate whether a medicine is correctly handled within the 
medicines management system, which comprises of prescribing, transcribing, dispensing, 
administration and monitoring stages (Aronson, 2009b; Avery et al., 2002; Vincent, 2010). 
An Adverse Drug Event (ADE) is said to occur when patient harm is caused by the use of 
medication – a preventable ADE therefore may occur as a result of a medication error 
(Aronson, 2009a; Aronson, 2009b). The specific rates of medication errors (and preventable 
ADEs) are unknown; most errors in medication go unnoticed. Of those identified, few result 
in patient harm (Campbell & Cantrill, 2001). For instance, of a prescribing error rate of 1.5% 
detected in 36,200 medication orders in a UK hospital, only 0.4% orders contained a serious 
error (Dean et al., 2002). In a recent UK primary care study, 4.9% prescriptions contained a 
prescribing or monitoring error when the medical records of 1,200 patients from 15 general 
practices were reviewed (Avery, Barber, et al., 2012); of these, 1 in 550 (or 0.18%) of all 
prescriptions was judged to contain a severe error. In a UK study of 55 care homes, although 
69.5% of all residents had one or more errors, the mean potential harm from errors in 
prescribing, monitoring, administration and dispensing were 2.6, 3.7, 2.1 and 2.0 (0 = no 
harm; 10 = death) respectively (Barber et al., 2009). These seemingly ‘low’ values of actual 
harm are better understood when interpreted in terms of the high volumes of prescriptions 
issued daily within any healthcare system. Even more so, associated patient morbidity and 
mortality is simply unquantifiable. 
The preventable nature of medication errors, and the potential for re-occurrence are perhaps 
their most important characteristics. These attributes underpin medication safety concepts 
such as error reporting and learning, and the development and implementation of prevention 
strategies, as errors are often the results of the systems that produce them (Leape et al., 1995). 
A few studies have estimated the preventability of medication errors in primary care 
(Abramson, Bates, et al., 2011; Gandhi et al., 2003; Gurwitz et al., 2003; Kaushal et al., 2007; 
Knudsen et al., 2007a; Kuo et al., 2008; Lynskey et al., 2007; Martínez Sánchez & Campos, 
2011; Miller et al., 2006). In the UK, approximately 5% admissions to secondary care have 
taken their roots from preventable drug-related problems at an estimated cost of over £750 
million per year to the NHS (Department of Health, 2008). A healthcare system, with safety 
and quality at its heart, is therefore expected to capture errors, and most importantly, prevent 
re-occurrence. 
System thinking has underpinned successful investigations into sub-optimal patient care – the 
events of the Bristol Royal Infirmary in the UK sparked an investigation, which focussed on 
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evaluations of the system rather than the events in isolation (Vincent, 2010). Most error 
studies focus on individual points within the medicines management system, instead of 
adopting critical and holistic evaluations of the whole system of the use of medicines 
(Garfield et al., 2009). Similarly, interventions have often concentrated on improving 
individual parts of the system. For instance, automation in hospital pharmacies has aimed at 
improving the dispensing process (Dean Franklin et al., 2008), – even though other parts of 
the system may also benefit from some form of automation . This individualistic approach 
fails to recognise that errors are indeed the results of the systems that produce them and does 
not provide information on the relationship between the units that make up the system (Leape 
et al., 1995; Reason, 2000). 
To date, there have been few systematic reviews to appraise the safety of the entire 
medication use system in primary care across healthcare systems. 
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4.3 Aim and objectives of review 
This paper reviewed the existing literature on the incidence of medication errors in primary 
care across the entire medicines management system. The objectives were:  
1. To appraise studies addressing medication error rates in primary care 
a. To report error rates at each point of the system 
b. To appraise the methods used to identify errors in the studies 
c. To identify of the most susceptible points and patient groups 
2. To identify studies on interventions to prevent medication errors in primary care. 
 
4.4 Methods 
4.4.1 Data sources 
Electronic databases of MEDLINE, International Pharmaceutical Abstracts (IPA), Embase, 
PsycINFO, PASCAL (searched together on Wolters Kluwer/OVID SP platform in the British 
Library, BL), Science Direct, Scopus, Web of Knowledge and CINAHL PLUS were 
searched. The choice of databases was based on the BL resources in Medicine and 
Healthcare, University of Hertfordshire Medicines-related database recommendations, and 
relevant publications. Reference lists of retrieved articles and relevant review articles were 
checked manually for further relevant studies. 
 
4.4.2 Search terms and strategy 
An initial scoping review retrieved 2,530 hits after removal of 450 duplicates. Following 
screening of the first 350, over 200 articles were secondary care-related studies; 
subsequently, a revised search strategy excluded secondary care terms. Furthermore, the term 
“adverse drug event” was used as a medication error search term. This returned over 10,000 
additional results. The first 300 articles were related to the harm due to drug use. However, 
this review aimed to identify failures in the medication use process in order to provide an 
overview of the overall reliability, efficiency and safety.  
The search strategy, tailored for each database, therefore included two concepts, medication 
error and primary care, and excluded a third, secondary care (see Table 3). “Medication error” 
was used as MeSH term and keyword. A hand search of key journals, which included 
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International Journal of Pharmacy Practice (IJPP), Quality and Safety in Healthcare, and 
Pharmacy World and Science, was also performed. 
 
4.4.3 Selection criteria 
Studies conducted in any country between January 1999 and November 2012 and reported in 
English, were included. Studies, which reported the frequency of errors in the medicines 
management process, and interventions to prevent errors, were included. All definitions of 
error such as inappropriate prescribing, prescribing-, dispensing-, administration- and 
monitoring- errors, irrational drug use, hazardous prescribing, drug interactions, were 
included. Studies estimating error rates of one medication or therapeutic group, and those that 
did not report the method used for collecting error data or evaluating interventions were 
excluded.  
The first author (JGO) screened all titles and abstracts to determine whether the article met 
the inclusion criteria and should be retrieved. Another reviewer (MG) screened a random 5% 
sample to check the reliability of the screening. JGO then read and extracted data from the 
articles included in this review. 
 
4.4.4 Process of data extraction 
Search results were exported to Endnote X5 (Thomson Reuters). Duplicates were removed. 
Article titles and abstracts were initially reviewed for relevance followed by actual article 
review to clarify any ambiguities. Information from incidence studies was extracted onto a 
pro-forma showing primary author, year of publication, study design and setting, sample size, 
error type, error definitions and reported error rates (Appendix 20). Intervention studies were 
grouped into broad categories (Table 4).   
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Table 3: Search terms 
Medication error terms  
 
 
 
 
And 
Primary healthcare terms 
 
 
 
 
 
 
Not 
Secondary care- 
terms 
Medication error, prescribing 
error, dispensing error, 
medication administration 
error, transcription error, drug 
error, drug mishap, 
medication mistake, 
medication mishap, 
dispensing mistake, 
prescribing mistake, wrong 
drug, wrong dose, incorrect 
drug, incorrect dose, drug 
death. 
Primary care, primary 
healthcare, general 
practice, family practice, 
patient admission, 
patient discharge, 
continuity of patient 
care, doctors’ office, 
ambulatory care, surgery. 
Secondary care, 
secondary 
healthcare, 
inpatient, hospital, 
ward, emergency 
department. 
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Number of articles 
retrieved from 
electronic search = 
1,755 
Number of 
duplicates 
removed = 583 
Number of articles 
after duplicates 
removed = 1,172 
Number of articles 
excluded after title 
screening = 862 
 Articles, letter, case 
series etc. = 10 
 Other medical errors = 
40 
 Study/article limited to 
one medication, 
therapeutic group or 
disease condition = 205 
 Study/article based in 
secondary care = 110 
 Study/article irrelevant 
to medication errors in 
primary care = 497 
Number of articles 
related to the safety 
and quality of 
medication use in 
primary care = 310 
Number or 
articles excluded 
after abstract 
screening review 
= 161 
 Expert opinions, 
articles, letters, case 
series, etc. = 42 
 Other articles/studies 
on the safety of 
medication use in 
primary or ambulatory 
care = 102 
 Abstract/full text 
unavailable = 14 
 Articles on studying 
medication safety in 
primary care = 3 
Number of full 
articles evaluated = 
149 
Number of 
articles excluded 
from review = 81 
 Causes/influences on 
medication errors = 2 
 Cost of errors = 2 
 Detection/classification/d
efinition = 16 
 Discharge and admission 
interface = 8 
 Qualitative studies = 20 
 Reporting/recording = 14 
 Safety culture and 
organizational culture 
and errors = 7 
 Systematic literature 
reviews = 12 
Number of articles 
included after 
evaluation  = 68 
 Incidence/rate/prevalence 
of medication errors in 
primary care = 32 (+1) 
 Interventions to reduce 
medication errors in 
primary care = 36 
Figure 4: Flow chart of titles screening 
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4.5 Results 
The output of the search process is shown in Figure 3. Thirty-two studies, which estimated 
the incidence of medication errors in primary care were identified; a manual search retrieved 
one additional study (Avery, Barber, et al., 2012). Thus, thirty-three studies were identified 
and reviewed. 
Summary of studies reviewed on the incidence of medication errors in primary care is shown 
in Appendix 20. 
 
4.5.1 Incidence of medication errors in primary care 
Of the studies reviewed, twelve were conducted in the USA, ten in the UK, two in Bahrain, 
one each in Malaysia, Italy, Germany, Saudi Arabia, Denmark, Spain, India, Australia and 
Ireland between 1995 and 2013, and published between 1999 and 2012. Prescribing error 
rates were comparable across countries in some instances – Bahrain – 7.7% prescriptions (Al 
Khaja et al., 2005); UK 7.5% & 5% prescriptions (Avery, Barber, et al., 2012; Shah et al., 
2001); USA 7.6% &11% prescriptions (Gandhi et al., 2005; Nanji et al., 2011); India 6.1% 
items (Marwaha et al., 2010) and Ireland 6.2% prescriptions (Sayers et al., 2009). 
Figure 5: Country distribution of studies 
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Study distribution by countries
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Of the studies reviewed, nine were conducted in primary care centres (general practices). Ten 
of the studies were conducted in the community pharmacy setting, ranging from one to 1,146 
pharmacies (Al Khaja et al., 2007; Ashcroft, Quinlan, et al., 2005; Chua et al., 2003; Dean 
Franklin & O'Grady, 2007; Flynn et al., 2009; Hämmerlein et al., 2007; Knudsen et al., 
2007a; Lynskey et al., 2007; Martínez Sánchez & Campos, 2011; Warholak & Rupp, 2009). 
Two studies were conducted in care facilities – aged care (Carruthers et al., 2008), and 
nursing or residential homes (Barber et al., 2009). Two studies each estimated medication 
error rates in elderly patients (Carruthers et al., 2008; Gurwitz et al., 2003) and paediatrics 
(Al Khaja et al., 2007; Kaushal et al., 2010). One study was conducted in the primary care 
setting of a university (Dhabali et al., 2011). 
 
The parts of the medication management system studied were sometimes apparent from the 
article title, aims or objectives; other times, they were inferred from the methods reported or 
the results presented. The part of the medication system studied comprised the prescribing 
stage (26 studies) (Abramson, Bates, et al., 2011; Al Khaja et al., 2007; Al Khaja et al., 2005; 
Avery, Barber, et al., 2012; Barber et al., 2009; Chen, Avery, et al., 2005; Dhabali et al., 
2011; Gagne et al., 2008; Gandhi et al., 2003; Gandhi et al., 2005; Gurwitz et al., 2003; 
Hämmerlein et al., 2007; Kaushal et al., 2010; Kaushal et al., 2007; Khoja et al., 2011; 
Knudsen et al., 2007a; Kuo et al., 2008; Lasser et al., 2006; Lynskey et al., 2007; Martínez 
Sánchez & Campos, 2011; Marwaha et al., 2010; Nanji et al., 2011; Runciman et al., 2003; 
Sayers et al., 2009; Shah et al., 2001; Warholak & Rupp, 2009), transcription (4 studies) 
(Dean Franklin & O'Grady, 2007; Kaushal et al., 2010; Knudsen et al., 2007a; Martínez 
Sánchez & Campos, 2011), dispensing (10 studies) (Ashcroft, Quinlan, et al., 2005; Barber et 
al., 2009; Carruthers et al., 2008; Chua et al., 2003; Dean Franklin & O'Grady, 2007; Flynn et 
al., 2009; Hämmerlein et al., 2007; Knudsen et al., 2007a; Kuo et al., 2008; Lynskey et al., 
2007), monitoring (8 studies) (Avery, Barber, et al., 2012; Barber et al., 2009; Gandhi et al., 
2003; Gurwitz et al., 2003; Kaushal et al., 2010; Knudsen et al., 2007a; Kuo et al., 2008; 
Lasser et al., 2006) and administration(10 studies) (Barber et al., 2009; Field et al., 2007; 
Gandhi et al., 2003; Gurwitz et al., 2003; Hämmerlein et al., 2007; Kaushal et al., 2010; 
Kaushal et al., 2007; Kuo et al., 2008; Lynskey et al., 2007; Szczepura et al., 2011).  
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Figure 6: Number of studies at each stage of the medication management system in 
primary care 
 
 
The studies used differing methods to collect error data. These methods were either 
retrospective or prospective and varied with the part of the medicines management system 
being studied:  
Studies, which evaluated prescribing or monitoring errors, used one of these methods: patient 
clinical record reviews (Abramson, Bates, et al., 2011; Avery, Barber, et al., 2012; Barber et 
al., 2009; Chen, Avery, et al., 2005; Dhabali et al., 2011; Gandhi et al., 2003; Gandhi et al., 
2005; Gurwitz et al., 2003; Kaushal et al., 2010; Khoja et al., 2011; Lasser et al., 2006), 
prescription audits (Abramson, Bates, et al., 2011; Al Khaja et al., 2007; Al Khaja et al., 
2005; Gandhi et al., 2005; Hämmerlein et al., 2007; Kaushal et al., 2010; Khoja et al., 2011; 
Lynskey et al., 2007; Martínez Sánchez & Campos, 2011; Marwaha et al., 2010; Nanji et al., 
2011; Sayers et al., 2009; Shah et al., 2001; Warholak & Rupp, 2009), incident reports 
reviews (Chua et al., 2003; Knudsen et al., 2007a; Kuo et al., 2008), patient surveys or 
interviews (Gandhi et al., 2003; Gandhi et al., 2005; Kaushal et al., 2010), and claims reviews 
(Gagne et al., 2008).  
There were important variations even within methods; for instance, retrospective prescription 
reviews were conducted by reviewing patient medical records (Avery, Barber, et al., 2012), 
0 5 10 15 20 25 30
 Prescribing
Monitoring
 Transcribing
Dispensing
 Administration
Number of studies evaluating stage 
 105 
through pharmacists’ screening and intervention (Lynskey et al., 2007), or researchers’ 
screening and/or observations (Abramson, Bates, et al., 2011; Al Khaja et al., 2007).  
Dispensing errors were evaluated using one of these methods: direct observations of 
dispensing activities (Ashcroft, Quinlan, et al., 2005), retrospective examination of dispensed 
medicines (Barber et al., 2009; Carruthers et al., 2008; Dean Franklin & O'Grady, 2007; 
Flynn et al., 2009), incident reporting (Kuo et al., 2008), and review of self-reported incidents 
and ‘near misses’ (Chua et al., 2003; Hämmerlein et al., 2007; Knudsen et al., 2007a; 
Lynskey et al., 2007).  
It was sometimes difficult to interpret the methods used to detect and evaluate administration 
errors; of those clearly stated, the methods used were direct observation (Barber et al., 2009), 
retrospective review of administration data (Kuo et al., 2008) or patient records (Field et al., 
2007; Gurwitz et al., 2003), barcode systems (Szczepura et al., 2011), patient surveys and/or 
self-reports (Gandhi et al., 2003; Hämmerlein et al., 2007; Kaushal et al., 2010). 
Three studies used more than one method to evaluate medication errors – in one study, 
prescriptions and clinical records were reviewed to evaluate prescribing errors (Abramson, 
Bates, et al., 2011); in another, patient surveys and medical record review were both used to 
study monitoring errors (Barber et al., 2009);  and finally one study used, medical record 
reviews and healthcare professional interviews to detect and evaluate prescribing and 
monitoring errors (Avery, Barber, et al., 2012). 
 
Of the studies reviewed, only a few studies stated the error definition used (Table 2). Two 
studies, which used the same definitions of prescribing and monitoring errors, had common 
authors (Avery, Barber, et al., 2012; Barber et al., 2009).  
 
Varying denominators were used to calculate and determine error rates. As such, the units of 
expression varied between studies. Studies reviewed expressed error rates as: a percentage of 
– total prescriptions (Abramson, Bates, et al., 2011; Al Khaja et al., 2007; Al Khaja et al., 
2005; Avery, Barber, et al., 2012; Flynn et al., 2009; Gandhi et al., 2005; Kaushal et al., 
2010; Knudsen et al., 2007a; Martínez Sánchez & Campos, 2011; Nanji et al., 2011; Sayers et 
al., 2009), patients (Avery, Barber, et al., 2012; Carruthers et al., 2008; Dhabali et al., 2011; 
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Gandhi et al., 2003; Kaushal et al., 2010; Lasser et al., 2006), items/packs (Ashcroft, Quinlan, 
et al., 2005; Chua et al., 2003; Dean Franklin & O'Grady, 2007; Gagne et al., 2008; Khoja et 
al., 2011; Marwaha et al., 2010; Sayers et al., 2009; Shah et al., 2001; Szczepura et al., 2011), 
opportunities for errors (Barber et al., 2009), total errors (Kuo et al., 2008; Lynskey et al., 
2007), and in patient/person years (Chen, Avery, et al., 2005; Gurwitz et al., 2003). 
 
The highest error rates were recorded for the prescribing stage as follows: for paediatric 
patients – 90.5% of prescriptions (Bahrain) (Al Khaja et al., 2007) and 74% of prescriptions 
(USA) (Kaushal et al., 2010), for elderly patients – 8.3% of opportunities for error (Barber et 
al., 2009), and when all errors (including administrative errors such as illegibility with hand-
written prescriptions) were recorded (Al Khaja et al., 2007). 
 
 
The lowest error rates were recorded as follows: for incident report reviews – 23/10,000 
prescriptions (prescribing error; Denmark) (Knudsen et al., 2007b), for dispensing error rates 
– 1.4/10,000 prescriptions (Denmark) (Knudsen et al., 2007b); 0.08% and 3.3% items and 
3.99/10,000 items (UK) (Ashcroft, Quinlan, et al., 2005; Chua et al., 2003; Dean Franklin & 
O'Grady, 2007), and in studies, which focused on a specific prescribing category – 0.2% total 
items (Italy, interactions) (Gagne et al., 2008); 0.7% patients (USA, interactions) (Lasser et 
al., 2006). 
 
4.5.2 Interventions to reduce medication errors in primary care 
Thirty-six studies evaluating interventions to prevent errors in primary care were reviewed – 
computerisation including provider order entry systems (CPOE), electronic prescribing, 
clinical decision support/clinical alerts and electronic health records (Abramson, Barrón, et 
al., 2011; Berner et al., 2006; Boockvar et al., 2010; Devine et al., 2010; Gandhi et al., 2005; 
Gandhi et al., 2002; Hazlet et al., 2001; Humphries et al., 2007; Moniz et al., 2011; Nemeth 
& Wessell, 2010; Raebel et al., 2007; Sweidan et al., 2011; Tamblyn et al., 2008), personal 
digital assistants (PDAs) (Dallenbach et al., 2007), educational outreach and prescribing 
support (Ahmad et al., 2006; Avery, Rodgers, et al., 2012; Bregnhoj et al., 2009; Hume et al., 
2011; Kennedy et al., 2011; Lafata et al., 2007; Lopez-Picazo et al., 2011; Nemeth & 
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Wessell, 2010; Stefanovic & Jankovic, 2011), formularies (Ahmad et al., 2006; Avery, 
Rodgers, et al., 2012), pharmacist-led interventions (Avery, Rodgers, et al., 2012; Booij et al., 
2003; Braund et al., 2010; Buurma et al., 2004; Raebel et al., 2007), barcode systems (Wild et 
al., 2011), medication reconciliation and patient engagement (Bernstein et al., 2007; 
Boockvar et al., 2006; Lemer et al., 2009; Varkey et al., 2007), quality management strategies 
(Singh et al., 2012) (Table 4) 
Previous systematic reviews and meta-analysis of interventions to prevent medication errors 
in primary care in the existing literature have demonstrated a weakness in the evidence of 
effectiveness interventions (Bayoumi et al., 2009; Eslami et al., 2007; Fischer et al., 2010; 
Royal et al., 2006). Most interventions have been individually implemented and evaluated. 
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Table 4: Interventions to reduce medication errors in primary care 
Interventions References1 
Computerization/electronic interventions:  
 Computerized physician/provider 
order entry (with or without clinical 
decision support, CDS e.g. monitoring 
alerts) 
Gandhi et al, 2005; 2002(Gandhi et al., 2005; 
Gandhi et al., 2002); Devine et al, 
2010(Devine et al., 2010); Palen et al, 
2006(Palen et al., 2006); Tamblyn et al, 
2008(Tamblyn et al., 2008)2, Gandhi et al, 
2005 
 Electronic Health Record (EHR), 
electronic prescribing, and electronic 
transfer of prescriptions 
Abramson et al, 2011(Abramson, Barrón, et 
al., 2011); Devine et al, 2010 (Devine et al., 
2010); Boockvar et al, 2010(Boockvar et al., 
2010); Moniz et al, 2011(Moniz et al., 2011); 
Nemeth et al, 2010(Nemeth & Wessell, 
2010) 
 Personal digital assistance with clinical 
decision support 
Berner et al, 2006(Berner et al., 2006); 
Dallenbach et al, 2007(Dallenbach et al., 
2007) 
 EHR with weight-based prescribing 
(CDS) 
Ginzburg et al, 2009 (Ginzburg et al., 2009) 
 CPOE with retrospective medication 
profiling 
Glassman et al, 2007 (Glassman et al., 2007)3 
 Community pharmacy Patient 
Medication Record (PMR) with drug 
interaction software/other alerts 
Hazlet et al, 2001 (Hazlet et al., 2001); 
Humphries et al, 2007(Humphries et al., 
2007); Raebel et al, 2007 (Raebel et al., 
2007) 
 Authentication at the point of 
dispensing (stand-alone, PMR-linked 
and electronic transfer of prescriptions 
(ETP)-linked) 
Franklin and O’Grady, 2007(Dean Franklin 
& O'Grady, 2007) 
 Pharmacy computer system with 
dispensing support (medication 
alert/verification) 
Norden-Hagg et al, 2010 (Norden-Hagg et 
al., 2010); Raebel et al, 2007 (Raebel et al., 
2007) 
 Computer-assisted feedback between Avery et al, 2012 (Avery, Rodgers, et al., 
                                                          
1 Studies demonstrating marginal impact (see footnotes 3 and 4 below) were included to 
reinforce the need for optimisation of interventions  
2 There was a significant reduction in therapeutic duplication problems in the computer-
triggered group (odds ratio 0.55; p = 0.02) and no effect on prevalence of prescribing 
problems at follow-up. 
3 Marginal improvements in ADE preventability was reported (16% in the Usual Care group 
and 17% in the Provider Feedback group had an associated warning; 95% CI for the 
difference, -7 to 5%; p = 0.79) 
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Interventions References1 
healthcare professionals 2012) 
 Pharmacy system improvement 
strategies 
 
Educational support, prescribing support and 
management: 
 
 Academic detailing and educational 
outreach, Pharmacological profiling of 
patients, use of formulary/drug lists 
Ahmad et al, 2006 (Ahmad et al., 2006); 
Avery et al, 2012 (Avery, Barber, et al., 
2012); Bregnhoj et al, 2009 (Bregnhoj et al., 
2009); Lafata et al, 2007 (Lafata et al., 2007); 
Lopez-Picaso et al, 2011 (Lopez-Picazo et 
al., 2011); Nemeth et al, 2010 (Nemeth & 
Wessell, 2010); Stefanovic et al, 2011 
(Stefanovic & Jankovic, 2011) 
Pharmacy or Pharmacist-led interventions  
 Collaborations between pharmacists 
and prescribers (general practice) 
Avery et al, 2012 (Avery, Barber, et al., 
2012); Braund et al, 2010 (Braund et al., 
2010); Buurma et al, 2004 (Buurma et al., 
2004); Humphries et al, 2007 (Humphries et 
al., 2007); Raebel et al, 2007(Raebel et al., 
2007); Bregnhoj et al, 2009 (Bregnhoj et al., 
2009) 
 Collaborations amongst healthcare 
providers (e.g. from other healthcare 
setting) 
Booij et al, 2003 (Booij et al., 2003) 
 Clinical Pharmacy Services  Sorensen et al, 2009 (Sorensen & Bernard, 
2009) 
 Pharmacy-led bar code medication 
administration systems 
Wild et al, 2009 (Wild et al., 2011) 
Medication reconciliation: medication reviews 
and medication monitoring 
Bernstein et al, 2007 (Bernstein et al., 2007); 
Varkey et al, 2007 (Varkey et al., 2007) 
Quality management strategies Singh et al, 2012 (Singh et al., 2012) 
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4.6 Discussion 
This review of the literature demonstrated that safety and quality issues currently exist at each 
stage of the medication management system, the prescribing stage being the most susceptible 
point. There is some evidence that children and the elderly are the more susceptible patient 
groups. Error rates ranged between <1% and 90% depending on the error definition, methods 
used, and on the patient population being studied. Direct comparison across settings was 
difficult due to variation in methodology, definitions and units of measurements. However, 
when error rates were expressed with a common denominator, rates were comparable 
between countries. Collaborations between practice and research may provide cost-effective 
options to interventions to prevent errors and improve patient outcomes (Garfield et al., 
2009).  
This review has tried to present a holistic view of the safety of the medication use pathway in 
primary care across different healthcare settings, and has evaluated a broad range of error 
types. By doing so, the susceptible points in the medicines use process, and the most 
vulnerable patient populations were identified. The results are applicable across a range of 
healthcare settings, and provide opportunities for stakeholders to influence practice and 
policies in a strategic, scientific manner. 
Most of the studies reviewed were actually conducted in community pharmacies, not within 
general practices (Al Khaja et al., 2007; Ashcroft, Quinlan, et al., 2005; Chua et al., 2003; 
Dean Franklin & O'Grady, 2007; Flynn et al., 2009; Hämmerlein et al., 2007; Knudsen et al., 
2007a; Lynskey et al., 2007; Martínez Sánchez & Campos, 2011; Warholak & Rupp, 2009) 
following patients’ receipt of their prescriptions from general practices – even though the 
studies are often described as “primary health centres”, (Al Khaja et al., 2007; Al Khaja et al., 
2005; Marwaha et al., 2010; Nanji et al., 2011; Sayers et al., 2009; Shah et al., 2001), they 
may be better described as community-based.  
The number of sites and the duration of observation were highly variable; one study was 
actually done in one community pharmacy (Martínez Sánchez & Campos, 2011). The 
absolute number of patients and/or prescription items is of significance based on the 
opportunities for errors. Only two studies (Avery, Barber, et al., 2012; Dean Franklin & 
O'Grady, 2007) reported a systematic and scientific determination of sample size. The 
sampling period is also an important variable. Study periods need to consider the effect of 
seasonal variations on prescription volumes and types, and hence error rates. As such, 
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prescription reviews conducted over a one-week period as reported in some of the studies 
reviewed (Al Khaja et al., 2007; Al Khaja et al., 2005; Hämmerlein et al., 2007) are not 
necessarily representative of day-to-day practice.  
Although some of the studies suggest that older and younger patients are more likely to 
experience a clinically significant medication error than the rest of the population (Avery, 
Barber, et al., 2012; Barber et al., 2009; Kaushal et al., 2007; Wong et al., 2004), only two 
studies each, focussed on elderly patients (Carruthers et al., 2008; Gurwitz et al., 2003) and 
children (Al Khaja et al., 2007; Kaushal et al., 2010). With an aging population, co-
morbidities, polypharmacy (Dhabali et al., 2011),  contact with multiple providers (Dhabali et 
al., 2011; Green et al., 2007), care transitions (Barber et al., 2009)  are on the increase. The 
need for weight-based therapeutic interventions in children (Ghaleb et al., 2005; Wong et al., 
2004) and lack of readily available proprietary medicines in strengths suitable for paediatric 
dosing often necessitating titration, have long influenced medication safety in the paediatric 
setting. Moreover, the elderly and children use primary healthcare more than the rest of the 
population with implications for medication safety in the face of the ever-pressured 
healthcare system. There is therefore an urgent need for more research into medication safety 
amongst these patient populations.  
Previous researchers have identified the prescribing and administration stages as the most 
dangerous stages of the medicines management system (Avery et al., 2002). Twenty-six of 
the thirty-three studies reviewed evaluated the prescribing stage in keeping with this finding. 
There is some suggestion in the existing literature that errors occur when patients take their 
medicines, and that there is a need to prioritize processes at the patient end of the system for 
interventions (Garfield et al., 2009). This review showed that there is a shortage of studies at 
the ‘patient end of the system,’ because of the obvious difficulties. Nonetheless, there is 
substantial evidence in practice that many patients may not be using their medicines as 
directed resulting in therapeutic failure and hospital admissions (Alldred et al., 2011; 
Coleman et al., 2005; Howard et al., 2003). Research and practice must therefore overcome 
the challenges of evaluating medication administration quality and safety in primary care to 
improve patient health outcomes. 
Although the use of varying error definitions by researchers in determining error rates has 
been previously identified (Alldred et al., 2008; Dean et al., 2000; Garfield et al., 2009; Lisby 
et al., 2010), this review has confirmed that this problem still exists. This is reflected in the 
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wide range (<1% - >90%) of error rates reported. Such variance in definitions and data 
capture could lead to erroneous evaluations of the system causes of error. Attempts to 
develop common definitions for practice and research have been made (Dean et al., 2000; 
Dean Franklin & O'Grady, 2007; Ghaleb et al., 2005), and although more studies and practice 
in secondary care are adopting the use of these definitions (Lewis et al., 2009), there is still 
significant variation among the studies reviewed. One study (Avery, Barber, et al., 2012) 
adapted a definition developed in secondary care for use in primary care but due to 
differences in the medication handling system between both settings, this approach may be 
burdensome, difficult to interpret, and result in loss of important data.  There is a need for a 
primary care practitioner-led definition of a prescribing error, where the highest error rates 
are recorded. 
This review has also demonstrated that error rates varied with the method of identification. 
For example, the highest error rate of 90.5% prescriptions (Al Khaja et al., 2007) was 
recorded in Bahrain following the audit of paper prescriptions issued for paediatric patients 
from 20 primary health care centres. Although all errors, including illegibility were captured, 
this figure excluded ‘minor errors of omission’. When paper prescriptions were reviewed in a 
prospective cohort study in the US, 94% of all medication errors (74% prescriptions) 
recorded were at the prescribing or ordering stage (Kaushal et al., 2010). While it may be 
argued that systems, which produce minor errors like incomplete prescriptions are also able 
to produce major errors that lead to patient harm (Leape et al., 1995), defences within the 
system would intercept some ‘minor’ errors such as illegibility; for example, a clinical check 
on a prescription prior to dispensing by a pharmacist is a major “defence process”. 
Conversely, in healthcare systems where pharmacists’ roles are circumvented (such as in a 
dispensing practice) or otherwise undeveloped (as in most developing countries), there is a 
breakdown in this defence. 
A high prescribing error rate of 8.3% opportunities for error or 39% of all patients was also 
recorded in a study of elderly patients in residential and care homes (Barber et al., 2009). The 
methods used to record medication errors were robust, comprising patient interviews, note 
reviews, practice observations and dispensed items examination. This was possible because 
all elements of the methods were applicable on the same sites. Incomparably with other 
studies, the dispensing error rate in this study was higher than both the prescribing and 
administration error rates reported in the same study. In the healthcare setting in this study, 
general practitioners and community pharmacists manage home patients’ prescribing and 
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dispensing activities. These patients also have carers who provide their intermediate 
healthcare needs, including medication administration. The challenge with this arrangement 
is that vulnerable patients who need healthcare the most do not have ample opportunities to 
interact directly with their practitioners and pharmacists. The use of cassette type monitored 
dosage systems appear to be a practical solution for dispensing their medication but the study 
demonstrated that the incidence of dispensing errors is highest with this type of delivery 
system. Should nursing and residential homes be viewed and treated like subsets of secondary 
care? This is a policy issue that should be thoroughly evaluated. 
The lowest error rates were from data captured from incident reports – prescribing error study 
in Denmark (23/10,000 prescriptions/0.23% prescriptions) (Knudsen et al., 2007b), and in a 
US study (Kuo et al., 2008). This is in keeping with the literature. Although incident 
reporting is very useful for organizational error learning, and provides valuable feedback to 
practitioners (Sarvadikar et al., 2010), research has shown that they can grossly underestimate 
error rates (Sarvadikar et al., 2010; Tam et al., 2008). In the study in Denmark, community 
pharmacists documented prescription errors they had intercepted. Although community 
pharmacists are a practical source of data, and perform important error interceptions (Brown 
et al., 2006; Teinilä et al., 2011), under-reporting remains a risk when pharmacy owners or 
managers collect study data themselves as evident in the lower rates reported in such studies 
(Ashcroft, Quinlan, et al., 2005; Chua et al., 2003; Hämmerlein et al., 2007; Knudsen et al., 
2007a; Kuo et al., 2008; Lynskey et al., 2007; Martínez Sánchez & Campos, 2011; Warholak 
& Rupp, 2009). In addition, when error rates are determined solely by recording pharmacists’ 
prescription interventions, the lack of access to patients’ medical histories at the time of data 
collection may become a barrier to adequate evaluation of the safety and quality of 
prescribing.  
Review of patient medical or clinical notes in general practices is perceived as a rigorous 
method for collecting prescribing error data (Tam et al., 2008). This is reflected in this review 
– studies, which included an element of case note reviews reported consistently higher rates 
of errors even across countries, when compared to the use of incident reports and review of 
pharmacists’ interventions (Appendix 20). However, notable issues around patient 
confidentiality, informed consent, and ethical provisions preclude access to patient medical 
records and prolong study duration. The gold standard is the use of a mix of methods for data 
collection (Tam et al., 2008), as a study showed no overlap when five methods were used 
(Wetzels et al., 2008). Studies, which used a mix of methods to evaluate the safety and 
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quality of the medication system provided pertinent information such as, causes of 
prescribing errors, clinical significance of errors, patient harm, and resultant hospital 
admission(Avery, Barber, et al., 2012; Barber et al., 2009; Field et al., 2007; Kaushal et al., 
2010). 
Dispensing error rates were consistently low across countries. A UK study where researchers 
directly observed dispensed items found higher rates than those studies where incident 
reporting and review of ‘near misses’ were used, emphasising the issue of under-reporting. 
The additional checks incorporated in the dispensing process impact accuracy. On another 
hand, the potential for detecting dispensing errors by patients is low when compared to the 
detection of prescribing errors by pharmacists and other healthcare professionals. 
It can be difficult to compare error rates when they are expressed in varying units: as 
percentage of – prescriptions or items (Abramson, Bates, et al., 2011; Al Khaja et al., 2007; 
Al Khaja et al., 2005; Avery, Barber, et al., 2012; Gandhi et al., 2005), packs/doses 
prescribed, dispensed or administered (Carruthers et al., 2008; Chua et al., 2003), multiples of 
items or packs (Ashcroft, Quinlan, et al., 2005; Gagne et al., 2008), opportunities for 
errors(Barber et al., 2009), total number of patients recruited to the study (Dhabali et al., 
2011), and in patient or person years(Chen, Avery, et al., 2005; Gurwitz et al., 2003). The use 
of varying denominators can also lead to variation in reported percentages. Based on the large 
volumes of prescription items used in primary care, error rates expressed as a percentage of 
total prescriptions or items will make easier interpretation. 
It is interesting to note that when comparable denominators (error expressed as a percentage 
of prescription items) were used, there is much consistency in prescribing error rates across 
countries – Bahrain – 7.7% (Al Khaja et al., 2005); UK 7.5% & 5% (Avery, Barber, et al., 
2012; Shah et al., 2001); USA 7.6% &11% (Gandhi et al., 2005; Nanji et al., 2011); India 
6.1% items (Marwaha et al., 2010) and Ireland 6.2% items (Sayers et al., 2009). 
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4.6.1 Optimising interventions to prevent medication errors in primary care 
Error-prevention strategies help to improve patient health outcomes, and reduce healthcare 
costs associated with drug-related harm (Adubofour et al., 2004). During the last decade, 
strategies to prevent error occurrence have been directed at secondary care (Dean Franklin et 
al., 2008). Attention is now being paid to methods for improving medication safety in 
primary care (Table 2). Interventions have been mostly implemented to individual parts of the 
medicines management system, without important collaborations between research and 
practice. Implementing interventions in an isolated manner may provide minimal effects as 
observed in previous studies (Glassman et al., 2007; Tamblyn et al., 2008).  
 
Healthcare is a complex system with an overarching aim of improving patient health 
outcomes. Isolated, spontaneous reactions to serious critical incidents without rigorous 
evaluations of the interactions between various units of the system only yield multiplicity of 
similar interventions with slight and ineffective modifications. Indeed, a systematic review 
and meta-analysis of interventions in primary care demonstrated the weakness of the 
evidence for effectiveness of interventions aimed at reducing hospital admissions or 
preventable drug related morbidity (Royal et al., 2006).  
 
With an aging population, availability of innovative but more expensive therapeutic agents, 
and tight healthcare budgets, optimising existing interventions becomes necessary. In the 
recently published Pharmacist-led Information Technology Complex Intervention (PINCER) 
Study, simple feedback plus PINCER (an educational outreach and dedicated support) in 
general practice, patients in the intervention group were significantly less likely to have 
experienced a range of medication errors (Avery, Rodgers, et al., 2012). This intervention 
demonstrated the benefit of collaborative interventions to improve the safety of medication 
use in primary care, and ultimately improve patient health outcomes. 
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4.7 Conclusion 
This review has provided an international perspective on the safety of medication use in 
primary care across the medication management system. Targeting the more susceptible 
population groups and the most dangerous aspects of the system may be more effective to 
error prevention in primary care. Collaborative implementation of existing interventions may 
offer time- and cost-effective options to improving medication safety and patients’ health 
outcome in primary care. 
 
4.8 Study limitations 
One of the limitations of this review is the exclusion of the term “adverse drug event” from 
the medication error terms, which may have meant that relevant articles were not identified. 
Furthermore, previous research show that patient safety incidents in hospitals take their roots 
from primary care management – in the UK, 6.5% admissions to hospital were related to 
adverse drug reactions in a study of 18,820 patients that were admitted to hospital 
(Pirmohamed et al., 2004). Valuable insight may have been obtained from studying the 
admission-discharge interface. However, due to the varying nature of the primary-secondary 
care interface across countries, studies at the admission-discharge interface were not 
included.  Lastly, studies included in this review were not of the same level of evidence; the 
aim was to provide an estimate of the incidence of medication errors in primary care. As 
such, limiting the studies to the same evidence levels would have precluded the international 
insight, which has been hopefully provided. 
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Chapter 5. Primary Care Trusts (PCTs) and Clinical 
Commissioning Groups (CCGs) systems for managing medication 
errors in primary care  
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5.0 Primary Care Trust (PCT) error management system (pre-CCG) 
5.1 Introduction 
Two of the principles the National Health Service (NHS) abides by are: to provide “high 
quality care that is safe,” and through its use of research, to “improve the current and future 
health and care of the population,” (NHS England, 2013). Therefore, medication safety has 
been at the forefront of an extensive volume of research for many years. 
The National Patient Safety Agency (NPSA) defines a medication safety incident as “any 
unintended or unexpected incident, which could have or did lead to harm for one or more 
patients” (NPSA, 2011, www.nrls.npsa.nhs.uk/). These incidents may include adverse drug 
reactions, contraindications, side effects and errors. Of all these medicines-related problems, 
medication errors are incidents, which are normally under the control of the healthcare 
professional or patient, thus making them preventable (National Coordinating Council for 
Medication Error Reporting and Prevention, NCC MERP). The NCC MERP takes the stance 
that there is no acceptable incidence rate for medication errors and that the goal should be to 
continually improve healthcare systems so that medication errors are prevented (NCC MERP, 
2002).  
Medication errors can occur at various stages during the delivery of a medicine to the patient, 
namely prescribing, verifying and dispensing or administration. A general practitioner, 
community nurse, dentist, optometrist or pharmacist may carry out prescribing in primary 
care. In secondary care, specialist doctors such as dermatologists, gynaecologists, etc. usually 
carry out most prescribing. 
Errors occurring at the prescribing stage include those referred to as ‘knowledge based 
errors,’ which are usually due to ignorance of the patient or ignorance of the medication 
(Ferner & Aronson, 2006). Ignorance of the patient may include unnoticed allergies or 
contraindication with underlying conditions. Although the majority of prescribing within the 
NHS is done electronically using software that highlight drug interactions, most of them do 
not have safety features such as contraindication alerts (Ferner, 2004). This demonstrates that 
though technology is becoming increasing beneficial in error prevention, prescribers still 
have much responsibility in detecting errors, which computer systems are not able to. 
Verification and dispensing of prescriptions follow prescribing, and usually remains the remit 
of the pharmacist, though in some cases, particularly within secondary care, doctors and 
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nurses may dispense directly to patients thereby eliminating the pharmacist from the process. 
Either way, healthcare professionals with the responsibility for prescription verification and 
dispensing are required to reduce the incidence of drug-related morbidity to optimise patient 
outcomes through the identification, resolution, and prevention of drug therapy problems 
(Planas et al., 2005). Problems, which should ideally be detected at this stage, may include 
improper drug selection, sub-therapeutic dose, over-dose, drug interactions or drug use 
without corresponding indication (Strand et al., 1990). 
Errors occurring at the administration stage would usually involve an inpatient healthcare 
setting, involving a healthcare professional administering a medicine, usually a nurse. Errors 
occurring at administration could result from an error earlier in the process, which may not 
have been detected at the verification stage. Errors at administration involving a patient alone 
would be regarded as a compliance issue, which will not be discussed, as this does not fall 
under the scope of this study. 
All the above-mentioned medicines-related problems are considered preventable, and 
therefore labelled as “errors.” Errors left unnoticed could lead to potential morbidity, leading 
to increased or prolonged hospital admissions. Winterstein et al (2002) found that 59% of 
drug-related admissions are preventable (Winterstein et al., 2002). Phillips et al (2001) found 
that of all errors reported onto an American database, 9.8% resulted in death (Phillips et al., 
2001).  
In order to reduce medication errors and in turn improve patient safety, lessons must be learnt 
(Kohn et al., 1999). The concept of learning from errors may be applied at different levels 
namely individual, team or departmental, and organizational levels – a trust, local health 
authority or the whole NHS (Dean, 2002). “An organisation with a memory” made 
recommendation to the government on how to ensure that the NHS learns from its 
experiences and reduces the risks associated with preventable harm (Department of Health, 
2000). Albeit, error reporting and meaningful analysis precede any learning from errors at an 
organizational level (Dean, 2002). Schemes for multidisciplinary error reporting have been 
set up by many hospitals and healthcare organisations so that common errors can be 
identified, and necessary preventative actions taken; this concept of error identification, 
reporting and learning has been extended nationally through the development and activities of 
the National Patient Safety Agency, NPSA (Dean, 2002). The Department of Health (DH) 
has established the NPSA, who has created the National Reporting and Learning System 
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(NRLS). DH highlights the importance of ‘learning from error and adverse events’ through 
the NRLS: 
“The system will enable reporting from local to national level. It will introduce a new 
integrated approach to learning from medical error, adverse event and near misses, and it 
will capture adverse event information from a wide variety of sources. Local reporting of 
adverse events and action to reduce risk within the organisation concerned is essential. On a 
selected basis, reports to national level will enable service-wide action where patterns, 
clusters or trends reveal the scope to reduce risk or prevent recurrence for future patients in 
other parts of the country,” (Department of Health, 2000). 
The NPSA has further created a guide called “Seven Steps to Patient Safety.” The fourth step 
particularly promotes reporting in primary care. 
Table 5: NPSA Seven Steps to Patient Safety (www.npsa.nrls.co.uk) 
Step 1 Build a safety culture 
Create a culture that is open and fair 
Step 2 Lead and support your staff 
Establish a clear and strong focus on patient safety throughout your organization 
Step 3 Integrate your risk management activity 
Develop systems and processes to manage your risks and identify and assess 
things that could go wrong 
Step 4 Promote reporting 
Ensure your staff can easily report incidents locally and nationally 
Step 5 Involve and communicate with patients and the public 
Develop ways to communicate openly with and listen to patients 
Step 6 Learn and share safety lessons 
Encourage staff to use root cause analysis to learn how and why incidents happen 
Step 7 Implement solutions to prevent harm 
Embed lessons through changes to practice, processes or systems 
 
In primary care, local health authorities, that is, the former Primary Care Trusts, PCTs (which 
have now migrated to the newly-formed Clinical Commissioning Groups (CCGs) provide 
clinical governance support including collating information on errors, reporting, and shared 
learning to general practices, community pharmacies, and other health organizations within 
their localities.  
It can be observed that much effort has been put into developing these systems for improving 
patient safety. However, the NRLS is a voluntary tool; therefore it is up to the healthcare 
professionals and the public to make use of it to harness any benefit. In 2007, over 70,000 
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incidents were reported via the NRLS as follows: 76% from hospitals, 5% from community 
pharmacy, and 1% from general practices. These figures are in line with Sarvadikar et al’s 
findings that pharmacists are more likely to report errors than doctors (Sarvadikar et al., 
2010).  
The high percentage of reports carried out in hospitals may mostly be due to reporting done 
by nurses, as Evans et al found that nurses had a greater awareness of, and used the incident 
reporting systems than doctors (Evans et al., 2006). Evans et al further showed that barriers to 
doctors completing incident forms included such forms taking too long to complete or the 
belief that incidents were trivial. Other studies have shown that while the medical culture has 
emphasised privacy, professional autonomy and self-regulation, nurses were more likely to 
be governed by the need to follow protocol and the notion of having to ‘cover themselves,’ 
(Kingston et al., 2004). 
The afore-mentioned studies may suggest why such little reporting is done in primary care. 
Patient safety and medication safety in primary care is extremely important, as primary care 
is the first port of call for patients. The majority of patients come in contact with primary care 
before referral to a secondary care setting, and will often return to primary care for continued 
care. To contextualise the relative importance of primary care, the NPSA estimates that 1 
million people see a family doctor, 1.5 million prescriptions are dispensed, and community or 
district nurses make up to 100,000 visits each day (National Patient Safety Agency, 2006). 
Most patients’ healthcare needs are not in secondary care but in primary care, where patients 
generally visit more than one site. Healthcare professionals working in primary care also tend 
to have less specialised knowledge and therefore may have lesser control over adequate 
medicines management. This is especially important with high-risk medicines that need 
regular monitoring such as Warfarin or Methotrexate. 
Researchers have investigated why primary care healthcare professionals are less likely o 
report incidents (Ashcroft et al., 2006; Fernald et al., 2004). One of the related concepts used 
to explain non-reporting of errors is ‘safety culture.’ Safety culture of an organisation is the 
“ability of individuals or organisations to deal with risks and hazards, so as to avoid damage 
or losses and yet achieve their goals,” (Reason, 2000). Safety culture has been an increasingly 
important concept in tackling medication errors, as errors, rather than being seen as personal 
failures, need to be opportunities to improve the system of medication use and prevent patient 
morbidity and mortality. The NHS and NPSA are working to develop a truly ‘open and fair 
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culture’ and a no-blame attitude towards reporting. This is however not as straightforward as 
it appears from the recent discussions on decriminalisation of dispensing errors. 
There is some contradicting evidence on the safety culture within primary care. Ashcroft et al 
(2005) found in their study, that the majority of community pharmacists may be categorised 
as ‘pathological,’ which corresponds to level one, the ‘least desirable’ of the five levels of 
organisational safety culture outlined by Parker and Hudson (2001) as cited in (Ashcroft, 
Morecroft, et al., 2005). On another hand, other researchers observed that Primary Care Trust 
(PCT) staff judged the safety culture within primary care organisations within their remit to 
be between the ‘reactive and calculative,’ which correspond to levels 2 and 3 of Parker and 
Hudson’s organisational safety culture (Kirk et al., 2007) – PCTs were the commissioning 
bodies at the time of the study. It is ironic that only 6% of all errors reported to the NRLS in 
2007 were from general practitioners and pharmacists. Is it possible that governing bodies 
may believe things are better than they are within their wards? 
The Health and Social Care Act of 2012 saw abolition of PCTs and Strategic Health 
Authorities to form Clinical Commissioning Groups (CCGs). In England, 212 CCGs were 
formed, each made up of several general practitioners, a registered nurse, a specialist 
secondary care doctor, a senior pharmacist, and other allied healthcare professionals. Under 
the Health and Social Care Act 2012 and the NHS Act 2006, a CCG will retain legal 
responsibility for its functions. CCGs will also be subject to public law duties, which will 
mean that they have legal responsibilities for the functions they carry out. As such, CCGs 
will take some responsibility for issued, which may affect patient safety such as a GP not 
reporting an error.  
The Health and Social Care Act, 2012 states that CCGs “must give advice and guidance…for 
the purposes of maintaining and improving the safety of services provided by the health 
service,” (NHS Commissioning Board, 2013). This further shows that CCGs have a 
responsibility to guide the healthcare professionals within their groups on how to improve 
patient safety, for example, by recording and reporting medication errors to aid error learning 
(NHS Commissioning Board, 2013). CCGs do not only hold a legal responsibility to improve 
the quality of care, they are also expected to promote continuous education and training of 
healthcare practitioners and organisations (NHS Commissioning Board, 2013), which has the 
potential to impact safety culture and drive organisations towards a more mature culture, 
described by Parker and Hudson (2001) as cited in (Ashcroft, Morecroft, et al., 2005) as 
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“proactive’ or ‘generative.’ It is therefore in order to surmise that CCGs have a role to play in 
the safety culture characteristics of their organisations, which improve error reporting and 
learning. Rather than assuming that incidents are not being reported solely as a result of the 
level of the organisations’ safety culture, CCGs should be equally accountable. Such 
approach is already in use in Canada, where minimum standards require each pharmacy to 
have a process for documenting all suspected and known medication incidents, with local 
authorities further requiring quarterly review of incidents to assess trends (Boyle et al., 2014; 
Boyle et al., 2011). 
It is against this background that PCTs and CCGs in England will be directly contacted with 
respect to their systems for managing medication errors in primary care to promote patient 
safety, in a before-and-after (CCG) study. The purpose will be to characterise existing 
systems for medication error identification, recording and reporting in primary care. The 
study will focus on incidents from general practices and community pharmacies in particular. 
Boyle et al conducted a similar study in community pharmacies in Canada (Boyle et al., 
2014). In their study Boyle et al analysed the perceived role of the pharmacy regulatory 
authority in enhancing and promoting quality-related event reporting through focus groups. 
The focus groups consisted of deputy registrars, practice managers and pharmacy inspectors. 
The researchers concluded on a consensus that the pharmacy regulatory body had a strong 
role in enhancing reporting of incidents, and that compliance with reporting was increased 
through the use of reporting standards. The study creates an ideal for governing bodies to 
actively support medication errors in primary care to enhance patient safety and ultimately 
the quality of care. However, pharmacy inspectors mentioned that community pharmacists 
‘did not know of the last time they made a mistake,’ which highlights the issue of the many 
definitions of medication errors. Furthermore, the ‘blame culture’ was evidently prevalent as 
members of the focus group highlighted that pharmacists are afraid to report errors (even 
anonymously) due to the fear of consequences. The research gives valuable evidence that 
regulatory bodies have a huge role in influencing healthcare professionals to report 
medication errors. Although the pharmacy regulator is doing well in ensuring logbooks are 
kept, the system is still limited as there is no protocol in place to ensure incidents are learnt 
from. One inspector stated ‘I don’t have to look at the incidents themselves; I look and see 
that you’re doing your job,’ (Boyle et al., 2014). The ultimate aim of reporting is to ensure 
that lessons are learnt.  
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To date, the systems used by PCTs (now CCGs) to identify, collate, analyse, and share 
learning from errors in general, and prescribing and dispensing errors in particular, have not 
been studied nor described. In the face of a changing NHS however, an understanding of 
local arrangements for error management and learning is pertinent to optimizing the system, 
and ultimately, improving patient health outcomes locally. The research questions, which 
arise from this background, are: 
 What types of incidents do English PCTs and CCGs record as prescribing or 
dispensing errors? 
 What systems exist for English PCTs and CCGs to identify errors in general practices 
and community pharmacies? 
 What systems are used to report and manage error learning within English PCTs and 
CCGs? 
 How do PCTs and CCGs support healthcare practitioners who have made an error, 
and what interventions have been implemented to prevent error occurrence? 
Information will be collated from PCTs and CCGs using a survey, and the results will be 
used to describe similarities and differences between different wards. The survey will consist 
of closed questions in order to establish demographics and open-ended questions in order to 
allow respondents to give their own opinions and not limit the information they provide. 
Although this will not allow for statistical analyses of the results, it will provide rich and 
varied data, upon which conclusions may be drawn. This will hopefully help to highlight 
unclear areas with suggestions on how to improve the systems.    
 
 
 
5.2 Aim and objectives 
The aim of this study was to investigate and describe the existing systems, processes and 
procedures used by Primary Care Trusts (PCTs) and now, Clinical Commissioning Groups 
(CCGs) to collate reports on medication errors from general practices and community 
pharmacies.  
The objectives were  
1. To describe the categories of incidents collated as prescribing and dispensing errors 
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2. To get an insight into the processes of identifying, reporting and reviewing prescribing 
and dispensing errors 
3. To understand the responsibilities for managing errors at PCT and CCG levels 
4. To make recommendations to improve the system of medication error management in 
primary care at PCT and CCG levels 
 
5.3 Methods 
5.3.1 Pre-CCG 
A questionnaire was designed and piloted with seven health care professionals within the 
Department of Pharmacy, who have clinical governance-related roles in primary care 
organisations. The questionnaire covered five sections, which intended to extract certain 
information from the respondent to make inferences with respect to management of 
medication error learning in primary care organisations from the point of view of local 
authorities (see below).  
The healthcare professionals found the questionnaire clear and easy to fill; the only 
amendment was to split the first question into two separate questions. 
Question 1 originally stated: 
“What types of incident(s) would you class as error(s) based upon your experience or reports 
from general practices (surgeries) and pharmacies?” 
The feedback was that as prescribing and dispensing errors varied, questions about these 
incidents should be asked separately. As such, the question was split into two. Addresses of 
the PCTs were compiled from the Research and Development Forum and the NHS Choices 
Website. The final questionnaire, made up of eight questions was sent by post to the Heads of 
Medicines Management and Chief Pharmacists in the 146 PCTs in England between 
December 2012 and January 2013 (see below). The questionnaire was sent with a consent 
form and a pre-paid envelope. A reminder was sent to non-respondents within two to four 
weeks from the initial post. The reminders also had a fresh questionnaire and pre-paid 
envelope to facilitate ease of response. Data collection ceased after six weeks of sending the 
original questionnaire. 
5.3.2 Post-CCG 
An MPharm student sent the Post-CCG study as part of their final year research project. 
  126 
Following the PCT or phase one study, it was deduced that there might have been some 
confusion regarding question 3. Question 3 originally stated: 
“How are critical incidents (prescribing and dispensing errors) reported to your PCT? 
a. Are general practices (surgeries) and community pharmacies instructed to submit their 
periodic critical incident reports OR 
b. Do you ask them for periodic critical incident reports? 
(Circle as appropriate, and add further comments below).” 
The question was re-worded to make it easier to understand, and the change was validated 
with the supervisors. 
The CCG survey was conducted in October 2013. A research-driven healthcare company 
(Merck Sharpe & Dohme, MSD) provided a list of CCG addresses. MSD had compiled the 
list for their use from the Health Research Authority. The list provided was compared to 
details on the NHS Choices Website to ensure correct addresses were provided. Although 
lists of 246 addresses were compiled, these only included 108 CCGs as some CCGs had more 
than one registered address. As it was not feasible to ascertain which site the participants 
were most likely to be located at, the questionnaire was sometimes sent to each known 
address for some CCGs. 
From the experience of the pre-PCT survey, each CCG were also sent two questionnaires by 
post: one was addressed to the Head of Medicines Management (HOMM), and the other to 
the Chief Pharmacist (CP). In order to identify the recipient, each questionnaire was coded: 
each CCG had a unique number 1 to 108, with HOMM questionnaires coded A and CP, 
coded B. For example, the HOMM in the first CCG was coded 1A. The full list was stored in 
an Excel spreadsheet. 
For both study phases, Microsoft Word was used to address each questionnaire using the 
Mail Merge tool. The Mail Merge tool was also used to produce address labels for each PCT 
and CCG, and for the return envelopes. Each process was repeated for the HOMM and the 
CP in all PCTs and CCGs. Each envelope consisted of a covering letter, a consent letter, a 
questionnaire, and a freepost envelope to return the questionnaire to the researcher. The 
covering letter included a description of the study. The consent letter outlined instructions 
and provided contact details of the researchers. The questionnaire began with five 
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demographic questions; this did not include the recipients’ names to maintain confidentiality. 
The questionnaire included the following question: 
 
 What types of incident(s) would you class as prescribing error(s) based upon your 
experience or reports from general practices (surgeries)? 
 
 What types of incidents(s) would you class as dispensing error(s) based upon your 
experience or reports from community pharmacies? 
 
 How are critical incidents (prescribing and dispensing errors) reported to your CCG –  
a. General practices (surgeries) and community pharmacies submit reports as and 
when incidents occur OR 
b. General practices (surgeries) and community pharmacies submit reports 
periodically OR 
c. Your CCG request reports periodically? 
(Circle as appropriate, and add further comments below) 
 How often are critical incident data from general practices (surgeries) and community 
pharmacies collated by your CCG?  
(Please tick as appropriate) 
Monthly □  Quarterly □  Yearly □  Other (Specify) □ 
 
 Could you describe any processes or protocols currently in use by general practices 
(surgeries) and community pharmacies in your CCG to identify, record, and report 
medication error incidents to the CCG clinical governance or medicines management 
department? 
 
 Does your clinical governance or medicines management department have any systems in 
place to review critical incidents? 
Yes □  No □ 
 If ‘Yes’, please describe the system briefly, adding how often this is done 
 
 Do you collect information on medication “near miss” incidents from general practices 
and community pharmacies? 
Yes □  No □ 
If ‘Yes’, how often? Please tick as appropriate: 
Monthly □  Quarterly □  Yearly □  Other (Specify) □ 
 What interventions have been implemented by your clinical governance/medicines 
management department to prevent occurrence of medication incidents in primary care 
organizations within your ward, notably in GP surgeries and community pharmacies? 
 
In the first week of sending the questionnaires out, majority of respondents indicated that it 
was not the CCGs’ responsibility to record or manage medication errors, and that it was in 
fact the NHS England (NHSE) Area Teams’ responsibility. As a result of this, rather than 
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sending a reminder letter to CCG HOMMs and CPs as initially planned and done under phase 
1 or Pre-CCG (PCT) study, the questionnaire was sent to each NHSE Area Teams. 
The NHSE Area Teams’ addresses were compiled from the website, www.england.nhs.uk. 
There are a total of 28 NHSE Area Teams across England, and each was sent a questionnaire 
addressed to the Medicines Management Department. These questionnaires were prepared in 
the same manner as those sent to PCTs and CCGs. Data collection ceased after five weeks 
from the initial post-CCG survey. 
 
5.4 Analysis and validation 
All responses were entered onto separate excel workbooks and/or sheets i.e. responses from 
PCTs, CCGs and NHSE Area Teams. Each question was assigned themes in order to allow 
inductive thematic analyses of responses.  
The results were inductively analysed by collating and interacting with data to identify 
themes. The principal academic supervisor (MG) verified all questionnaires and data entry, 
and randomly selected 7 (≈ 25%) responses for separate analysis. There were no 
disagreements in the resulting themes. 
 
 
5.5 Results 
5.5.1 PCT phase (Pre-CCG) 
 
Responses 
Of the 146 PCTs contacted, 27 (response rate, 18.5%) completed and returned the 
questionnaire. The low response rate may be attributed to the imminent changes within the 
structure of the NHS at the time of the survey. The most relevant change was the abolition of 
PCTs with the formation of general practitioner-led CCGs on April 1st 2013; as such, many 
roles within local health authorities were changing. Also at the time, some PCTs were 
operating as clusters such that two or more PCTs had a joint Head and/or Department of 
Medicines Management. As such, the true response rate is not known. 
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All (10) the then Strategic Health Authorities (SHA) of the NHS were represented, with 
Yorkshire and The Humber having the highest response rate (18.5% of all responses). The 
“current role” as stated by respondents widely varied – eleven different titles were used, the 
most frequently occurring being Head, Medicines Management (33% responses). The 
average “number of years in role” of the respondents was 6.1, ranging from 6 months to 12 
years. However, most respondents (81% responses) had held related roles for more than 5 
years. Most respondents (85% responses) were aged over 40 years, with 48% of respondents 
being over 50 years. 
 
Categories of incidents classed as prescribing or dispensing errors: 
Twenty-three categories each of prescribing and dispensing errors were identified following 
analysis. The most frequently occurring categories included wrong drug, dose, patient, 
strength, direction, formulation and quantity for both prescribing and dispensing errors. The 
least frequently mentioned categories for prescribing errors included omission, duplication, 
reconciliation, prescribing outside local guidance/tariff, prescribing on repeats without checks 
and excessive prescribing, and for dispensing errors, dispensing without prescription, 
dispensing in the face of known allergies, and missing patient information leaflets (PIL). 
 
Mode of receipt of critical incident data from general practices and community pharmacies 
by PCTs: 
PCTs mostly received critical incident data from general practices and community 
pharmacies through spontaneous reports from third parties, and occasionally from general 
practices and community pharmacies on ad hoc bases. Such third parties included patients 
(often as complaints), hospitals (during admissions), other healthcare professionals (such as 
practice reporting a dispensing error), and through the NPSA database. Only three PCTs 
requested periodic incident reports from general practices and community pharmacies bi-
monthly or quarterly. General practices and community pharmacies were also able to submit 
error reports anonymously in which case PCTs could not follow up. Organizations 
(community pharmacies in particular) are also able to report errors via their own reporting 
systems. Another commonly occurring theme was in relation to controlled drug (CD) error 
reporting – ten PCTs mentioned that as a legal requirement, it was mandatory to report all CD 
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errors unlike other incidents. In addition to CD errors, a few PCTs mentioned that all “serious 
incidents” such as “death”, “press-relevant”, “serious consequences”, were to be reported by 
general practices and/or community pharmacies as soon as they are made aware of them. 
General practices are also able to report via DATIX®-web4, which feeds directly to the 
National Report and Learning System (NRLS) of the NPSA. Prescribing incident information 
is also captured occasionally through ePACT5 prescribing data under the Quality of 
Outcomes Framework (QoF).  
 
Frequency of collation of critical incident data from general practices and community 
pharmacies by PCTs: 
The themes in responses were: following spontaneous error reports from general practices 
and community pharmacies, from third parties, and via the NRLS, PCTs collate incident data 
from general practices and community pharmacies monthly (3 PCTs), quarterly (mostly CDs, 
2 PCTs) and at least annually (3 PCTs). Others collate reports  “as and when” i.e. following 
occurrence and on an ad hoc basis. 
 
Existing protocols by PCTs for general practices and community pharmacies to manage 
critical incidents: 
PCTs were also asked if they had any existing protocol for general practices and community 
pharmacies to identify, record and report critical incidents. The responses to this question 
were very varied. Only one PCT appended a full protocol to their response: following an 
error report, PCTs commonly request significant event analyses, SEA or internal event 
analysis, IEA, or root cause analysis, RCA for serious untoward incidents, SUI. Other 
responses include the use of standard operating procedures (SOPs) and practice prescribing 
policies for managing critical incidents. Other themes, which occurred in response to this 
question, included provision of many avenues to report serious incidents to PCT (telephone 
                                                          
4 DATIX is the leading supplier of patient safety software for healthcare risk management, incident reporting 
software and adverse event reporting www.datix.co.uk 
5 ePACT is an application, which allows nominated users at PCT or Trust or National level to electronically 
access prescription data. It allows real time on-line analysis of the previous sixty months prescribing data held 
on the NHS Prescription Services Prescribing Database 
http://www.nhsbsa.nhs.uk/PrescriptionServices/3230.aspx 
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call, letter or email, use of online voluntary reporting, DATIX, NPSA, own system), contract 
monitoring, RCA, use of standard forms for reporting CD errors, the use of policy documents 
relating to error recording and reporting, use of prescribing protocols or algorithms, reporting 
systems in care homes, and learning from errors and prevention. Two PCTs reported they had 
no existing protocols. 
 
Existing systems within PCT to review critical incident data: 
While 3 PCTs (11%) answered no, most PCTs (92%) answered yes to having existing 
systems to review critical incident data within their medicines management departments. 
These include practice or pharmacy follow-up by medicines management to ensure 
corresponding action is taken, discussion of case summaries, SEA/RCA, interrogations of 
data captured, investigations of practices or pharmacies, facilitated discussions at prescribing 
lead meetings, dissemination of learning points with primary care providers, analysis of 
safety trends, and dedicating an incident team to work with and support pharmacies/practices.  
 
Collation of “near miss” incidents from general practices and community pharmacies: 
17 PCTs (17; 63%) did not collect “near miss” logs from general practices or community 
pharmacies. Of the 10 PCTs who collected “near miss” data, most of them did so at irregular 
intervals; three PCTs, however collated “near miss” data annually “as part of contract 
monitoring” procedures. One PCT, which collated “near miss” data, noted that “it is hard to 
define a near miss” in their response. 
 
Existing PCT interventions to prevent medication incidents in general practices and 
community pharmacies: 
Lastly, PCTs were asked about the interventions they have implemented to prevent 
occurrence of medication incidents within general practices and community pharmacies. One 
respondent mentioned that no interventions had been implemented “as far as they were 
aware”. Two PCTs did not answer this question. Therefore, 24 PCTs (88%) mentioned one or 
more interventions; these included issuance of prescribing and dispensing policies and 
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updates, shared learning, development and dissemination of newsletters, raising awareness of 
common incidents via memos, letters, “learning from reporting” bulletins, annual safety 
audits of prescriptions of high risk drugs in practices, altering GP computer systems on 
security access and formulary, SOP, updates through ScriptSwitch, reviews of service level 
agreement, contract monitoring, reporting concerns to the General Pharmaceutical Council 
(GPhC), inspection visits, and contractual sanctions and warnings. 
The most important data from the PCT study are summarised below 
Questionnaire survey enquiries PCT responses (main themes) 
Mode of receipt of critical 
incident (CI) data by PCT from 
Primary Care Organisations, 
PCOs (general practices and 
community pharmacies) 
Most PCTs received information through 
spontaneous reports from general practice 
Frequency of collation of CI data 
from PCOs by PCT 
Most PCTs collated or reviewed information on “as and 
when” bases.  
Existing PCT protocols for PCOs 
to manage their CI data 
Practices follow their own prescribing policies and 
practices may report via DATIX-Web 
Existing PCT systems to review 
CI data from PCOs locally 
Most PCTs agreed that they had systems in place. These 
comprised internal reviews of incident data, completion 
of Significant Event Analyses (SEA) and Root Cause 
Analyses (RCA) for Serious Untoward Incidents (SUI) 
by practices or pharmacies with support from PCT 
medicines management, PCT reviews and 
recommendations with action plansx 
Collation of near miss incident 
reports from PCOs 
PCTs did not often review near miss logs from PCOs 
PCT interventions to prevent 
medication incidents in PCOs 
Shared learning practices, periodic issue of newsletters 
highlighting trends in incidents, use of education memos 
such as “Learning from Reporting Bulletins,” policy 
guidance development and reviews, review of service 
level agreements. 
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5.5.2 CCG phase (Post-CCG) 
 
Response 
Of the 108 CCGs contacted, 16 (response rate = 14.8%) responded.  
Categories of incidents classed as prescribing or dispensing errors: 
68.6% (n=11) of respondents mentioned that a prescribing error would have occurred if a 
‘wrong medication’ or ‘wrong dose’ were prescribed.  The respondents also judged that 
dispensing the wrong medication would be an error; however, only 6 respondents mentioned 
‘wrong dose’ as a category of dispensing error. 
43.8% of respondents mentioned that errors involving ignorance of a patient’s history would 
result in a prescribing error; for example, where a prescriber issues a ‘drug combination that 
harms a patient,’ or a drug, to which a patient has known allergies. These errors were mostly 
considered to be an error from a prescriber as opposed to a dispenser, even if they were 
dispensed. Only one respondent thought that a dispensing error would have occurred if 
interacting drugs were dispensed against a doctor’s prescription.  
A large number of respondents suggested that dispensing errors were related to issues that do 
‘not match up with what was on a prescription.’ These included labelling errors (n=8), wrong 
formulation (n=7), wrong quantity (n=6), and wrong strength (n=6). A lower percentage of 
respondents mentioned these types of incidents as prescribing errors; for example, 4 
respondents mentioned that a prescribing error would be said to have occurred if the wrong 
formulation were prescribed; 3 respondents mentioned that wrong quantities and wrong 
strengths were considered prescribing errors. 
Other incidents, which respondents considered would be categorised as prescribing errors 
were wrong brand, hospital consultants’ letters not being acted upon, prescribing outside 
licensing recommendations without a ‘good’ reason, controlled drug writing errors, 
oversupply of prescription items. The only miscellaneous dispensing error mentioned by one 
recipient was ‘providing incorrect advice,’ which is assumed to mean oral advice as opposed 
to directions on a label. These are summarised in Figure 7 and Figure 8 below. 
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Figure 7: Incidents listed by respondents as prescribing errors 
 
 
Figure 8: Incidents listed by respondents as dispensing errors 
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Mode of receipt of critical incident data from general practices and community pharmacies 
by CCGs: 
This related to questions three and four: mode of receipt of critical incident data from general 
practices and community pharmacies by CCGs, and the frequency of collation of critical 
incident data from general practices and community pharmacies by CCGs. Of the 16 
recipients, 62.5% (n=10) did not provide an answer to these questions. Some of the common 
responses to these questions were “currently, all GP and pharmacy incidents are reported to 
NHSE Area Teams,” and “please note CCGs do not commission community pharmacy or GP 
practices since April 1st, so there is no obligation for errors to be reported to the CCG.” 
 
Frequency of collation of critical incident data from general practices and community 
pharmacies by CCGs: 
6 respondents answered the two questions: four stated that incidents are reported to the CCG 
“as and when they occurred,” though some of these CCGs deleted community pharmacies. 
Two CCGs mentioned that serious incidents should ideally be reported to them though the 
Area Teams were now directly responsible. 
In response to question 4, which asked about the frequency of collation of critical incident 
data, 3 respondents mentioned that errors were collated monthly, and 1 respondent each 
mentioned that errors were collated quarterly, “when required,” and “on an on-going basis 
through the use of DATIX system.” 
 
Existing protocols by CCGs for general practices and community pharmacies to manage 
critical incidents: 
This section comprised of questions five and six: question five asked what CCGs protocols 
existed for general practices and community pharmacies to manage critical incidents, and 
question six asked if there were existing systems within the CCG to review critical incident 
data. Of the respondents, 7 mentioned the protocols used to record incidents as follows: 
standardised incident reporting forms, risk scoring forms, and DATIX (electronic incident 
reporting forms). 9 respondents did not mention any protocol, often leaving the question 
blank or stating “not applicable,” or “this is NHSE’s role.”  
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9 of respondents stated that there was a system in place to review critical incidents. Some of 
the comments provided by respondents suggested that management of medication incidents 
was under the remit of the medicines management teams. 
 
Collation of “near miss” incidents from general practices and community pharmacies: 
Question 7 asked if information is collected with respect to near misses, and if so, how often. 
18.8% (n=3) mentioned that information on ‘near misses’ was collected. The respondents 
mentioned that information on ‘near misses’ was collated via DATIX, self-reporting or 
complaints. 50% (n=8) mentioned that information was not collated about ‘near misses.’  One 
of the respondents added that Eclipse Live categorised potential errors according to their 
likelihood of harm. 31.3% (n=5) did not give any comment on the question but left it blank or 
stated that ‘near misses’ were reported to NHSE. 
 
Existing CCG interventions to prevent medication incidents in general practices and 
community pharmacies 
Newsletters were mostly mentioned as an intervention used to prevent reoccurrence of 
medication incidents. 37.5% (n=6) respondents stated that their CCG used newsletters and 
bulletins about potential incidents. 25% (n=4) respondents mentioned that medication 
incidents are routinely highlighted during training, while 12.5% (n=2) discussed them during 
forums. One CCG mentioned that incidents were addressed during monitoring visits to sites. 
25% (n=4) respondents mentioned two tools used to prevent reoccurrence of medication 
errors namely ‘Script Switch’ and ‘Eclipse Live.’ 18.8% (n=3) respondents mentioned other 
methods, which included monitoring CD prescribing, querying large doses and quantities, 
and using ‘prescribing incentive schemes,’ which focus on safety in the use of Lithium and 
Methotrexate. 
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5.5.3 Results on survey sent to NHS England Area Teams (Post-CCG formation) 
A further 28 surveys were sent to NHSE Area Teams across England. Two respondents 
returned their completed surveys (response rate = 7.1%).  Their responses are discussed 
below. 
Categories of incidents classed as prescribing or dispensing errors 
Issues considered to be both prescribing and dispensing errors, by either one or both of the 
respondents, included wrong medication, wrong dose, wrong strength, wrong patient, wrong 
formulation, omission error and ignorance of patient history, [which may lead to contra-
indication or interaction errors]. Issues highlighted as dispensing errors only include wrong 
quantity, labelling error, and “any aspect of pharmacy law and ethics.” Complaints and near 
misses were also highlighted as possible prescribing errors. 
 
How reporting takes place 
Both respondents mentioned that errors reported “as and when they occur.” A respondent 
further commented that “otherwise, how will they remember, and some have to be resolved 
immediately.” One of the respondents mentioned that there is no scheduled collation of 
critical incident data, while the other stated that “CD occurrences are collated quarterly.” 
 
Protocols to manage errors 
With respect to protocols used to identify, record, and report medication errors, one NHSE 
Area Team mentioned that each institution have their own system in place, and that all 
pharmacies and GP surgeries must report controlled drug errors to them. The other Area 
Team mentioned that institutions either use a template provided by them or in some cases, 
multiple pharmacy groups use their own processes. Both respondents stated that systems are 
in place to review critical incidents either on “an incident by incident basis,” or “weekly 
patient safety meetings to review incidents across the Area Team.” 
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Near misses 
One NHSE Area Team stated that ‘near misses’ are not recorded, while the other mentioned 
that they collated via self-reporting or complaints. ‘Near misses’ were also mentioned as a 
type of prescribing error to question 1. 
 
Prevention of reoccurrence of errors 
One of the respondents did not answer the question relating to prevention of errors. The other 
respondent mentioned the use of newsletters, and action plans on designated forms. Also, the 
involvement of GPhC, Police, and “NHS protect,” were highlighted as part of the Area 
Team’s patient safety group. 
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5.6 Discussion 
This survey provided the opportunity for the recently abolished PCTs and recently formed 
CCGs medicines management teams to characterise their existing systems for identification 
and management of medication incidents in primary care, particularly general practices and 
community pharmacies. 
A survey was sent to 146 PCTs, with 27 responses (response rate=18.5%), 108 CCGs, with 
16 responses (response rate=14.8%), and 28 NHS Area Teams, with 2 responses (response 
rate=7.2%). There are various theories as to why questionnaire surveys may achieve a low 
response rate; a few are discussed below. 
The study design has a major impact on results achieved and conclusions made. The study 
had intended to send the survey electronically via email. To obtain the email addresses of the 
relevant person, phone calls were made to about 50 PCTs. However, it proved difficult and 
near impossible to obtain the email addresses of potential respondents. With increasing use of 
technologies and computers to conduct surveys, it is possible that some people were less keen 
to fill out and post a research questionnaire. 
Another challenge, which was encountered, was identifying the most relevant person or role 
to address the questionnaire to. Although the questionnaire was initially designed with 
“clinical governance leads” as the potential respondents, following the telephone 
conversations to PCTs, it had become apparent that various titles were used for related roles. 
Since the survey was therefore invariably aimed at any member of the PCT or CCG dealing 
with medication incidents, it was difficult to ascertain exactly who should be completing the 
questionnaire. It was therefore decided to mail the questionnaire to the “Heads of Medicines 
Management” and “Chief Pharmacists” as these were the most relevant titles. This was a 
limitation as Dillman states as part of his ‘Total Design Method’ (TDM), that personalizing 
questionnaires achieves a higher response rate (Dillman, 1978; Hoddinott & Bass, 1986). 
This could be because the recipient was then less likely to assume someone else would take 
responsibility for it. In UK secondary care, medicines management personnel are readily 
‘visible,’ and organizational structures are clearer. This is necessary in primary care to 
promote accountability. An important role like the Head of Medicines Management or the 
Clinical Governance Lead of a local health authority or commissioning groups should indeed 
be readily available on the PC/CCG or NHS website. This is even more relevant in the face of 
  140 
changes in the NHS. Standardization of roles and titles across CCGs in England may promote 
this. 
Questionnaires were sent to a subset of CCGs, which were conveniently chosen.  This may 
have introduced some bias. Furthermore, the list of addresses was supplied by a research 
driven health care company, who may have only had CCGs they were interested in contacting 
on their mail list. The list may also have been compiled during the early stages of abolition of 
PCTs and formation of CCGs, which may have consisted of those CCGs, developed first. 
Nevertheless, the use of this mailing list was the most convenient option due to time 
constraints. The list contained approximately 51% of CCGs in England (108 of 211), which is 
a sufficient sample to obtain an overall idea of how CCGs dealt with medication incidents. 
This was a cross-sectional study, as a portrait of one group’s opinion at a particular time was 
required (Fink, 1995b) (pg. 3). The survey mostly required qualitative responses, and was 
self-administered. The fact that the survey was self-administered may have led to bias, as it is 
possible that only those interested in the topic may have been willing to complete it.  
As the questionnaire was aimed at senior members of the PCT/CCG, it is possible that as 
busy individuals, they may not have had the time to complete it. Jenkins and Dillman surmise 
that self-administered questionnaires require cognition and motivation. Hence, the 
questionnaire included a covering letter as it was hoped that this would highlight the 
importance of the study, thereby persuading the respondents to take some time out of their 
busy schedule to complete and return it (Jenkins & Dillman, 1997).  
The questionnaire consisted mostly of open-ended questions. These required respondents to 
use their own words. Open-ended questions are generally used when answers are 
unanticipated, and respondents are judged capable of voicing their own opinions in writing 
(Fink, 1995a) (pg. 32). The disadvantage of this is that the researcher is unable to rate or rank 
data, and statistical tests cannot be used to report on results. Interpreting answers may require 
elaborate coding systems, which may be complicated (Fink, 2006) (pg. 14). 
The questionnaires covered 5 sections. The first section covered what incidents members of 
PCTs, CCGs and NHSE considered to be prescribing and dispensing errors. This question 
was asked due to existing ambiguities around the definitions of medication errors. Research 
and practice do not often clarify their working definitions on medical errors leading to 
assumptions and multiplicity of definitions (Sandars & Esmail, 2003). Sandars and Esmail 
found 16 different definitions of medication-related errors; some of these included incidents 
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that caused actual harm to the patient, incidents that could have potentially caused harm, 
adverse drug reactions, and not conforming to the British National Formulary. Other 
researchers have further highlighted this issue (Olaniyan et al., 2014). Although the various 
categories of incidents categorised as prescribing and dispensing errors by respondents were 
in keeping with the literature (Ashcroft, Quinlan, et al., 2005; Avery, Barber, et al., 2012; 
Dean Franklin & O'Grady, 2007; Spencer et al., 2011), it would appear that most PCTs did 
not have a validated reference source for categorizing errors as different descriptors were 
used for similar types or categories of errors. In addition, what appeared to be a “major” error 
category or “irritate” respondents were fairly varied; for example, the only category of 
prescribing error described by one respondent was “prescribing on repeats without 
appropriate checks”, and another “wrong strength, commonly MST (morphine sulphate) 
100mg instead of 10 mg, Oramorph® concentrated versus 10mg/5ml”. It may therefore be 
concluded that healthcare professionals working within primary care do not have a working 
definition of what constitutes a prescribing error so that error management is somewhat 
subjective and dependent on the opinion of a person rather than an organisation. 
It was further interesting to observe that during some respondents considered ‘near misses’ as 
a medication error. The NPSA’s “Seven Steps to Patient Safety in Primary Care” stated that 
‘near misses’ are under-reported, as healthcare professionals do not understand what they are. 
The NPSA has further recommended that the term ‘near miss’ should no longer be used, but 
should be replaced by the term ‘patient safety incident (prevented).’ NPSA further highlights 
that it is important that prevented or potential incidents are reported and analysed, as they are 
a good way to learn about which controls have worked and which need to be improved 
(National Patient Safety Agency, 2006). Figure 2 (Page 10) highlights the definition of a 
medication error that should be understood by healthcare professionals working for the NHS 
or alongside the NHS. The figure shows that medication-related incidents fall under two 
categories: those that are preventable and those that are not. Only those, which are 
preventable, are considered as errors. Also, medication errors do not necessarily have to 
cause harm to the patient and could be incidents, which may have potentially caused harm 
(Morimoto et al., 2004). 
Another issue that was highlighted when analysing the first section on error categories was 
that there are differences between what is considered a prescribing error and a dispensing 
error. There are certain categories of errors, which may be common to both prescribing and 
dispensing namely issuing the wrong product, wrong dose, wrong strength, wrong 
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formulation, wrong quantity etc. However, results showed differences between those 
included as answers to questions one and two. This may not be because, for example, issuing 
the wrong product is considered as a only a prescribing error, but could possibly be due to 
respondents finding the task of writing the same answer twice repetitive and time consuming. 
This is evident as some respondents suggested referring to question one when they answered 
question two. This is further highlighted by up to a 6% reduction in error categories 
mentioned in question two compared to question one. 
Respondents also suggested that errors that occurred as a result of ignorance of a patient’s 
history, for example, allergies or contraindications, were errors of a prescriber rather than a 
dispenser. On the other hand, a dispensing error would generally occur when exactly what a 
prescriber intends is not supplied. 
Another interesting error mentioned by a respondent was giving incorrect oral advice about a 
medication. According to the definitions highlighted in Figure 1, incorrect oral advice will 
count as an error, as it has the potential to cause harm to a patient. However, an incorrect 
advice is difficult to quantify or record. As there is rarely any written evidence to suggest 
incorrect advice was given, it is difficult to trace whether a patient’s health outcome was 
compromised as a result of the incorrect advice. There is also the problem of inaccurate 
interpretation, as a healthcare professional may argue that patient’s interpretation was 
inaccurate.  
Section two (questions three and four) of the survey sought to understand how reporting took 
place within the PCT/CCG: how critical incidents were reported to the CCG, and how often 
the reports were reviewed. Respondents referred to the use of DATIX, ePACT (see above), 
and more recently, ScriptSwitch6 and Eclipse Live7 to capture medication incidents. These 
aid the prescriber’s decisions on medication switches and dosage optimisation while 
identifying inappropriate prescribing and safer alternatives. 
Most of respondents from CCGs did not think this was under their remit though, and often 
commented that this was now under the NHSE Area Team’s administration. It was however 
                                                          
6 ScriptSwitch is a prescribing decision support for healthcare professionals within the primary care sector. 
Although it’s main aim to provide savings at the point of prescribing, it can provide patient safety effect by 
supporting clinicians to optimise prescribing and improve patient health outcomes (www.scriptswitch.com). 
7 Eclipse Live: Eclipse stands for Education & Cost-analysis Leading to Improved Prescribing Safety & 
Efficiency. Eclipse is a new service to optimise prescribing by using powerful computer technology to improve 
cost-effectiveness of prescribing and patient safety in primary care (www.eclipsesolutions.org).  
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interesting to observe some CCG’s actually had their own protocol to capture medication 
errors. For example, one CCG stated, “critical incident data is reviewed by our GP 
governance lead,” and “serious incident reporting policy in place and contains process to be 
followed.” Such variations in responses may indicate some confusion at management level, 
which may compromise patient safety. If roles around managing the reporting and collation 
of medication incidents are unclear, it is possible to assume that errors may go unnoticed. In 
the National Patient Safety Agency (NPSA) document ‘Seven Steps to Patient Safety,’ step 4 
relates to promoting reporting of incidents within the NHS. The NPSA recognizes that one of 
the key areas that the NHS needs to address is to successfully achieve a unified mechanism 
for reporting and analysing incidents when things go wrong. What is readily apparent from 
this study is the lack of such ‘unified mechanisms,’ particularly within local authorities or 
commissioning groups. 
 
5.7 Conclusion 
There appeared to be a consensus that the NHSE Area Teams have responsibility for 
capturing and managing the recording, reporting and review of medication errors. This led 
the research team to take the decision to send the intended reminder to the NHSE Area Teams 
as opposed to the CCG. Again, after contacting some Area Teams directly, it became 
apparent that the most relevant addressees would be members of the Medicines Management 
Department, to which the surveys were sent. It was therefore surprising that only 2 (7.1%) of 
28 NHSE Area Teams completed the survey. Nevertheless, it is possible to conclude that 
responsibilities for managing medication errors in primary care laid with the now defunct 
PCTs, though processes were not necessarily standardised across PCTs at the time. Although 
CCGs have some responsibility to “maintain and improve the safety of services provided by 
the health service,” it is the within the remit of the NHSE Area Teams to collate and review 
medication error reports to facilitate learning in primary healthcare organisations. Without 
clear guidelines as to who is responsible and accountability within CCGs however, there is 
potential that important lessons are not being learnt within primary care. 
This is particularly important as the NHS has been put under the spotlight to get patient safety 
right in the wake of scandals such as the Mid Staffordshire Scandal (Holmes, 2013). 
Furthermore, the fourth report from the Patient Safety Observatory states that the annual cost 
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of avoidable harm to patients on the NHS is £774 million, £359 million of which are a result 
of avoidable admissions to hospital (National Patient Safety Agency, 2007). 
 
5.8 Study limitations 
The response rate is determined from the number of eligible respondents included in the 
study, as a percentage of the total eligible study population (Bowling, 2014). Over the past 
two decades, academic, policy and government survey researchers have found themselves 
competing with market researchers, leading to increased time pressures on people’s daily 
lives (Bowling, 2014). Although there is no agreed standard for a minimum response rate, a 
response rate of 60% is generally acceptable (Groves and Couper, 1998) as cited in (Bowling, 
2014). Response rate greater than 75% is considered good. Non-response can therefore affect 
the quality of research data and reduce the accuracy of results. 
There is general consensus that response rates are higher for interviews than for postal or 
telephone surveys, with up to a 20% difference (Cartwright, 1988) as cited in (Bowling, 
2014). Bowling (2014) has summarised some of the methods for increasing response. These 
include including a covering letter, use of an advance letter, provision incentives, use of 
postal reminders, impact of length of questionnaire and sponsorship, etc. Although the 
current study attempted to improve response rates by applying some of these principles, the 
study’s response rate was still very low. The NHS primary care climate was less outlined as 
at the time of this survey due to the abolition of PCTs and creation of CCGs with 
uncertainties and handovers. It is therefore highly possible that this adversely impacted 
response rates. 
Considering some of the recommendations by (Bowling, 2014; Dillman, 1978; Fink, 1995a), 
the survey may be improved to include closed questions. This would make the questionnaire 
easier to complete and allow statistical tests to be conducted thereby making conclusion 
valid. The use of closed questions will further improve the reliability of the instrument and 
enable to researcher to achieve similar results each time. 
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Chapter 6. The prevalence and nature of prescribing and 
monitoring errors in older patients and in children: introduction and 
study setting 
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6.0 Introduction 
This chapter will explore the aim, methods, data validation, data cleansing and the 
characteristics of the GP settings where the studies were undertaken. 
Chapter 7 will then describe the characteristics of older patients and prescriptions studies, and 
the results of the investigations on older patients 
Chapter 8 will explore the paediatric data – characteristics and results of investigations. 
Chapter 8 will also provide the discussions on the findings of the investigations in older 
patients and children. 
Medication errors are a common source of preventable harm (Department of Health, 2000). 
The National Patient Safety Agency (NPSA) reported that between April 2008 and March 
2009, the most common incident type reported to the National Reporting and Learning 
Service (NRLS) from general practice were related to the use of medication at 24% (National 
Patient Safety Agency, 2009). Research has estimated that about 6.5% of hospital admissions 
take their root from management in primary care (Pirmohamed et al., 2004); for elderly 
patients however, the figure rises to 19% of hospital admissions as a result of medicines-
related problem Cannon and Hughes, 1997 in (Barber et al., 2009).  
The problem of medication errors has been studied; however, much of this work has been 
focused in secondary care, though most patients get treated in the community, with ≥ 1.03 
billion items prescribed in 2013 compared to 649.7 million 2003 (Prescribing and Primary 
Care Health and Social Care Information Centre, 2014). Research is emerging on the 
prevalence and nature of medication errors in primary care (Avery, Barber, et al., 2012; 
Barber et al., 2009), with suggestions that older patients and children may be more 
susceptible to significant risk of harm from medication errors (Avery, Barber, et al., 2012; 
Barber et al., 2009; Garfield et al., 2009).  
Older patients are more susceptible to risks of harm from medication errors and subsequent 
adverse drug events (ADE) due to co-morbidities and resultant polypharmacy, susceptibility 
to changes in pharmacodynamics and pharmacokinetics, possible renal and hepatic 
impairment, contact with various multi-disciplinary healthcare practitioners within and 
between visits, etc. For example, Barber et al (2009) found an error rate of 8.3% prescriptions 
or 69.5% of patients when they studied medication errors in older patients in care homes with 
a mean age of 85 years, while a GMC-commissioned study of medication errors in all 
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patients with a mean age of 39.3 years found an error rate of 4.9% prescriptions or 12% of 
patients (Avery, Barber, et al., 2012). 
Evolution of newer drugs and therapeutic procedures, and increase in an aging population has 
posed even more challenges for the art of prescribing (Maxwell et al., 2002). In addition, 
some conditions, which were previously managed in secondary care, are increasingly being 
managed in primary care. These have meant an increase in the potential for errors in 
prescribing and primary care management. There has however, been no study to date in the 
UK to evaluate the incidence and nature of medication errors in older patients living in the 
community, though a higher number of older patients would normally live in the community. 
The need for weight- or age- or surface area-related dosage determinations, titration of 
strengths of existing proprietary medicines to make them safe for use in children, unlicensed 
or off-label drug use, etc. may account for the inherent challenges and risk of harm from 
medication errors in children (Wong et al., 2004). The evidence suggesting higher prevalence 
of medication errors and corresponding harm in children is sparse, although some research 
suggest that errors and harm could be higher in children than in adults. For example, in a 
prospective cohort study of paediatrics patients in six outpatient offices, researchers found 
that 68% of patients (53% of prescriptions) contained an error with minimal potential for 
harm, and 26% of patients and (21% of prescriptions) had potentially harmful medication 
errors (i.e. near misses) (Kaushal et al., 2010). These rates were much higher than the 13.2% 
of medication orders, which contained prescribing error from an in-patient evaluation of 
paediatric medication errors in the UK (Ghaleb et al., 2010). There have also been no studies 
to evaluate the incidence and nature of prescribing and monitoring errors in children in the 
community in the UK. 
 
6.1 Aim and objectives 
Aim 
To determine the prevalence and nature of prescribing and monitoring errors in older patients 
and children in general practice 
Objectives 
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1. To investigate the rates and types of prescribing errors in older patients ≥65 years old 
and in children 0-12 years old 
2. To investigate the rates and types of monitoring errors for prescribed medications, 
which require laboratory blood monitoring in older patients ≥65 years old and in 
children 0-12 years old 
3. To determine the nature of prescribing and monitoring errors in older patients ≥65 
years old and in children 0-12 years old 
4. To explore if prevalence and nature of identified errors vary with characteristics of the 
general practice, of patients or of prescriptions: 
a. To identify drugs, which are most commonly associated with a prescribing or 
monitoring error 
b. To identify the British National Formulary, BNF sections most commonly 
associated with a prescribing error 
c. To investigate associations between error rates and age 
d. To investigate associations between error rates and prescription types 
e. To investigate associations between error rates and patients’ sex 
f. To investigate associations between error rates and number of prescription 
items issued 
5. To provide feedback to participating practices, with identification and 
recommendation of best practices and/or pragmatic educational interventions to 
prevent error occurrence in older patients and in children in general practice 
 
Participants and methods 
Data collection commenced in November 2013 and was completed in October 2014.  
6.2 Recruitment of PCTs, CCGs, and general practices 
The study approached all the general practices in Luton CCG through their Prescribing and 
Medicines Optimisation team, by sending out a letter of invitation to participate, and 
participant information sheets (see appendices). A reminder was sent two weeks after the 
initial invite. Due to very low response rates, the study purposively selected two practices, 
which then agreed to participate. 
Based on the experience of recruitment from Luton, the study approached the Prescribing and 
Medicines Optimization team in Bedfordshire CCG to identify five practices, with different 
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deprivation levels, and a mix of suburban, rural and urban settings, from those of Luton. Two 
practices, with a larger list size and different levels of deprivation, than those of Luton CCG 
were then purposively selected from the initial list. In all, four practices, two each from both 
CCGs were recruited to participate in the study, although the study was eventually conducted 
in one practice in each CCG, with a decision to increase the number of patients reviewed per 
practice. 
A clinical pharmacist, the chief investigator, reviewed the patients’ electronic medical 
records. The pharmacist received 2 days training on the use of the Vision and SystmOne 
clinical computer systems, and on the identification of prescribing and monitoring errors in 
general practice using the study’s definition from the research supervisory team and CCG 
pharmacists, whose roles involved retrospective review of electronic medical records. 
 
6.3 Quantitative data collection 
The practices’ were requested to provide information on their list size, age-sex breakdown, 
number of GPs and other independent prescribers, clinical computer system used, whether 
they were a dispensing practice or not, their performance in the NHS Quality and Outcomes 
Framework, QoF, and whether they were a training practice. A pilot study was conducted in 
each practice over two days to estimate how long it took to review records, and the 
practicalities of collecting study data on electronic forms.  
A list of all registered patients aged 65 years and over, and 0-12 years was generated from the 
electronic record in each practice. From these lists of all registered patients in the study age 
groups of interest, a random sample of patients was selected using computer-generated 
random numbers as follows: 18% and 11% of older patients ≥65 years old, and 18.76% and 
16.28% of younger patients 0-12 years, from the two practices, which were named L1 and B1 
respectively for the purposes of the study. 
The clinical pharmacist then conducted a thorough review of the medical records of those 
patients, whose records were randomly selected, to identify potential prescribing and 
monitoring errors for each unique prescription item issued in the 12-months preceding the 
data collection date. The pharmacist included everything they thought would fit within the 
error definition, and reviewed only the last issues of prescriptions, which had been issued 
more than once in the 12-months period. The pharmacist recorded prescription data on 
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specially designed forms, which had been used in a previous study of medication errors in 
primary care, and piloted for the current study: 
 Appendix 13: form used to record data on patient demographics and prescription items 
 Appendix 14: form used to record details of prescribing and monitoring errors  
 Appendix 15: form used to record details of omission errors relating to failure to 
prescribe for an existing clinical condition 
 
6.3.1 Definition and classification of prescribing and monitoring errors 
The definition of a prescribing error used in this study is as follows (Dean et al., 2000): 
“A prescribing error occurs when, as a result of a prescribing decision or prescription-writing 
process, there is an unintentional, significant reduction: in the probability of treatment being 
timely and effective or increase in the risk of harm when compared to generally accepted 
practice.” A list of examples of what should, and should not, be included as an error 
accompanied this definition (Dean et al., 2000). 
The following definition was used for a monitoring error (Alldred et al., 2008): 
“A monitoring error occurs when a prescribed medicine is not monitored in the way which 
would be considered acceptable in routine general practice. It includes the absence of tests 
being carried out at the frequency listed in the criteria, with tolerance of +50%. This means 
for example, that if a drug requires liver function tests at 6 monthly intervals, we would class 
as an error if a test has not been conducted within 9 months. If a patient refused to give 
consent for a test, then this would not constitute an error.” 
The pharmacist referred to a list of medicines requiring blood test monitoring Appendix 16), 
which was created and used by primary care researchers in a previous study of monitoring 
errors in general practice (Avery, Barber, et al., 2012). Potential errors were then classified 
by type (Appendix 17). 
6.3.2 Identification of prescribing and monitoring errors 
An error-judging panel, which comprised of an academic pharmacist, primary care or 
community pharmacist and a clinical pharmacist, discussed each error identified by the 
reviewer using the study definitions outlined above. The panel also reviewed the error 
classification and either agreed or disagreed with the recorded classification by the reviewer. 
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When two of the three panellists and reviewer agreed that an error had occurred, or on the 
error classification, it was judged accordingly. 
 
6.3.3 Data collection on potential omission errors relating to failure to prescribe for an 
existing clinical condition 
A third category of errors, in addition to prescribing and monitoring errors, which was 
captured by the study was potential omission errors relating to failure to prescribe for an 
existing clinical condition. An example of this type of error may be failure to prescribe a 
bisphosphonate/calcium supplement for an older patient with diagnosed osteoporosis where 
no allergies, contraindications nor patient preferences were recorded (Avery, Barber, et al., 
2012). 
 
6.3.4 Data entry 
The raw data were entered into a Microsoft Access database, which was previously created 
and used by the PRACtISE study. The database forms were made to be similar to the original 
paper copies of the data collection forms used to collect data from practices. A sample of the 
form used to record patient demographics and prescription data onto the database is shown in 
Figure 9 below. The information recorded in this section of the database form included 
database number, practice and patient identity codes, gender, age, number of months patient 
had been registered with the practice, and a tick box displaying if patient had had medication 
within the 12-months review period. Drop down menus were available for selecting 
prescriptions issued to the patient during the review period, and for selecting the type of 
prescriber who had issued the prescription item. There were also tick boxes for each 
prescription item to indicate if a prescription was on the monitoring list, and if it was an acute 
or repeat prescription. Lastly, there was a section to record the number of potential error(s) 
identified for the prescription item.  
Information on prescription items with a potential error was entered on Form 2 (Figure 10). 
This form contained information on drug name, strength, dose, quantity, and a unique 
reference number. There was a drop-down menu to select the error type from. The description 
of the error and potential reason for occurrence were also recorded in this form.  
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Figure 9: Example of a Microsoft Access database form used for entering data on 
patient demographics and prescription items 
 
 
Figure 10: Example of a Microsoft Access form used for recording information on 
potential prescribing and monitoring errors 
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6.3.5 Data cleansing 
The number of electronic patient data collections forms recorded in each practice and 
transcribed into the database was reconciled with the randomised patient list in an Excel 
worksheet. Then, the database entries were checked for errors. For example, a table of patient 
codes was generated to ascertain if the information was exactly as recorded in the Excel 
worksheet. Age-specific medication information was checked to match patients’ recorded 
ages. All errors were also reviewed to ensure that complete information had been recorded, 
and that there were no duplications. Medicines, which were routinely used for more than one 
indication and therefore belonged to more than one BNF section, were checked to ensure that 
the appropriate section had been entered; for example, dispersible aspirin as an antiplatelet 
(BNF chapter 2) or an NSAID (BNF chapter 4). A detailed review of 10 randomly selected 
database records was also conducted. 
Due to the identification of approximately 2% errors in the database entries, each database 
record was double-checked against the original electronic data by the reviewer: patient 
demographics, gender, age, prescription information etc. For example, age- and gender-
related dosage forms and medications. Patients and prescriptions with potential prescribing 
and monitoring errors were thoroughly checked for any inconsistencies. The research degree 
student performed this exercise twice. A log was created to document changes made 
following the thorough checking of the database.  
 
6.3.6 Data extraction 
Tables were generated in Microsoft Access database using existing and newly created 
queries. These tables were exported into Excel worksheets for analyses. Queries included 
information on: 
 Patient demographics 
o Age 
o Sex 
o Number of drugs prescribed during the 12-months review period 
 Drugs prescribed 
o Name, strength, quantity, formulation, BNF drug class, BNF section for each 
drug 
o Number of acute and repeat prescription 
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o Number and type of drugs on monitoring list 
 Errors 
 Prescriber types 
Each of these queries was combined onto the patient demographics detail. Also, queries 
captured prescription information with patient demographics including age, gender, practice 
codes, acute or repeat medication etc., to enable interrogation of how prescription 
information varied with patient demographics. 
 
6.3.7 Severity assessment of errors 
A validated method for assessing the severity of medication errors, which was adapted for 
use with prescribing errors, was used in this study (Dean & Barber, 1999). The current study 
also used an adapted version of the National Patient Safety Agency, NPSA severity 
assessment tool for comparison and applicability (Table 2). A short summary of each 
identified potential error, the visual analogue scale (Figure 11), and NPSA severity categories 
were presented to the judging panel. The panel comprised three clinical pharmacists. The 
mean score across all the three judges and the reviewer was calculated to determine severity.  
Figure 11: An example of the visual analogue scale used to assess error severity 
Patient 
ID 
Error summary Scale 
L1E3_25 
 
76-year old male taking 
Priadel 400mg at night. 
Lithium requires 12-
monthly Thyroid Function 
Tests (TFTs). TFTs last 
ordered in 2011 (2 years) 
 
L1E3_25 
 
76-year old male 
prescribed Diprosalic 
ointment with the 
directions: use on the skin 
in the mornings as advised 
by dermatologist. Part of 
the body to be treated, and 
duration thin application 
not specified. Patient's 
mental difficulties 
documented in notes 
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6.3.8 Quantitative data analyses 
A framework for analyses was designed for the study (Appendix 19). Most of the data analysis 
was undertaken in Microsoft Excel. Descriptive statistics were used to analyse many 
variables relating to patient, practice and prescriber, and prescription characteristics, error 
types, BNF chapters of drugs commonly prescribed, and commonly associated with errors, 
and types of medication errors identified. Frequencies, percentages, means, and standard 
deviations or medians and interquartile ranges were used to characterise continuous variables, 
based on the their distribution. 
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6.4 Results 
Sample characteristics 
Information on the characteristics of the study boroughs/towns, general practices, patients 
and prescriptions are presented in the following section, followed by analyses of errors. 
Two general practices, L1 located in Luton, and B1, located in Central Bedfordshire, were 
recruited for this study. Their characteristics are described below. 
6.4.1 Characteristics of Boroughs/Towns 
Bedfordshire County is made up of three unitary authorities namely Luton, Central 
Bedfordshire and Bedford boroughs.  
Luton Borough is predominantly an urban area located about 30 miles north of London. From 
the Office of National Statistics, OFN and Luton Borough Council, the 2011 census 
estimated that 203,201 people live in Luton; the proportion of male and female residents were 
50.2% and 49.8% respectively (49.2% and 50.8% for both East of England and England and 
Wales). Luton has a much higher population density per square kilometre at 4,690/Km2, 
compared with 310/Km2 for the East of England, and 370/Km2 for England and Wales.  
Ethnicities for Luton were reported as 54.7% White, 29.9% Asian, 9.8% Black, 4.2% Mixed, 
and 1.5% others; in England and Wales ethnicities were reported as 85.9% White, 7.5% 
Asian, 3.4% Black, 2.2% Mixed, and 1% others. Therefore, Luton has a diverse ethnic 
combination with a significant population of Asian descent mainly Pakistani, Indian and 
Bangladeshi (14.4%, 5.2% and 6.7% of Luton’s population respectively. 21.7% of the 
population are younger people 0-14 years old (17.6% in England & Wales). Older people ≥ 
65 years account for 11.8% compared with 16.5% in England & Wales 
(www.luton.gov.uk/about).  
Central Bedfordshire is a predominantly rural area made of countryside and market towns. 
From the 2011 Census, its population was estimated as 264,500 people. Population-wise, 
Central Bedfordshire is the 15th largest unitary council in England. None of her 
neighbourhoods are in the 10% most deprived nationally, although pockets of deprivation do 
exist. It occupies 716Km2, with a density of 369 people/Km2, making it one of the least 
densely populated unitary councils. 61% of residents live in areas classed as urban. When 
compared with England as a whole, Central Bedfordshire is less diverse, with 89.7% people 
of White British ethnicity. The biggest ethnic minority groups were White other – 2.8% (not 
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White Irish or Gypsy or Irish Traveller), White Irish (1.2%), and Indian (1%). About 92% of 
Central Bedfordshire residents were born in the UK. The most common countries of birth 
outside of the UK were the Republic of Ireland, Poland, India, Germany and South Africa.  
Younger people aged 0-15 accounted for 19.5% of the population, while 19.8% of the 
population were older people ≥ 65 years old. One or more persons aged 65 years and over 
occupied 19.9% of households in 2011 while 31.5% of households had dependent children, 
defined as a person aged 0-15 or 16-18 in full-time education. 
(www.centralbedfordshire.gov.uk). 
 
6.4.1.1 Indices of Multiple Deprivation (IMD) 2010 scores 
The Department for Communities and Local Government’s Indices of Deprivation is an 
umbrella name, which measure and provide a comparative measure of deprivation in small 
areas across England. The scores and ranks produced for each index are based on the view 
that deprivation is not just due to poverty, but also points to a general lack of resources and 
opportunities. In addition to examining income-based measures, deprivation further looks at 
other socio-economic issues such as crime, education, employment and health 
(https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010). 
Seven domains are created from grouping thirty-eight separate indicators. These domains 
show different aspects of deprivation, and are used to produce an overall Index of Multiple 
Deprivation (IMD) score for each English small area. The seven domains are income, 
employment, health, education, crime, access to services, and living environment. Each 
domain has their scores and ranks enabling focus on specific areas of deprivation. The 
income measure is divided into two: the Income Deprivation Affecting Children Index 
(IDACI), which examines specifically, income deprivation in households containing children 
0-15 years, and Income Deprivation Affecting Older People Index (IDAOPI), which looks 
specifically at income deprivation in households containing older people aged 60 and over.  
Deprivation is measured for small areas known as Lower layer Super Output Areas (LSOAs), 
boundaries of which were created by the Office for National Statistics in 2001. England has 
been divided into 32,482 small areas, each with similar estimate of the number of people. The 
most and least deprived small areas in England could be identified and compared from 
rankings according to their IMD score. If the proportion of people living in a small area who 
  158 
are classed as deprived is higher, such an area has a higher deprivation score than another 
one.  
Of 326 district and unitary local authorities in England, Luton was ranked the 69th most 
deprived local authority district according to the 2010 IMD summaries. Central Bedfordshire 
has a Rank of Average Score of 269. The first general practice L1, which participated in the 
current study, is located in Wigmore LSOA in Luton, while the second practice, B1 is located 
in Leighton Buzzard South LSOA in Central Bedfordshire. Both LSOAs have an IMD rank 
for 2010 in the top 10%-20% least deprived areas nationally. However, there are numerous 
LSOAs in the least deprived areas in Central Bedfordshire, when compared with Luton.  
Wigmore LSOA is ranked in the top 20%-50% least deprived area nationally according to the 
Indices of Deprivation for Education, Health, and Income Deprivation Affecting Children in 
Luton in 2010. However, for Employment and Income Deprivation Affecting Older People 
(IDAOPI), it is ranked in the top 10% least deprived area nationally, although the levels of 
deprivation were particularly high in Luton for IDAOPI, with 22 LSOAs in Luton in the top 
10% most deprived areas in the country. Summarily, Luton has higher levels of deprivation 
than neighbours, Bedford and Central Bedfordshire. Luton had the most LSOAs in the top 
10% most deprived areas in England for the deprivation categories measuring indices 
affecting children and older people. 
There are 154 LSOAs in Central Bedfordshire. Central Bedfordshire has relatively low levels 
of deprivation with 127 LSOAs in the least deprived 50% of areas in England. Six LSOAs 
(including Leighton Buzzard North) were however in the 20-30% most deprived areas in 
England, and three LSOAs in the 10-20% most deprived areas. Central Bedfordshire LSOAs 
are in the most deprived 20% of LSOAs in England in all but one of the domains, namely 
Living Environment. 
In Central Bedfordshire, 9 LSOAs were in the most deprived 30% for Employment in 
England, 19 LSOAs are in the most deprived 30% in England for Education, Skills and 
Training Deprivation domain, and 15 LSOAs were in the most deprived 10%-20% in 
England for Barriers to housing and services domain. Leighton Buzzard North LSOA was in 
all three categories, although Leighton Buzzard South, were B1 is located, was not named in 
any of these categories. Six LSOAs in Central Bedfordshire were in the most deprived 30% 
in England for Health Deprivation and Disability in 2010. All of these areas are in the South 
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of Central Bedfordshire, and include both Leighton Buzzard North and South where B1 is 
Located.  
15 LSOAs in Central Bedfordshire (including Leighton Buzzard North and Leighton Buzzard 
South) are in the most deprived 30% in England for the Income Deprivation Affecting 
Children Index, with 36% of children in Leighton Buzzard living in income-deprived 
households; the average figure for Central Bedfordshire was 13% of children living in 
income-deprived households, while the average for England was 22%. 
On the other hand, 11 LSOAs in Central Bedfordshire (including Leighton Buzzard North 
and Leighton Buzzard South) are also in the most deprived 30% in England for the Income 
Deprivation Affecting Older People Index, with 26% of older people in Leighton Buzzard 
living in income-deprived households; the average figure for Central Bedfordshire was 13% 
of older people living in income deprived households, and the average for England was 18%. 
Table 6 provides a summary of the rank of scores for Indices of Deprivation and IMD scores 
and ranks for L1 and B1 LSOAs. 
Summarily, Luton has higher levels of deprivation than neighbours, Bedford and Central 
Bedfordshire. Luton had the most LSOAs in the top 10% most deprived areas in England for 
the deprivation categories measuring indices affecting children and older people.  
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Table 6: Indices of Deprivation Ranks for Central Bedfordshire (B1) and Luton (L1)8 
Local 
Authority 
Code 
Local 
Authority 
Name 
Rank of Local 
Concentration 
Rank 
of 
Extent  
Rank of 
Income 
scale 
Rank of 
Employment 
Scale 
Average 
score 
Rank of 
Average 
Score 
Rank of Average Rank 
00KC Central 
Bedfordshire 
227 224 110 117 10.73 269 278 
00KA Luton 112 74 63 87 25.78 69 60 
 
                                                          
8 Rank of score of English Indices of Deprivation 2010  (available from https://www.gov.uk/government/collections/english-indices-of-
deprivation)  
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6.4.2 Characteristics of general practices 
L1 is a five-doctor, five-nurse, training practice, with over 8000 registered patients and high 
Quality of Outcomes Framework (QOF) scores. Housing in the practice area attracts young 
families, so that the practice has about twice the usual number of young children, and fewer 
elderly patients.  
It is a National Minor Illness, which the holds University-accredited courses during the year for 
health professionals who need to assess urgent care, “Is it minor illness or not?” The practice 
has written the definitive textbook on the subject. Most of their students are practice nurses, 
who wish to improve access to healthcare in their own practices by being first contacts for 
assessment. The practice is also involved in teaching GP registrars, Foundation Year Doctors, 
nurses, medical students from University College London, and runs courses for practice 
administrative staff on repeat prescribing.  
L1 is a Royal College of General Practitioners (RCGP) research accredited practice. 
Historically, the practice had undertaken independent research in broad areas including 
childbirth, urinary infection in children, prescribing and patient perceptions of medication, etc. 
However, due to funding difficulties, the practice currently participates more in collaborative 
and multi-centre projects. The practice mentions that it holds regular clinical team meetings 
including audit discussion, significant event reviews, and meetings with the extended primary 
care team including district nurses and other nurses. 
The practice building also houses a different practice, and has a Lloyds Pharmacy just outside 
its front door. The practice used INPS Vision clinical computer system when records were first 
reviewed. The system has since changed to SystmOne. Surgery hours are between 08.00 am 
and 18.30pm Monday to Friday. The practice information mentions that although patients are 
registered with the practice rather than an individual GP, continuity of care is encouraged. 
Routinely, a doctor has twenty pre-booked fifteen-minute appointments plus slots for urgent 
care. Visits are fewer than for many comparable practices because of the practice’s young list. 
The on-call rota is shared with the neighbouring practice so that urgent visit requests are less 
disruptive to the practice’s schedule.  
In their “Ethos of the Practice” statement, the practice notes that although they want to 
maximize the practice’s income, they are happy to forego money when they see no benefit to 
patients from “chasing a particular target.” They state that they are not a high-earning practice 
  162 
but hope to gain their rewards mainly from achieving more than might be expected for their 
patients and ensuring their students develop great skills. 
B1 is also a five-doctor, four-nurse, practice with just under 11,000-registered patients. Unlike 
L1, housing in the practice area attracts working families, so that the practice has comparable 
proportions of younger patients 0-12 years old and older patients 65 years and over, which 
account for approximately 16.0% and 17.9% of the surgery’s registered population, 
respectively 
The practice states in its policy that it is a training and research practice, which encourages 
patient participation to “shape the future of healthcare” in primary care where the treatment 
outcomes are important being the “real setting,” when compared to secondary care or hospital 
care. The practice’s research interests lie in “important conditions affecting primary care.” 
Although the practice does not mention specific types of training undertaken, it states that 
medical students may see patients with their permission before their appointment with a GP. 
The practice is open from 8.00 am to 6.30 pm Monday to Friday. Opening times have also been 
extended to include Saturdays 8.30 am -12.30 pm, and varied late opening on Thursdays and 
Fridays. Like L1, the practice uses SystmOne clinical computer system. The practice lists 
services offered as counselling, community nursing, family planning, smoking cessation, travel 
health, and other non-NHS services. There is a pharmacy next to the surgery, and a door links 
both. There are also several pharmacies within 300 yards walk of the practice. 
 
The characteristics of the two practices are compared below in Table 7 and Table 8. 
 The mean list size was 9,518 (standard deviation, SD = 1359) 
 Both are involved in some form training, although L1 gives more information on this 
 Neither were dispensing practices, though both had dispensing pharmacies next to them 
Table 7: Characteristics of the two English General Practices involved in the SAFECaRE 
study 
GP 
Practic
e code1 
Practice 
List 
size 
Is the 
practice a 
GP 
training 
practice? 
Is the 
practice 
urban 
or 
rural? 
Dispensin
g practice 
or non-
dispensing 
Deprivation 
score2 
Numbe
r of 
GPs 
Clinical 
computer 
system used 
within the 
practice 
L1 8,159 Yes Urban No 25.78 5 SystmOne 
B1 10, 877 Yes Rural No 10.73 5 SystmOne 
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1Code is for the purposes of the study only; 2Based on 2010 Index of Multiple Deprivation figures 
 
Table 8: Comparison of characteristics of general practices involved in the study with 
national figures for England 
Characteristic Mean (practices studied) Mean National Figure 
Practice list size 9,518 7,294 
IMD 2010 score 18.26 19.15 
QOF total points per practice 79% 92.4%2 
22013/2014 Quality and Outcomes Framework figures for England (available from: http://www.ic.nhs.uk/qof)
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Chapter 7. Results of the investigations of the prevalence and nature 
of prescribing and monitoring errors in older patients 
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7.0 Characteristics of older patients reviewed 
Chapter 6 above has provided the introduction, aim and objectives, the general methods, and 
descriptions of the study settings on the prevalence and nature of prescribing errors in older 
patients and in children. This chapter provides the results of the investigations on older patients 
and Chapter 8 below provides the results of the investigations in younger patients, and the 
general discussions of this study. 
The study involved the retrospective review of the records of 364 older patients 65 years and 
over, with a mean age of 73.68 years (standard deviation, SD = 7.75) and 193 (53.02%) female 
patients. Of the 12-months retrospective record review period, these patients were registered 
for an average of 11.84 months (SD = 0.97).  
 
Of the 364 older patients reviewed, 323 (88.74%) had had at least one prescription during the 
12-months retrospective review of their records; the percentage of patients reviewed, in each of 
the following age categories that had received at least one prescription, were  
 93% of all patients ≥85 years old (40 of 43) 
 93% of all patients 75-84 years old (93 of 100) and 
 85% of all patients 65-74 years old (190 of 221). 
 
The percentage age distribution of older patients whose records were examined is shown below 
in Figure 12. It can be seen that over a third of patients were ≥75 years old (n=143). 
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Figure 12: Age distribution of older patients ≥65 years old 
 
 
At practice level, the study involved the examination of 150 of 840 (17.86%) registered older 
patients 65 years and over in L1; the number of records reviewed in B1 was 214 of 1978 
(10.82%) registered patients. The mean ages of these patients were 72.90 years (SD = 7.39) 
and 74.22 years (SD = 7.94) in L1 and B1 respectively. The proportion of older male and 
female patients reviewed in L1 was comparable with national figures at 50.67% and 49.33% 
respectively. In B1 however, a higher proportion of patients reviewed in this study were 
females, at 55.61%. Of the 12-months retrospective record review period, these patients were 
registered for an average of 11.71- and 11.93-months in L1 and B1 respectively.  
 
The proportion of older patients who had had at least one medication in the 12-months record 
review period in L1 and B1 were 84.67% and 91.59% respectively. This difference reached 
statistical significance (two-tailed Chi-squared test at p<0.05; P-Value=0.04), and showed that 
significantly more prescriptions are issued to older patients in B1 than in L1 for patients, ≥65 
years old. The percentage of patients reviewed, in each of the following age categories that had 
received at least one prescription in L1, were 
 100% of all patients, ≥85 years old (8 of 8) 
41%
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 93% of all patients 75-84 years old (40 of 43)  
 81% of all patients 65-74 years old (79 of 97) in L1; 
 
 100% of all patients, ≥85 years old (32 of 32) 
 93% of all patients 75-84 years old (53 of 57)  
 90% of all patients 65-74 years old (111 of 124) in B1. 
 
It can therefore be observed that 65-74 year old patients in B1 were more likely to receive a 
prescription when compared with L1. This however did not reach statistical significance (two-
tailed z-test at p<0.05; P-Value = 0.09). 
 
At practice level, the age distribution of patients whose records were reviewed in L1 and B1 
were mostly comparable for patients 65-84 years old; however, older patients ≥85 years old 
were relatively fewer in L1 as shown below in  
Table 9. 
Table 9: Comparison of age distribution of older patients ≥65 years old in L1 and B1 
Age range Number of 
patients L1 
Percentage  
L1 (%) 
Number of 
patients B1 
Percentage  
B1 (%) 
65-69 68 45.33 83 38.79 
70-74 29 19.33 41 19.16 
75-79 21 14.00 35 16.36 
80-84 22 14.67 22 10.28 
85-89 7 4.67 24 11.21 
90-94 1 0.67 8 3.74 
≥95 2 1.33 1 0.47 
All ≥65 years 150 100.00 214 100.00 
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7.1 Characteristics of the prescriptions reviewed for older patients 65 years and 
over 
In total, 2739 unique prescription items for 364 older patients 65 years and over were reviewed. 
Of these, 1884 (68.78%) were repeat prescriptions, and 855 (31.22%) were acute prescriptions. 
548 (20%) were items, which were considered as requiring blood test monitoring.  
When those patients without a prescription item issued in the 12-months record review period 
were included, the median number of prescriptions per older patient was 6 (interquartile range, 
IQR 8.75); excluding patients without a prescription item, the median number of prescriptions 
was 7 (IQR 7). The highest number of unique prescription items issued to any older patient 
during the review period was 39.  
Of the 2739 prescriptions items, female patients received the majority of 1578 (57.61%). Table 
10 below provides information on how the number of prescription items varied with older 
patients’ age ranges. It can be seen that average number of prescriptions per patient increased 
with age. 
Table 10: How prescription items varied with age in older patients ≥65 years 
Age range 
(years) 
Number of 
prescriptions 
Number of patients with at 
least one prescription item 
Average number of 
prescription items per patient  
65-74  1358 190 7.15 
75-84 849 93 9.13 
≥85 532 40 13.30 
All ≥ 65  2739 323 8.48 
  
 
At practice level, 1041 unique prescription items for 150 patients were reviewed in L1. Of 
these, 734 (70.51%) were repeat prescriptions and 307 (29.49%) were acute. In B1, 1698 
unique prescription items for 214 older patients were reviewed. The proportions of repeat and 
acute prescriptions in B1 were comparable with those of L1 at 1150 (67.73%) and 548 
(32.27%) respectively (Figure 13). 
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Figure 13: Percentage of acute and repeat prescription items in older patients in L1 and 
B1 
 
 
The proportions of drugs, which were considered as requiring blood test monitoring, were 
comparable in L1 and B1 at 191 (18%) and 357 (21%) respectively. 
Including and excluding patients without a prescription item in the 12-months review period, 
the median number of prescriptions per older patient in both L1 and B1 were comparable at 6 
(IQR 8) and 7 (IQR 8) respectively. 
Of the 1041 and 1698 unique prescription items reviewed in L1 and B1, female patients 
received the majority in both L1 and B1, at 544 (52.26%) and 1034 (60.90%) respectively.  
Table 11 below compares how the number of prescription items varied with older patients’ age 
ranges in L1 and B1. It can be seen that average number of prescription items per patient 
increased with age in both practices. It can be observed that patients who were ≥85 years had 
the more items. 
Table 11: How prescription items varied with age in older patients between L1 and B1 
Age 
range 
(years) 
Number 
of Rx 
items 
L1 
Patients 
with at 
least one 
Rx item 
Average 
number of 
prescription 
items per 
 Number 
of Rx 
items 
B1 
Patients 
with at 
least one 
Rx item 
Average 
number of 
prescription 
items per 
29.49%
70.51%
32.27%
67.73%
0%
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20%
30%
40%
50%
60%
70%
80%
Acutes in L1 Repeats in L1 Acutes in B1 Repeats in B1
Percentage of acute and repeat prescription 
items reviewed in patients ≥65 years old per 
practice
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L1 patient L1 B1 patient B1 
65-74  553 79 7.00 805 111 7.25 
75-84 405 40 10.13 444 53 8.38 
≥85 83 8 10.38 449 32 14.03 
All ≥ 65  1041 127 8.20 1698 196 8.66 
 
 
7.1.1 Characteristics of acute and repeat prescription items reviewed in older patients 
Acute prescription items were recorded for 251 older patients, and the median number of 
unique acute prescription items per older patient was 3 (IQR 3), with the highest number of 
acute prescriptions issued to any patient being 16. 
Repeat prescription items were recorded for 300 older patients, and the median number of 
unique repeat prescription items per older patient was 5 (IQR 5.75), with the highest number 
prescribed being 31. 
Table 12 below shows the number of older patients who were prescribed a range number of 
acute and repeat prescriptions. It can be seen that over two thirds of older patients had four or 
more repeat prescription items, and almost two thirds of patients had three or less acute 
prescription items.  
Table 12: Number of older patients with ranges of acute and repeat prescription items 
Number of acute 
prescription items 
Number of older 
patients ≥65 yrs. (%)  
 Number of repeat 
prescription items 
Number of older 
patients ≥65 yrs. (%) 
 ≤3 159 (63.35)   ≤3 101 (33.67) 
4-7  73 (29.08) 4-7  109 (36.33) 
8-11 15 (5.98) 8-11 54 (18.00) 
12-15 3 (1.20) 12-15 18 (6.00) 
≥16  1 (0.40) ≥16  18 (6.00) 
855 251 (100) 1884 300 (100) 
 
 
At practice level, acute prescription items were recorded for 98 older patients in L1, and the 
median number of unique acute prescription items per older patient was 2 (IQR 3), with the 
highest number of acute prescriptions issued to any patient being 14. Acute prescription items 
were recorded for 153 older patients in B1, and the median number of unique acute 
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prescription items per older patient was comparable with L1 at 3 (IQR 3), with a maximum of 
16 acute prescriptions issued to any patient. 
In L1, repeat prescription items were recorded for 120 older patients, and the median number 
of unique repeat prescription items per older patient was 5 (IQR 6.75) with the highest number 
prescribed to any patient being 25. Repeat prescription items were recorded for 180 older 
patients in B1, and the median number of unique repeat prescription items per older patient was 
5 (IQR 5), the maximum number of repeat prescription items issued to any patient being 31. 
Table 13 below compared the number of older patients who were prescribed a specific number 
of acute and repeat prescriptions in L1 and B1. Almost two thirds and over two thirds of older 
patients had four or more repeat prescription items in L1 and B1 respectively. Over 60% of 
patients had three or less acute prescription items in both practices. 
Table 13: How the number of older patients with ranges acute and repeat prescription 
items varied between L1 and B1 
Number of 
acute 
prescription 
items 
Number of older patients 
≥65 years 
 Number of 
repeat 
prescription 
items 
Number of older 
patients ≥65 years 
 L1 B1  L1 (%) B1 (%) 
 ≤3 66 (67.35) 93 (60.78)  ≤3 46 (38.33) 55 (30.56) 
4-7  25 (25.51) 48 (31.37) 4-7  37 (30.83) 72 (40.00) 
8-11 5 (5.10) 10 (6.54) 8-11 23 (19.17) 31 (17.22) 
12-15 2 (2.04) 1 (0.65) 12-15 5 (4.17) 13 (7.22) 
≥16  0 (0) 1 (0.65) ≥16  9 (7.50) 9 (5.00) 
Total 98 (100) 153 (100)  120 (100) 180 (100) 
 
Results on how the average number of acute and repeat prescription items varied with older 
patients’ age is provided in Table 14 below. It can be seen that the average numbers of acute 
prescriptions per patient were comparable across the three age ranges, while the average 
number of repeat prescription items increased with age. This was similar at practice level as 
shown in Table 15 below. 
Table 14: How acute and repeat prescription items varied with older patients’ age 
Age 
range 
(years) 
Total 
Acute 
items 
Number 
of 
patients 
Average 
number of 
acute 
prescriptions 
per patient 
Total 
Repeat 
items 
Number 
of 
patients 
Average 
number of 
repeat 
prescriptions 
per patient 
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65-74  461 142 3.25 897 175 5.13 
75-84 250 73 3.42 599 86 6.97 
≥85 144 36 4.00 388 39 9.95 
All ≥ 65  855 251 3.41 1884 300 6.28 
 
 
Table 15: How acute and repeat prescription items varied with older patients' age 
between L1 and B1 
Age 
range 
(years) 
Total 
Acute 
items 
Number 
of 
patients 
Average 
number of 
acute 
prescriptions 
per patient 
Total 
Repeat 
items 
Number 
of 
patients 
Average 
number of 
repeat 
prescriptions 
per patient 
L1 
65-74  190 57 3.33 363 73 4.97 
75-84 94 33 2.85 311 39 7.97 
≥85 23 8 2.88 60 8 7.50 
All ≥ 65  307 98 3.13 734 120 6.12 
B1 
65-74  271 85 3.19 534 102 5.24 
75-84 156 40 3.90 288 47 6.13 
≥85 121 28 4.32 328 31 10.58 
All ≥ 65  548 153 3.58 1150 180 6.39 
 
 
7.1.2 Characteristics of drugs commonly prescribed to older patients 
7.1.2.1 BNF chapters 
The different groups of drugs prescribed to older patients by British National Formulary, BNF 
chapter are shown in Table 16 below. It can be observed that the most commonly prescribed 
drugs for older patients were those for cardiovascular disease, central nervous system (CNS), 
gastro-intestinal system, and infections. These drugs made up almost a third of prescriptions. 
Table 16: Distribution of prescription items reviewed by British National Formulary, 
BNF Chapter for older patients ≥65 years 
Chapter BNF Chapter name Frequency  Percentage  
2 Cardiovascular system 765 27.93 
4 Central nervous system 441 16.10 
1 Gastro-intestinal system 255 9.31 
5 Infections 238 8.69 
6 Endocrine system 207 7.56 
  173 
13 Skin 196 7.16 
3 Respiratory system 172 6.28 
11 Eye 114 4.16 
10 Musculoskeletal and joint diseases 109 3.98 
9 Nutrition and blood 88 3.21 
12 Ear, nose and oropharynx 65 2.37 
7 Obstetrics, gynaecology, and urinary-tract disorders 63 2.30 
8 Malignant disease and immunosuppression 11 0.40 
15 Anaesthesia 10 0.37 
14 Immunological products and vaccines 4 0.15 
 Unclassified (Deep freeze gel) 1 0.04 
  2739 100.00 
 
 
At practice level, drugs for cardiovascular disease, CNS, gastro-intestinal system were three of 
the top four BNF chapters most commonly prescribed in both practices; the fourth BNF chapter 
in L1 was skin, and infections in B1 (Table 17). 
Table 17: Comparison of the distribution of prescription items reviewed by BNF chapter 
between L1 and B1 
BNF chapter BNF chapter name Frequency 
L1 
% 
L1 
 Frequency 
B1 
% 
B1 
1 Gastro-intestinal system 89 8.55 166 9.78 
2 Cardiovascular system 257 24.69 508 29.92 
3 Respiratory system 77 7.40 95 5.59 
4 Central nervous system 162 15.56 279 16.43 
5 Infections 89 8.55 149 8.78 
6 Endocrine system 70 6.72 137 8.07 
7 Obstetrics, gynaecology, 
and urinary-tract disorders 
31 2.98 32 1.88 
8 Malignant disease and 
immunosuppression 
5 0.48 6 0.35 
9 Nutrition and blood 34 3.27 54 3.18 
10 Musculoskeletal and joint 
diseases 
53 5.09 56 3.30 
11 Eye 42 4.03 72 4.24 
12 Ear, nose and oropharynx 31 2.98 34 2.00 
13 Skin 92 8.84 104 6.12 
14 Immunological products 
and vaccines 
4 0.38 0 0.00 
15 Anaesthesia 4 0.38 6 0.35 
Deep freeze gel Unclassified 1 0.10 0 0 
 Total 1041 100 1698 100 
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7.1.2.2 Drugs commonly prescribed in older patients 
Of 389 different drugs, the top 20 most frequently prescribed to older patients are shown in 
Table 18 below. It can be observed that these drugs made up more than a third of prescriptions. 
This was also true in both practices L1 and B1 as shown in Table 19 
Table 18: Top 20 drugs most commonly prescribed to older patients ≥65 years old 
Preparation name Frequency Percentage (%) 
Simvastatin 92 3.36 
Paracetamol 75 2.74 
Amoxicillin 68 2.48 
Omeprazole 66 2.41 
Amlodipine 64 2.34 
Aspirin 61 2.23 
Levothyroxine 57 2.08 
Warfarin 50 1.83 
Salbutamol 49 1.79 
Codeine Phosphate or Codeine Linctus 46 1.68 
Bendroflumethiazide 45 1.64 
Lansoprazole 45 1.64 
Lisinopril 44 1.61 
Ramipril 43 1.57 
Furosemide 42 1.53 
Macrogol Oral Powder, Compound 42 1.53 
Prednisolone 38 1.39 
Co-codamol 30/500 (and 15/500)  36 1.31 
Metformin 34 1.24 
Lipitor® (Atorvastatin) 34 1.24 
Total 1031 37.64 
 
 
At practice level, fourteen and eighteen of the combined top 20 drugs, were most frequently 
prescribed in L1 and B1 respectively (see Table 19 below). It can be observed that these to 20 
drugs made up consistently over a third of all prescriptions issued in both practices. 
Table 19: Comparison of the top 20 drugs most commonly prescribed to older patients in 
L1 and B1 
L1  B1 
Preparation name Frequency % Preparation name Frequency % 
Simvastatin 41 3.94 Simvastatin 51 3.00 
Paracetamol 32 3.07 Amoxicillin 50 2.94 
Omeprazole 30 2.88 Aspirin 44 2.59 
Amlodipine 21 2.02 Amlodipine 43 2.53 
Ramipril 20 1.92 Paracetamol 43 2.53 
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Salbutamol 20 1.92 Levothyroxine 39 2.30 
Amoxicillin 18 1.73 Lisinopril 39 2.30 
Bendroflumethiazi
de 
18 1.73 Lansoprazole 37 2.18 
Levothyroxine 18 1.73 Omeprazole 36 2.12 
Aspirin 17 1.63 Warfarin 36 2.12 
Codeine Phosphate  17 1.63 Macrogol Oral 
Powder 
33 1.94 
Furosemide 17 1.63 Co-codamol  29 1.71 
Flucloxacillin 16 1.54 Codeine Phosphate  29 1.71 
Candesartan 15 1.44 Salbutamol 29 1.71 
Metformin 15 1.44 Bendroflumethiazide 27 1.59 
Warfarin 14 1.34 Atorvastatin 27 1.59 
Beclometasone  12 1.15 Losartan Potassium 27 1.59 
Ibuprofen 12 1.15 Prednisolone  27 1.59 
Atenolol 11 1.06 Furosemide 25 1.47 
Cetirizine 11 1.06 Calcium/Colecalcifero
l 
23 1.35 
Total 375 36.02  694 40.87 
 
High-risk drugs prescribed included Warfarin, various NSAIDs, Amiodarone, Azathioprine, 
Slo-Phyllin, etc. 
 
7.1.2.3 Therapeutic classes of commonly prescribed drugs in older patients 
When the drugs prescribed to older patients were grouped into their therapeutic classes, 
antibacterial drugs were topmost on the list. This was also the case in both L1 and B1. The top 
20 drug classes most commonly prescribed to older patients are shown in Table 20 below. It can 
be seen that these drug classes made up almost three quarters of the prescriptions.  
Table 20: Top 20 drug classes most commonly prescribed to older patients ≥65 years 
Therapeutic Drug class Frequency Percentage (%) 
Antibacterial 250 9.13 
ACE-I/ACE Antagonist, and with diuretic 165 6.02 
Corticosteroid 155 5.66 
Statin 132 4.82 
Antisecretory and mucosal protectants 130 4.75 
Diuretic 116 4.24 
Opioid 115 4.20 
NSAID 92 3.36 
Antiplatelet 83 3.03 
Calcium Channel Blockers 82 2.99 
Laxative 81 2.96 
Antidepressant 77 2.81 
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Non-opioid analgesic 75 2.74 
Bronchodilator 71 2.59 
Emollient 71 2.59 
Beta blocker 62 2.26 
Thyroid and antithyroid hormones 58 2.12 
Antidiabetic 56 2.04 
Anticoagulant 53 1.94 
Calcium supplement 49 1.79 
Total 1973 72.03 
 
 
At practice level, antibacterial drugs were also topmost on the list of the therapeutic drug 
classes prescribed to older patients. Angiotensin Receptor Antagonists and Angiotensin II 
Receptor Blockers, Corticosteroids, and Statins, were in the top five therapeutic drug classes 
most commonly prescribed to older patients in both practices as shown in Table 21. 
Table 21: Comparison of the top 20 drug classes most commonly prescribed to older 
patients in L1 and B1 
L1  B1 
Therapeutic Drug 
class 
Frequency  % Therapeutic Drug 
class 
Frequency % 
Antibacterial 87 8.36 Antibacterial 163 9.60 
Corticosteroid 66 6.34 ACE-I/ACE II 
Antagonist, and with 
diuretic 
116 6.83 
Statin 51 4.90 Corticosteroid 89 5.24 
Diuretic 50 4.80 Antisecretory and 
mucosal protectants 
88 5.18 
ACE-I/ACE 
Antagonist, and with 
diuretic 
49 4.71 Statin 81 4.77 
Antisecretory and 
mucosal protectants 
42 4.03 Opioid 78 4.59 
NSAID 42 4.03 Diuretic 66 3.89 
Opioid 37 3.55 Antiplatelet 58 3.42 
Emollient 36 3.46 CCB 57 3.36 
Non-opioid analgesic 32 3.07 Laxative 50 2.94 
Antidepressant 30 2.88 NSAID 50 2.94 
Bronchodilator 30 2.88 Antidepressant 47 2.77 
Antihistamine 25 2.40 Non-opioid 
analgesic 
43 2.53 
Antiplatelet 25 2.40 Bronchodilator 41 2.41 
CCB 25 2.40 Beta blocker 40 2.36 
Antidiabetic 23 2.21 Thyroid and 
antithyroid 
40 2.36 
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hormones 
Laxative 23 2.21 Anticoagulant 38 2.24 
Beta blocker 22 2.11 Non-opioid + opioid 36 2.12 
Anti-infective 19 1.83 Emollient 34 2.00 
Calcium supplement 18 1.73 Antidiabetic 33 1.94 
Total 732 70.32  1279 75.32 
 
 
7.1.2.4 Characteristics of drug formulations commonly prescribed in older patients 
Table 22 shows the distribution of different formulations for the 2739 prescription items issued 
to older patients. It can be seen that oral medications made up over 75% of prescriptions for 
this age group. 
Table 22: Distribution of different types of formulation prescribed to older patients ≥65 
years 
Formulation Frequency Percentage 
Solid oral 2035 74.30 
Topical 260 9.49 
Eye/ear/nose ointment or drops or sprays 162 5.91 
Inhalers 124 4.53 
Liquid oral 73 2.67 
Injection 47 1.72 
Patches 16 0.58 
Pessaries/suppositories 12 0.44 
Shampoo 6 0.22 
Mouthwash 3 0.11 
Implant 1 0.04% 
Total 2739 100.00% 
 
 
At practice level, the distribution of the formulations for the prescription items to older patients 
were comparable as shown below in Table 23. Oral medications made up over 70% of 
prescriptions in both practices.  
Table 23: Comparison of the distribution of different types of formulation prescribed to 
older patients between L1 and B1 
Formulation Frequency 
L1 
Percentage 
L1 
 Frequency 
B1 
Percentage 
B1 
Eye/ear/nose ointment or 
drops or sprays 
50 4.80 79 4.65 
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Implant 1 0.10 0 0.00 
Inhalers 71 6.82 75 4.42 
Injection 16 1.54 31 1.83 
Liquid oral 33 3.17 36 2.12 
Mouthwash 2 0.19 1 0.06 
Patches 0 0.00 12 0.71 
Pessaries/suppositories 4 0.38 8 0.47 
Shampoo 0 0.00 4 0.24 
Solid oral 733 70.41 1299 76.50 
Topical 131 12.58 153 9.01 
Total 1041 100.00 1698 100.00 
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7.2 Drugs on the monitoring list prescribed to older patients ≥65 years old 
548 of the 2739 unique prescription items prescribed to 224 older patients were considered as 
drugs requiring laboratory blood test monitoring. The median number of prescriptions on the 
monitoring list per older patient was 2 (IQR 2). The highest number of unique prescription 
items on the monitoring list issued to any older patient during the review period was 9.  
Table 24 below provides information on the average number of prescriptions on the monitoring 
list per older patients’ in three age ranges. It can be observed that the average number of 
prescription items, which required monitoring was consistent across the age groups. 
Table 24: How prescription items on the monitoring list varied with older patients' age 
Age 
range 
(years) 
Number of 
prescription items on 
the monitoring list9 
Number of patients with at 
least one prescription item 
on the monitoring list 
Prescription items on 
monitoring list per 
patient  
65-74  269 125 2.2 
75-84 190 67 2.8 
≥85 89 32 2.8 
All ≥ 65  548 224 2.4 
1  
 
At practice level, 83 patients received 191 prescriptions on the monitoring list in L1; in B1, 141 
patients received 357 prescriptions, which required monitoring. The median number of 
prescriptions on the monitoring list per older patient was 2 (IQR 2) in both L1 and B1. The 
average number of prescription items on the monitoring list was comparable in both practices 
across the three age groups as shown in Table 25. 
Table 25: Comparison of how prescription items on the monitoring list varied with older 
patients' age in L1 and B1 
Age 
range 
(years) 
Number of 
prescription items on 
the monitoring list1 
Number of patients with at 
least one prescription item 
on the monitoring list 
Prescription items on 
monitoring list per 
patient  
 L1 B1 L1 B1 L1 B1 
65-74  96 173 51 74 1.9 2.3 
75-84 84 106 28 39 3.0 2.7 
≥85 11 78 4 28 2.8 2.8 
All ≥ 65  191 357 83 141 2.3 2.5 
 
                                                          
9The list of drugs, which were considered to require monitoring 
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7.2.1 BNF Chapters of drugs on the monitoring list prescribed to older patients 
The different categories of drugs on the monitoring list prescribed by BNF chapter for older 
patients are shown in Table 26. It can be seen that the most commonly prescribed drugs on the 
monitoring list were for cardiovascular disease. 
Table 26: Prescription items on the monitoring list prescribed to older patients ≥65 years 
old 
Chapter  BNF Chapter name Frequency Percentage  
2 Cardiovascular system 480 87.59 
3 Respiratory system 2 0.36 
4 Central nervous system 2 0.36 
6 Endocrine system 58 10.58 
8 Malignant disease and immunosuppression 3 0.55 
9 Nutrition and blood 1 0.18 
10 Musculoskeletal and joint diseases 2 0.36 
 Total 548 100.00 
 
At practice level, cardiovascular drugs accounted for over 85% of drugs on the monitoring list 
in L1 and B1 as shown in Table 27 below.  
Table 27: Comparison of the prescription items on the monitoring list prescribed to older 
patients in L1 and B1 by their BNF chapters 
Chapter BNF chapter name Frequency 
L1 
Percentage 
L1 
 Frequency 
B1 
Percentage 
B1 
2 Cardiovascular system 169 88.48 311 87.11 
6 Endocrine system 18 9.42 40 11.20 
4 Central nervous 
system 
2 1.05 0 0 
3 Respiratory system 1 0.52 1 0.28 
10 Musculoskeletal and 
joint diseases 
1 0.52 1 0.28 
8 Malignant disease and 
immunosuppression 
0 0.00 3 0.84 
9 Nutrition and blood 0 0.00 1 0.28 
 Total 191 100 357 100 
 
7.2.2 Specific drugs on the monitoring list prescribed to older patients 
The top 20 drugs on the monitoring list most commonly prescribed to older patients are shown 
in Table 28 below. For older patients, these drugs made up 95% of the prescriptions. 
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Table 28: Top drugs on the monitoring list most commonly prescribed to patients ≥65 
years old 
Preparation name Frequency Percentage 
Simvastatin 92 16.79 
Levothyroxine 57 10.40 
Warfarin 50 9.12 
Bendroflumethiazide 45 8.21 
Lisinopril 44 8.03 
Ramipril 43 7.85 
Furosemide 42 7.66 
Atorvastatin 34 6.20 
Losartan Potassium 28 5.11 
Candesartan 23 4.20 
Digoxin 16 2.92 
Enalapril Maleate 10 1.82 
Perindopril 10 1.82 
Spironolactone 7 1.28 
Indapamide 6 1.09 
Co-amilozide/Moduretic 5 0.91 
Pravastatin 5 0.91 
Amiloride 3 0.55 
Azathioprine 3 0.55 
Irbesartan 3 0.55 
Total 528 96.35 
 
 
In the two practices, the top 20 drugs on the monitoring list commonly prescribed to older 
patients were comparable as shown in Table 29 below. These drugs made up over 95% of the 
prescriptions.  
Table 29: Comparison of the top 20 drugs on the monitoring list commonly prescribed to 
older patients in L1 and B1 
Preparation name Frequency 
L1 
% 
L1 
 Preparation name Frequency 
B1 
% 
B1 
Simvastatin 41 21.47  Simvastatin 51 14.29 
Ramipril 20 10.47  Levothyroxine 39 10.92 
Bendroflumethiazide 18 9.42  Lisinopril 39 10.92 
Levothyroxine 18 9.42  Warfarin 36 10.08 
Furosemide 17 8.90  Bendroflumethiazide 27 7.56 
Candesartan 15 7.8  Atorvastatin 27 7.56 
Warfarin 14 7.33  Losartan Potassium 27 7.56 
Atorvastatin 7 3.66  Furosemide 25 7.00 
Digoxin 5 2.62  Ramipril 23 6.44 
Lisinopril 5 2.62  Digoxin 11 3.08 
Indapamide 4 2.09  Candesartan 8 2.24 
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Enalapril Maleate 3 1.57  Enalapril Maleate 7 1.96 
Perindopril 3 1.57  Perindopril 7 1.96 
Pravastatin 3 1.57  Spironolactone 4 1.12 
Spironolactone 3 1.57  Irbesartan 3 0.84 
Amiloride 2 1.05  Azathioprine 3 0.84 
Co-amilozide 2 1.05  Co-amilozide 3 0.84 
Priadel® 2 1.05  Valsartan 2 0.56 
Amiodarone 1 0.52  Indapamide 2 0.56 
Bumetanide 1 0.52  Pravastatin 2 0.56 
Total 184 96.34   346 96.92 
 
 
7.2.3 Therapeutic classes of monitored drugs commonly prescribed 
The drugs on the monitoring list prescribed to older patients were grouped into their 
therapeutic drug classes as shown in Table 30 below. It can be observed that ACE-I and 
angiotensin II receptor agonists, statin and diuretics accounted for approximately 75% of all 
drugs requiring monitoring. 
Table 30: Drug classes of prescriptions on the monitoring list 
Drug class Frequency Percentage 
ACE-I/Angiotensin II receptor antagonist 164 29.93% 
Statin 132 24.09% 
Diuretic 115 20.99% 
Thyroxine 57 10.40% 
Coumarins 50 9.12% 
Digoxin 16 2.92% 
Methotrexate/Azathioprine 4 0.73% 
Amiodarone 2 0.36% 
Lithium 2 0.36% 
ACE-I/Diuretic 1 0.18% 
Theophylline 2 0.36% 
Carbimazole 1 0.18% 
Hydroxocobalamin 1 0.18% 
Sulfasalazine 1 0.18% 
Total 548 100.00% 
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7.3 Prevalence of prescribing and monitoring errors in older patients 65 years 
and over 
From the review of the 2739 prescription items in older patients 65 years and over, 216 
medication errors were identified as shown: 
1. 168 prescribing errors 
2. 23 omission errors relating to failure to prescribe for an existing condition, and 
3. 25 monitoring errors (total, 216). 
 
7.3.1 Prescribing and monitoring error rates in older patients 
7.3.1.1 Error rate per patient 
 108 of 323 older patients ≥65 years old (33.44%, 95% CI 28.52%-38.75%) that had 
been prescribed at least one prescription item in the record review period, had at least 
one prescribing error. There was a mean of 1.56 errors per patient. 
 When prescribing and omission errors (relating to failure to prescribe for an existing 
condition) were combined, 116 patients of 323 older patients, (35.91%, 95% CI 
30.87%-41.28%), had at least one prescribing error. 
 21 older patients (9.38%, 95% CI 6.22%-13.91%), out of 224 patients who had been 
prescribed at least one prescription on the monitoring list in the 12-months review 
period, had at least one monitoring error, with a mean of 1.2 errors per patient. 
 For all three categories of errors studied (prescribing, monitoring and omission errors), 
132 of 323 older patients ≥65 years old (40.87%, 95% CI 35.65% – 46.31%), with at 
least one prescription item in the 12-months review period, had at least one error with a 
mean of 1.63 errors per patient.  
The prevalence of prescribing and monitoring errors in older patients grouped into three age 
bands is shown in Table 31 below: 
Table 31: Error rate per older patient with at least one prescribed item and at least one 
potential error 
Age 
(yrs.) 
Number of patients 
with errors 
Number of patients with at 
least one prescription item 
Prevalence of all 
errors %; (95% CI) 
65-74 74 190 38.95; (32.30-46.04) 
75-84 41 93 44.05; (34.43-54.22)| 
≥85 17 40 42.50; (28.51-57.80) 
Total 132 323 40.87; (35.65-46.31) 
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It can be observed that error rate increased with patient’s age but decreased slightly in patients 
who were ≥85 years old. This may be due to the relatively few number of patients in this age 
range whose prescriptions were reviewed. There was no statistically significant difference 
between L1 and B1 with respect to the number of patients with or without errors (Chi-square 2-
tailed test P-value=0.256, p < 0.05).  
 
7.3.1.2 Error rate per item 
 Of 2739 prescription items reviewed, 168 prescribing errors were identified with a 
prevalence rate of prescribing errors per item being 6.13% (95% CI 5.29%-7.09%). 
 When prescribing and omission errors (relating to failure to prescribe for an existing 
condition) were combined, 191 errors were identified. This gave a prevalence of 
prescribing errors per item of 6.97% (95% CI 6.08%-7.99%). 
 25 monitoring errors were identified from the review of 548 prescription items on the 
monitoring list, with a prevalence error rate of 4.56% (95% CI 3.11%-6.65%). 
 For all three categories of errors, the prevalence of prescription items with prescribing or 
monitoring errors was 7.89% per item (95% CI 6.94%-8.96%).  
At practice level, there was no significant difference in error rate. In L1 (7.88%) and B1 
(7.89%) (P-value = 0.99; Z-test for two population proportions). 
 
Summarily, the prevalence of prescribing and monitoring errors by age range in older patient in 
the 12-months record review period is shown in Table 32 below. 
Table 32: Prevalence of prescribing and monitoring errors for older patients over the 12-
months record review period 
Age 
(yrs.) 
Prescribing (and omission 
error) error rate (%) 
Monitoring error 
rate (%) 
Prescribing and monitoring 
error rate (total) % 
 Per item Per patient Per item Per patient Per item Per patient 
65-74 7.22 34.74 4.83 8.00 8.17 38.95 
75-84 7.30 36.56 5.26 13.43 8.48 44.05 
≥85 5.83 40.00 2.25 6.25 6.20 42.50 
All ≥65  6.97 35.91 4.56 9.38 7.89 40.87 
 
The error rates per patient shown above did not reflect that one patient could have had more 
than one error. When the error rate was determined by expressing the total number of errors as 
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a percentage of patients with at least one prescription item, a higher prevalence of 66.87% 
(95% CI 61.57%-71.78%) was obtained. The prevalence of errors per patient in L1 and B1 was 
comparable at 64.57% (95% CI 55.94%-72.35%) and 68.37% (95% CI 61.56%-74.47%) 
respectively, with any difference not significant (Z-test for 2 population proportions, p<0.05, P-
Value = 1.0). Error rate per patient age range were also comparable in both practices, and 
tended to increase with age, but this did not reach statistical significance (Chi-square test at 
p<0.05, P-value = 0.49) (Figure 14 and Figure 15 below). 
Figure 14: Error rates per patient ≥65 years old 
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Figure 15: Prescribing and monitoring error rates per patient ≥65 years old in L1 and B1 
 
 
7.3.2 How prescribing and monitoring error rates varied with older patients’ sex 
The prevalence of prescribing and monitoring errors per older male and female patients over 
the 12-months record review period is presented in Table 33 below. It can be observed that 
more errors were associated with female patients when compared with male patients. 
Table 33: Prevalence of prescribing and monitoring error for older male and female older 
patients over the 12-months record review period 
 
When the prevalence of errors was determined by expressing the number of patients who had at 
least one error, as a percentage of patients with at least one prescription item, error rate per 
female and male patients were 46.07% and 34.48% respectively as shown in Table 34 below. It 
can be observed that over two thirds of female patients had at least one error compared with 
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Female 133 1578 8.43% 178 74.72% 
Male 83 1161 7.15% 145 57.24% 
Total 216 2739 7.89% 323 66.87% 
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just over a third of male patients. Chi-square two-tailed test showed that the result was 
significant (P-Value=0.035). This was also observed in individual practices with no significant 
difference between practices. 
Table 34: Prevalence of errors with the numbers of older female and male patients 
Sex Number of patients with 
at least one error 
Number of patients with at 
least one prescription item  
Error rate per patient 
(95% CI) 
Female 82 178 46.07% (38.91-53.40) 
Male 50 145 34.48% (27.23-42.53) 
Total 132 323 40.87% (35.65-46.31) 
 
 
7.3.3 How prescribing and monitoring errors varied with acute and repeat prescriptions 
in older patients 
The prevalence of prescribing and monitoring errors on acute and repeat prescriptions over the 
12-months record review period is presented in Table 35 below. It can be seen that repeat 
prescription items were associated with more errors than acute prescription items issued to 
older patients. Chi-squared two-tailed test showed that the difference was significant at p < 
0.05 (P-Value=3.3E-05). This was also true at practice level. 
Table 35: Prevalence of prescribing and monitoring error for acute and repeat 
prescriptions prescribed to older patients ≥65 years old 
Type of prescription Number of errors on prescription  Percentage (95% CI) 
Acute items 86 44.56% (37.72-51.61) 
Repeat items 107 55.44% (48.39-62.28) 
Total 193 100% 
 
 
7.3.4 Reoccurrences of prescribing and monitoring errors in older patients ≥65 years 
old 
During data collection, potential errors were reviewed as to whether they had occurred as a 
single event or had been repeated.  Figure 16 below shows that comparable proportions of errors 
had occurred as single events and repeated in both practices.  
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Figure 16: Reoccurrences of potential prescribing and monitoring errors in older patients 
 
 
7.3.5 How prescribing and monitoring error rates varied with the number of 
prescription items in older patients 
Figure 17 below shows that number of errors identified in older patients increased with the 
average number of prescription items issued. This was also true in both practices. 
Figure 17: How the average number of prescription items varied with the number of 
errors identified 
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7.4 Types of prescribing and monitoring errors in older patients 65 years and 
over 
The distributions of the different types of prescribing and monitoring errors for older patients 
are shown in Table 36 and Table 37 below respectively. It can be observed that more than a third 
of prescription errors were associated with information being incomplete on the prescription. 
Over two thirds or 70% of prescribing errors were associated with the top four categories of 
prescribing errors namely incomplete information on prescription, omission error relating to 
failure to prescribe concomitant medication, duplication, and inadequate review. 
Table 36: Distribution of different types of prescribing errors for older patients ≥65 years 
Types of prescribing error Frequency Percentage 
Incomplete information on prescription 62 37% 
Omission error relating to failure to prescribe concomitant 
medication 22 13% 
Duplication 21 13% 
Inadequate Review 11 7% 
Dose/strength error 8 5% 
Quantity error 8 5% 
Timing error 7 4% 
Frequency error 6 4% 
Interaction error 5 3% 
Inadequate documentation on medical records 5 3% 
Allergy error 4 2% 
Formulation error 4 2% 
Duration Error 4 2% 
Incorrect drug 1 1% 
Unnecessary drug 0 0% 
Contraindication error 0 0% 
Generic/brand name error 0 0% 
Not classified 0 0% 
Total 168 100% 
 
 
Table 37: Distribution of different types of monitoring errors in older patients ≥65 years 
Types of monitoring error Frequency Percentage 
Monitoring not requested 23 92.00% 
Requested but not done 0 0.00% 
Results not available 0 0.00% 
Results not acted upon 2 8.00% 
Total 25 100.00% 
 
Most monitoring errors were associated with laboratory testing not ordered (Table 37). 
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At practice level, incomplete information on prescription remained the most frequently 
occurring type of prescribing error representing 42% and 32% of all categories in L1 and B1 
respectively. The top four categories accounted for just over 70% of all types of errors in each 
individual practice, and comprised the top four categories shown in Table 36 above in B1; inL1, 
dose/strength error, was 4th in place of inadequate review (Table 38 below). 
Table 38: Comparison of distribution of different types of prescribing errors for older 
patients ≥65 years old in L1 and B1 
Types of prescribing 
error 
Frequency
L1 
%, 
L1 
 Types of 
prescribing error 
Frequency
B1 
%, 
B1 
Incomplete 
information on 
prescription 
32 42.11 Incomplete 
information on 
prescription 
30 32.61 
Duplication 9 11.84 Omission error 
relating to failure to 
prescribe 
concomitant 
medication 
15 16.30 
Omission error 
relating to failure to 
prescribe 
concomitant 
medication 
7 9.21 Duplication 12 13.04 
Dose/strength error 6 7.89 Inadequate Review 10 10.87 
Timing error 6 7.89 Inadequate 
documentation on 
medical records 
5 5.43 
Quantity error 6 7.89 Formulation error 4 4.35 
Interaction error 5 6.58 Frequency error 4 4.35 
Frequency error 2 2.63 Duration Error 4 4.35 
Incorrect drug 1 1.32 Allergy error 3 3.26 
Allergy error 1 1.32 Dose/strength error 2 2.17 
Inadequate Review 1 1.32 Quantity error 2 2.17 
Unnecessary drug 0 0 Timing error 1 1.09 
Contraindication 0 0 Unnecessary drug 0 0 
Formulation error 0 0 Incorrect drug 0 0 
Generic/brand name 
error 
0 0 Contraindication 
error 
0 0 
Inadequate 
documentation on 
medical records 
0 0 Interaction error 0 0 
Not classified 0 0 Generic/brand name 
error 
0 0 
Duration Error 0 0 Not classified 0 0 
Total 76 100  92 100 
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7.4.1 Drugs commonly associated with potential errors in older patients 
Table 39 below shows the drugs most commonly associated with prescribing errors in older 
patients. There were 73 different drugs associated with prescribing errors in older patients in 
total, and the 14 shown in the table accounted for over 50% of the errors. 
Table 39: Drugs most commonly associated with prescribing errors in older patients ≥65 
years old 
Preparation name Dosage form Frequency Percentage 
Naproxen Tablets 17 10.12 
Eumovate® Cream and ointment 12 7.14 
Prednisolone Tablets 10 5.95 
Betamethasone/Betnovate® Cream/ointment/scalp application 7 4.17 
Hydrocortisone Cream and ointment 7 4.17 
Levothyroxine Tablets 7 4.17 
Dermovate® Cream and ointment 6 3.57 
Daktacort® Cream and ointment 5 2.98 
Chloramphenicol Eye drops and eye ointment 4 2.38 
Simvastatin Tablets 4 2.38 
Alendronic acid Tablets 3 1.79 
Diprosalic® Ointment and scalp application 3 1.79 
Furosemide Tablets 3 1.79 
Ibuprofen Tablets 3 1.79 
Paracetamol Capsules and tablets and caplets 3 1.79 
Total  94 55.95 
 
 
Table 40 below shows the drugs most commonly associated with prescribing errors in older 
patients in L1 and B1. There were 43 and 46 drugs associated with prescribing errors in total, 
in L1 and B1 respectively, and the 16 shown in Table 40 below accounted for 64% and 65% of 
the errors in both practices respectively. 
Table 40: Comparison of drugs most commonly associated with prescribing errors in 
older patients ≥65 years old in L1 and B1 
Preparation 
name 
Frequency 
L1 
%  
L1 
 Preparation name Frequency 
B1 
% 
B1 
Levothyroxine 6 7.89 Naproxen 11 11.96 
Naproxen 6 7.89 Clobetasone 7 7.61 
Betamethasone 
valerate  
5 6.58 Prednisolone 6 6.52 
Clobetasone 5 6.58 Miconazole/Hydrocortiso
ne 
5 5.43 
Prednisolone 4 5.26 Hydrocortisone 5 5.43 
Clobetasol 3 3.95 Chloramphenicol 4 4.35 
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Diprosalic® 2 2.63 Alendronic acid 3 3.26 
Etodolac 2 2.63 Clobetasol 3 3.26 
Furosemide 2 2.63 Betamethasone Valerate  2 2.17 
Gliclazide 2 2.63 Bisoprolol Fumarate 2 2.17 
Hydrocortisone 2 2.63 Co-codamol 30/500 2 2.17 
Indometacin 2 2.63 Ibuprofen 2 2.17 
Hydrocortisone 
butyrate 
(Locoid®) 
2 2.63 Atorvastatin 2 2.17 
Paracetamol 2 2.63 Ramipril 2 2.17 
Simvastatin 2 2.63 Simvastatin 2 2.17 
Spironolactone 2 2.63 Timodine® 2 2.17 
Total 49 64.47  60 65.22 
 
 
7.4.2 Therapeutic classes of drugs commonly associated with potential errors in older 
patients 
When the drugs associated with errors in older patients were grouped into their therapeutic 
classes, topical corticosteroids were topmost on the list as shown in Table 41 below. The top 12 
therapeutic drug classes associated with a prescribing error accounted for over two thirds of all 
errors in older patients. 
Table 41: Therapeutic drug classes associated with a prescribing error in older patients 
≥65 years 
Therapeutic drug class Frequency  Percentage 
Corticosteroid-topical 37 22 
NSAID 26 15 
Corticosteroid-topical + antimicrobials and anti-inflammatory 15 9 
Corticosteroid-oral 10 6 
Diuretic 7 4 
Thyroid and antithyroid hormone 7 4 
Statin 6 4 
ACE-I/Angiotensin II blocker 5 3 
Antibacterial 5 3 
Antidepressant 4 2 
Bisphosphonate 4 2 
Opioid  4 2 
Total 130 77 
 
The top 8 therapeutic classes associated with a prescribing error in older patients in L1 and B1 
are shown in Table 42 below. It can be seen that topical corticosteroids and NSAIDS were the 
two topmost drug classes mostly associated with prescribing errors in both practices. 
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Table 42: Comparison of the therapeutic drug classes associated with a prescribing error 
in older patients ≥65 years old 
Therapeutic drug 
class 
Frequency 
L1 
%  
L1 
 Therapeutic drug 
class 
Frequency 
B1 
% 
B1 
Corticosteroid-
topical 18 23.68 Corticosteroid-topical 19 20.65 
NSAID 13 17.11 NSAID 14 15.22 
Diuretic 6 7.89 
Corticosteroid-topical 
with antimicrobial 10 10.87 
Thyroid/Anti-
thyroid hormone 6 7.89 Corticosteroid-oral 6 6.52 
Corticosteroid-
topical with 
antimicrobial 5 6.58 Antibacterial 5 5.43 
Corticosteroid-oral 4 5.26 
ACE-I/Angiotensin II 
blocker 4 4.35 
Antidepressant 3 3.95 Bisphosphonate 4 4.35 
NSAID-topical 3 3.95 Statin 4 4.35 
Total 58 76.32   66 71.74 
 
 
7.4.3 BNF chapters of the drugs commonly associated with prescribing errors in older 
patients 
Table 43 below outlines the proportion of prescribing errors by their BNF chapters. It can be 
observed that the top BNF chapters associated with prescribing errors were those that also 
accounted for the highest numbers of prescriptions in Table 16 above. 
Table 43: Proportion of prescribing errors from different BNF chapter 
BNF 
Chapter 
British National Formulary chapter Frequency Percentage 
13 Skin 55 32.74 
10 Musculoskeletal and joint diseases 30 17.86 
6 Endocrine system 25 14.88 
2 Cardiovascular system 24 14.29 
4 Central nervous system 18 10.71 
11 Eye 7 4.17 
1 Gastro-intestinal system 2 1.19 
3 Respiratory system 2 1.19 
5 Infections 2 1.19 
9 Nutrition and blood 2 1.19 
7 Obstetrics, gynaecology, and urinary-tract disorders 1 0.60 
 Total 168 100.00 
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At practice level, the top five BNF chapters associated with prescribing errors were identical in 
L1 and B1, and included Skin, Cardiovascular system, Endocrine system, Central Nervous 
System, and Musculoskeletal and joint diseases. 
 
7.4.4 Drugs commonly associated with monitoring errors in older patients 
Table 44 shows the drug preparations associated with monitoring errors. It can be seen that 
Bendroflumethiazide, Lisinopril, Levothyroxine, and Losartan accounted for 60% of the errors. 
Table 44: Drugs associated with monitoring errors 
Preparation name Formulation Frequency  Percentage 
Bendroflumethiazide Tablets 5 20.00 
Lisinopril Tablets, 5 20.00 
Levothyroxine Tablets 4 16.00 
Losartan Potassium Tablets 2 8.00 
Simvastatin Tablets 2 8.00 
Amias® (Candesartan) Tablets 1 4.00 
Amiodarone Tablets 1 4.00 
Carbimazole Tablets 1 4.00 
Co-amilozide Tablets 1 4.00 
Furosemide Tablets 1 4.00 
Priadel® Tablets 1 4.00 
Total  25 100 
 
7.4.5 BNF Chapters of drugs commonly associated with monitoring errors 
Table 45 shows the proportion of monitoring errors by their BNF chapters. Most of the drugs, 
which were associated with a monitoring error, were from the cardiovascular chapter.  
Table 45: Proportion of monitoring errors by the different BNF Chapters 
BNF chapter BNF chapter name Frequency Percentage 
2 Cardiovascular system 19 76 
6 Endocrine system 5 20 
4 Central nervous system 1 4 
 Total 25 100 
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7.5 Information on different types of prescribing errors in older patients 
Additional information is provided below on the drug preparations, which were most 
commonly associated with the different types of potential prescribing errors discussed in (Table 
36) above. 
 
7.5.1 Incomplete information on prescription 
62 incomplete information errors in older patients involved 23 different preparations as shown 
in Table 46. Some of the prescriptions were associated with directions such as “as directed,” and 
“as advised by hospital prescriber.” The other categories of incomplete prescription 
information related to the use of topical steroid or steroid-containing preparations in patients 
≥65 years old, without specifying either the duration of use or part being treated, when the 
quantity prescribed and patient’s mental health state had been assessed from the medical notes. 
Table 46:Drug preparations most commonly associated with incomplete information on 
the prescription in older patients 
Preparation name Frequency Percentage 
Betacap*, Betamthasone Valerate, Betnovate® 6 10 
Canesten HC ®  1 2 
Daktacort ®  5 8 
Dermovate ®  5 8 
Diprosalic ®  2 3 
Dovobet®  1 2 
Elocon®  1 2 
Etopan XL ®  1 2 
Eumovate® 10 16 
Fucibet®  2 3 
Fucidin H®  2 3 
Furosemide 2 3 
Gliclazide 2 3 
Hydrocortisone 7 11 
Indometacin 1 2 
Locoid®  1 2 
Lumigan® 1 2 
Metformin 1 2 
NovoMix® 1 2 
Prednisolone 2 3 
Spironolactone 1 2 
Synalar® 1 2 
Timodine® 2 3 
Trimovate® 2 3 
Xalatan® 2 3 
Total 62 100 
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The therapeutic classes of the drugs most commonly associated with incomplete information 
on the prescription from Table 46 are shown in Table 47 below. It can be observed that topical 
steroids accounted for over 75% of all prescriptions with this type of prescribing error. 
Table 47: Therapeutic drug classes most commonly associated with incomplete 
information on the prescription in older patients 
Therapeutic class Frequency Percentage 
Topical steroid 31 50 
Topical steroid containing 17 27 
NSAID 2 3 
Diuretic 3 5 
Anti-diabetic 3 5 
Anti-glaucoma 3 5 
Insulin 1 2 
Oral steroid 2 3 
Total 62 100 
 
The BNF chapters most commonly associated with incomplete prescription information in 
older patients are shown in Table 48 below. It can be seen that skin preparations made up over 
75% of this type of error. 
Table 48: BNF chapters associated with incomplete information on prescriptions in older 
patients 
Chapter name Chapter number Frequency Percentage 
Skin 13 48 77 
Musculoskeletal and joint disease 10 2 3 
Cardiovascular system 2 3 5 
Endocrine system 6 6 10 
Eye 11 3 5 
Total  62 100 
 
7.5.2 Duplication 
The 21 duplication errors involved 19 different drug preparations. Of these, 5 (24%) were 
associated with co-prescription of two oral (or oral and topical) non-steroidal anti-
inflammatory drugs (NSAIDs) without information to avoid concomitant use; 5 (24%) were 
associated with co-prescription of two paracetamol-containing opioid analgesic, or one 
alongside paracetamol, with no advice to avoid concomitant use; 4 (19%) scenarios were 
related to continued prescription of beta-blockers and diuretics, when a prescriber had noted 
their discontinuation while prescribing alternative preparations or strengths. 
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7.5.3 Omission error relating to failure to prescribe concomitant medication 
Of the 22 omission errors relating to failure to prescribe concomitant treatment, 19 (85%) 
involved the use of oral non-steroidal anti-inflammatory drugs, NSAIDS in older patients ≥65 
years, without co-prescription of gastro-protective agents to protect against gastrointestinal 
bleeding. One omission error related to failure to prescribe a Bisphosphonate as an adjunct 
treatment to a patient with osteoporosis despite previous recommendation from their hospital 
consultant as detailed in a discharge note. Another omission error related to a 79-year old 
female on long-term Prednisolone daily without concomitant regular administration of a 
bisphosphonate (in this case, Zoledronic acid), although a plan for annual administration of 
Zoledronic acid was specified by a different GP in the patient’s medical record. 
 
7.5.4 Inadequate review 
The 11 inadequate review errors involved 10 different drug preparations. Three of these (27%) 
were associated with Angiotensin receptor inhibitors namely Ramipril, Lisinopril and 
Enalapril. In all three cases, the prescriber had noted in patients’ record to discontinue the 
medications for various reasons. However, they continued to be prescribed, in one case, up to 3 
repeats before being discontinued. Two (18%) were related to discontinuation of Simvastatin 
on account of side effects, by the prescriber or patient, without attempting a switch to other 
suitable statins with better side effect profiles even though patients’ cardiovascular risks 
suggested potential therapeutic benefits with cholesterol-regulating agents. 
 
7.5.5 Dose/strength error 
The 8 dose or strength errors involved 7 different drug preparations. Two of this error type 
related to Simvastatin. In one case, Simvastatin 40mg daily at night was prescribed to a 70-year 
old female on repeat prescription alongside Amlodipine 5mg daily against the Medicines and 
Healthcare Regulatory Agency (MHRA) advice to limit the dose of Simvastatin to 20mg daily 
when co-prescribed with Amlodipine to reduce the incidence of side effects. The second 
Simvastatin error was, a random strength reduction from 20mg to 10mg for three months and 
then back up to 20mg, with no notes in the medical record to explain the sudden change 
suggesting a strength selection error.  
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One error was associated with the prescription of Etodolac 600mg modified-release tablets 
daily, for pain and inflammation, to an 89-year old female patient with reduced renal function 
(GFR at last test was 39ml/min (low; normal = >60ml/min) with elevated serum creatinine 
from previous biochemistry results.  
One error was associated with the prescription of Naproxen at a high starting daily dose of 
500mg twice daily to a 67-year old male for sciatica. 
The other preparations associated with this error type further included one each for Gaviscon 
advance, Atorvastatin, Spironolactone and Zopiclone.  
 
7.5.6 Quantity error 
The 8 quantity errors involved 6 different drug preparations. Of these, 2 were associated with 
consecutive and overlapping supply of paracetamol to 82- and 98-year old female patients. In 
one case, it was documented in the medical record that the patient had made suicidal threats a 
month after the supplies were made. 
2 quantity errors were associated with the prescription of Prednisolone for acute exacerbations 
of respiratory disease. In both cases, the numbers of tablets supplied to the patients were each 
34 tablets short of the quantity required as per the directions on the prescription i.e. 40 tablets 
of 30mg (6 tablets) of Prednisolone 5mg daily for 14 days.  
2 quantity errors were associated with consecutive and overlapping supply of the Schedule 2 
controlled drugs, OxyContin® and OxyNorm®. 
7.5.7 Timing error 
Only two drug preparations associated with 7 timing errors were identified. 6 of these were due 
to Levothyroxine being prescribed with advice to take at bedtime for underactive thyroid. The 
BNF currently advises that Levothyroxine is taken preferably 30 minutes before breakfast and 
caffeine-containing liquids (e.g. coffee, tea), or other medication. Another potential timing 
error was associated with oral Prednisolone prescribed to an 84-year old female patient for 
acute exacerbation of respiratory disease, with the directions “take 6 daily,” and no advice to 
take as a single dose in the morning after breakfast as recommended by the BNF. 
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7.5.8 Frequency error 
The 6 frequency errors involved 3 different drug preparations. Of these, 4 (67%) were 
associated with Chloramphenicol eye drops and ointment, which appeared to have a default 
direction in one practice’s clinical computer system as “apply 4 times a day for 2 days and 
continue for 48 hours after resolution.” The BNF recommends that Chloramphenicol is 
administered “1 drop at least every 2 hours then reduce frequency as infection is controlled and 
continue for 48 hours after healing.” Moreover, most over-the-counter preparations contain 
similar directions to the BNF. Another frequency error related to Locoid ointment, a potent 
steroid, which is recommended for once or twice daily application but had been prescribed 
irregularly over 2 years to an older patient for three times daily application. The last frequency 
error related to a repeat prescription for Gabapentin 300mg capsules issued over three months 
to a 69-year old patient with unclear frequency of use – one to three times daily or three times 
daily. 
 
7.5.9 Interaction error 
There were 5 drug combinations, which were classed as potential interaction errors from 
information obtained from the BNF online and drug information on SystmOne GP clinical 
computer system. They included 
 Clomipramine (tricyclic and related antidepressant) with Sodium Valproate 
(antiepileptic) – tricyclic and related antidepressants antagonize anticonvulsant effect of 
antiepileptics lowering the convulsive threshold 
 Clomipramine with Amitriptyline (both tricyclic antidepressants) to an older patient 
 84-year old female patient on Digoxin (cardiac glycoside) 125mcg daily with 
Furosemide (loop diuretic) 80mg daily – increased cardiac toxicity with cardiac 
glycosides if hypokalemia occurs with loop diuretics. Patient had shortness of breath 
and exercise intolerance with resulting hospital investigations for most of the year 
 Fluoxetine (a selective serotonin reuptake inhibitor, SSRI) with Warfarin (a coumarin), 
to an 82-year old female patient – anticoagulant effect of coumarins possibly enhanced 
by SSRIs, leading to increased risk of bleeding. Patient has been prescribed iron 
supplements though it was unclear if this was linked to this potential error 
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 67-year old female prescribed oral fluconazole (enzyme inhibitor) 50mg daily for 14 
days alongside repeat Simvastatin 20mg at night, with no advice to temporarily 
discontinue Simvastatin. 
7.5.10 Other errors in older patients 
Important points from the analyses of the other types of error are highlighted below: 
 Of the 5 inadequate documentation errors, three related to medications for long-term 
conditions (Alendronate, Ramipril and Atorvastatin), which were not necessarily 
discontinued by the GP at any point, but which were not regularly issued thereby raising 
questions during routine medicines’ reviews at the surgery. One case related to Citalopram 
at a dose of 10mg daily, which was changed to ‘alternate days’ on two consecutive 
prescriptions, following which a surgery reception staff re-printed the original 10mg daily 
prescription. There was no documentation in the record to indicate if these dose variations 
were intentional. The last scenario was associated with a patient on repeat Levothyroxine 
tablets whose medical notes indicated that they were “not on any thyroid treatment as 
euthyroid.” 
 Of the 4 allergy errors, three were associated with prescriptions for Risedronate, 
Amoxicillin and Clopidogrel, despite there been clear documentation of previous allergies 
or sensitivities. There were no details with respect to the severity or nature of their 
sensitivities in the cases involved Risedronate and Clopidogrel. The last case was 
associated with a 66-year old female patient with a history of uncontrolled asthma (and two 
oral prednisolone courses in the 12-months review period) who was also prescribed 
Naproxen at a high daily dose of 1000mg twice in the review period. 
 Of the 4 formulation errors, three involved Prednisolone prescriptions to a patient 
diagnosed with oesophagitis, gastritis and bile reflux, at three different strengths with a 
missed opportunity to prescribe the enteric-coated formulation to alleviate gastric 
symptoms. The 4th potential formulation error was also related to Prednisolone: 70-year old 
male on long-term Prednisolone 40mg daily on repeat with documented gastric acid 
problems. 
 All the duration errors related to topical steroids at quantities, which could result in 
extended use without corresponding advice on duration of use. 
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7.6 Information on different types of monitoring errors in older patients 
Additional information is provided below on the drug preparations, which were most 
commonly associated with the different types of monitoring errors discussed in  
Table 37. 
Monitoring not requested: The 23 monitoring-not-requested errors were associated with 12 
medications: Candesartan, Amiodarone, Bendroflumethiazide, Carbimazole, Co-amilozide, 
Furosemide, Levothyroxine, Lisinopril, Losartan, Lithium, Ramipril and Simvastatin. In all the 
instances, laboratory tests were not ordered when due. 
Results not acted upon: The two results-not-acted-upon, were both associated with 
Levothyroxine doses not adjusted according to endocrinology results. 
 
 
7.7 Analysis of omission errors related to failure to prescribe a drug for an 
existing clinical condition in older patients ≥65 years old 
The reviewer identified 20 older patients with 23 possible omission errors relating to failure to 
prescribe for an existing clinical condition, from the review of 364 case notes. These scenarios 
were those there were no notes in the medical records to suggest a decision not to supply had 
been made by the GP or in accordance with a patient’s preference. They were separate from 
those errors associated with failure to prescribe concomitant treatment. These cases included 
the following: 
Drug implicated Description of Omission error 
Statin 4 possible cases of failure to prescribe in patients who may benefit 
from the primary or secondary prevention of cardiovascular events 
Aspirin 5 possible cases of failure to prescribe aspirin in patients with 
coronary heart disease 
Bisphosphonate 
and/or calcium 
6 possible cases of failure to prescribe a bisphosphonate and/or 
calcium to maintain bone mineral density in confirmed cases of 
osteoporosis or long-term oral steroid treatment 
Colchicine and 
Allopurinol 
For acute and chronic gout treatments as opposed to continued use of 
NSAIDs to manage inflammation 
Brufen M/R ® Dose-reduction of long-term 800mg of Brufen M/R up to twice daily 
(patient was adamant he did not require PPI) 
Addition of diuretic 
(or dose optimisation 
Diuretic, or dose optimization of Losartan in a 71-year old female 
with uncontrolled hypertension who was on Losartan 25mg daily 
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of Losartan) 
Anti-diabetic agent Anti-diabetic drugs not prescribed to a patient who was referred to 
the DESMOND diabetes structured programme but who did not 
attend, with sustained elevated Plasma Fasting Glucose level 
Vitamin D 
supplement 
Vitamin D supplement not prescribed to an 85-year old male with 
low levels of Vitamin D – 29.9nmol/L (reference range 80-
150nmol/L) and documented limited or restricted movement, on-
going tiredness and weight-loss 
Metformin Metformin to a patient following an elevated HbA1c level – the GP 
had suggested that Metformin would “give patient better CV 
protection than Gliclazide.” Metformin was subsequently prescribed 
but not issued due to “repeat inactivation.” 
Iron supplements  Two cases of failure to prescribe iron supplements when 
haematology tests showed low iron levels. 
  
 
7.8 Severity assessment of medication errors 
207 case summaries representing a total of 216 prescribing and monitoring errors identified in 
older patients were presented to the judges (to reduce the judges’ workload, some errors were 
summarised as one if they were for the same patient since some of the errors were identical). 
The distribution of severity scores amongst the judges was sometimes skewed, though most of 
the errors were judged as having lower severity scores. Descriptive statistics were therefore 
presented using median scores and IQR. Mean scores were also calculated to provide 
comparison with the median and the existing literature. 
For older patients, the mean severity score was 3.1, and the median was 3.0 (IQR 2.5, 4.0). The 
minimum severity score was 0 (no harm), and the maximum score was 9. Monitoring errors 
had a median score of 3.5 (IQR 3.5, 4.0). Overall, 104 (~50%) errors had scores of less than 3 
(minor), 102 (~50%) had scores of 3 to 7 (moderate). Although there were isolated cases of 
‘severe’ category by each individual judge, no two judges classed the same error as severe. 
Most monitoring errors were judged as being of moderate severity. Appendix 21 provides 
examples of judgments made by the panel. 
Examples of minor and moderate errors, and some errors judged as severe by individual judges 
is shown below: 
Table 49: Examples of errors and their severities 
Minor errors Moderate errors Severe (individual judges) 
Diprosalic® ointment and 76-year old male taking 67-year old female prescribed 
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Dovobet® gel prescribed to 
76-year old male at the same 
time. Both the ointment and 
gel contain Betamethasone 
0.05% (as dipropionate), a 
potent steroid. Duration of use 
not specified. Also on other 
steroids Patient's mental 
difficulties documented. 
Priadel 400mg at night. 
Lithium requires 12-
monthly Thyroid 
Function Tests (TFTs). 
TFTs last ordered in 
2011 (2 missed 
opportunities from date 
of review for testing 
thyroid function) 
Prednisolone tablets 5mg 
(Acute) with the directions 
'COPD: Take six daily as a 
single dose for 14 days. 
Steroid.' At the stated dose, a 
14-day course will require a 
total of 84 tablets. Only 40 
tablets were prescribed 
83-year old female prescribed 
30 Cetirizine tablets (acute) for 
hayfever. Two weeks after, 30 
tablets of Loratadine (repeat) 
10mg tablets were prescribed 
for 'itch.'  
An 81-year old female 
prescribed Ketoprofen 
gel 2.5%, (Acute) 
Ketoprofen capsules 
50mg (Repeat) and 
Diclofenac gel 1% 
(Repeat) on the same day 
81-year old female prescribed 
Naproxen 250mg three times 
daily on acute prescription 
without gastro-protection in 
Dec 2013. Patient presented 
with "…small blood after 
wiping and epigastric pain in 
Jan 2014 
77-year old male on Losartan 
12.5mg daily on repeat 
prescription. Angiotensin II 
receptor antagonists require 12 
monthly urea and electrolytes 
test, which was last ordered for 
the patient in May 2013 
(record was reviewed Aug 
2014) 
40mg Simvastatin tablets 
issued to 70-year old 
female on repeat with 
Amlodipine 5mg. MHRA 
advice is to limit dose of 
Simvastatin to 20mg 
when co-prescribed with 
Amlodipine 
 
79-year old female prescribed 
acute Amoxicillin capsules 
500mg three times daily for 7 
days despite recorded 
sensitivity to Amoxicillin in 
2010. Details of the sensitivity 
was not recorded in patient's 
record 
 
65-year old female prescribed 
HRT Estradiol® pessaries 
10micrograms daily for two 
weeks then twice weekly. 
Patient's last recorded blood 
pressure reading was 
180/90mmHg  
Acute 112 Naproxen 
250mg tablets issued to 
67-year old male at a 
dose of two twice daily 
for Sciatica. No gastro-
protective agent for 28-
day course of Naproxen 
tablets 
79-year old female on repeat 
Ramipril capsules 10mg daily. 
In Sep 2013, a prescriber 
recorded in patient's record 
"needs to stop Ramipril see 
comment re renal artery." 
However, Ramipril continued 
to be issued till May 2014 
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Chapter 8. Results of the investigations on the prevalence and nature 
of prescribing errors in children   
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8.0 Characteristics of paediatric patients 0-12 years old 
The study involved the retrospective review of the records of 525 younger patients 0-12 years 
old. These younger patients had a mean age of 6.49 years (SD=3.54), and 254 (48.38%) were 
female. Of the 12-months retrospective record review period, these patients were registered for 
an average of 11.40 months.  Of the 525 younger patients 0-12 years reviewed, 282 (53.71%) 
had had at least one prescription during the 12-months retrospective examination of their 
records. 
The percentage age distribution of older patients whose records were examined is shown in 
Figure 18. 
Figure 18: Age distribution of younger patients 0-12 years old 
  
 
At practice level, the study involved the examination of 237 (18.76%) of 1263 registered 
patients aged 0-12 years old in L1; the number of records reviewed in B1 was 288 (16.28%) of 
1769 registered patients aged 0-12 years. The mean ages of these patients were 5.92 years (SD 
= 3.35) and 6.96 years (SD = 3.62) in L1 and B1 respectively. The proportion of younger male 
patients reviewed in L1 was higher than that of female patients at 54.85%. In B1 however, the 
proportion of younger male and female patients reviewed were comparable at 48.96% and 
51.04% respectively. Of the 12-months retrospective record review period, these younger 
patients were registered for an average of 11.00- and 11.72-months in L1 and B1 respectively. 
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The proportion of younger patients who had had at least one medication in the 12-months 
record review period in L1 and B1 were comparable at 56.96% and 51.04%% respectively. 
 
Age distribution of patients whose records were reviewed was comparable for patients 5-9 
years old in both practices; this patient age group accounted for over 40% of all younger 
patients reviewed. However, the proportion of younger patients ≤4 years old reviewed was 
higher in L1 than in B1. Conversely, the proportion of younger patients ≥10 years old was 
higher in B1 than in L1. 
The percentage age distribution of younger patients in L1 and B1 are compared below in Table 
50: 
Table 50: Comparison of age distribution of younger patients 0-12 years old in L1 and B1 
Age range Number of 
patients L1 
Percentage age 
frequency L1 (%) 
Number of 
patients B1 
Percentage age 
frequency B1 (%) 
≤4 years old 76.00 32.07 73.00 25.35 
5-9 years old 110 46.41 116 40.28 
≥ 10 years old 51 21.52 99 34.38 
All 0-12 years 237.00 100.00 288.00 100.00 
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8.1 Characteristics of prescriptions reviewed for younger patients 0-12 years 
old 
In total, 755 unique prescription items for 282 younger patients 0-12 years were reviewed. Of 
these, 188 (24.90%) were repeat prescriptions, and 567 (75.10%) were acute prescriptions. 
Only one item (Epilim Chronosphere®) prescribed to a child was an item, which was 
considered as requiring blood test monitoring.  
Including those patients without a prescription item issued in the 12-months record review 
period, the median number of prescriptions per younger patient was 1 (IQR 2); excluding 
patients without a prescription item, the median number of prescriptions per younger patient 
was 2 (IQR 2). The highest number of prescription items issued to any younger patient 0-12 
years during the review period was 14.  
Of the 755 prescriptions items, male patients received the majority at 437 (57.88%). Table 51 
below provides information on how the number of prescription items varied with younger 
patients’ age ranges. It can be seen that the average numbers of prescriptions per patient were 
comparable across the three age ranges. 
Table 51: How prescription items varied with age for younger patients 0-12 years 
Age range 
(years) 
Number of 
prescriptions 
Number of patients with at 
least one prescription item 
Average number of 
prescription items per patient  
0-4.99  344 124 2.77 
5.00-6.99 311 113 2.75 
≥10.00 100 45 2.22 
All 0-12 
years 
755 282 2.68 
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At practice level, 359 unique prescription items for 135 younger patients were reviewed in L1. 
Of these, 106 (29.53%) were repeat prescriptions and 253 (70.47%) were acute prescriptions. 
In B1, 396 unique prescription items for 147 younger patients were reviewed. The proportions 
of repeat and acute prescriptions for younger patients in B1 were 82 (20.71%) and 314 
(79.29%) respectively as shown in Figure 19 below.  
Figure 19: Percentage of acute and repeat prescription items reviewed in younger 
patients in L1 and B1 
 
 
Including and excluding patients without a prescription item issued in the 12-months review 
period, the median number of prescriptions per younger patient in both L1 and B1 were 
comparable at 1 (IQR 2) and 2 (IQR 2) respectively. 
Of the 359 and 396 unique prescription items reviewed in L1 and B1 younger male patients 
received the majority in both L1 and B1 at 234 (65.18%), and 203 (51.26%) respectively. Table 
52 below compares how the number of prescription items varied with older patients’ age ranges 
in L1 and B1. It can be seen that average number of prescription items per patient were 
comparable across the three age ranges in both practices. 
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Table 52: How prescription items varied with age in younger patients between L1 and B1 
Age 
range 
(years) 
Numbe
r of Rx 
items 
L1 
Patients 
with at 
least one 
Rx item 
L1 
Average 
number of 
prescription 
items per 
patient L1 
 Number 
of Rx 
items 
B1 
Patients 
with at 
least one 
Rx item 
B1 
Average 
number of 
prescription 
items per 
patient B1 
0-4.99  155 58 2.67 189 66 2.86 
5.00-6.99 158 57 2.77 153 56 2.73 
≥10.00 46 20 2.30 54 25 2.16 
All 0-12 
years  
359 135 2.66 396 147 2.69 
 
 
 
8.1.1 Characteristics of acute and repeat prescription items reviewed in younger 
patients 
Acute prescription items were recorded for 257 younger patients, and the median number of 
unique acute prescription items per younger patient was 2 (IQR 2), with the highest number 
prescribed to any patient being 9. 
Repeat prescriptions were recorded for 86 younger patients, and the median number of unique 
repeat prescription item per younger patient was 2 (IQR 1.25), with the highest number 
prescribed to any patient being 12.  
Table 53 below shows the number of younger patients, who were prescribed a range of acute 
and repeat prescriptions. It can be seen that over three quarters of younger patients had three or 
less acute and repeat prescription items. 
Table 53: Number of younger patients with ranges of acute and repeat prescription items 
Number of acute 
prescription items 
Number of younger 
patients 0-12 yrs. (%) 
 Number of repeat 
prescription items 
Number of younger 
patients 0-12 yrs. (%) 
 ≤3 213 (82.88)  ≤3 78 (90.70) 
4-7  39 (15.18) 4-7  6 (6.98) 
8-11 5 (1.95) 8-11 1 (1.16) 
12-15 0 (0) 12-15 1 (1.16) 
≥16  0 (0)  ≥16  0 (0) 
567 257 (100) 188 86 (100) 
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At practice level, acute prescription items were recorded for 121 younger patients in L1, and 
the median number of unique acute prescription items per younger patient was 2 (IQR 2), with 
the highest number of acute prescriptions issued to any patient being 8. Acute prescription 
items were recorded for 136 older patients in B1, and the median number of unique acute 
prescription items per younger patient was comparable with L1 at 2 (IQR 2), with a maximum 
of 9 acute prescriptions issued to any patient. 
In L1, repeat prescription items were recorded for 44 younger patients, and the median number 
of unique repeat prescription items per younger patient was 2 (IQR 2) with the highest number 
prescribed to any patient being 12. Repeat prescription items were recorded for 42 younger 
patients in B1, and the median number of unique repeat prescription items per older patient was 
2 (IQR 1), the maximum number of repeat prescription items issued to any patient being 8. 
Table 54 below compared the number of younger patients who were prescribed a range of acute 
and repeat prescriptions in L1 and B1. It can be seen that over 80% of patients had three or less 
acute and repeat prescription items in both practices. 
Table 54: How the number of younger patients with ranges of acute and repeat 
prescription items varied 
Number of 
acute 
prescription 
items 
Number of younger 
patients 0-12 years 
 Number of 
repeat 
prescription 
items 
Number of younger 
patients 0-12 years 
 L1 (%) B1 (%)  L1 (%) B1 (%) 
 ≤3 103 (85.12) 110 (80.88)  ≤3 38 (86.36) 40 (95.24) 
4-7  17 (14.05) 22 (16.18) 4-7  5 (11.36) 1 (2.38) 
8-11 1 (0.83) 4 (2.94) 8-11 0 (0) 1 (2.38) 
12-15 0 0 12-15 1 (2.27) 0 
≥16  0 0 ≥16  0 0 
All 0-12 years 121 136  44 42 
 
 
Results on how the number of acute and repeat prescription items varied with younger patients’ 
age is provided in Table 55 below. It can be seen that the average numbers of acute and repeat 
prescriptions per patient were comparable across the three age ranges. This is similar at 
practice level as shown in Table 56 below. 
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Table 55: How acute and repeat prescription items varied with younger patients' age 
Age range 
(years) 
Total 
Acute 
items 
Number 
of 
patients 
Average 
number of 
acute 
prescriptions 
per patient 
Total 
Repeat 
items 
Number 
of 
patients 
Average 
number of 
repeat 
prescriptions 
per patient 
0-4.99  271 114 2.38 73 37 1.97 
5.00-6.99 222 105 2.11 89 34 2.62 
≥10.00 74 38 1.95 26 15 1.73 
All 0-12 
years  567 257 2.21 188 86 2.19 
 
 
Table 56: Comparison of acute and repeat prescription items varied with younger 
patients' age between L1 and B1 
Age range 
(years) 
Total 
Acute 
items 
Number of 
patients 
Average 
number of 
acute 
prescriptions 
per patient 
Total 
Repeat 
items 
Number of 
patients 
Average 
number of 
repeat 
prescriptions 
per patient 
L1 
0-4.99  116 52 2.23 39 16 2.44 
5.00-6.99 103 53 1.94 55 20 2.75 
≥10.00 34 16 2.13 12 8 1.50 
All 0-12 
years  253 121 2.09 106 44 2.41 
B1 
0-4.99  155 62 2.50 34 21 1.62 
5.00-6.99 119 52 2.29 34 14 2.43 
≥10.00 40 22 1.82 14 7 2.00 
All 0-12 
years  314 136 2.31 82 42 1.95 
 
 
8.1.2 Characteristics of drugs commonly prescribed to younger patients 
8.1.2.1 BNF chapters 
The different groups of drugs prescribed to younger patients by British National Formulary, 
BNF chapter are shown in Table 57 below. It can be observed that the most commonly 
prescribed drugs for younger patients were those for skin, infections, and respiratory system; 
these drugs made up almost two thirds of prescriptions.  
  212 
Table 57: Distribution of prescription items reviewed by BNF Chapter for younger 
patients 0-12 years 
Chapter  Chapter name Frequency Percentage 
13 Skin 235 31.13% 
5 Infections 188 24.90% 
3 Respiratory system 139 18.41% 
11 Eye 52 6.89% 
1 Gastro-intestinal system 40 5.30% 
12 Ear, nose and oropharynx 24 3.18% 
9 Nutrition and blood 19 2.52% 
4 Central nervous system 18 2.38% 
6 Endocrine system 15 1.99% 
7 Obstetrics, gynaecology, and urinary-tract  12 1.59% 
15 Anaesthesia 5 0.66% 
Appendix 2 Borderline substances 5 0.66% 
10 Musculoskeletal and joint diseases 2 0.26% 
2 Cardiovascular system 0 0.00% 
8 Malignant disease and immunosuppression 0 0.00% 
14 Immunological products and vaccines 0 0.00% 
 Total 755 100.00% 
 
 
At practice level, drugs for skin, infections, respiratory system, eye and gastro-intestinal system 
were the top five BNF chapters most commonly prescribed for younger patients in both L1 and 
B1 Table 58. These drug classes made up over 80% of all prescriptions in both practices. 
Table 58: Comparison of drug distribution by BNF chapter in L1 and B1 
BNF chapter name Frequency 
L1 
% 
L1 
 BNF chapter 
name 
Frequency 
B1 
% 
B1 
Skin 132 36.77 Infections 114 28.79 
Infections 74 20.61 Skin 103 26.01 
Respiratory system 56 15.60 
Respiratory 
system 83 20.96 
Gastro-intestinal 
system 19 5.29 Eye 33 8.33 
Eye 19 5.29 
Gastro-intestinal 
system 21 5.30 
Ear, nose and 
oropharynx 15 4.18 
Nutrition and 
blood 10 2.53 
Central nervous system 10 2.79 
Ear, nose and 
oropharynx 9 2.27 
Obstetrics, 
gynaecology, and 
urinary-tract disorders 10 2.79 
Central nervous 
system 8 2.02 
Nutrition and blood 9 2.51 Endocrine system 7 1.77 
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Endocrine system 8 2.23 
Borderline 
substances 4 1.01 
Anaesthesia 3 0.84 
Obstetrics, 
gynaecology, and 
urinary-tract 
disorders 2 0.51 
Musculoskeletal and 
joint diseases 2 0.56 Anaesthesia 2 0.51 
Borderline substances 1 0.28    
Unclassified (Eqe Q 
capsules) 1 0.28  
  
Total 359 100  396 100 
 
 
8.1.2.2 Drugs commonly prescribed in younger patients 
The top 20 drugs most frequently prescribed to younger patients are shown in Table 59 below. It 
can be observed that these drugs made up almost two thirds of prescriptions. 
Table 59: Top 20 drugs most commonly prescribed in younger patients 0-12 years 
Preparation name Frequency Percentage 
Amoxicillin 106 14.04 
Salbutamol 61 8.08 
Chloramphenicol 30 3.97 
Hydrocortisone 29 3.84 
Fusidin® 26 3.44 
Clenil Modulite® 26 3.44 
Flucloxacillin 21 2.78 
Cetirizine 19 2.52 
Oilatum® 19 2.52 
Clotrimazole 15 1.99 
Fucithalmic® 14 1.85 
Phenoxymethylpenicillin 14 1.85 
Doublebase® 13 1.72 
Movicol® Paediatric Plain 12 1.59 
Miconazole 11 1.46 
Trimethoprim 11 1.46 
Zerobase® 11 1.46 
Dioralyte® 10 1.32 
Chlorphenamine 9 1.19 
Co-amoxiclav 8 1.06 
Total 465 61.59 
 
At practice level, Amoxicillin and Salbutamol were the top two most frequently prescribed 
drugs to younger patients in both L1 and B1. Most of the drugs in this list were comparable, 
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and made up approximately 65% of all drugs prescribed to younger patients in both practices as 
shown in Table 60 below. 
Table 60: Comparison of the top 20 drugs most commonly prescribed to younger patients 
in L1 and B1 
L1  B1 
Preparation name Frequency % Preparation name Frequency % 
Amoxicillin 44 12.26 Amoxicillin 62 15.66 
Salbutamol 25 6.96 Salbutamol 36 9.09 
Fusidic acid  16 4.46 Chloramphenicol 18 4.55 
Hydrocortisone 15 4.18 Clenil Modulite® 17 4.29 
Cetirizine 13 3.62 Hydrocortisone 14 3.54 
Oilatum® 13 3.62 Fucithalmic® 13 3.28 
Chloramphenicol 12 3.34 Flucloxacillin 11 2.78 
Flucloxacillin 10 2.79 Fusidic acid 10 2.53 
Clenil Modulite® 9 2.51 Zerobase® 9 2.27 
Miconazole 9 2.51 Chlorphenamine 8 2.02 
Clotrimazole 8 2.23 
Phenoxymethylpenicil
lin 8 2.02 
Doublebase® 8 2.23 Clotrimazole 7 1.77 
Movicol  7 1.95 Cetirizine 6 1.52 
Aveeno® 6 1.67 Miconazole HC 6 1.52 
Dioralyte® 6 1.67 
Erythromycin Ethyl 
Succinate 6 1.52 
Diprobase® 6 1.67 Gaviscon  6 1.52 
Hydrous Ointment 6 1.67 Oilatum® 6 1.52 
Phenoxymethylpeni
cillin 6 1.67 Trimethoprim 6 1.52 
Prednisolone 6 1.67 Clarithromycin 5 1.26 
Clotrimazole HC  5 1.39 Co-amoxiclav 5 1.26 
Total 230 64.07  259 65.40 
 
 
8.1.2.3 Therapeutic classes of commonly prescribed drugs in younger patients 
When the drugs prescribed to younger patients were grouped into their therapeutic classes, 
antibacterial drugs were topmost on the list, similar to older patients. This was also true in both 
L1 and B1. The top 20 drug classes most commonly prescribed to younger patients are shown 
in Table 61 below. It can be seen that these drug classes made up over 90% of the prescriptions. 
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Table 61: Top 20 therapeutic drug classes most commonly prescribed in younger patients 
0-12 years 
Drug class Frequency Percentage 
Antibacterial 251 33.25% 
Corticosteroid/corticosteroid-containing 112 14.83% 
Emollient 104 13.77% 
Bronchodilator 62 8.21% 
Antihistamine 32 4.24% 
Laxative 25 3.31% 
Antifungal 24 3.18% 
Anti-infective 13 1.72% 
Antacid 10 1.32% 
Electrolyte replacement 10 1.32% 
Anthelmintic 8 1.06% 
Leukotriene receptor antagonist 8 1.06% 
Anti-warts 7 0.93% 
Sodium Chloride 7 0.93% 
Anaphylaxis treatment 6 0.79% 
Multivitamin 6 0.79% 
Non-opioid 6 0.79% 
ADHD management 5 0.66% 
Anaesthetic 5 0.66% 
Anti-inflammatory 5 0.66% 
Total 706 93.50% 
 
 
At practice level, antibacterial drugs were also topmost on the list of the therapeutic drug 
classes prescribed to younger patients, comparable with older patients (see Table 21). 
Corticosteroids and corticosteroid combinations, Emollients, Bronchodilators, and 
Antihistamines, and Anti-infective agents, were the topmost therapeutic drug classes most 
commonly prescribed to younger patients in both practices as shown in Table 62, It can be 
observed that these top therapeutic classes made up approximately 94% of all prescriptions in 
younger patients.  
Table 62: Comparison of the top 20 therapeutic drug classes commonly prescribed to 
younger patients 0-12 years in L1 and B1 
L1  B1 
Therapeutic Drug 
class 
Frequency  % Therapeutic Drug 
class 
Frequency % 
Antibacterial 101 28.13 Antibacterial 144 36.36 
Emollient 62 17.27 
Corticosteroid/cortic
osteroid-containing 67 16.92 
Corticosteroid/cortic 48 13.37 Emollient 42 10.61 
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osteroid-containing 
Bronchodilator 25 6.96 Bronchodilator 37 9.34 
Antifungal 22 6.13 Antihistamine 15 3.79 
Antihistamine 17 4.74 Laxative 9 2.27 
Laxative 16 4.46 Antacid 8 2.02 
Anti-infective 7 1.95 Anti-infective 6 1.52 
Electrolyte 
replacement 6 1.67 
Anaphylaxis 
treatment 5 1.26 
Sodium Chloride 5 1.39 Anthelmintic 5 1.26 
Anti-inflammatory 4 1.11 Cough suppressant 5 1.26 
Non-opioid analgesic 4 1.11 
Leukotriene receptor 
antagonist 5 1.26 
Anaesthetic 3 0.84 ADHD management 4 1.01 
Anthelmintic 3 0.84 Anti-warts 4 1.01 
Anti-warts 3 0.84 Antifungal 4 1.01 
Leukotriene 
receptor antagonist 3 0.84 
Electrolyte 
replacement 4 1.01 
Lubricant 3 0.84 Specialised formula 4 1.01 
Multivitamin 3 0.84 Multivitamin 3 0.76 
Shampoo 3 0.84 Anaesthetic 2 0.51 
Antacid 2 0.56 
Antisecretory and 
mucosal protectant 2 0.51 
Total 340 94.71  375 94.70 
 
 
8.1.2.4 Characteristics of drug formulations commonly prescribed in younger patients 
Table 63 shows the distribution of different formulations for the 755 prescription items issued to 
younger patients. It can be seen that oral and topical medications made up over 70% of 
prescriptions for this age group. 
Table 63: Distribution of different types of formulation prescribed to younger patients 0-
12 years 
Formulation Frequency Percentage 
Liquid oral 255 33.77% 
Topical 254 33.64% 
Inhalers 92 12.19% 
Solid oral 72 9.54% 
Eye/ear/nose/ointment or drops/sprays 70 9.27% 
Injection 10 1.32% 
Mouthwash 1 0.13% 
Suppositories/Pessaries 1 0.13% 
Total 755 100.00% 
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In L1 and B1, the distributions of the different formulations for the prescription items issued to 
younger patients were comparable as shown below in Table 64.  
Table 64: Comparison of the different types of formulation prescribed to younger 
patients 0-12 years in L1 and B1 
Formulation Frequency 
L1 
Percentage 
L1 
 Frequency 
B1 
Percentage 
B1 
Eye/ear/nose/ointment or 
drops/sprays 33 9.19 37 9.34 
Inhalers 36 10.03 56 14.14 
Injection 1 0.28 9 2.27 
Liquid oral 109 30.36 148 37.37 
Mouthwash 1 0.28 0 0.00 
Solid oral 36 10.03 36 9.09 
Suppositories/Pessaries 0 0.00 1 0.25 
Topical 143 39.83 109 27.53 
Total 359 100.00 396 100.00 
 
 
8.1.3 Types of prescriber 
The distributions of different types of prescriber for the prescription items are shown in Figure 
20. It can be seen that the vast majority of prescription items were issued by the surgery’s GPs. 
The percentage of prescriptions issued by nurse prescriber was higher than for older patients 
(see Error! Reference source not found.) 
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Figure 20: Types of prescribers that issued the prescription items in the study to younger 
patients 0-12 years old 
Percentage type of prescriber for younger 
patients 0-12 years old
GP
Nurse prescriber
Locum GP
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8.2 Prevalence of prescribing errors for younger patients 0-12 years old 
From the review of the 755 prescription items in younger patients 0-12 years, the following 
numbers of medication problems were identified: 
1. 70 prescribing errors and 3 omission errors relating to failure to prescribe for an existing 
condition (73 in total). 
2. No monitoring errors were identified in children 0-12 years old. 
 
8.2.1 Prescribing and monitoring error rates in younger patients 
8.2.1.1 Error rate per patient 
 57 of 282 younger patients 0-12 years, (20.21%, 95% CI 15.94%-25.28%) with at least 
one prescription item in the review period, had at least one prescribing error. There was a 
mean of 1.23 errors per patient. 
 When prescribing and omission errors (relating to failure to prescribe for an existing 
condition) were combined, 59 of 282 younger patients, (20.92%, 95% CI 16.58%-
26.04%) with at least one prescription in the record review period had at least one error. 
 
The prevalence of prescribing errors in younger patients grouped into three age bands is shown 
in Table 65 below: 
Table 65: Prevalence of prescribing errors in younger patients 
Age (yrs.) Number of patients 
with errors 
Number of patients with at 
least one prescription item 
Prevalence of all 
errors (95% CI) 
≤4.99 23 124 18.55 (12.69-26.30) 
5.00-≤9.99 31 113 27.43 (20.05-36.30) 
≥10.00 5 45 11.11 (4.84-23.50) 
Total 59 282 20.92 (16.58-26.04) 
 
It can be observed that patients 5.00-9.99 years old were more likely to have an error though this 
did not reach statistical significance at p<0.05 (Chi-square test, p=0.051). 
The Chi-square two-tailed statistic test demonstrated that paediatric patients in B1 were 
significantly more likely to have a potential error when compared with paediatric patients in L1. 
(P-Value=0.033). 
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8.2.1.2 Error rate per item 
 Of 755 prescription items reviewed in younger patients 0-12 years old, 70 prescribing errors 
were identified with a prevalence rate of prescribing errors per item being 9.27% (95% CI 
7.4%-11.55%). 
 When prescribing and omission errors (relating to failure to prescribe for an existing 
condition) were combined, 73 errors were identified. This gave a prevalence of prescribing 
errors per item of 9.67% (95% CI 7.76%-11.99%). 
 
At practice level, paediatric patients in B1 (12.12%) were significantly more likely to have an 
error compared with L1 (6.96%) (P-value = 0.017; Two-tailed Z-test for two population 
proportions). 
 
Summarily, the prevalence of prescribing and monitoring errors per item and per patient, in the 
12-months record review period is shown Table 66 below. 
Table 66: The prevalence of prescribing errors in younger patients 0-12 years old 
Age (years) Prescribing error rate (and 
omission) per item 
Prescribing error rate per patient 
with at least one prescription 
0-4.99  8.43% 18.55% 
5.00-6.99 12.22% 27.43% 
≥10.00 6.00% 11.11% 
All 0-12 years  9.67% 20.92% 
 
 
The error rates per patient shown above did not reflect that one patient could have had more than 
one error. When the error rate was determined by expressing the total number of errors as a 
percentage of patients with at least one prescription item, a higher prevalence of 25.89% (95% 
CI 21.13%-31.30%) was obtained (see Figure 21 below); the figures were 18.52% (95% CI 
12.87%-25.91%) and 32.65% (95% CI 25.60%-40.59%), in L1 and B1respectively (a two-tailed 
Z test for 2 population proportions demonstrated that the difference was significant, P-
value=0.0067;). The prevalence of errors in younger patients for the three age groups was 
consistently higher in B1 than in L1 (see Figure 22 below). 
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Figure 21: Prevalence of errors per patient 0-12 years old 
 
 
Figure 22: Comparison of prevalence of errors per patients 0-12 years old in L1 and B1 
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8.2.2 How prescribing and monitoring error rates varied with younger patients’ sex 
The prevalence of errors per patients’ sex is presented in Table 67 below. It can be observed that 
comparable proportions of female and male patients had a potential error though more items 
prescribed to female patients were associated with errors.  
Table 67: Prevalence of prescribing errors for male and female younger patients 0-12 years 
 
 
When the prevalence of errors was determined by expressing the number of patients who had at 
least one error as a percentage of patients with at least one prescription item, error rate per 
patient 0-12 years were 20.30% (95% CI 14.34%-27.92%) for female patients, and 21.48% (95% 
CI 15.65%-28.75%) for male patients. It can be observed that comparable proportions of female 
and male patients had at least one error. Two-tailed Chi-square statistical test showed that there 
was no statistical difference between male and female younger patients (P-Value=0.808).  
Female patients in B1 were however significantly more likely to experience an error when 
compared with L1 (P-value=0.02); errors in male patients were comparable in both practices (P-
Value=0.45). 
 
8.2.3 How prescribing errors varied with acute and repeat prescriptions in younger 
patients 0-12 years 
The prevalence of prescribing errors for acute and repeat prescriptions over the 12-months 
record review period is presented in Table 68 below. It can be seen that acute prescription items 
were associated with significantly more errors than repeat prescription items in younger patients 
(two tailed Chi-square test at 0 p<0.05; P-Value=0.00031). Acute prescriptions in B1 were more 
likely to have an error when compared with acute prescriptions in L1; this reached statistical 
significance. 
 Number of 
prescription 
errors 
Total 
prescription 
items 
Prescription 
error rate 
per item 
Patients with at 
least one 
prescription item 
Prescription 
error rate 
per patient 
Female 36 318 11.32% 133 27.07% 
Male 37 437 8.47% 149 24.83% 
Total 73 755 9.67% 282 25.89% 
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Table 68: Prevalence of prescribing errors for acute and repeat prescription items 
prescribed to younger patients 0-12 years 
Type of prescription Frequency of errors on 
prescription items 
Percentage (95% CI) 
Acute prescription items 65 92.86% (8.44%-9.69%) 
Repeat prescription items 5 7.14% (3.09%-15.65%) 
Total 70 100% 
 
 
8.2.4 Reoccurrences of prescribing errors in younger patients 0-12 years 
During data collection, potential errors were reviewed as to whether they had occurred as a 
single event or had been repeated one or more times.  Figure 23 below shows that most errors in 
younger patients had not been repeated, and approximately 20% errors had been repeated in 
younger patient. 
Figure 23: Reoccurrences of potential prescribing errors in younger patients 
 
 
8.2.5 How prescribing error rates varied with the number of prescriptions in younger 
patients 
Figure 24 below showed that the number of errors identified in the younger patient group 
increased with the average number of prescriptions. 
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Figure 24: Error variation with prescription items in younger patients 
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8.3 Types of prescribing errors in younger patients 0-12 years old 
The distributions of the different types of prescribing errors for younger patients are shown in 
Table 69. It can be observed that more than a third of prescription errors were associated with 
information being incomplete on the prescription. Over three quarters of prescribing errors 
were associated with the top three categories of prescribing errors as shown in below. 
Table 69: Distribution of different types of prescribing errors for younger patients 0-12 
years old 
Types of prescribing error Frequency Percentage 
Incomplete information on prescription 32 45.71 
Dose/strength error 17 24.29 
Frequency error 8 11.43 
Inadequate documentation on medical records 3 4.29 
Quantity error 3 4.29 
Inadequate Review 3 4.29 
Unnecessary drug 2 2.86 
Formulation error 2 2.86 
Total 70 100 
 
 
At practice level, incomplete information on prescription remained the most frequently 
occurring type of prescribing error in younger patients, representing 52.17% and 42.55% of all 
categories in L1 and B1 respectively as shown in Table 70 below.   
Table 70: Comparison of distribution of different types of prescribing errors for younger 
patients 0-12 years old in L1 and B1 
Types of prescribing 
error 
Frequency
L1 
%, L1  Types of 
prescribing error 
Frequency
L1 
%, 
L1 
Incomplete 
information on 
prescription 12 52.17 
Incomplete 
information on 
prescription 20 42.55 
Dose/strength error 5 21.74 Dose/strength error 12 25.53 
Quantity error 3 13.04 Frequency error 8 17.02 
Formulation error 2 8.70 
Inadequate 
documentation on 
medical records 3 6.38 
Inadequate Review 1 4.35 Unnecessary drug 2 4.26 
   Inadequate Review 2 4.26 
Total 23 100.00  47 100 
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8.3.1 Drugs commonly associated with potential errors in younger patients 
Table 71 below shows the drugs most commonly associated with prescribing errors in younger 
patients. There were 20 different drugs associated with prescribing errors in younger patients in 
total, and the 7 shown in the table below accounted for over 80% of the errors 
Table 71: Drugs most commonly associated with prescribing errors in younger patients 0-
12 years 
Preparation name Dosage form Frequency Percentage 
Amoxicillin Oral suspension 17 24.29 
Hydrocortisone Ointment and cream 10 14.29 
Chloramphenicol Eye drops 8 11.43 
Daktacort® Cream 8 11.43 
Canesten HC® Cream 7 10.00 
Timodine® Cream 4 5.71 
Fucidin H® Cream 3 4.29 
Total  57 81.43 
 
 
Table 72 below shows the drugs most commonly associated with prescribing errors in younger 
patients in L1 and B1. In total, there were 11 and 13 drugs associated with prescribing errors in 
L1 and B1 respectively. In both practices, Amoxicillin topped the list. 
Table 72: Comparison of drugs most commonly associated with prescribing errors in 
younger patients 0-12 years old in L1 and B1 
Preparation 
name 
Frequency 
L1 
%  
L1 
 Preparation name Frequency 
B1 
% 
B1 
Amoxicillin 6 26.09 Amoxicillin 11 23.40 
Canesten HC® 5 21.74 Chloramphenicol 8 17.02 
Hydrocortisone 3 13.04 Hydrocortisone 7 14.89 
Daktacort® 2 8.70 Daktacort® 6 12.77 
Cetirizine 1 4.35 Timodine® 4 8.51 
Clenil Modulite 1 4.35 Fucidin H® 3 6.38 
Eumovate® 1 4.35 Canesten HC® 2 4.26 
Eurax-HC 1 4.35 Clarithromycin 1 2.13 
Ketoconazole 1 4.35 
Erythromycin Ethyl 
Succinate 1 2.13 
Movicol 1 4.35 Kolanticon® 1 2.13 
Qvar® 1 4.35 Mebeverine  1 2.13 
   Salbutamol 1 2.13 
   Trimethoprim 1 2.13 
Total 23 100  47 100 
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8.3.2 Therapeutic classes of drugs commonly associated with potential errors in younger 
patients 
When the drugs associated with errors in younger patients were grouped into their therapeutic 
classes, antibacterial drugs were topmost on the list as shown in Table 73 below.  
Table 73: Therapeutic drug classes associated with prescribing errors in younger patients 
0-12 years old 
Therapeutic drug class Frequency Percentage 
Antibacterial 28 40.00 
Corticosteroid-topical with antimicrobial 22 31.43 
Corticosteroid-topical 11 15.71 
Bronchodilator 3 4.29 
Antifungal 1 1.43 
Antihistamine 1 1.43 
Antisecretory and mucosal protectants 1 1.43 
Antispasmodic 1 1.43 
Corticosteroid-topical with antipruritic 1 1.43 
Laxative 1 1.43 
Total 70 100 
 
The topmost therapeutic drug class associated with prescribing errors in L1 and B1 were 
Corticosteroid (with antimicrobial agents) and antibacterial drugs respectively as shown in 
Table 74 below. 
Table 74: Comparison of the therapeutic drug classes associated with prescribing errors 
in younger patients 0-12 years old 
Therapeutic drug 
class 
Frequency 
L1 
%  
L1 
 Therapeutic drug 
class 
Frequency 
B1 
% 
B1 
Corticosteroid-
topical with 
antimicrobial 
7 30.43 
Antibacterial 
20 42.55 
Antibacterial 
6 26.09 Corticosteroid-topical 
with antimicrobial 
15 31.91 
Corticosteroid-
topical 
4 17.39 
Corticosteroid-topical 
6 12.77 
Bronchodilator 2 8.70 Bronchodilator 4 8.51 
Antifungal 1 4.35 Antihistamine 1 2.1 
Antihistamine 
1 4.35 Corticosteroid-topical 
with antipruritic 
1 2.13 
Corticosteroid-
topical with 
antipruritic 
1 4.35 
 
  
Laxative 1 4.35    
Total 23 100  47 100 
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8.3.3 BNF chapters of the drugs commonly associated with prescribing errors in 
younger patients 
Table 75 below outlines the proportion of prescribing errors in younger patients by their BNF 
chapters. It can be observed that the five BNF chapters associated with prescribing errors were 
those that also accounted for the highest numbers of prescriptions in Table 57 above. 
Table 75: Proportion of prescribing errors in younger patients 0-12 years from different 
BNF chapters 
BNF 
Chapter 
British National Formulary chapter Frequency Percentage 
13 Skin 35 50.00 
5 Infections 20 28.57 
11 Eye 8 11.43 
3 Respiratory system 4 5.71 
1 Gastro-intestinal system 3 4.29 
 Total 70 100 
 
At practice level, the proportions of prescribing errors in younger patients by their BNF 
chapters were comparable with Table 76 below. 
Table 76: Errors in younger patients by BNF chapters 
BNF 
chapter 
number 
BNF 
chapter 
name 
Frequency %  BNF 
chapter 
number 
BNF 
chapter 
name 
Frequency % 
13 Skin 13 56.52  13 Skin 22 46.81 
5 Infections 6 26.09  5 Infections 14 29.79 
3 Respiratory 
system 
3 13.04  11 Eye 8 17.02 
1 Gastro-
intestinal 
system 
1 4.35  1 Gastro-
intestinal 
system 
2 4.26 
     3 Respiratory 
system 
1 2.13 
Total  23 100    47 100 
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8.4 Information on different types of prescribing errors in younger patients 
Additional information is provided below on the drug preparations, which were most 
commonly associated with the different types of prescribing errors in younger patients 
discussed in (Table 69) above. 
 
8.4.1 Incomplete information on prescription 
32 incomplete information errors involved 7 different skin preparations as shown in Table 77 
below. The most common form of incomplete information related to the use of topical steroid 
or steroid and antimicrobial-containing preparations in young patients, with no specific advice 
on either duration of use or part being treated, when the quantity prescribed had been taken into 
consideration. It can be observed that hydrocortisone only, and in combination with 
Clotrimazole and Miconazole, were mostly associated with this error type. Quantities 
prescribed ranged mostly from 30grams to 60grams.  
Table 77: Drug preparations most commonly associated with incomplete information on 
the prescription in younger patients 
Preparation name Frequency Percentage 
Canesten HC® (Clotrimazole and hydrocortisone) 6 19 
Daktacort® (Miconazole and hydrocortisone) 7 22 
Eumovate® (Clobetasone) 1 3 
Eurax-Hydrocortisone® 1 3 
Fucidin H® (Fusidic acid and hydrocortisone) 3 9 
Hydrocortisone 10 31 
Timodine® 4 13 
Total 32 100 
 
 
8.4.2 Dose/strength error 
The 17 dose or strength errors involved 4 different drug preparations. Fourteen of this error 
type related to the prescription of incorrect doses of Amoxicillin to younger patients ≥5 years. 
For example, a 9-year old female patient was prescribed 100mls of Amoxicillin 125mg/5ml 
oral suspension three times daily, twice in seven days, following suspected treatment failure. 
(The BNF recommends a dose of 250mg three times daily for children ≥5 years old). The 
patient later presented at a NHS walk in centre with “yellowish discharge and eardrum 
perforation,” and was later discharged with co-amoxiclav 250mg/5ml three times daily. One 
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dose error was also identified in a prescription of Erythromycin Ethyl Succinate 125mg/5ml 
every 6 hours to an 8year 2months old female.  
 
8.4.3 Other errors in younger patients 0-12 years 
Important points from the analyses of the other types of error in younger patients are 
highlighted below: 
 Frequency error: the eight frequency errors related to unclear directions on 
Chloramphenicol eye drops or ointment, which were judged to have the potential to result 
in treatment failure. 
 Inadequate documentation in medical notes: involved three scenarios: a 37 weeks old 
male child presented in June with a suspected penicillin allergy. As at August when the 
record was reviewed, there was still no annotation in the allergy and sensitivities section of 
the patient’s notes; an almost 7-year old male prescribed Salbutamol inhaler twice in one 
week with no notes to suggest worsening symptoms or the possibility of storage in a 2nd 
place or school; lastly, a 9-year old female child prescribed two steroid-containing cream 
(with Clotrimazole and Fusidic acid) when patient presented with suspected ‘eczema and 
fungal infection,’ with no notes to suggest why an antibacterial-containing cream had been 
supplied in addition to a antifungal-containing cream. 
 Quantity error: this error type involved only Amoxicillin where the quantity prescribed 
was short by a dose to complete the stated week’s dosage. 
 Inadequate review: Of the three inadequate review errors, two were associated with 
prescription of Kolanticon® gel and Mebeverine oral suspension to a 10 year old child with 
on-going stomach problems, despite a documented plan for hospital referral one month 
prior to both prescriptions. The third case was associated with non-optimization of asthma 
therapy in a 7-year old child with worsening asthma symptoms. 
 Unnecessary drug: This error type was associated with the prescription of Trimethoprim 
with Gaviscon infant oral powder for a 51 week old baby for acid reflux, and Daktacort ® 
cream to a 2-year old child following a history of “hurt on passing faeces… which on 
examination showed a degree of phimosis and marginal discomfort.” 
 Formulation error: The two scenarios were prescription of Ketoconazole shampoo for 
suspected generalized rash on skin, and a switch from Clenil Modulite® to Qvar®, with no 
notes suggesting these were intended by GP. 
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8.5 Analysis of omission errors related to failure to prescribe a drug for an 
existing clinical condition in younger patients 0-12 years 
The reviewer identified 3 younger patients with 3 possible omission errors relating to failure to 
prescribe for an existing clinical condition, from the review of 525 case notes. These scenarios 
were those, where there were no notes in the medical records to suggest a decision not to 
supply had been made by the GP or in accordance with a patient’s preference. They were 
separate from those errors associated with failure to prescribe concomitant treatment. These 
cases were all related to failure to prescribe a “preventer” medication in accordance with the 
step-wise management of asthma in children. 
 
8.6 Severity assessment of errors 
71 case summaries representing a total of 72 prescribing errors identified in younger patients 
were presented to the judges (to reduce the judges’ workload, some errors were summarised as 
one if they were for the same patient since some of the errors were identical). Similar to older 
patients, the distribution of severity scores amongst the judges was sometimes skewed, though 
most of the errors were judged as having lower severity scores. Descriptive statistics were 
therefore presented using median scores and IQR. Mean scores were also calculated to provide 
comparison with the median and the existing literature. 
For younger patients, the mean severity score was 2.8, and the median was 3.0 (IQR 2, 3.5). 
The minimum severity score was 0 (no harm), and the maximum score was 8. Overall, 48 
(~68%) errors had scores of less than 3 (minor), 23 (~32%) had scores of 3 to 7 (moderate). 
Although there were isolated cases of ‘severe’ category by each individual judge, no two 
judges classed the same error as severe.  
Examples of minor and moderate errors, and some errors judged as severe by individual judges 
is shown below: 
Table 78: Examples of error severities in paediatrics 
Minor Moderate Severe 
2-year 1month old 
child prescribed 
30grams of 
Hydrocortisone/Micon
azole 1%/2% cream 
acute prescription for 
twice daily application 
7-year 1month old male 
prescribed 150mls of 
Amoxicillin 125mg/5ml 
with the dosage 
instructions "5ml three 
times daily for 7 days." 
BNF recommended dose 
37-week old male child: In June 2014, 
patient presented with "rash, which was 
widespread, chest clear, bilateral tonsil 
inflammation, no photophobia, no neck 
sickness," following administration of 
an antibiotic given from hospital. The 
GP diagnosed "likely penicillin 
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to nappy area. 
Duration of use not 
stated 
 
for children over 5years 
old require Amoxicillin 
250mg/5ml three times 
daily 
allergy." This information was however 
not completed in the 
"sensitivities/allergy" section of the 
patient's record till date (Aug 2014) 
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Chapter 9. Discussions on the findings of the investigation on 
prescribing and monitoring errors in older patients and children in 
general practice  
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9.0 Discussion 
9.1 Summary of findings 
From a 12-month retrospective review of the electronic medical records of a random sample of 
older patients ≥65 years from two purposively selected English general practices, prescribing 
and monitoring errors were identified in approximately 1 in 12 prescriptions, with 1 in 3 
patients being exposed to a prescribing or monitoring errors. Most of the errors identified were 
of mild to moderate severity as judged by a multi-disciplinary group of clinical pharmacists. 
The factors associated with increased risk of prescribing or monitoring errors included: 
prescription of an increasing number of medications, being prescribed medications required 
laboratory blood testing, being ≥75 years old, being prescribed medication from the following 
therapeutic areas: corticosteroid (oral, topical, and topical in combination with antimicrobial 
agents), NSAID, diuretic, thyroid and antithyroid hormones, statins and ACE-I/ARB, and 
being prescribed medications from the following BNF chapters: Skin, Musculoskeletal and 
joint diseases, endocrine, cardiovascular, and central nervous systems, and eye. 
For younger patients 0-12 years old who were also studied during the same period, 
approximately 1 in 10 prescriptions and 1 in 5 patients were exposed to a prescribing error. 
Most of the errors identified for this age group were also of mild to moderate severity. The 
factors associated with increased risk of prescribing errors included: being aged ≤10 years old, 
being prescribed three or more medications, being prescribed medication from the following 
therapeutic areas: topical corticosteroids, and when in combination with antimicrobial agents, 
bronchodilator, antibacterial, and being prescribed medication from the following BNF 
chapters: skin, infections, eye, respiratory and gastrointestinal systems. 
This study was a small but pragmatic study undertaken to identify the prevalence and nature of 
prescribing and monitoring errors in general practices among older patients ≥65 years old, and 
children 0-12 years, following suggestions in the literature that these patient groups are more 
susceptible to significant errors compared with the rest of the population. One of the main 
strengths of the study is that it is the first study in England to estimate the prevalence and 
nature of prescribing and monitoring errors in the study populations of older patients in 
children in primary care. This section discusses the methods used, and the results of the 
investigation. 
 
  235 
9.2 The methods used in the study 
9.2.1 Recruitment of CCGs (formerly PCTs) and general practices 
During recruitment of local authorities and general practices, Primary Care Trusts, PCTs, were 
abolished to form the current Clinical Commissioning Groups, CCGs, structure. This change 
posed many challenges for the study, some of which are highlighted below: 
 Researchers observed that using a multi-faceted approach to recruit healthcare 
professionals to participate in error studies was very useful (Howard et al., 2006). This was 
true under the PCT structure. The CCG structure has general practices as its member 
organizations, and as such, unlike PCTs, CCGs have little regulatory authority/role over 
practices. This meant that although the CCGs’ medicines management teams welcomed the 
study and desired that general practices would seize the opportunity to review their 
medication safety practices, it was really down to the practices to decide to participate or 
otherwise. If the medicines management team under the old PCT structure knew a general 
practice, which may really benefit from the study, they could encourage and support them 
as necessary. With CCGs, however, the medicines management team became ‘employed’ 
by the general practices’ body, the CCG, and may not have felt equipped to provide the 
encouragement and support to general practices to participate. 
 The formation of the CCGs at the time meant many changes in staff roles and 
organizational structures. This meant, in many instances, starting the approval and consent 
to participate procedures all over again. Furthermore, the CCG boards were quite tied up 
with ensuring as smooth a transition as possible, meaning further delays for approvals and 
meetings. Obtaining consent from the Caldicott guardians of each organisation was 
challenging due to temporary overlap of staff roles. 
 One example of the challenges experienced with the changeover: a PCT had previously 
given their consent to participate under the old structure. When the PCT was abolished, 
changes in local research governance resulted in unprecedented delays with uncovering the 
needs of the board with elements of the study.  
 Due to these unprecedented delays, and time pressures on the project, two purposively 
selected general practices from two purposively selected CCG were used as the study sites 
for this aspect of the doctoral research. 
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During recruitment, it was also observed that PCTs and subsequently CCGs operated 
differently with respect to obtaining approval for research. For example, NHS South London 
wanted the study to identify practices and obtain some form of consent from them prior to the 
R and D’s consent. Most of the other CCGs however, were happy to provide consent at the 
CCG level, and serve as a communication channel to the practices. One CCG, which was 
eventually lost, had given consent; however, certain members of the board requested further 
information, which the study provided but they were unable to reach a conclusion. Therefore, 
although the British healthcare system is meant to be a national health system, practices vary 
significantly across governance levels. Some standardisation of roles and procedures would be 
gainful for research, the findings and inferences of which could be potentially improve patient 
outcomes. 
 
9.2.2 Sampling of general practices 
The two general practices recruited to the study were moderately representative of general 
practices in England, with respect to their average list size, number of general 
practitioners/other prescribers, age profile and QOF points. The practices were both located in 
more deprived LSOAs, although L1 more than B1. As healthcare is one of the domains 
reflected by the IMD score, these results of these findings may be more generalizable to other 
English LSOAs in the top 20%-50% most deprived areas.   The sampling strategy however did 
not give the study the opportunity to cover a range of locations (urban, rural, suburban and 
city) as originally intended. It is therefore possible that both practices had special interest in the 
safety and quality of prescribing when compared with other practices, and may have had a bias 
to the review of their records to identify potential prescribing errors. 
 
9.3 Evaluating the prevalence and nature of prescribing and monitoring errors 
Medication error rates reported in the literature vary with the methods and definitions used 
(Olaniyan et al., 2014).  
This study used a retrospective quantitative review of electronic medical records to investigate 
the prevalence and nature of prescribing and monitoring errors in older patients and children in 
primary care. This approach involved the step-wise application of clinical judgement by a 
clinical pharmacist to review the patient, their diagnosis, and the therapeutic or drug 
intervention during a consultation, its effectiveness, and progress of the condition(s) being 
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managed (Barber et al., 2009; Zermansky et al., 2001). For each patient, the pharmacist 
provided a summary of the medicines prescribed, and described what was considered a 
prescribing or monitoring error. The literature on medication errors described this as a practical 
and reliable method for obtaining information on errors in prescribing as it consistently 
detected more errors when compared with other methods (Avery, Barber, et al., 2012; Olaniyan 
et al., 2014).  
The other methods, which are commonly used to detect prescribing errors, include prospective 
observation of consultation or real-time data collection, which is cost- and labour-intensive and 
invasive, retrospective review of prescriptions, which potentially lacks vital and relevant 
patient information, incident reporting or analyses of other forms of databases, which is 
challenged by under-reporting, and patient and prescriber interviews, which is time- and 
interviewee(s) memory-dependent (Avery, Barber, et al., 2012). As observed by (Franklin et 
al., 2009) and (Tam et al., 2008), these methods have different strengths and weaknesses, and 
usually detect different types of errors. 
Researchers investigated the methodological variability in detecting prescribing errors for the 
evaluation of interventions and found that, of four different methods namely prospective 
detection by ward pharmacist, retrospective health record review, retrospective use of a trigger 
tool, and spontaneous reporting, the most sensitive tool was retrospective health record review 
(Franklin et al., 2009). This tool picked up 69% and 83% pre- and post-intervention compared 
with very low figures for the other tools. In addition, there was little overlap in error detected 
by these different methods. Other researchers also found that, chart review determined the 
highest yield for detecting overall ‘medication misadventures’ or preventable adverse drug 
events of three methods, the other two being patient survey and voluntary reporting (Tam et al., 
2008). In primary care, many relevant studies have also used record review in successful and 
consistent detection of prescribing and other medication-related errors (Abramson, Bates, et al., 
2011; Avery, Barber, et al., 2012; Barber et al., 2009; Chen, Avery, et al., 2005). 
As noted by Avery et al (2012), this method particularly relies on computerised general 
practices, such as those used in the current study, as patient demographic information, 
consultation notes, information on allergies or sensitivities, co-morbidities, laboratory test 
results, hospital correspondence or discharge notes, etc. are readily available in electronic 
format in one place to aid review. It was however observed during data collection, that 
inaccuracies and incompleteness could challenge this otherwise robust method. In one instance, 
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a hospital discharge note for a patient was inadvertently stored under a different patient’s 
record. Although incidents like this may be rare, they could still pose a risk for retrospective 
review of records where data collection relies solely on accuracy of medical records. 
Furthermore, it was not always practical to read a prescriber’s intention through the notes they 
had made. In their study, Avery et al included an element to detect the causes of prescribing 
errors by interviewing prescribers. However, this was outside the scope of the current study.  
The results of any investigation into any quantitative estimation of medication errors may also 
be dependent on the definition used. The current study had intended, much earlier at the 
research conception stage, to develop and validate a general practitioner-led definition of 
prescribing error in primary care. However, following a literature review, it was assessed that 
adopting an existing definition would have been sufficient and suitable for the study. This was 
in part due to limited resources, and the increasing use and adoption of Dean et al’s definition 
in the UK NHS.  
Prescribing errors were identified using the definition developed and validated by Dean et al 
(Dean et al., 2000). This definition has been previously used in a DH report “Building a safer 
NHS for patients – improving medication safety (Department of Health, 2004). It has also been 
successfully operationalized in secondary and primary care studies on medication error (Avery, 
Barber, et al., 2012; Barber et al., 2009; Dean Franklin et al., 2007). This definition included 
omissions, overlooking patient’s clinical status, transcription errors etc. Failures to adhere to 
prescribing guidelines were however, not considered as an error. 
The monitoring error definition and criteria used in this study was developed and validated by 
(Alldred et al., 2008; Barber et al., 2009), and recently adapted for use in general practice by 
(Avery, Barber, et al., 2012). These definitions were practitioner-developed, clinically useful, 
and internally and externally validated. They were further deemed suitable to this study 
following the professional and media attention given to the GMC study by Avery et al (2012). 
The results of Avery et al’s primary care study of medication errors in primary care provided a 
baseline to compare the results of the current study with. 
Patients, whose medical records were examined, were randomly selected using computer-
generated random numbers. This ensured that study population sampling bias was mainly 
eliminated. 
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The doctoral degree student, a clinical pharmacist, conducted all record reviews, which meant 
data collection was fairly consistent, when compared with those studies that use different 
pharmacists for different sites. 
The research degree student also collected data on omission errors related to failure to 
prescribe for an existing condition. Dean et al’s definition included omissions, as decision not 
to prescribe a medication, which other prescribers may, would be considered an error. 
However, as these errors were not directly related to prescribed medications, it is possible that 
some may have been overlooked during reviews (Avery, Barber, et al., 2012). 23 and 3 
omission errors were identified in older patients and children respectively. 
A validated method was used for severity assessment of potential prescribing and monitoring 
errors (Dean & Barber, 1999). As a judging panel reviewed each error, it is hoped that 
consistency in severity assessment has been achieved.  
An MSc student did most of the data entry. All data entered, including patient demographics, 
prescriptions, and information of potential errors were checked for errors and corrected as 
necessary by the research degree student prior to data extraction and analyses. 
 
9.4 The prevalence and nature or prescribing and monitoring errors 
The percentage prevalence of prescriptions with prescribing and monitoring errors in older 
patients ≥65 years old was 7.89% (95% CI 6.94%-8.96%). One in three or 40.87% of all older 
patients were exposed to a prescribing or monitoring error during the 12-mnonth data 
collection period. Most of the errors were however of mild to moderate severity.  
The percentage prevalence of prescriptions with prescribing and monitoring errors in children 
0-12 years old was higher than that of older patients at 9.67% (95% CI 7.76%-11.99%). 1 in 5 
or 20.92% of all children were exposed to a prescribing or monitoring error during the 12-
months record review period. There were more errors of moderate severity than mild in 
younger patients than in older patients. 
Although the absolute number of prescriptions and patients’ records reviewed per practice and 
overall were sizeable, the small number of practices studied may preclude generalizability. 
However, this is a pragmatic study, which can be successfully adapted by practice pharmacists, 
to review the safety of prescribing during any specified time period (Zermansky et al., 2001). 
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General practices can also review the prescribing safety and quality associated with specific 
therapeutic classes, co-morbidities or age groups, by retrospectively reviewing a sample of 
their patients’ records to identify potential risks for harm. This can lead them to identify and 
implement practical interventions to improve patient health outcomes. 
A wide range of types of errors associated with different drugs and therapeutic groups were 
identified. Some of the specific ones, which require attention in the care of the older patient in 
primary care may include but not limited to 
 Evaluating prescriptions of corticosteroids – oral – to ensure that the patients who may 
benefit from enteric-coated tablets are offered this, and for topical, to specify duration of 
use as required or prescribe small pack sizes, especially for potent steroids 
 Identifying older patients who are regularly prescribed oral non-steroidal anti-inflammatory 
drugs to offer them gastro-protective agents, and to introduce checks on repeat issues of 
these items 
 Identifying patients taking drugs, which require laboratory blood test monitoring to see to it 
that such tests are regularly ordered and acted upon as necessary 
 Identifying those older patients who may benefit from more regular review of their 
medications – patients with increasing number of prescriptions or doctor’s visits, frail 
patients who may increasingly become unable to demonstrate concordance, patients who 
are not regularly ordering their medication for long-term management of chronic diseases 
etc. 
 
 
For children, these may include: 
 Reviewing the doses of commonly prescribed antibiotics and possibly providing a chart, 
which summarizes these doses in every consultation room. It may be useful to perform 
periodic audits to review the prescription of antibiotics in the younger patient population as 
antibacterial prescriptions, mostly oral, made up a third or 33.25% of all prescriptions 
issued to children. It is therefore pertinent to get it right 
 Topical steroids – the volume and quantity of steroids issued to younger patients was large 
112 prescriptions accounting for 14.83% of all prescriptions. When it came to the errors 
however, 110 prescriptions, which accounted for 47.14% of all errors, were associated with 
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topical steroid-containing medications. It can be safely said that some standardization is 
required on prescriptions of topical steroids, particularly in the younger and older patient 
populations 
 Identifying prescriptions for respiratory disease and ensuring adherence to the step 
management of asthma in children. 
   
There is a dearth of studies, which have investigated the prevalence of prescribing and 
monitoring errors in older patients and children in primary care. The results of the current study 
are compared with those of other medication error studies in primary care. 
The methods adopted in the current study were comparable to those of the recently published 
GMC-funded study, the PRACtISE Study (Avery, Barber, et al., 2012). This was in part due to 
the likelihood that the findings of that study would have influenced general practices’ 
prescribing behaviour and sensitised them to some of the issues raised in the report. 
Furthermore, it was important to be able to compare the findings of the current study with 
another UK study, as this would hopefully highlight key areas of need in the care of the 
vulnerable patient populations.  
Avery et al, found that older patients are more likely to have a medication error In keeping with 
this finding, the current study consistently showed a higher prevalence of prescriptions with 
prescribing and monitoring errors, when compared with the findings of the PRACtISE study, 
which investigated prevalence of medication errors across the whole population: 
 The prevalence of prescriptions with prescribing or monitoring errors was 4.9%; in the 
current study, this was 7.89% confirming that older patients are at increased risk of 
medication errors 
 All patients (n=1,777: the researchers found a prevalence of 12%; in the current study, in 
all older patients (n=364), the prevalence of errors was 36.23% 
 Patients who had received at least one medication (n=1,200), the prevalence was 17.8%; in 
the current study, for older patients who had received at least one medication, prevalence 
was 40.87% (n=323)  
 Patients aged 75 years and older who had received at least one medication (n=129) the 
prevalence was 38%; in the current study, the prevalence was 43.60% (n=133). 
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The error rate per patient, who had had at least one prescription item in the review period, 
increased with age and with the number of prescription items, in keeping with the findings of 
the GMC study. It was particularly of interest to find that the number of prescription errors 
increased with increase in the average number of prescription items in older patients Figure 17. 
There were other similarities between the current study and the GMC study: incomplete 
information on the prescription was the most common category of errors; the bulk of errors, 
which comprised the ‘omission to prescribe concomitant medication’ were associated with the 
prescription of NSAIDs without gastro-protection; the most common monitoring error category 
was ‘monitoring not requested;’ drugs, therapeutic classes and BNF chapters associated with 
both prescribing and monitoring errors were mostly comparable. 
Another UK study, conducted in 256 residents across 55 nursing or residential homes using 
record review, estimated the prescribing error rate as 8.3% of opportunities for error, with a 
mean harm of 2.6 (mild) (Barber et al., 2009).  The result of the current study is in keeping 
with their findings that error rates are higher in older patients with co-morbidities and 
polypharmacy. The denominator used in Barber and colleagues’ study, number of opportunities 
for error, was the number of prescription items written, plus any omissions. The denominator 
used in the current study was the number of prescription items written, without any omissions. 
Including the 23 omission errors identified in older patients, the prescribing error rate in the 
current study was approximately 7%, which was still higher than Avery and colleagues’ 
prescribing error rate of 4.5% prescriptions across the population. It should however be born in 
mind that Barber and colleagues’ study was done in possibly more vulnerable and high-risk 
patients who resided in nursing or residential homes, with an average age of 85.2 years (SD 
8.6), higher than the average age of 73.68 years (SD = 7.75) recorded in the current study. 
Furthermore, Barber et colleagues’ study was not limited to record review but also included 
other methods including patient interviews and direct observations, which may have led to the 
identification of more errors. 
Another UK study, which used retrospective record review to identify potential prescribing 
errors from four general practices, found a comparatively lower error rate of 1.9 incidents per 
1,000 patients or 4.3 per 1,000 patients on 2 or more medications (Chen, Avery, et al., 2005). 
This study however, focused on potential for serious drug-drug interactions or drug-disease 
interactions (contraindications), and was not limited to older patients. The proportion of errors, 
which were drug interactions identified in the current study was 3% of all errors, translating to 
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approximately 1.8 incidents per 1,000 prescriptions or 16.6 incidents per 1,000 patients with 2 
or more medications. This loosely shows the higher prevalence of drug interactions in older 
patients, whose median number of prescriptions was much higher than Chen et al’s study at 7 
(IQR 7). 
A USA study of 1,879 prescriptions of 1,202 patients at four adult primary care practices found 
a prescribing error rate of 7.6% prescriptions (95% CI 6.4%-8.8%) in a prospective cohort 
study using prescription review, patient survey and chart review (Gandhi et al., 2005). This 
study was conducted in outpatients 18 years and over. Errors in frequency and dose were 
common. The prescribing error rate in Gandhi et al’s study interestingly compares with the 
results of the current study. The computerized prescribing systems used at the study sites in 
Gandhi et al’s study were basic, and paralleled with handwritten prescriptions by the 
researchers. The GP clinical computer systems used at the practice sites of the current study 
were more advanced with dose and frequency checks, which may have been responsible for the 
relatively fewer numbers of these types of errors in older patients.  
Abramson et al (2011) found a much higher error rate of 36.7% prescriptions (95% CI 30.7-
44.0) when they conducted a non-randomised retrospective record review of 78 community-
based primary care providers across two US states. The higher error rate reported in this study 
might be due to the use of paper prescriptions, which are generally associated with increased 
errors, when compared with electronic medical records. As concluded by Gandhi et al (2005), 
electronic prescribing could have prevented up to 95% of the potential ADEs (prescribing 
errors) identified in their study due to the advanced checks performed by these systems. 
 
In Bahrain, researchers found a prescribing error rate of 90.5% prescriptions when they 
conducted a retrospective clinical prescription review (Al Khaja et al., 2007). This study 
differed from the current study because it did not include any element of record review. 
Prescribing errors included omission, commission and integration errors. It was very inclusive, 
and this may explain the high error rate reported. Also, paper prescriptions were used. 
 
In the USA, researchers evaluated medication errors in 1,788 patients from six paediatric (<21 
years) outpatient practices in Massachusetts in a prospective cohort study (Kaushal et al., 
2010). Data was collected using duplicate prescription review, parental surveys and chart 
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review. The authors found a prescribing error rate of 68% of patients, and 53% of prescriptions 
for medication errors with minimal potential for harm, and 26% patients and 21% of 
prescriptions, for potentially harmful medication errors (near misses). In both of these 
instances, 90% and 60% errors occurred at the prescribing stage. Again, this study evaluated 
paper prescriptions. Although it is difficult to compare the findings of this study to the current 
study, it is evident that the prescribing stage was associated with more errors, and that fewer 
errors were associated with the potential for harms in the paediatric outpatient setting. 
 
9.5 Factors associated with prescribing and monitoring errors 
From the analyses of the results of the current study, factors, which may be associated with 
prescribing and monitoring errors, are highlighted below: 
Older patients and children are at risk of more significant errors as suggested in the literature 
(Rees et al., 2015). Interventions such as tailored medication reviews can significantly reduce 
the risk of harm in this patient group in primary care. The problem of the use of incorrect doses 
in children has been documented (Ghaleb et al., 2010). This was also true in Avery et al’s 
study. Urgent attention needs to be given to optimal paediatric doses to reduce the risk of harm 
associated especially with under dosing of antibiotics in children. 
This study observed that female patients might be at a greater risk of error than male patients 
though Avery et al (2012) found that men seemed to be at higher risk of prescribing and 
monitoring errors than women. The literature suggests that women are more susceptible to 
adverse drug reactions (Zopf et al., 2008). 
 
9.6 Study limitations 
The number of general practices studied is a limitation of this study, although the absolute 
number of patients reviewed in this study was high when compared to other studies to 
compensate for this In the PRACtISE study, Avery and colleagues studied a 2% sample in each 
general practice (Avery, Barber, et al., 2012). The current study included a minimum of 10% 
sample per practice. Nevertheless, the results of the current study should be interpreted with 
caution, as findings may not be generalizable to all practices or patient groups studied. 
Furthermore, a relevant enquiry from the findings of the study may be to construct some form 
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of logistic regression to explore the relationships between the variables associated with 
prescribing errors. 
The general practices, which participated in the study, were conveniently sampled. It is 
therefore possible that practices that were more open to discussing medication safety and 
having their records reviewed consented to study. This may have further introduced bias into 
the study. 
Although review of electronic health records provide information on error, which may not be 
possible to obtain through routine reporting, it relies heavily on completeness and correctness 
of patient electronic medical records held in GP practices. Research has however suggested 
that some of these records may not be accurate or complete. Where the available information 
made it impossible to judge a situation, such cases were not included in the data. It is therefore 
possible that relevant information may have been missing. Furthermore, the psychological and 
social dimensions of medication error occurrence could not be explored through retrospective 
reviews of health records, as these records do not convey an information or meaning to the 
interactions between a patient and the GP. However, this was also out of the scope of the 
current study. Incorporating interviews with GPs and patients and other practice members and 
carers may have provided further insight into the causes of the errors identified in the current 
study. The researcher has attempted to provide some insight into the causes of errors by 
mapping the findings onto Vincent and colleagues’ Patient Safety Framework in the final 
discussion. 
For use of their error severity assessment scale, Dean and Barber recommended a 5-member 
multidisciplinary judging panel (Dean & Barber, 1999). Three judges and the researcher 
participated in assessing the severity of errors using Dean and Barber’s scale. This may have 
been a source of bias. However, severity assessment of errors is a value judgement, which is 
not completely free from the influences of the professional and other background and 
experiences of the members of the judging panel. This was reflected in the current study where 
opinions of potential outcome of errors were subject to variation between judges.   
 
  246 
Chapter 10. Medicines-related problems in community pharmacies 
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10.0 Introduction 
Reason’s accident causation model adopts a systems approach to human error (Reason, 1990). 
This model has been used to analyse the systems failures that underlie medication errors 
leading to adverse drug events (ADE) and potential ADEs (Leape et al., 1995). The model has 
also been used to analyse the causes of prescribing and administration errors in primary and 
secondary care (Barber et al., 2009; Dean, 2002; Dean et al., 2002; Slight et al., 2013). 
Reason’s accident causation model describes an interaction between the ‘latent’ failures within 
the medication management system, and error-producing conditions within the environment, as 
factors, which lead to active failures by the individual who eventually makes an error. Active 
failures may be mistakes (wrong plan to achieve a desired objective), slips (doing another thing 
other than that intended), lapses (forgetting to do) or violations (not following guidelines or 
rules). 
Defences within the system identify error, and rectify it before harm results. When these 
defences break down, errors and harm occur. Within primary care, defences may include those 
within general practices, community pharmacies, and patients.  
Although the pharmacist’s role has shifted from the traditional compounding duties, the role of 
the clinical pharmacist has developed significantly over the past two decades (Hepler & Strand, 
1990).  
Community pharmacists have been the first point of advice to members of the public about 
their health, and are strategically placed to tackling Medicines Related Problems (MRPs). 
Pharmacists use their professional qualifications and knowledge for “counter-prescribing” or 
“responding to symptoms.” This traditional role of a community pharmacist underwent a 
decline following the inception of the NHS, and a decline in drug manufacturing and 
compounding of medicines. This was due to free access to doctors, no cost to medicines 
prescribed on a prescription, and a decline in the number of pharmacies. The practice of 
pharmacy has however come back to its roots. 
Expansion of the roles and responsibilities of community pharmacists have led to the concepts 
of pharmaceutical care and medicines optimisation. Hepler and Strand (1990) describe 
pharmaceutical care as a system where practitioners are held accountable for a patient’s 
medicines-related need. Pharmacists play a vital role in designing, implementing and 
monitoring the plan by liaising with other healthcare professionals in secondary and primary 
care, and the admission-discharge interphase (Nazar et al., 2015). The provision of 
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pharmaceutical care that considers medication appropriateness, patient compliance as well as 
alternative treatment plan leads to specific or desired therapeutic outcome. Medicines 
optimisation ensures that patients get the best possible use from their medicines, and that 
treatment is cost-effective, as £150 million of the NHS budget is spent of avoidable medication 
wastage (Trueman et al., 2010). 
The community pharmacist therefore has a fundamental role as a ‘defence’ within the system 
of medicines management, and this has been strengthened over the past decade. In the UK, 
pharmacists perform clinical checks on prescriptions before they are dispensed and handed to 
the patient or carer in both secondary and primary care. The new NHS reforms have identified 
the move to integrated health care systems, and a shift in patients from secondary to primary 
care, as well as better chronic disease prevention and admission avoidance (Nazar et al., 2015).  
The role of the pharmacist in community practice is therefore increasingly relevant to patient 
safety. The Pharmaceutical Services Negotiating Committee (PSNC) estimated that community 
pharmacists provide services to some 1.6million patients daily in England. Establishment of the 
Community Pharmacy Contractual Framework (CPCF) in 2005 means services provided by 
community pharmacists are now greater than ever. These services have been broadly 
categorised into three namely essential, enhanced and advanced services: essential services 
include dispensing of medication and provision of over-the-counter advice (counter 
prescribing). Enhanced services include smoking cessation advice, minor ailments, needle 
exchange etc. Advanced services include conducting Medicines Use Reviews (MUR) and the 
New Medicine Service (NMS) (Noyce, 2007). The main additions of the CPCF were the 
advanced services, which utilise the clinical expertise of pharmacists to provide patient focused 
service to ensure effective medicines usage and improve patient safety. For example, MURs 
involve pharmacists completing consultations with patients regarding their medications, 
identifying any problems they have and providing appropriate interventions. 
Community pharmacists are strategically placed to provide legal and clinical appropriateness 
checks on prescriptions, and to identify and intervene on medicines-related problems including 
prescription errors, as they represent the last healthcare-professional ‘defence,’ prior to patient 
administration. The Pharmaceutical Care Network Europe (PCNE) defines medicines related 
problems (MRP) as circumstances involving medication therapy that does or has the potential 
to interfere with the desired health outcome (Pharmaceutical Care Network Europe, 2006). 
  249 
This includes medication errors occurring at every stage of the medicines use system, and 
adverse drug reactions. 
In the systematic review underpinning this thesis, studies that identified prescription errors 
through a prospective observational or retrospective review of prescriptions in general practice 
and community pharmacies were identified (Al Khaja et al., 2007; Al Khaja et al., 2005; 
Hämmerlein et al., 2007; Knudsen et al., 2007a; Martínez Sánchez & Campos, 2011; Sayers et 
al., 2009; Shah et al., 2001; Warholak & Rupp, 2009). Those studies, where a researcher 
observed and documented pharmacist interventions on prescription errors consistently recorded 
higher error rates when compared with those studies where the pharmacist was expected to 
document their own interventions. 
Shah et al (2001) retrospectively analysed prescriptions from 23 doctors (from three general 
practices in the UK) in three community pharmacies over a two-month period. The researchers 
found a prescribing error rate of 7.5 per 100 items. Errors were found on 140 of the 1,373 
handwritten items (10.2%) compared with 1,233 of the 33,772 computer-generated items 
(7.9%).  
With an ageing population, increased use of high-risk drugs in community or general practice, 
electronic prescribing, increase in the number of prescriptions dispensed in community 
practice, it is important to explore the defences within the medicines management system in 
primary care, not just from general practice but also within community pharmacy. 
 
10.1 Aim and objectives 
Therefore, the aim of this study was to explore the role the community pharmacist plays, 
identifying the nature of MRPs in community pharmacies and other roles that could contribute 
to medication safety. The objectives were 
 Estimate the prevalence of MRPS, with particular focus on prescriber-related problems 
(prescribing errors), in community pharmacies 
 Describe the nature MRPs in community pharmacies 
 Describe the drugs commonly associated with MRPs in community pharmacies 
 Identify if particular patient groups were at risk of getting specific MRPs 
 Identify and describe the actual and potential severity of MRPs identified in community 
pharmacies 
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 Describe pharmacists’ intervention and resolution of medicines-related problems 
 To establish the role of the pharmacist in identifying medicines-related problems 
through categorization of the activities they perform most frequently and the time taken 
to complete them. 
10.2 Setting 
The study was carried out in three conveniently selected community pharmacies, CP1, CP2, 
and CP3 over three week periods. CP1 and CP3 were part of a nationwide multiple pharmacy 
chain in Luton and Leighton Buzzard respectively, both in Bedfordshire, England. CP2 was an 
independent pharmacy also located in Luton located in close proximity to a GP surgery, a 
dental practice, and Luton and Dunstable University Hospital. CP3 was also located in close 
proximity to neighbouring general practices, dental practices, and was in the town centre. The 
indices of deprivation for Luton and Bedford have been described in Chapter 6 above. The 
three pharmacies were opened for business during similar hours, between 9am and 6.00pm or 
6.30pm, in the case of CP1. The three pharmacies provided NHS essential, enhanced and 
advanced services. Additional services performed at CP3 included diabetes screening and 
administration of flu vaccinations. All three pharmacies were located on high streets with easy 
access to train stations or public transport. 
 
10.3 Methods 
A prospective observational study of pharmacists’ interventions on medicines-related problems 
was conducted in three community pharmacies, CP1, CP2 and CP3, located in Luton and 
Bedford, within a 2-mile radius of the general practices that participated in the record review 
study, with support for data collection from final year MPharm students. This study involved 
the students observing the pharmacists’ interventions on prescriptions and interventions on 
medicines-related problems in community pharmacies. Data collection was not restricted to 
vulnerable age groups because of the small number of MRPs intervened upon in community 
pharmacies as reported in the existing literature above (systematic review chapter). The 
principal supervisor and doctoral degree student trained the MPharm students on observation 
and identification of MRPs in community pharmacies. Each MPharm student was then 
observed by the doctoral degree student during the pilot study at each site to ensure that they 
were recording relevant information and identifying MRPs. In order to ensure the MPharm 
student completed data collection forms and categorised medicines-related problems 
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appropriately, the doctoral degree student validated a small sample of completed data 
collection forms by reviewing relevant information relating to medicines-related problems 
chosen for validation. 
A data collection form, which had been previously used in other studies for documenting 
pharmacists’ interventions, was used Appendix 22. Pilot studies were conducted at each site on 
the first two days of the study, mainly to test accessibility to information, and the practicality of 
having extra persons within the usually small dispensaries, as this was the main concern of 
participating pharmacies. Following the pilot study, no amendments were necessary to the data 
collection form; therefore the data collected were included in the overall analyses.  
All prescriptions presented by patients/carers, or collected by individual pharmacies were 
screened for MRPs. MRPs identified by individual responsible pharmacists were also included 
in the study. The investigator documented relevant information on patient demographics, 
details of the drug associated with MRP, and the actions taken to resolve the problem. The 
number of items and prescriptions dispensed during the study period were recorded. MRPs 
were grouped as prescriber-related, drug-related, delivery-related, patient-related problems, and 
other (near misses and other pharmacy-related interventions such as advanced services, 
including MURs etc.).  The responsible pharmacists and investigator judged actual or potential 
severity of errors as mild, moderate or severe as defined below, based on their therapeutic 
knowledge and experience.  
For the purposes of this study, the following definitions and severity classification were used: 
A medicines-related problem was defined as an event or circumstance involving drug therapy 
that actually or potentially interferes with the desired health outcomes (Pharmaceutical Care 
Network Europe, 2006). A DRP is said to exist when a patient experiences or is likely to 
experience either a disease or symptom having an actual or suspected relationship with drug 
therapy (Strand et al., 1990). A ‘near miss’ was defined as any incident, which was detected up 
to and including the point at which the medication was handed over to the patient or their 
representative; any incidents, detected after the patient or their representative had taken 
possession of the medication were recorded as dispensing errors (Ashcroft, Quinlan, et al., 
2005). The prescribing error definition used was that of Dean et al (2000), as stated above. 
Levels of severity were assigned as mild, moderate and severe, based on the studies of 
Pirmohamed et al (2004) and Zed et al (2008): Mild – laboratory parameters may be 
disturbed/appear abnormal of tested, or the presentation of a symptom not requiring treatment 
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may occur. MRPs regarded to have a minor potential inconvenience to the patient, thus not 
harming the patient were classed as mild. Moderate - laboratory parameters may be 
disturbed/appear abnormal, or the presentation of a symptom requiring treatment/admission to 
hospital, or a problem resulting in non-permanent disability (low degree of harm meaning it 
can be corrected). Severe – disturbed or abnormal laboratory parameters, or the presentation of 
a symptom that was considered to be life threatening or that resulted in permanent disability 
(led to patient harm to the extent of intensive treatment) (Pirmohamed et al., 2004; Zed et al., 
2008). 
A secondary objective of this study was to observe and document the activities undertaken by 
the responsible pharmacist through a timed-activity log during the three-week data collection 
period. Pharmacists’ activities were categorised into essential, enhanced, advanced and ‘other’ 
services. The activity log for the pharmacist was completed during the study period during ten- 
to 20-minute intervals. 
 
10.4 Results 
10.4.1 Prevalence and nature of MRPs in community pharmacies 
In CP1, 99 interventions were identified for 88 patients, with some patients requiring multiple 
interventions. The median age of patients who required at least one intervention was 66 years, 
with over 80% of patients being ≥21 years old. The age group, which required the most 
interventions, were patients, ≥65 years old at 53%. There was no statistically significant 
difference in the proportions of male and female patients receiving interventions (50% and 
49% respectively). The numbers of prescription and items filled during the study period were 
2,098 and 4210 respectively. The mean intervention rate was therefore 4.72% of prescriptions. 
Most interventions were carried out for newly initiated drugs (40%) and prescription items, 
which patients had had previously (39%), with repeat prescriptions accounting for 22% of all 
problems. Prescriber-related problems in CP1 accounted for just over 17% of all MRPS 
(n=17), and 47% of all prescription-related MRPs originated from local practices.  
The top five problems, which accounted for over 75% of all problems identified in CP1 were 
associated insufficient patient knowledge (27%), dispensing near misses (20%), insufficient 
dispensary stock (11%), advanced services-related problems (9%), and legal problems (7%). In 
CP1, 67% of all problems identified were due to prescriber- and patient-related problems. The 
top six BNF drug classes requiring interventions in CP1 were Central Nervous System, CNS 
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(17%), Cardiovascular drugs, CVS (14%), ENT agents (14%), Skin (10%), gastrointestinal 
drugs, GI (9%), and Anti-infective agents (9%).  
The most frequently taken actions to resolve MRPs in CP1 were practical instruction to patient, 
patient counselling, and change in quantity, strength, form or dosage (following clarification 
and approval by the prescriber in most cases). The responsible pharmacist spent an average of 
8.10 (range = 2 to 30) minutes to resolve MRPS. Over 75% of all MRPs were considered mild, 
with only over 2% classified as severe. Prescriber-related problems identified in CP1 were 
inappropriate quantity, inappropriate dosage, regular item missing, incomplete prescription, 
wrong drug, inappropriate instruction and formulation.  
In CP2, a total of 37 MRPs were identified for 36 patients during the study period. The MRPs 
identified in CP2 were on prescriptions from general practices (FP10), with only one MRP 
identified on a hospital prescription. As no MRPs were identified on dental, nurse and private 
prescriptions, it can be said that 100% of all prescriber-related problems were from 
prescriptions from doctors, mostly in GP surgeries. During the study period, 1460 prescriptions 
or 3173 prescription items were dispensed in CP2. This gave a prescribing error prevalence of 
1.17%, or 12 errors in every 1,000 items.  
Prescriber-related problems accounted for 38% of all MRPs, identified in CP1. The other 
categories of MRPs identified in CP2 were delivery-related problems (2.7%), and patient –
related problems (5.4%), and other problems (54%). Therefore, other problems and prescriber-
related problems accounted for the highest categories of MRPs in CP2.  
The most commonly prescribed medication, which were associated with an MRP according to 
their BNF chapters in CP2 were, CNS drugs, CVD drugs, endocrine system, drugs for 
musculoskeletal and joint diseases, and GI drugs. Incomparably with CP1, more patients under 
60 experienced an MRP in CP2. 
95% of all MRPs requiring pharmacists’ interventions in CP2 were associated with contacting 
the prescriber since most of the MRPs identified were prescriber-related problems. Such 
interventions included patient counselling (5%), pharmacist to dispense temporarily, while 
prescriber will forward an ‘updated’ prescription (38%), pharmacist looked into patient 
medication history and made a new request to GP surgery for a missing item (16%), pharmacist 
made own decision (11%), pharmacist referral to GP (16%), and interventions proposed by 
pharmacist and approved by GP (14%).  Approximately 60% of all MRPs were considered 
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mild in CP2, with 13.5% errors classed as severe. The average intervention time in CP2 was 
9.33 minutes (range = 4 to 30 minutes). This was comparable to CP1 above.  
In CP3, 256 MRPs were detected from 1831 prescriptions (or 3632 items) dispensed for 254 
(of 1356 seen) patients. This gave an MRP incidence rate of 7.05% items. The numbers of 
female and male patients with MRPs were comparable at 52% and 48% respectively. Similar to 
CP2, prescriber-related problems accounted for the highest proportion of MRPs (52%, n=132). 
In CP3, the majority of MRPs were considered as of moderate severity (51%, with 47% and 
2% accounting for ‘mild’ and ‘severe’ categories respectively. BNF chapters of medications 
associated with an MRP in CP3 were CVS (39%), musculoskeletal (19%), Anti-infective 
(12%), respiratory (8%), Endocrine system (7%), CNS (6%) and GI (5%). A significant 
number of MRPs (50%, n=127, p=0.034) were identified in patients, ≥65 years old. Patients 
who took an average of 7 medicines in CP3 were at risk of experiencing an MRP (n=102, 
p=0.041). Paediatric patients were not significantly at risk of MRPs in CP3. 55% of all MRPs 
in CP3 were prescriber-related MRPs. Newly issued items and repeat prescriptions were 
associated with the most MRPs in CP3. Although MRPs from general practices accounted for 
48% of all prescriber-related MRPs in CP3, more MRPs per prescriptions were recorded for 
hospital prescriptions (9 MRPs on 21 hospital prescriptions). Prescriber-related problems 
identified in CP3 were mostly duplication, regular item missing, and unsigned prescriptions. 63 
dispensing errors and near misses were identified in CP3.  
In summary, the MRPs detected in the community pharmacies are shown in Table 79 below. 
Table 79: MRPs detected in community pharmacies 
Pharmacy Number of 
patients 
Number of 
prescription
s 
Number of 
items 
MRPs % MRPS per 
items 
CP1 88  2,098 4210 99 2.4 
CP2 36 1460 3173 37 1.2 
CP3 254 1831 3632 256 7.1 
 
Prescriber-related problems identified in each community pharmacy were related to 
inappropriate quantities, inappropriate dosage, regular prescription item missing, 
incomplete/missing data and illegible prescription, inappropriate drug, inappropriate direction 
or instruction, inappropriate strength, drug duplication, inappropriate duration of use, and 
wrong data. Of these, inappropriate quantity, dosage, regular item missing and incomplete 
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information were most commonly identified in CP1. In CP2, regular item missing, 
inappropriate strength, wrong duration of use, and inappropriate dosage, direction and quantity, 
were the prescriber-related problems identified. Prescriber-related problems identified in CP3 
were missing data or incomplete information, inappropriate dosage, inappropriate directions, 
inappropriate formulation, incorrect quantity, regular item missing, inappropriate strength, drug 
duplication, inappropriate duration of use, inappropriate drug, and illegible prescription. It can 
therefore be seen that regular item missing, inappropriate strength, duration of use, dosage, 
direction and quantity, were commonly identified in all three pharmacies. 
Delivery-related problem identified in CP1 included insufficient stock in the dispensary, 
unavailability of product (not on the market), and items out on delivery. In CP2, unavailability 
of drug (not on the market) was the only delivery-related problem identified. This was also the 
case in CP3. 
Patient-related problems identified in CP1 included insufficient knowledge, for example, about 
administration, and compliance issues (patient cannot swallow capsules/tablets or cannot open 
drug container). Patient-related problems in CP2 included difficulty opening container and 
non-adherence. In CP3, patient-related problems identified were also administration problems; 
for example, patient was unable to use their Salamol® (Salbutamol) CFC free inhaler. 
Other problems identified in CP1 were dispensary near misses, dispensing error, over-the-
counter-related problems, and legal problems. These were also identified in CP2, and in CP3, 
other problems identified were drug-food interaction and adverse drug reactions. 
Examples of prescriber-related MRPs in each of these severity categories are provided in Table 
80 below. Examples of interventions performed by pharmacists on prescriber-related problems 
(prescribing errors) are shown below in Table 81. 
Table 80: Examples of interventions performed by pharmacists on prescriber-related 
problems (prescribing errors) in community pharmacies 
Type of prescriber-
related problems 
Example 
Missing data Total quantity in words and figures was missing on a prescription 
for Tramadol Hydrochloride 
Inappropriate dosage Child weighing 9kg prescribed 
500mg Amoxicillin three times daily for moderate Otitis Media, 
leading to overdose 
(Recommended dosage is 360mg three times daily) 
Incorrect Patient prescribed Simvastatin 40mg every morning, instead of at 
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directions/information night; Patient address was incorrect 
Inappropriate 
formulation 
Ibuprofen 200mg tablets prescribed to a 4-year old patient but oral 
suspension required 
Incorrect quantity 28 tablets of Lisinopril 10mg prescribed to a patient, instead of the 
normal 2x28 (or 56) 
Regular item missing Aspirin 300mg dispersible tablets missing on repeat prescription 
Wrong duration of 
use 
Patient prescribed Colchicine 500mg twice daily for three weeks 
instead of for no more than three days 
 
Table 81: Examples of mild, moderate and severe prescriber-related MRPs detected in 
community pharmacies 
Severity  Example 
Mild 67-year-old patient prescribed a Salbutamol aerosol inhaler. The patient had 
insufficient knowledge about medication administration and the New 
Medicines Service (NMS). Practical instruction was given to the patient 
regarding administration of her medication, alongside information regarding 
the NMS follow-up procedure 
Moderate 3-year-old patient prescribed Flucloxacillin 250mg capsules. The formulation 
was inappropriate due to the patient’s age and inability to swallow capsules. 
The pharmacist changed the formulation from capsules to suspension. The 
prescriber was not contacted to elicit the change, but was contacted in order to 
obtain a corrected prescription; Simvastatin 10mg twice daily prescribed 
rather than once daily 
Severe Amoxicillin prescribed to a patient with severe penicillin allergy 
 
 
10.4.2 Activities of community pharmacists 
The top five activities performed by the responsible pharmacist in CP1 included clinical and 
accuracy checking of prescriptions (29%), dispensing or filling of prescriptions (20%), 
labelling of prescriptions (11%), attending to telephone enquiries or queries (11%), and other 
administrative work (9%). This meant 60% of the activities undertaken by the pharmacist 
involved checking, labelling and dispensing of prescriptions. 
Similar to CP1, pharmacist mostly engaged in clinical and accuracy checking of prescriptions 
and dispensing activities (62%), with only 10% and 9% of their time spent on MURs/NMS and 
patient counselling respectively. 20 dispensing errors and near misses were identified in CP1. 
Pharmacists in CP3 spent most of their time clinically checking and dispensing prescription 
(40%). 6% of pharmacists’ time was spent on advanced services (MURs and NMS). Enhanced 
services, which included minor ailments scheme, supervised administration, flu vaccination, 
blood pressure checks and diabetes screening, occupied 18% of pharmacists’ time. 
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Table 82: Summary of findings on MRPs in community pharmacies 
Site Prescriber-
related  
Delivery
-related  
Drug-
related  
Patient-
related  
Other Proportion 
of 
prescriber-
related 
problems 
Total 
MRP 
Total 
prescriptions 
Total 
items 
Prevalence of 
prescriber-related 
problems  
          % Rx % Items 
CP1 17 14 1 26 41 17.17% 99 2098 4210 0.8 0.40 
CP2 14 1 0 2 20 37.84% 37 1460 3173 1.0 0.44 
CP3 140 32 0 21 63 54.67% 256 1831 3632 7.6 3.85 
 
The table above shows the proportion and prevalence of MRPs, which were prescriber-related. 
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10.5 Discussion 
The community pharmacist acts as the last line of defence for minimising prescribing and 
medicines-related problems. The study showed the types of MRPs pick up and the degree of 
harm prevented. 
This study has described the prevalence of medicines-related problems in community 
pharmacies, with particular focus on prescriber-related problems (prescribing errors) 
intervened upon by community pharmacists. The findings in the three studies were comparable 
and are summarised below. 
10.5.1 Summary of findings 
 Over 50% of all prescriptions requiring a pharmacist intervention originated from local 
general practices in all three pharmacies 
 Drugs, which were most commonly associated with MRPs in the pharmacies, belonged to 
the following BNF classes: CVs CNS, Skin, Gastrointestinal drugs (GI), Anti-infective, and 
musculoskeletal and joint disease agents. 
 The actions most frequently taken by the pharmacist to resolve problems included practical 
instructions to the patient, medication counseling, contacting prescribers for alteration of 
quantity, strength, form, or dosage of the medication. More interventions were associated 
with new prescriptions and repeat prescriptions. 
 Majority of prescriber-related MRPs were of ‘mild’ severity, while a small proportion were 
considered ‘severe.’ 
 Older patients were more at risk of MRPs, notably prescriber-related MRPs 
 Responsible pharmacists spent more than 60% of their time on the physical aspects of 
dispensing, involving clinical assessment of prescriptions labeling and dispensing, and 
leaving little time for advanced services such as MURs and NMS. 
The findings in the current study are in keeping with other studies of interventions performed 
by community pharmacists as discussed below. 
Incomplete information was identified in this study as one of the problems associated with 
prescribing errors in keeping with Chen et al, who found that most prescriber-related errors 
arose from prescriptions with incomplete or incorrect information (Chen, Neil, et al., 2005). 
Young et al found that over three-quarters of the interventions were on new prescriptions, and 
that dosage information and missing prescription information were two common prescriber-
related problems (Young et al., 2012). The researchers further found that the prescriber was 
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contacted for most of the interventions, which resulted in most prescriptions being changed, 
and led to limiting the time pharmacists can spend on patient-focussed activities. In keeping 
with the study by Young et al, the current study also found that when an intervention on a 
prescription was necessary, it was based on more technical issues, for example, signature 
missing on prescriptions quantity-related problems, rather than on clinical issues such as 
interactions and contra-indications. 
In addition to new prescriptions, interventions were also commonly documented for repeat 
prescriptions, consistent with other studies (Hämmerlein et al., 2007; Rupp et al., 1992; Young 
et al., 2012). The New Medicines Service (NMS) was commissioned in 2011 to deal with this 
problem, particularly to empower patients who may be prescribed medication for long-term 
management of chronic diseases for the first time. This promotes engagement with the 
expertise and experience of healthcare professionals, such as pharmacists, to enable patients to 
get the most from their new medicines. However, this study consistently demonstrated that less 
than 10% of pharmacists’ time was actually available for these advanced services. For repeat 
prescriptions, adequate monitoring of chronic diseases and medicines optimization can often 
prevent ADEs in community care, which often lead to hospital admission (Pirmohamed et al., 
2004). As such, pharmacists need to spend more of their time on clinical and patient-facing 
roles and less on technical roles, to ensure that patients are truly benefitting from the services. 
With an ageing population, and continued increase in primary care management of chronic 
conditions and complex medications, pharmacy regulatory bodies, and NHSE need to work 
together to ensure protected quality time for clinical community pharmacy services if they are 
to be successful in improving patient outcomes. 
This study found that the top categories of problems identified were either related to the patient 
of the prescriber (prescription). In CP1 for example, insufficient patient knowledge was 
identified as the most prevalent type of medicines-related problem. This could reflect a lack of 
understanding of their conditions and management, or even problems with interpretation of 
dosage or monitoring instructions on patients’ part as observed by researchers (Wolf et al., 
2007). As Vincent (2010) pointed out, patient safety is all about putting the ‘patient’ back into 
the art of clinical and therapeutic management. Vincent pointed that patients are not passive 
victims of errors and safety failures, but can be actively involved in making sure that their care 
is effective, fitting and safe. It is right to include patients in their care by seeing them as 
partners, rather than nuisances. Patients can be actively involved in the safety of healthcare in 
many diverse ways – by contributing to safe medication use, making informed choices about 
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who treats or manages them, providing information to make accurate diagnoses, being involved 
in infection control initiatives, checking the accuracy of medical records, observing and 
checking care processes, identifying and reporting complications from their management and 
adverse events, effectively managing their own medication and condition (including helping 
with drug or other treatment monitoring), and contributing immensely to healthcare service 
design and improvements (Coulter & Ellins, 2007). Therefore, patients should be empowered 
by being informed and carried along as partners in their therapeutic knowledge. 
This study has also demonstrated that pharmacists are traditionally providers of medicine, 
although they are increasingly involved in clinical roles (enhanced and advanced NHS 
services), in keeping with other studies (Gidman & Cowley, 2013; Kheir et al., 2014). Gidman 
and Cowley (2013) found, from their qualitative study of the public’s opinions and experiences 
of pharmacy services, that although participants made positive comments about pharmacy 
services, many preferred to see a GP. The public in Gidman and Cowley’s study viewed 
community pharmacy services as “incomplete,” and “which did not co-ordinate well with other 
primary-care services.” The researchers commented that the public considered pharmacy 
environments and retail area as being less than ideal for private healthcare conversations. 
Consultation rooms in community pharmacies usually look like, and come across as “after-
thoughts.” Some consultation rooms are indeed very small, and offer no privacy for 
consultation with patients, many of whom are unwilling to be cramped in such small spaces for 
ten to fifteen minutes, particularly when they have a choice of seeing their GP and practice 
nurses in more practical spaces. Should those services, requiring private clinical conversations 
with pharmacists, not have been commissioned in GP surgeries for clinical pharmacists in the 
first instance?  
The current study also identified that older patients with chronic medications and 
polypharmacy are also at risk of MRPs. This is in keeping with the findings of the records 
review section of this thesis, and other studies, which have been extensively cited in this work. 
Medicines optimisation and successful reviews of chronic drug use by pharmacists have been 
documented (Avery, Rodgers, et al., 2012; Zermansky et al., 2001). There is copious evidence 
to support the current debate around the potential benefit of clinical pharmacists’ presence in 
general practice. The Royal Pharmaceutical Society (RPS) believes that similar to what 
currently exists in hospital, primary care patients should have the benefit of a pharmacist’s 
clinical expertise. The RPS made three recommendations: to general practitioners to welcome 
the innovation that pharmacist can bring to the care of their patients; to local commissioners to 
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include the expertise of pharmacists in all care path ways that use medicines; and to NHS 
England to publish evidence showing the benefits of pharmacists in GP surgeries (Royal 
Pharmaceutical Society, 2014). The RPS has highlighted the role of pharmacists working with 
GP surgeries: resolving problems with medicines, prescribing, and audits and processes-related 
work. This provides a more robust safety net before the patient gets the prescription, and can 
enable them to get the most from their medication. Policy and research must collaborate on the 
model of care as a study found that some pharmacists may require additional relevant training, 
though perhaps their mode of remuneration for clinical services is a contributing factor to why 
pharmacists may appear reluctant to increase their roles (Morton et al., 2015)  
Perhaps the current skill-mix in community pharmacy further poses a challenge to really 
freeing up the pharmacist’s time for clinical services. The current study has demonstrated that 
when pharmacists undertake activities that can be performed by other members of the 
dispensary, the time available for providing enhanced and advanced services and patient 
engagement dramatically decreases. Most pharmacy contractors in the UK employ dispensing 
assistants and healthcare assistants fresh from secondary education, and then provide training 
on the job. Community pharmacists are expected to provide the necessary training support to 
these entrants. There is therefore enormous pressure on the community pharmacist, leading to 
inadequate training of these dispensing assistants, and the continuous need for pharmacists to 
be deeply involved in technical aspects of dispensary functions such as stock and retail 
management. Is the business of medication safety not too risky to allow this mediocre entry 
and training requirement? The GPhC and Royal Pharmaceutical Society, RPS, along with the 
other stakeholders need to urgently review this arrangement, particularly with the imminent 
introduction of clinical pharmacists in GP surgeries. Until clarification and establishment of the 
pharmacist’s roles in medicines management and medicines optimisation, the general public’s 
confusion and limited use of the pharmacist’s expertise will remain. 
Although community pharmacists are one of the defences in primary care medicines 
management system, this study shows that this system can sometimes break down leading to 
dispensing errors and near misses. Innovative ways to then improve and strengthen the 
defences in GP practices and pharmacies need to be researched and integrated in practice to 
improve patient safety. 
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10.6 Study limitations 
Although this study was relatively smaller than those conducted previously in the UK and 
elsewhere with consequently less representative results, the methods and definitions used 
remained robust, and produced results comparable with other findings. 
The pharmacies that participated in this study were not selected at random. They were selected 
based on their willingness to participate. As such, pharmacist(s) were aware that any MRPs, 
which occurred in the pharmacy, during data collection, would be observed and documented. 
Moreover, the opportunities to screen and selectively identify problems to be recorded by the 
principal investigator were therefore provided. Consequently, the results may not provide an 
accurate representation of the frequency, type, origin and resolution of MORS that occurred in 
the selected pharmacies. It is therefore possible that the true rate of MRPs may have been 
underestimated. The effect of the principal investigator’s observation may also help to explain 
why very few MRPs, and in some instances none at al, were identified following the 
investigator’s work at 16.00pm, even though pharmacies opened till 6.00pm or 6.30pm. 
It is possible that a different investigator may have interpreted, and therefore applied the 
methods and definitions differently. The principal supervisor reviewed a small sample of the 
MRPs documented in an attempt to account for this individual interpretation, and to ensure 
consistent application of definitions used by the MPharm students. However, the act of 
observation was not validated. 
The doctoral researcher, MPharm student and responsible pharmacists were not given any 
formal training in the identification of MRPs requiring intervention for the purposes of this 
study. Competence in this task was therefore assumed based on the training and education 
received in identification and documentation of problems and interventions by the investigators 
and pharmacists during their education (Young et al., 2012). It is therefore possible that these 
individuals varied in their ability to detect potential MRPs. This is evident in the disparity in 
the numbers of MRPs detected in each of these pharmacies. 
Nevertheless, it is important to note that the responsible pharmacists had their inputs in the 
severity rating of MRPs, and standardised forms and definitions were used when categorising 
MRPs. Moreover, direct observation as opposed to incident reporting by community 
pharmacists was a robust method used to study MRPs in community pharmacies.
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Chapter 11. Final discussion  
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11.0 Summary of the doctoral research 
The overall aim of this PhD research was to explore the safety of medication use in primary 
care through the determination of the prevalence and nature of prescribing errors in two 
vulnerable age groups, older patients and children, and to provide some insight into the locals 
systems for managing medication errors in primary care. The key findings from the research 
highlight the following: 
 Guidance on local arrangements and pathways for clinical governance may be less defined 
and therefore lead to loss of important learning from adverse prescribing events and near 
misses locally. This has raised significant issues around the culture of patient safety in 
primary care. The literature on medication safety in primary care is very sparse with respect 
to evaluating local arrangements for management of medication errors 
 Older patients 65 years and over and children 0-12 years old are at increased risk of 
prescribing and monitoring errors 
 Older patients experience an unacceptable level of monitoring errors for routinely 
prescribed drugs including Angiotensin Converting Enzyme inhibitors (ACE-I) and 
Angiotensin II receptor antagonists or blockers (ARB), diuretics, statins, and Thyroid 
hormones. Older patients may experience more monitoring errors since these drugs are 
commonly prescribed, as people get older. However, considering the routine use of most 
these drugs to manage cardiovascular problems in primary care and prevent hospital 
admissions, this level of failure in the monitoring system has enormous potential to 
increase the burden of disease on patients, healthcare practitioners and the healthcare 
system 
 Specific drug classes, which need to be the focus of continued professional development 
(CPD) for general practitioners include non-steroidal anti-inflammatory drugs (NSAIDs), 
and topical and oral steroids and anti-infectives 
 Antibiotic dosing in children is a major source of prescribing errors, considering they were 
most commonly prescribed in this age groups (Table 61 above) 
 Community pharmacists are the last healthcare professional ‘defense’ within the 
medication management system in primary care prior to medication use by patients. The 
role of the community pharmacist in interventions on prescription errors and other MRPs 
was evident from this study. The healthcare system needs to urgently review the role of 
pharmacists to strengthen this defense. 
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 Patients and their carers are not just ‘casualties’ of medication errors. Their role as active 
members of the prescribing process needs to be explored to prevent medication errors in 
primary care. 
 
11.1 Discussions of findings against models of causes of error 
Although the current study did not set out to explore the causes of prescribing errors 
experimentally, the findings outlined above have been mapped onto the conclusions of the 
qualitative exploration of the causes of prescribing errors in general practice from the 
PRACtISE study and Reason’s model of human error (Reason, 1990).  
Thorough analysis of incident often exposes a range of activities and deviations from safe 
practices though specific actions or inactions may have led to the immediate cause of an 
incident. These activities and deviations from safe practices, also known as ‘latent conditions,’ 
provide the bases for accidents in the first place. As Vincent (2010) surmised, some accidents 
in historical high profile accidents such as the Paddington Rail accident of October 1999, the 
loss of Space Shuttle Columbia in February 2003, the Piper Alpha oil disaster in July 1988 etc., 
often happened due to inadequate training, problems with scheduling, balancing safety and 
profit requirements, failures of communication, failure to solve already known safety issues 
and laid-back or reactive attitudes from management (Vincent, 2010). The problem with latent 
conditions is that almost no one makes a decision to allow ‘slips’ to happen. However, other 
decisions, which influence safety indirectly without anyone noticing, erode safety in a gradual 
but dangerous process. Recent example within the British healthcare system is the high-profile 
failings within the Mid-Staffordshire Hospitals, which attracted a lot of media attention. 
Apart from the latent conditions within any organization, safety and organizational culture are 
related concepts used to explain accidents. The term safety culture is difficult to define, but it 
can be understood as the ambience, which describes an organisation with respect to 
conscientiousness and care.  As Vincent points out, culture is an aggregate of good or bad 
habits that are largely malleable. 
The psychology of error has underpinned analysis of errors. According to Reason, errors are 
divided into two broad categories namely slips and lapses, which are associated with actions, 
and mistakes, which are associated with knowledge. Slips and lapses are associated with using 
the wrong action to achieve the right plan: slips are external actions while lapses are internal 
events. Mistakes are associated with using the wrong plan in the first place to achieve the right 
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action. Mistakes may be rule-based or knowledge-based. Violations, on the other hand are 
intentional deviations from standards or rules. These concepts describe the active failures by 
those people at the ‘sharp end’ of the system who are working the system, in healthcare, the 
providers and users of the system. It is the interaction between the ‘active and latent failures,’ 
which lead to errors as shown in the Figure 25 below. 
 
Figure 25: Reason's "Swiss Cheese" Model (image with permission from 
www.patientsafety.duhs.duke.edu) 
 
To provide understanding, accidents in healthcare and other industries are to be reviewed from 
a wider systems view. Reason’s model of organizational accident shows that although 
individual actions and failures are important in analysing accidents or errors, their working 
environment and organizational processes produce the latent conditions that lead to errors. As 
explained in Vincent (2010), the sequence of accident starts with the unfavourable and 
complex issues of organizational procedures, which include planning, design, maintenance, 
strategy and policy. The latent conditions created are then carried along different organizational 
and departmental systems to the workplace where local conditions created contribute to the 
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ideal environment for errors and violations. Some of the unsafe acts unfortunately penetrate the 
system defences to produce incidents. This model is represented in the figure below 
 
 
Figure 26: Organisational accident model (adapted from Reason, 1997) 
Figure 26 above shows a simple visual representation of Reason’s accident model. The latent 
failures describe the organisation and culture; the error and violation producing conditions 
describe contributory factors and active failures describe the care delivery problems (Vincent, 
2010). Reason points out that this model does not seek to shift the responsibility from workers 
at the sharp end of the system to the managers, but that both levels have a shared responsibility 
when it comes to accidents. Vincent points out in addition that beyond the organization itself, 
regulatory and professional organizations, government institutions, etc. also impact patient 
safety. 
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Vincent and colleagues have therefore extended Reason’s model as summarised in Table 83 
below, and produced a single all-encompassing framework of factors impacting clinical 
practice by grouping the error producing conditions and organizational factors. 
Table 83: Framework of contributory factors influencing clinical practice (Vincent et al., 
1998) 
Factor types Contributory influencing factor 
Patient factors Condition (complexity and seriousness) 
Language and communication 
Personality and social factors 
Task and Technology Factors Task design and clarity of structure 
Availability and use of protocols 
Availability and accuracy of test results 
Decision-making aids 
Individual (staff) Factors Knowledge and skills 
Competence 
Physical and mental health 
Team Factors Verbal communication 
Written communication 
Supervision and seeking help 
Team leadership 
Work and Environmental Factors Staffing levels and skills mix 
Workload and shift patterns 
Design, availability and maintenance of 
equipment 
Administrative and managerial support 
Physical environment 
Organizational and Management Factors Financial resources and constraints 
Organizational structure 
Policy, standards and goals 
Safety culture and priorities 
Institutional Context Factors Economic and regulatory context 
National health service executive 
Links with external organizations 
  
Error-producing conditions identified from the current research are summarised below using 
the framework highlighted above. It is however important to note that not every slip, lapse or 
violation needs to be explained in terms of Reason’s organizational framework and Vincent 
and colleagues’ framework. Some errors are very much related to the local context and specific 
characteristics of related tasks (Vincent, 2010). Moreover, the demarcation between the factor 
types outlined in Table 83 above is more blurred than distinct. All major incidents however 
mostly happen over time, involve many different people and influencing factors (Vincent, 
2010).  
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11.1.1 Patient factors  
At the top of the framework are patient factors. The patient’s condition directly influence 
practice and outcome. In the current study, older patients were observed to have on-going 
co-morbidities, which needed to be managed as rationally as possible. This led to 
significant polypharmacy, with average number of acute and repeat prescriptions per older 
patient ≥65 years old recorded as approximately 4.0 and 6.0 respectively (Table 14). The 
total average item per older patient ≥65 years old was recorded as 8 (Table 10). With age-
related diminishing pharmacokinetics, older patients were at increased risk of errors such as 
drug interactions, renal impairment affecting drug dosing, and potential adverse drug 
effects. Cognitive challenges were also observed as related to some of the error identified in 
these patient groups. For example, a patient with well-documented mental difficulties, who 
was prescribed a few different potencies of topical steroids, without specific advice on 
areas being treated or duration of use. Older patients were also observed to require more 
secondary-care related visits and investigations when compared with the rest of the 
population. Moreover, general practice management of older patients was not restricted to 
only their own GP. As such, an older patient with many on-going medical needs, could be 
seen by more than GP even for the same issue, thereby creating an error-producing 
opportunity. Age-related dosing has long-influenced clinical practice in children. This 
study has highlighted unprecedented levels of suboptimal antibiotic dosing in children.  
Assumptions about the age and appropriate dosing in children may also contribute to the 
errors identified. 
The patient personality and social factors, which influence practice and patient outcome, 
were unfortunately not amenable to evaluation in the current study consultation room 
interactions could not be captured from patients’ record reviews. However, factors such as 
patient personality, language and psychological issues may contribute no less to issues of 
quality identified in the current study. For example, a 67-year old patient had been 
prescribed Brufen Retard ® (modified-release Ibuprofen) regularly for six years at a dose 
of 800mg twice daily. Two GPs had documented patient’s refusal of a gastro-protective 
agent, such as a PPI despite having had long chats with him. This example demonstrates 
how the personality of a patient can influence the quality of prescribing. The BNF clearly 
advises gastro-protection, particularly for NSAIDs use in patients, ≥65 years old. It is 
possible that the patient may be unaware of the risks associated with his treatment regime 
or the patient may have come across as demanding and assertive as observed in the patient 
characteristics from the PRACtISE study  
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11.1.2 Task and Technology Factors  
The task design, adoption of protocols and test results were observed to influence the care 
process and the quality of care in the current study as outlined below: 
1. The medicines management process – the medicines management process in primary 
care is currently not owned by any specific group of healthcare professional. Although 
advanced services provided by pharmacists, such as MURs and NMS were 
implemented to provide some form of link within the many arms of the primary 
healthcare system, the current model does not establish this link properly. This was 
observed to lead to poor communication and chaos within the system leading to 
increased risk of errors. For example, an older patient’s dose is changed and they 
receive both the new dose and the erstwhile dose at the same time. This is a common 
observation in my practice as a community pharmacist. Someone somewhere should be 
bringing the loose ends together 
2. New and repeat prescriptions – as observed in the community pharmacies studied, the 
responsible pharmacist intercepted more errors relating to newly issued items and 
repeat prescriptions. In the records review study, the current study demonstrated that 
repeat prescriptions were significantly more likely to be associated with an error when 
compared with acute prescriptions (P-Value=3.3E-05) and (Table 35). Avery et al have 
outlined the process of issuing repeat prescriptions in GP surgeries in the PRACtISE 
study. Sometimes, repeat prescriptions are printed by prescribing clerks and are in turn 
signed by GPs, sometimes without immediate access to the PMR. The system of repeat 
requests by a patient’s pharmacy may sometimes complicate repeat dispensing. In a bid 
to increase their loyalty and lock-in, pharmacies offer free repeat management for many 
patients. With such a system, patient safety does not have patients at its heart anymore. 
The patient is eliminated from the process completely. Pharmacists should ideally have 
conversations with patients before dispensing the next repeat. In practice however, this 
seldom happens. 
Avery and colleagues recommended that new drugs should ideally not be placed on 
repeat prescriptions until at least after a 6-week review. This study has shown that new 
medications are added onto an existing repeat list even without taking out the drugs that 
have been discontinued. The question is who is ultimately responsible for repeat 
dispensing– the patient, GP, receptionist or pharmacist?  
3. Availability and accuracy of test results – the current study found that 1 in 3 older 
patients experienced a monitoring error (Table 32). Ensuring timely and adequate blood 
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test for drug monitoring was a challenge. The most common monitoring errors were 
however for routinely used drugs. Perhaps the most challenging factor was the 
continued re-issuing of those drugs requiring monitoring even when such monitoring 
had not been done  
4. GP clinical computer system – incompleteness of patient medical records posed a risk 
to increased harm. Information on allergies, referrals, blood test results and off-site 
prescribing (such as in patient’s homes or for other hand-written prescriptions) were 
sometimes missing. Overriding alerts and relevant information due to the sheer volume 
of alerts also seems to be a potential problem. In an instance, a hospital discharge note 
and treatment regime was stored under a different patient’s record. This was brought to 
the attention of the manager who then passed a comment that that situation would be 
rectified.  
 
11.1.3 Individual (staff) Factors –  
1. The prescriber-related factors – Although prescribers’ views were not sought in the 
current study, the nature of some of the errors identified in the current study have 
highlighted a range of issues with GP prescribing in primary care namely their 
therapeutic training, experience with use of some drugs, and their knowledge of specific 
patient groups such as children and older patients, and their professional responsibilities 
to update their knowledge with advances in medical practice.  
a. From the interviews conducted in the PRACtISE study, Avery and colleagues 
mentioned that many GPs felt their therapeutic training received much less 
attention than they judged was required to enable them to safely conduct the art 
of prescribing. The types of errors summarized in the records review section 
above have also demonstrated this. For example, a patient with compromised 
renal function who continued to be prescribed Etodolac® (NSAID) at a high 
dose. The antibiotic dosing errors in children also demonstrates the problem 
with inadequate therapeutic training.  
b. These dose/strength errors identified in children and older patients in this study 
also demonstrate GPs’ inadequate knowledge of the therapeutic needs of 
specific patient groups. Some potential errors identified in the current study 
emphasize the importance of keeping up to date with new evidence. For 
example, the MHRA has advised that the dose of Simvastatin is limited 20mg 
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when a patient is taking Amlodipine. In one dose/strength error described above, 
a 70-year old patient was receiving 40mg Simvastatin. Also, the BNF advises 
gastro-protection with NSAIDs in older patients. However, 19 of the 22 
omission errors relating to failure to prescribe concomitant medication were 
related to the use of NSAIDs without gastro-protection, which has been 
documented to lead to preventable hospital admissions 
2. The community pharmacist – this research has also suggested that while pharmacists 
are trained and equipped to provide clinical services (Al-Khani et al., 2014), the 
physical acts of dispensing often preclude the delivery of these services. Perhaps they 
are not located in the right environment where their skill and training could be 
harnessed. From the view of the pharmacists’ who participated in the study, the 
physical barrier between GPs and hospital prescribers, and pharmacists with respect to 
location may be an source of error-producing condition 
 
11.1.4 Team Factors  
The need for multi-disciplinary co-working amongst community healthcare providers has been 
known to influence patient safety and the quality of care in primary care. Community 
pharmacists recounted how challenging it is to contact hospital prescribers by phone to obtain 
clarifications as necessary. Incomplete medical records or inadequate documentation were 
observed to contribute to written communication errors. For example, a patient with suspected 
antibiotic-allergic was asked to ring the name of the medication implicated through. Three 
months after this advice was given, the patient’s record was still not annotated with this 
information creating an environment for this adverse reaction to re-occur 
11.1.5 Work Environmental Factors  
This study showed that the skill mix and staffing levels in community pharmacy practice might 
contribute to the inability of pharmacists to perform important clinical roles and patient advice. 
The current arrangement for remunerating the services conducted by community pharmacists 
supports a target-driven culture amongst owners and management of pharmacy chains. The 
retail environment has been documented to deter patients from wanting to benefit from 
consultations with community pharmacists 
11.1.6 Organizational and Management Factors 
1. Local arrangements for clinical governance – although primary care organizations 
are expected to have systems in place for reviewing their errors and near misses, it 
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would appear from this study that such systems are less well defined. Under the 
defunct PCTs, review, analysis and learning from near misses were not perceived 
as being important to prevent errors from reaching patients. Although this forms a 
part of contract monitoring, again no one appears to be responsible for this 
process. With the new structure of CCGs and NHS Area Teams, the process of 
local clinical governance is unclear. Overall, the culture within these local health 
organizations appears to be reactive (Ashcroft, Morecroft, et al., 2005; Parker et 
al., 2006). Particularly, investigating incidents, learning from incidents, team 
working, and communication with primary care organizations such as general 
practices and community pharmacies were dimensions, were not well defined. 
 
11.1.7 Institutional Context Factors 
The current economic and political climate may put additional pressures on healthcare 
professionals who may not want to challenge “management authorities” due to the fear of 
loosing their jobs. For example, the practice of clinical pharmacy in the community is 
challenged by targets to conduct specific numbers of advanced services; this pressure can lead 
to missing those patients who really need the service because it is more about numbers than 
about patient benefit. 
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11.2 Summary and recommendations 
Following suggestions in the literature (from key landmark studies including the PRACtISE 
study by Avery et al, 2012 and the CHUMS study by Barber et al, 2009) that older patients and 
children may be more susceptible to medication errors, this work sought to establish the 
prevalence, types and nature of medication errors in these two population groups, estimating 
the ensuing harm, and proposing pragmatic interventions to reduce the prevalence of errors. In 
keeping with other UK studies on medication errors, most errors identified had the potential to 
cause minimal harm to these patient groups. This study found that approximately 1 in 3 older 
patients or 1 in 12 prescription items issued to older patients were exposed to a prescribing or 
monitoring errors. For monitoring errors only, this increased to 1 in 9 patients, being 
susceptible to a monitoring error. Factors influencing the occurrence of prescribing errors in 
older patients included taking multiple medications, being female, and being aged 75 years and 
over, being prescribed medication from the following groups: cardiovascular, corticosteroid 
(oral and topical), and musculoskeletal and joint disease agents.1 in 5 younger patients or 1 in 
10 prescription items issued to patients aged 0-12 years experienced a prescribing error. 
Factors influencing the occurrence of prescribing errors in younger patients included being 
aged 5-10 years, being prescribed multiple medications, and being prescribed antibiotics.  
The current study also sought to characterise community pharmacists’ interventions on 
prescription errors and MRPs. The results showed that community pharmacists intervene on a 
diverse range of MRPs from general practice, and are therefore important and pragmatic points 
of ‘defence’ within the medicines management process, though this role is often challenged by 
the more technical aspects of dispensing. This study has therefore added evidence to the current 
discussions around the potential benefit of clinical pharmacists in GP surgeries. 
This research used a mixed method approach to achieve the set objectives of this research. 
Established and tested quantitative methods were used to determine the prevalence of 
prescribing and monitoring errors in older patients and children, and to estimate pharmacists’ 
interventions on prescription errors and other MRPs. The retrospective record review and 
prospective observation of pharmacists’ intervention allowed a more in-depth review of events 
leading up to an error or MRP. Quantitative and qualitative methods were used to study and 
characterise the systems of error management at former PCTs, CCG and NHS England levels. 
Researchers have investigated the prevalence of prescribing errors in secondary care, and more 
recently in primary care and in residential or nursing care homes, and made recommendations 
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with varied outcomes (Royal et al., 2006). This is however, the first study to estimate the 
prevalence and nature of prescribing errors in older patients and in children in primary care, 
and to estimate community pharmacists’ intervention on MRPs, and based on the findings, to 
make recommendations to prevent errors. 
The typology of errors on prescriptions for older patients however showed that patients were 
more likely to experience errors, not just as a consequence of their age (i.e. due to 
polypharmacy, pharmacokinetic/dynamic changes, etc.), but also as a consequence of being 
prescribed a medication. If experiencing an error was purely age-related, the types of errors one 
would have expected to see more of are dose/strength errors, allergy, intolerance and 
contraindication errors, incorrect drug errors, etc. However, the most common errors were 
incomplete information on prescription, omission errors relating to failure to prescribe for an 
existing condition, inadequate review errors, and an unacceptable level of monitoring-not-
requested errors. This study has demonstrated that there is an unacceptable prevalence of 
medication errors primary care, affecting the most vulnerable patient groups. Interventions are 
urgently required to reduce patient morbidity and improve patient outcomes. This has immense 
implication for policy. 
From the systematic literature review underpinning this study, researchers agree that GP 
training and continued educational development need to focus more on therapeutic drug use. 
Indeed, one of the key recommendations of the PRACtICe Study following identification of 
many errors that could have been prevented with greater attention to safe prescribing, was the 
professional development of GPs (Avery, Barber, et al., 2012). The researchers made 
recommendations to the General Medical Council to review the Royal College of General 
Practitioners (RCGP) curriculum to give more focus to therapeutic knowledge, and to develop 
an educational tool, which can be used by GPs to improve their skills of comprehensive 
medication reviews to identify and correct errors. The researchers also highlighted the 
importance of continued professional development (CPD), especially for established GPs who 
are already practicing. For instance, one of the common errors identified in younger patients 0-
12 in the current study was the prescription of suboptimal strengths of antibiotics. Although the 
recommended dosages are stated in the BNF for children and other reference sources, 
physicians and other prescribers sometimes do not have ‘the time’ to refer to these, or even 
assume that they know it already. CPD portfolios for GPs must incorporate case studies from 
research findings to highlight common errors to doctors. While this is a very important step in 
  276 
the right direction, the current debate about the role of pharmacists in GP practices aligns 
perfectly with this recommendation. 
Pharmacists’ current training gives therapeutic knowledge and skills the prominence it 
deserves. Pharmacists are already the final healthcare professional defense in Reason’s Swiss 
Cheese Model, detecting medication errors before they reach patients (Brown et al., 2006). 
Many medication error studies have successfully employed pharmacists to conduct thorough 
medication reviews to identify potential errors from medical records, and from prescriber and 
patient interviews, and observation (Alldred et al., 2011; Avery, Barber, et al., 2012; Barber et 
al., 2009; Franklin et al., 2009). In their study to determine whether a pharmacist can 
effectively review repeat prescriptions through consultations with elderly patients in general 
practice, Zermansky et al (2001) found that patients in the intervention group (pharmacist 
reviewed) were more likely to have changes made to their repeat prescriptions, and that the 
drug costs were less in the intervention group (Zermansky et al., 2001). Other studies else 
where have underscored the strategic position of community pharmacists (Al-Khani et al., 
2014; Mossialos et al., 2015; Odukoya et al.) 
Another randomised controlled trial found that a pharmacist-led information technology 
intervention (PINCER) was an effective method for reducing a range of medication errors in 
general practices with computerised clinical records (Avery, Rodgers, et al., 2012). The 
PINCER intervention comprised feedback, education outreach and dedicated support. The 
primary outcomes were the proportion of patients who had had any of three clinically 
important errors: prescription of NSAID to patients without co-prescription of proton-pump 
inhibitor to patients with a history of ulcer, beta blockers to those with a history of asthma, and 
long-term ACE-I use in the elderly without urea and electrolytes check up. It is note-worthy to 
mention that these types of errors were identified in the current study. With such evidence on 
the role of pharmacists in conducting medication reviews and medication safety interventions, 
is the current debate about pharmacists’ role in GP practices stating the obvious? Research and 
practice must collaborate urgently to establish policies and models to support pharmacists’ 
roles in general practice. The cost of pharmacists’ interventions cannot be compared with the 
cost of medication errors to the healthcare system, the practitioner and the patient. 
In their study, Barber et al found that for each prescribing, dispensing or administration event, 
there was an 8-10% chance for an error to occur. This rose to 15% for a monitoring error to 
occur (Barber et al., 2009). Avery et al (2012) found an increased risk of error (odds ratio 3.18, 
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P<0.001) for drugs on the monitoring list. The current study found a monitoring error 
prevalence of 9.38% items among older patients Table 32. This figure was higher than the 
prevalence of prescribing errors only (~7.0% items), even though drugs requiring blood test 
monitoring accounted for only a fifth of all reviewed prescriptions. It can be concluded that 
monitoring errors are even more prevalent than prescribing errors in primary care management. 
During data collection, it was observed that one GP clinical computer system made it easier to 
see the last time a monitoring test was done. This could probably have contributed towards the 
higher percentage of monitoring errors identified in this surgery. Although general practices 
have different systems to ensure blood test monitoring is done on time, these defences slip 
sometimes (Avery, Barber, et al., 2012). Unlike Avery and colleagues’ finding, very few of the 
monitoring errors identified in the current study were related to high-risk drugs such as 
anticoagulants (e.g. Warfarin) or drugs with narrow-therapeutic indices (e.g. Lithium). The 
most common monitoring errors were identified in ‘regular’ drugs such as Angiotensin 
Converting Enzyme Inhibitors (ACE-I) and angiotensin II receptor antagonists, Statins, 
Diuretics, Thyroid hormones, etc. (Table 44). This was in keeping with Barber and colleagues’ 
study (2009), where the researchers found that the drugs most commonly involved in 
monitoring errors in care homes were diuretics (53.1%), ACE inhibitors (15.6%), Amiodarone 
(12.5%) and Levothyroxine (9.4%) (Barber et al., 2009). This raises the question of getting the 
‘basics’ right. Interventions such as the use of monitoring ‘books,’ like Warfarin (Yellow) 
book, Lithium book, Steroid card, etc. have increased the safety of monitoring high-risk drugs, 
which is laudable. However, more patients take the drugs where monitoring was observed to 
have failed in this study, when compared with high-risk drugs, further emphasising the need for 
interventions to prevent monitoring errors. Avery et al suggested that alerts, which highlight 
the need for blood test monitoring for certain drugs, should be created on clinical computer 
systems. However, researchers have observed that such alerts are not sufficient in themselves 
to prevent errors due to prescribers overriding them (Tamblyn et al., 2008).  
Perhaps the repeat prescribing system contributes to the problem of suboptimal monitoring in 
primary care. Often, messages are left on the repeat dispensing slips by GP practices, so that 
they are passed onto the patient by the dispensing pharmacy. With many pharmacies retaining 
repeat slips to increase loyalty and lock-in, the communication often breaks down. At the 
practice, the GP may not necessarily have access to patients’ record at the time of signing. 
Therefore, it is easy for monitoring reminders to get overlooked. 
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This raises the same question, which was raised by Barber et al (2009) – who is responsible for 
ensuring adequate blood test monitoring for certain drugs in general practice – the GP who 
signs the prescription, the practice nurse who sends reminders for reviews, the practice 
receptionist who takes repeat orders, the pharmacist who fills the prescription, or the patient 
who should know when their blood test is due? Barber et al found that the lack of any one 
person taking responsibility for the ‘whole system’ was one of the factors, which led to the 
unacceptable prevalence of medication errors in care homes. This study will suggest that 
monthly-quarterly audits of drugs requiring monitoring within individual GP practices may 
help to highlight problems, with action taken as necessary.  Perhaps a trigger tool like the NHS 
Safety Thermometer could be adapted for primary care drug monitoring system.  
The NPSA 2007 report ‘Safety in Doses: improving the use of medicines in the NHS,’ 
recommends that healthcare organisations should assess whether current arrangements around 
medication incident reports received locally are enabling local learning and action to reduce the 
risk of harm to patients, by reviewing the numbers and completeness of those reports (National 
Patient Safety Agency, 2007). A national error learning system is very useful. However, local 
actions are still necessary to establish local improvements. This study has raised serious 
concerns about the current local arrangements for managing error reporting, reviews and 
learning. Under the now defunct PCTs, it would appear that protocols and action plans for 
managing error learning were suboptimal and hazy. Although CCGs referred the researcher to 
the NHSE Area Teams citing not being responsible for error reporting and learning, only 2 
NHSE Area teams returned a completed questionnaire. This very low response rate may not be 
solely due to the limitations of the study, like using a postal survey, but may reflect the current 
safety climate within NHSE Teams. With the new CCG structure, urgent actions to clarify 
responsibilities and accountabilities for local error reporting and learning are needed. The roles 
and responsibilities of the medicines management teams of both the CCGs and NHSE Area 
teams need to be amalgamated in the interests of patient safety. Also, the idea of individual 
organisations, such as community pharmacy multiples having own incident reporting systems 
is commendable. However, this may lead to loss of vital information when these data are not 
pulled together and analysed locally for relevant actions and learning. Moreover, there is 
evidence that GPs and pharmacists may not necessarily report all errors and near misses 
(Ashcroft et al., 2006; Kingston et al., 2004). Toolkits such as the NHS Safety Thermometer, a 
local improvement tool for measuring, monitoring and analysing patient harms and ‘harm free’ 
care, are useful. However, it should be noted that this toolkit helps to analyse patient ‘harm.’ 
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Collating information on ‘near misses,’ and using them to inform local improvement strategies 
may prevent such harm in the first place. 
This study has also raised important issues for policy with respect to managing older people 
with chronic co-morbidities and the resultant polypharmacy, and paediatric patients, with the 
associated dose titrations, in the community. In secondary care, specialists, by training and 
practice, have the skills and experience required to deal with the ‘same’ issue and same patient 
over and over again. Perhaps it sounds simplistic that this model could be replicated in primary 
care. However, looking at the types and nature of errors identified in UK primary care in the 
current study, and the studies by Avery et al (2012) and Barber et al (2009), the suggestion of 
some form of specialisation in primary care may be effective. For instance, the 17-
dose/strength errors (25% of all errors) associated with paediatric dosing of antibiotics, may be 
prevented if GPs with special interests in paediatrics managed such patients. The same applies 
to older patients. Patients, whose conditions require medication switches and dose adjustments 
over time really need to see one GP during such periods at least, to ensure continuation of a 
care plan. One of the seven main error-producing conditions perceived to lead to an increased 
risk of errors was related to the Prescriber, when Avery et al qualitatively studied the causes of 
prescribing errors in primary care. The researchers noted that experience as well as training, 
were prescriber-related factors, which determined the likelihood of mismanagement (Slight et 
al., 2013). The more such GPs deal with such cases, the better they become at dealing with 
complex patient needs.   
This research has also highlighted the role of the patient and/or care in patient and medication 
safety. The study found that the top categories of problems identified in community pharmacies 
were either related to the patient or the prescriber. As Vincent (2010) pointed out, patient safety 
is all about putting the ‘patient’ at the centre of safety. Unruh and Pratt (2007) describe the 
“invisible work of “patients” in a healthcare system – identifying errors of procedures, 
managing therapeutic and non-therapeutic treatment tasks, handing over to new staff and 
ensuring continuity of their care, and providing relevant information about their health and 
well-being (Unruh & Pratt, 2007) as cited in Vincent (2010). Although patients may decide to 
engage to various degrees, all patients should be treated as individuals and provided the 
opportunity to speak or comment on aspects of their care. Empowering patients to be involved 
in their care can help prevent medical errors. This can be achieved by patient education 
supported by health campaigns. Healthcare professionals need to encourage the participation 
and involvement of patients. Patients are increasingly represented in hospital groups, and this 
  280 
needs to be brought into community practice. The next paragraph has attempted to pull together 
what the current study adds to the literature and the body of knowledge on medication safety in 
primary care. 
 
11.3 Conclusion  
Errors are common in older patients and in children in primary care. The majority of errors 
were of mild to moderate severity. Similar to secondary care, there is a gap for primary care 
healthcare professionals with special interest in geriatric and paediatric medicine. Furthermore, 
there is ample opportunity for pharmacist-led record review to identify potential errors and risk 
for harm, which in turn could potentially inform improvement in the safety and quality of 
prescribing in primary care. 
 
11.4 What this study adds 
 This study has provided important information on the prevalence of prescribing and 
monitoring errors in general practice in older patients ≥65 years old and in children 0-12 
years old, and the nature of these errors 
 The defenses in the medication management system in primary care that prevent errors – 
the prescriber-related defenses, community pharmacy-related defenses and patient-related 
defenses 
 Local arrangements for error management and learning needs to be reviewed and clarified 
as the current system is relatively porous 
 Underutilized roles of community pharmacists in primary care and an urgent review into 
the mode of delivery of NHS advanced services (MUR and NMS) in primary care 
 This study has also highlighted the need for patient and carer involvement in healthcare to 
improve health outcomes. Campaigns and adverts related to improved safety in the use of 
medication need to be put out to patients. 
 
11.5 Opportunities for further research 
Opportunities exist for further research to explore factors, which contribute to medication 
mishaps in these vulnerable age groups by exploring the relationships between the variables 
identified. Patient and healthcare professional inputs can be pointers to potential interventions 
to improve the safety of medication use in primary care. 
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The models of pharmaceutical care provided by community pharmacists need to be further 
explored. If pharmacists are going to be successful in GP practices, a solid foundation needs to 
be laid. One of the challenges of interventions to prevent errors is that the similar interventions 
may be duplicated if existing systems are not thoroughly reviewed to draw out their drawbacks. 
Although there is evidence to support pharmacists’ interventions, the proposed model needs to 
be thoroughly planned through rigorous research. 
 
11.6 Outputs from this research 
 Journal publication - Olaniyan, Janice; Ghaleb, Maisoon; Dhillon, Soraya; Robinson, 
Paul (2015): Safety of Medication Use in Primary Care – A systematic review – IJPP Vol. 
23, pp. 3-20 
 Olaniyan, Janice; Ghaleb, Maisoon; Dhillon, Soraya; Robinson, Paul (2013): Medication 
Error Management System in Primary Care: Royal College of General Practitioners 
Annual Primary Care Conference: Progressive Primary Care, Harrogate, Yorkshire, 
October 2013 
 Olaniyan, Janice; Ghaleb, Maisoon; Dhillon, Soraya; Robinson, Paul (2013): Safety of 
Medication Use in Primary Care: A systematic Review: Royal College of General 
Practitioners Annual Primary Care Conference: Progressive Primary Care, Harrogate, 
Yorkshire, October 2013 
 Olaniyan, Janice; Ghaleb, Maisoon; Dhillon, Soraya; Robinson, Paul (2015): Prevalence 
and Nature of Medication Errors in Older Patients in Primary Care: International Forum 
on Quality and Safety in Healthcare: Inspiring healthcare for 20 years London 2015 
 Poster accepted for presentation at the upcoming Royal College of General Practitioners 
Annual Primary Care Conference, SECC, Glasgow, 2015: Prevalence of Prescribing and 
Monitoring Errors in Older Patients and Children in Primary Care 
 Poster accepted for presentation at the upcoming British Hypertension Society meeting in 
Staffordshire, September, 2015: Assessment of Electronic Patient Records in Two Primary 
Care Centres for Quality of Prescribing and Monitoring. 
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Appendix 1: Approval Letter from NHS Bedfordshire 
 
 
 
Unit 12, Doolittle Mill 
Froghall Road, Ampthill 
Bedfordshire 
MK45 2NX 
 
01525 636915 
Fax: 01525 636976 
  
PA: Ruth Sawford 
Tel: 01525 636936 
Mrs Carolyn Read 
Chair, 
NRES Committee East of England - Cambridge Central 
Victoria House 
Capital Park 
Fulbourn 
Cambridge. 
CB21 5XB 
 
 
RE: Consent to carry out the Safety of Medication Use in Primary Care, SAFECaRE Study in 
Bedfordshire Primary Care Trust (REC reference number 12/EE/0166) 
I write with respect to the above-named study. The research team have been in contact with us, and 
NHS Bedfordshire has agreed to work with the researchers, and for the study to be done in those 
general practices and community pharmacies within our area that are willing to take part. The PCT will 
provide honorary contracts for the research team. 
The research team have mentioned that this study aims to extend the work done by the recently 
published General Medical Council (GMC) commissioned-study, the PRACtiSE Study. The SAFECaRE 
Study aims to estimate the rates of prescribing errors in the elderly (aged 65 years and older), and in 
children (0 to 12 years) as the PRACtISe Study demonstrated that these patient groups experience 
more medication errors than the rest of the population.  
Should you have any further questions, please do not hesitate to contact me. 
Kind regards 
A.D.Cooke 
Andrew Cooke 
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Head of Medicines Management 
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Appendix 2: Primary Care Research Assurance Letter Bedfordshire 
  
The West Anglia Primary Care Research Management Team undertakes research management services for primary 
care in Bedfordshire, Cambridgeshire & Peterborough, Luton and Cambridgeshire Community Services 
 
 
   
 
23 July 2013 
 
 
 
Mrs Janice Olaniyan 
University of Hertfordshire 
Department of Pharmacy, Practice and Public 
Health 
School of Life and Medical Sciences 
University of Hertfordshire 
AL10 9AB 
Research Management Team 
Hosted by NHS Cambridgeshire & 
Peterborough CCG 
Lockton House 
Clarendon Road 
Cambridgeshire 
CB2 8FH 
Tel: 01223725466 
Email:  
Vivienne.shaw@cambridgeshire.nhs.uk  
www.camstrad.nhs.uk                                                                                               
 www.camstrad.nhs.uk 
 
Dear Mrs Olaniyan 
Letter of assurance for research project 
Re: L01238 Safety of Medication Use in Primary Care 
REC: 12/EE/0166 
 
The Research Management Team is funded by the West Anglia Comprehensive Local 
Research Network and hosted by the NHS Cambridgeshire & Peterborough Clinical 
Commissioning Group. 
 
This assurance letter confirms that the Research Management Team has reviewed your 
submission in accordance with Department of Health Research Governance Framework for 
Health and Social Care. This assurance letter relates to the following primary care localities: 
Bedfordshire and Luton primary care. 
 
This assurance is subject to obtaining IG toolkit reference for practices and pharmacies 
and Caldicott Guardian confirmation. In addition, any group work and observations will 
need the appropriate consent and prior agreements in place.  
 
Primary Care Sites/GP practices decide on their own accord to agree participation for a 
given study. 
 
This assurance letter is subject to the Investigators meeting the following specific conditions: 
 
Please ensure that any amendments are submitted to the research ethics committee and the 
Research Management Team for review as appropriate 
 
Investigator responsibilities can be found on our website, please familiarise yourself with these 
and the site file instructions.  
 
The project must follow the agreed protocol and be conducted in accordance with Primary Care 
Sites/GP practices policy and procedures in particular in regard to data protection, health & 
safety and information governance standards. The research team are required to follow the 
reasonable instructions of the Primary Care Site/GP practice manager and can contact the 
Research Management Team for research management advice.  
  303 
 
  
  304 
Appendix 3: Bedfordshire Non-NHS Letter for Assurance for Access to Research 
 
 
 
 
 
 
24 July 2013 
 
Mrs Janice Olaniyan 
Department of Pharmacy 
University of Hertfordshire 
College Lane Campus 
Hatfield 
AL10 9AB 
 
 
 
 
 
 
 
Research Governance Team 
Hosted by NHS Cambridgeshire & 
Peterborough CCG 
Lockton House 
Clarendon Road 
Cambridgeshire 
CB2 8FH 
Tel: 01223725466 
Email:  Vivienne.shaw@cambridgeshire.nhs.uk  
www.camstrad.nhs.uk 
Dear Mrs Olaniyan, 
 
Letter of assurance for research access in Primary Care: Project-specific L01238 
Safety of Medication use in Primary Care (SAFECaRE) 
 
The Research Management & Governance (RMG) Team is funded by the West Anglia 
Comprehensive Local Research Network and hosted by the NHS Cambridgeshire & 
Peterborough Clinical Commissioning Group. 
 
This assurance letter confirms that the RMG Team have checked your Research Passport 
and associated HR documents and that they are compliant with the NIHR ‘Research in the 
NHS: Human Resource (HR) Good Practice Resource Pack’. This assurance letter relates to 
the following primary care localities: Bedfordshire and Luton Primary Care. 
 
You need to take this assurance letter with you and present to Primary Care Sites/GP 
practices so that they have evidence of RMG checks.  
 
Assurance for research access to primary care sites will be subject to having received 
Primary Care Sites/GP practices agreement to participate in a given study (Agreement 
is usually facilitated via the Primary Care Research Network). 
 
Your assurance for research access in Primary Care is on the terms and conditions set out 
below. This assurance commences on 24/07/2013 and ends on 01/12/2015 unless 
terminated earlier in accordance with the clauses below.  
 
You will be considered to be a legal visitor at any Primary Care Sites/GP practices that you 
are allowed to do your research in. You are not entitled to any form of payment or access to 
other benefits and this letter does not give rise to any other relationship between you and the 
Primary Care Sites/GP practice, in particular that of an employee.  
 
While undertaking research through Bedfordshire and Luton Primary Care Sites/GP 
practices you will remain accountable to your employer, University of Hertfordshire, but 
you are required to follow the reasonable instructions of the Primary Care Sites/GP practice 
manager in relation to the terms of this assurance for research access. 
 
Where any third party claim is made, whether or not legal proceedings are issued, arising 
out of or in connection with your assurance for research access, you are required to co-
operate fully with any investigation in connection with any such claim and to give all such 
assistance as may reasonably be required regarding the conduct of any legal proceedings. 
 
You must act in accordance with local policies and procedures, which are available to you 
upon request, and the Research Governance Framework. 
 
  305 
 
  
  306 
Appendix 4: Caldicott Guardian Confirmation, Bedfordshire 
 
 
 
24 September 2013 
 
 
Janice Gbemisoye Olaniyan 
Division of Pharmacy, Practice and Public Health 
Department of Pharmacy 
School of Life and Medical Sciences 
University of Hertfordshire 
Hatfield 
AL10 9AB 
 
 
 
 
Dear Janice 
 
Re: Safecare Project
 
I would like to confirm in writing that, as the Caldicott Guardian of Bedfordshire Clinical 
Commissioning Group, I am happy for the Safecare project to take place in Bedfordshire. 
 
 
Yours sincerely 
 
 
Dr Nick Curt 
Caldicott Guardian 
Bedfordshire Clinical Commissioning Group 
 
 
 
 
 
 
Suite 1 
Capability House 
Wrest Park 
Silsoe 
Bedfordshire 
MK45 4HR 
 
Telephone:  01525 864430 
Email: Nicholas.curt@nhs.net 
Website: www.bedfordshireccg.nhs.uk 
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Appendix 5: NHS Luton Letter of Approval 
  
 
 
 
Mrs Carolyn Read 
Chair, 
NRES Committee East of England - Cambridge Central 
Victoria House 
Capital Park 
Fulbourn 
Cambridge. 
CB21 5XB 
 
 
RE: Consent to carry out the Safety of Medication Use in Primary Care, SAFECaRE Study in Luton 
Primary Care Trust (REC reference number 12/EE/0166) 
I write with respect to the above-named study. The research team have been in contact with us, and 
Luton Primary Care Trust has agreed to work with the researchers, and for the study to be done in 
general practices and community pharmacies within our area. The PCT will provide honorary 
contracts for the research team. 
The research team have mentioned that this study aims to extend the work done by the recently 
published General Medical Council (GMC) commissioned-study, the PRACtiSE Study. The SAFECaRE 
Study aims to estimate the rates of prescribing errors in the elderly (aged 65 years and older), and in 
children (0 to 12 years) as the PRACtISe Study demonstrated that these patient groups experience 
more medication errors than the rest of the population.  
Should you have any further questions, please do not hesitate to contact me. 
 
Kind regards 
 
 
Richard A Jones 
Head of Medicines Management and Accountable Officer for Controlled Drugs 
Luton Clinical Commissioning Group (LCCG) 
The Lodge 
4 George Street West 
Luton 
 
Tel:-01582 532114 (ext 2114)  
Mobile: 0790 0980 606 
Safe Haven Fax number (Medicines Management Office): 01582 511054 
Email: richard.jones@luton-pct.nhs.uk or richard.jones15@nhs.net  
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Appendix 6: Luton CCG Caldicott Guardian Approval 
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Appendix 7: Consent Letter from Kingfisher Practice 
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Appendix 8: NHS Harrow Letter of Approval 
  
Rob Larkman: Accountable Officer (Designate)  Chair: Jeff Zitron 
Brent, Ealing, Harrow and Hillingdon Clinical Commissioning Groups   
 
 
Harrow 
 
Executive Office 
Wembley Centre for Health & Care 
116 Chaplin Road 
Wembley 
Middlesex HA0 4UZ 
Tel:  
Fax: 020 8795 6483 
Executive Office 
The Heights 
59-65 Lowlands Road 
Harrow on the Hill 
Middlesex HA1 3AW 
Tel:  
Fax: 020 8426 8646 
 
 
24th September 2012 
 
 
Mrs Carolyn Read 
Chair 
NRES Committee East of England - Cambridge Central 
Victoria House 
Capital Park 
Fulbourn  
Cambridge 
CB21 5XB 
 
 
RE: Consent to carry out the Safety of Medication Use in Primary Care, SAFECaRE 
Study in Harrow Primary Care Trust (REC reference number 12/EE/0166) 
 
I write with respect to the above-named study. The research team have been in contact with 
us, and Harrow Primary Care Trust has agreed to work with the researchers, and for the 
study to be done in general practices and community pharmacies within our area. The PCT 
will provide honorary contracts for the research team but NHS Harrow is not responsible for 
any financial contributions to support this pilot project. 
 
The research team have mentioned that this study aims to extend the work done by the 
recently published General Medical Council (GMC) commissioned-study, the Practice Study. 
The SAFECaRE Study aims to estimate the rates of prescribing errors in the elderly (aged 
65 years and older), and in children (0 to 12 years) as the Practice Study demonstrated that 
these patient groups experience more medication errors than the rest of the population.  
 
Should you have any further questions, please do not hesitate to contact me. 
 
Kind regards 
 
 
Javina Sehgal 
Borough Director, NHS Harrow 
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Appendix 9: South London Primary Care Letter of Approval 
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Appendix 10: Health Research Authority (HRA) NRES Approval Letter 
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Appendix 11: Health Research Authority (HRA) Confidentiality Advisory Group (CAG) 
Approval 
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Appendix 12: PCT/CCG Questionnaire 
  
Department of Pharmacy 
Pharmacy, Practice and Public Health, 
School of Life and Medical Sciences, 
University of Hertfordshire  
Hatfield 
AL10 9AB 
UK  
Tel +44 (0)1707 285087 
Fax +44 (0)1707 284506 
m.ghaleb@herts.ac.uk 
 
 
Date: 
A Charity Exempt from Registration under the 
Second Schedule of the Charities Act 1993  
 
 
 
 
Dear Sirs, 
 
Re: “Safety of Medication Use in Primary Care Research Project” 
 
We are writing to invite you to participate in a survey questionnaire to understand your Clinical 
Commissioning Group’s (CCG) current systems for medication error identification, recording and 
reporting. This research project is part of a doctorate (PhD) degree investigating the safety culture within 
primary care organisations, and the prevalence of prescribing errors in this setting.  
 
Previous research has shown that patients are exposed to risks from preventable adverse drug events in 
primary care (Avery et al, 2012, PRACtICE Study). Critical incidents are increasingly being recorded, and 
now reported routinely following the Department of Health (DH) 2001 report, “An organisation with a 
memory”, which emphasised the importance of error reporting and learning within the National Health 
Service (NHS). To date, CCGs’ error management procedures (including identification, recording and 
reporting) have not been documented. We would therefore like to describe the CCGs’ current processes of 
error management, with the hope to highlight strengths and weaknesses of these systems to facilitate 
learning from errors and to improve patient safety. 
 
This research has obtained ethical approval from the Cambridge Central Research Ethics Committee, REC 
(Reference number 12/EE/0166), and is funded by a University of Hertfordshire studentship. 
 
Please find enclosed information on the survey. All the information you provide will remain strictly 
confidential and no individual or CCG will be identified. 
 
Thank you for your participation 
 
Yours sincerely 
 
 
---------------------      
Dr Maisoon Ghaleb  
Senior Lecturer 
Pharmacy, Practice and Public Health 
 
  326 
 
 
 
“Safety of Medication Use in Primary Care Research Project” 
Title: To investigate the Clinical Commissioning Group procedures for “error 
management” 
Participant Information for SAFECaRE study 
This survey is being conducted across Clinical Commissioning Groups (CCG) in England, and 
will only take about 10 minutes of your time. By participating in this survey, you are 
consenting to the research. 
 
Please kindly answer all questions below as completely as possible. All the information you 
provide will remain strictly confidential and no individual or CCG will be identified  
Should you require any clarifications, please contact: 
Dr. Maisoon Ghaleb, Researcher and Senior Lecturer, Department of Pharmacy, Pharmacy, 
Practice and Public Health School of Life and Medical Sciences, University of Hertfordshire. 
Hatfield AL10 9AB.  Telephone: 01707285087; fax: 01707284506. Email address: 
m.ghaleb@herts.ac.uk 
If you would like to complete the survey online, please send an email to the address above to 
request an electronic version the survey. 
Thank you so much for helping with this survey. 
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Safety of Medication Use in Primary Care (SAFECaRE) Study 
 
Title: To investigate the Clinical Commissioning Groups procedures for “error 
management” 
Current role: _________________ 
Number of years in current role: _____________________ 
Number of years of related role (please tick) :    <5□ 5-10□  11-20□  >20□ 
Sex: Male/Female (please circle) 
Age (please tick):  20-29 □  30-39 □  40-49 □  50+ □ 
 
Please kindly answer these questions below: 
1) What types of incident(s) would you class as prescribing error(s) based upon your 
experience or reports from general practices (surgeries)? 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
............................................................ 
...................................................................................................................................................
...................................................................................................................................................
.................... 
...................................................................................................................................................
...................................................................................................................................................
.................... 
 
2) What types of incidents(s) would you class as dispensing error(s) based upon your 
experience or reports from community pharmacies? 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
............................................................ 
...................................................................................................................................................
...................................................................................................................................................
.................... 
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...................................................................................................................................................
...................................................................................................................................................
.................... 
 
 
3) How are critical incidents (prescribing and dispensing errors) reported to your CCG –  
a. Are general practices (surgeries) and community pharmacies instructed to submit their periodic 
critical incident reports OR 
b. Do you ask them for periodic critical incident reports? 
(Circle as appropriate, and add further comments below) 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
............................................................ 
...................................................................................................................................................
.......... 
 
4) How often are critical incident data collated from general practices (surgeries) and 
community pharmacies by your CCG?  
(Please tick as appropriate) 
Monthly □  Quarterly □  Yearly □  Other (Specify) □ 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
.................................................. 
 
5) Could you describe any processes or protocols currently in use by general practices 
(surgeries) and community pharmacies in your CCG to identify, record, and report 
medication error incidents to the CCG clinical governance or medicines management 
department? 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
............................................................ 
...................................................................................................................................................
...................................................................................................................................................
.................... 
 
6) Does your clinical governance or medicines management department have any systems in 
place to review critical incidents? 
  329 
Yes □  No □ 
 If ‘Yes’, please describe the system briefly, adding how often this is done 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
................................................................................ 
 
7) Do you collect information on medication “near miss” incidents from general practices and 
community pharmacies? 
Yes □  No □ 
If ‘Yes’, how often? Please tick as appropriate: 
Monthly □  Quarterly □  Yearly □  Other (Specify) □ 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
.................................................. 
 
8) What interventions have been implemented by your clinical governance/medicines 
management department to prevent occurrence of medication incidents in primary care 
organisations within your ward, notably in GP surgeries and community pharmacies? 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
............................................................ 
...................................................................................................................................................
...................................................................................................................................................
.................... 
...................................................................................................................................................
...................................................................................................................................................
.................... 
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Appendix 13: Form 1 - for collecting data on patient demographics and drugs prescribed 
 The SAFECaRE Study 
“Safety of Medication Use in Primary Care” 
 
Form 1: Prescribing Record Sheet     Database Unique ID No.___ 
Instructions: Please use one sheet per patient (use extra sheets if more than 15 prescriptions) and record any possible 
prescribing errors. 
 
 
 
 
 
If no prescriptions for this patient, tick here ----- and move on to the next patient. 
In the table below, please record summary data on the prescriptions for this patient over the last 12 months (record data in relation to the latest 
prescription if a drug (at a particular dose) has been prescribed more than once during the year). 
If you pick up any potential errors, please fill in Form 2 for each of these errors. 
If you pick up any omission errors relating to failure to prescribe for an existing condition, please fill in Form 3. 
 
Rx1No. Drug name/dose/form2 Acute (A) or Repeat 
(R) 3 
Prescriber (GP, 
nurse or other) 4 
No. Of possible Rx 
error (s) 5 
 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
1: Rx = prescription; 2: Name of drug/preparation as it appears in the patient record; 3: Record “A” for acute prescription and 
“R” for repeat prescription; 4: Record prescriber type (1 = GP; 2 = nurse prescriber; 3 = non-medical prescriber; 4 = other; 5 = 
unknown); 5: if no error, please put zero (0); 
If this patient has more than 15 prescriptions, please tick here--- and do an extra Form 1 
 
 
 
 
Initials of student doing review: ___________   Date ____________ 
Practice ID code: ______________ (assigned by research team) 
Patient ID code: _______________ (for internal use by practice) 
Patient information: 
Age: ____________ Years/Months (indicate as appropriate)  Sex: Male/Female (please circle) 
Months registered with practice during the 12-month data collection period: ________________ 
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Appendix 14: Form 2 - Form for collecting information on potential error 
The SAFECaRE Study 
“Safety of Medication Use in Primary Care” 
 
Form 2: Details of possible prescribing errors   Database Unique ID No.___  
For the possible errors identified on Form1, please provide further details below and overleaf (use additional sheets as 
required). 
ONE FORM PER POSSIBLE ERROR 
 
 
 
 
Rx No from Form 11  
Drug name and  
Formulation2 
 
 
Strength  
Dosage instructions 
 
 
Quantity  
Initials of prescriber 
 
 
Error code3 
 
 
1: Please use the appropriate prescription number from Form 1; 2: Name of drug/preparation as it appears in the patient 
record; 3: please use the following error code: 
Prescribing error codes are 
1. Unnecessary drug     17. Inadequate review 
2. Incorrect drug     18. Duration error 
3. Duplication     Monitoring errors  
4. Allergy/error     19. Monitoring not requested 
5. Contraindication error     20. Requested but not done 
6. Interaction error     21. Results not available 
7. Dose/strength error     22. Results not acted upon 
8. Formulation error 
9. Frequency error 
10. Timing error 
11. Information incomplete 
12. Generic/brand name error 
13. Omission error relating to failure to prescribe concomitant medication 
14. Not classified 
15. Inadequate documentation in medical records 
16. Quantity error 
 
Initials of student doing review: ___________   Date: _______________ 
Practice ID code: _____________ (assigned by research team) 
Patient ID code: _______________ (for internal use by practice) 
Patient information: 
Age ____________ Years/Months (indicate as appropriate)  Sex: Male/Female (please circle) 
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Form 2: Details of possible prescribing errors 
1) Please describe the potential error: 
 
........................................................................................................................................................... 
........................................................................................................................................................... 
........................................................................................................................................................... 
....................................................................................................................................................... .... 
........................................................................................................................................................... 
 
2) Was the potential error a single event?   
Yes/No (please circle as applicable)   If ‘Yes’ (go to Question 4) 
       If ‘No’ (go to Question 3) 
 
3) If the potential error has been repeated, how many weeks/ months/ years has the error been repeated over? 
.............................................................Weeks/ months/ years (please circle as appropriate) 
 
4) Why do you think the error occurred? And what happened in the lead up to the error? 
(Give details as much as you can) 
 
.............................................................................................................................................................................
.............................................................................................................................................................................
.............................................................................................................................................................................
.............................................................................................................................................................................
................................................................................... 
5) Has there been any adverse event associated with the possible error? 
 
Yes/No/Uncertain (Please circle as applicable) If ‘Yes’ (go to Question 6) 
       If ‘No’ (go to Question 7) 
 
6) If you think there may have been an adverse event associated with the error, please describe this below: 
.............................................................................................................................................................................
......................................................................................................................................................................... ....
.............................................................................................................................................................................
..................................................................................................... 
 
7) Was the error reported through the PCT normal reporting procedure? 
 
Yes/No /Unknown (Please circle as applicable) 
 
8) Was the error reported to NPSA? 
 
Yes/No /Unknown (Please circle as applicable) 
 
9) If there is any evidence that the error has been rectified? 
 
Yes/ No (Please circle as applicable, and give brief details below).   
.............................................................................................................................................................................
.............................................................................................................................................................................
.......................................................................................................................
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Appendix 15: Form 3 - for collecting information on omission errors relating to failure 
to prescribe for an existing clinical condition 
The SAFECaRE Study 
“Safety of Medication Use in Primary Care” 
 
Form 3: Omission errors relating to failure to prescribe for an existing clinical condition 
        Database Unique ID No._______ 
Please note that this form is for recording medication that, after careful examination of the patients’ records, you 
think should have been prescribed because of an existing condition e.g. aspirin, ACE inhibitor, beta-blocker 
and/or statin post-MI. 
Note: use Forms 1 and 2 to record possible omission errors relating to failure to prescribe necessary concomitant therapy in 
relation to patients’ existing medications, e.g. failure to prescribe a PPI to a patient taking NSAID when they are at high risk 
of GI bleed. 
  
 
 
Please describe the possible omission error(s) in this patient. 
1. Clinical condition(s) for which you believe medication should have been prescribed: 
.............................................................................................................................................................................
.............................................................................................................................................................................
.............................................................................................................................................................................
..................................................................................................... 
2. Medicine(s) that you believe should have been prescribed: 
.............................................................................................................................................................................
......................................................................................................................................... 
3. Please provide an explanation for why you think this was an omission error: 
.............................................................................................................................................................................
................................................................................................................................................... ..........................
.............................................................................................................................................................................
.............................................................................................................................................................................
................................................................................... 
4. Having thoroughly reviewed the patient’s records is there anything to suggest that the medicine you think 
should have been prescribed may not be indicated e.g. due to previous ADR, expressed patient preference, 
caution or contraindication? 
 
Yes/No/Uncertain (Please circle as applicable) 
If ‘Yes’ or ‘uncertain’, please give details below
Initials of student doing review: ______________    Date ______________ 
Practice ID code: ______________ (assigned by research team) 
Patient ID code:  _______________ (for internal use by practice) 
Patient information: 
Age______________ Years/Months (indicate as appropriate)  Sex: Male/Female (please circle) 
  334 
Appendix 16: List of drugs requiring monitoring 
1) Monitoring following the initiation of therapy  
Drug/drug group  Monitoring on initiation  
ACE inhibitor/Angiotensin-II receptor 
antagonists  
On initiation: Pre U&E and 2 weeks after  
Digoxin  Pre U&E  
Diuretics  Pre U&E and 1 month after starting  
Glitazones  Pre LFT  
Statins  Pre LFT before starting treatment  
 
 
 
2) Monitoring of maintenance therapy  
Drug/drug group  Maintenance monitoring  
ACE inhibitor/Angiotensin-II receptor 
antagonists  
12 monthly U&E  
Amiodarone  6 monthly TFT  
6 monthly LFT  
Azathioprine  3 monthly FBC  
Carbimazole  3 monthly TFT (6 monthly if patient been 
stabilised for over 1 year)  
Digoxin  Digoxin level if toxicity or lack of 
efficacy suspected.  
Diuretics  12 monthly U&E  
Glitazones  12 monthly LFT  
Levothyroxine  12 monthly TFT  
Lithium  3 monthly lithium levels  
12 monthly TFT  
Methotrexate  3 monthly FBC  
3 monthly LFT  
6 monthly U&E  
Sulfasalazine  FBC 3 monthly in 1st year  
LFT 3 monthly in 1st year  
FBC 6 monthly in 2nd year  
LFT 6 monthly in 2nd year 
No further monitoring if stable  
 
Theophylline  Theophylline level if toxicity suspected  
Valproate  3 monthly LFT for first 6 months  
Warfarin  12 Weekly INR  
Statin  3 monthly and 12 monthly LFT in the first 
year following initiation  
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Prescribing errors 
 
1. Unnecessary drug 
2. Incorrect drug 
3. Duplication 
4. Allergy error 
5. Contraindication error 
6. Interaction error 
7. Dose/strength error 
8. Formulation error 
9. Frequency error 
10. Timing error 
11. Information incomplete 
12. Generic/brand name error 
13. Omission error relating to failure to prescribe concomitant treatment 
14. Not classified 
15. Inadequate documentation in medical records 
16. Quantity error 
17. Inadequate review 
18. Duration error 
 
Monitoring errors 
19. Monitoring not requested 
20. Requested but not done 
21. Results not available 
22. Results not acted upon 
Appendix 17: Types of prescribing and monitoring errors 
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Appendix 18: Examples of judgements made in the PRACtISE Study (Avery et al, 2012) 
Scenario  Judgement  Rationale for judgement  
Helicobacter eradication treatment 
to a patient who is Helicobacter 
negative.  
Error: unnecessary drug.  Significant increased risk of harm 
with no likely benefits from the 
antibiotic components of the 
treatment.  
Combined oral contraceptive pill 
left on repeat prescription after an 
alternative hormonal contraceptive 
had been given.  
Sub optimal prescribing: risk of 
duplication low.  
The panel felt that it was 
suboptimal prescribing to leave a 
combined oral contraceptive pill 
on repeat prescription and 
alternative hormonal 
contraception had been given. 
Nevertheless, the panel felt that it 
was highly unlikely that the 
patient would request this 
medication having been given an 
alternative hormonal 
contraceptive.  
Prescription of a second dose of 
the same influenza vaccine within 
one flu season (whether or not the 
patient received the second dose).  
Error: duplication.  Significant increased risk of harm 
if patient was to receive a second 
dose (even if this was just a local 
reaction to the injection) without 
any benefits.  
Prescription of paracetamol when 
another paracetamol containing 
product is on the patient's repeat 
prescription (or vice-versa): both 
products prescribed at the same 
time with no warning that they 
should not be taken together.  
Error: duplication.  Significant increased risk to the 
patient if they were to take the two 
products together.  
Prescription of paracetamol when 
another paracetamol containing 
product is on the patient's repeat 
prescription (or vice-versa): 
products not prescribed at the 
same time, e.g. >3 months 
between prescriptions, but no 
warning that the preparation 
should not be taken together.  
Assess on a case-by-case basis.  The panel felt that it was difficult 
to produce case law on this 
scenario and so cases should be 
judged individually.  
Prescription of a drug in 
circumstances where the 
pharmacist notes that an allergy to 
that drug has been recorded, and 
the prescriber gives no 
acknowledgement/justification for 
prescribing in light of the previous 
allergy documentation.  
Error: allergy error.  Significant increased risk of harm. 
Not all allergy recordings 
represent true allergy. 
Nevertheless, at a minimum one 
would expect a prescriber to 
acknowledge that previous 
(potential) allergy had been 
recorded and to justify their 
prescription in these 
circumstances.  
Prescription of a drug that is 
contraindicated according to the 
BNF (unless a clear and 
defensible justification has been 
given by the prescriber or in 
correspondence from secondary 
care). An example would be the 
prescription of combined 
Error: contraindication error.  Significant increased risk of harm.  
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hormonal contraceptives in 
patients with two or more risk 
factors for thromboembolism.  
 
Prescription of two oral NSAIDS 
at the same time.  
Error: interaction error.  Significant increased risk of harm, 
e.g. from GI Bleed.  
Aspirin 150 mg daily as secondary 
prevention for coronary heart 
disease.  
Suboptimal prescribing: 
dose/strength error.  
While the panel felt that doses 
>75mg daily increased the risk of 
harm while not being likely to 
increase benefits, it was felt that 
the increased risks were not 
sufficiently high to label this as an 
error. It was also noted that 
150mg daily was a standard dose 
in the US.  
Calcium tablets prescribed at 
lower than the recommended 
dose.  
Suboptimal prescribing: 
dose/strength error.  
Risk of harm (or reduction in 
probability of treatment being 
timely or effective) is probably 
low. Also, BNF is not very 
specific about calcium doses 
noting that dietary intake also 
needs to be taken into account.  
Failure to act on a suggested dose 
change from secondary care 
correspondence, where that dose 
change was aimed at either 
increasing therapeutic benefits or 
reducing risk of harm.  
Error: dose/strength error.  Significant increased risk of harm 
or reduced probability of 
treatment being timely and 
effective.  
Overdose of an oral medication in 
a child, e.g. clearly above that 
recommended by BNF for 
height/age, unless the medication 
has extremely low risk of harm.  
Error: dose/strength error.  Significant increased risk of harm.  
Overdosage of an oral medication 
in an adult where there is clear 
increased risk of harm (unless a 
clear and defensible justification 
has been given by the prescriber 
or in correspondence from 
secondary care).  
Error: dose/strength error.  Significant increased risk of harm.  
Overdosage of a single dose of an 
oral medication (e.g. 
sulphonylurea) where BNF 
recommends dividing the dose 
above a certain dosage level 
(unless a clear and defensible 
justification has been given by the 
prescriber or in correspondence 
from secondary care).  
Error: dose/strength error.  Significant increased risk of harm.  
Prescription of a drug with 
significant potential for harm at a 
dose above that recommended by 
the BNF (for a specific indication) 
e.g. Rosuvastatin 40mg in a 
patient without sever 
hypercholesterolaemia or with 
high cardiovascular risk and under 
specialist supervision. 
Error: dose/strength Significant increased risk of harm.  
  338 
Scenario  Judgement  Rationale for judgement  
 
Underdosing of oral antimicrobial 
agents.  
Error: dose/strength error.  Significant increased risk of harm 
if infection not treated adequately 
(or if infecting organism not fully 
eradicated, thus increasing the risk 
of resistant strains developing)  
Underdosing for a condition that 
is not serious and where failure to 
prescribe the recommended dose 
is unlikely to have a significant 
deleterious effect on the patient in 
terms of lack of control of 
symptoms.  
Suboptimal: dose/strength error.  The panel felt that for non-serious 
symptomatic conditions it was not 
appropriate to label underdosing 
as an error because prescribers 
may have consciously used a low 
dose to avoid side effects.  
When a patient is under the care 
of a specialist, prescription of a 
drug with significant potential for 
harm at a dose above that 
recommended, e.g. failure to 
adjust doses in response to 
correspondence from secondary 
care.  
Error: dose/strength error.  Significant increased risk of harm 
from prescribing a drug that a 
higher dose than that 
recommended.  
Drug not prescribed in the correct 
formulation when this might lead 
to increased risk of patient harm, 
e.g. tacrolimus and other 
medications where the BNF states 
the importance of prescribing the 
correct formulation.  
Error: formulation error.  Significant increased risk of harm, 
or reduction in the probability of 
treatment being timely or 
effective.  
Oral antibiotics prescribed at a 
frequency below that 
recommended in the BNF.  
Error: frequency error.  Significant increased risk of harm 
(development of antibiotic 
resistance) or reduced probability 
of treatment being timely and 
effective (due to failure to 
maintain adequate plasma levels 
of antibiotic).  
Prescription of a hydrocortisone 
containing products in a child at a 
frequency higher than that advised 
by BNFC or SPC.  
Error: frequency error.  The panel debated this at length, 
but with input from a paediatrician 
decided that prescribing 
hydrocortisone at a frequency 
greater than that recommended 
could increase the risk of harm to 
a child.  
Prescription of a topical product 
which has low potential for harm, 
e.g. antifungal, mild corticosteroid 
(in an adult and not on the face), 
at a frequency different to that 
recommended by the BNF.  
 
Suboptimal prescribing: frequency 
error 
Risk of harm not significant.  
Bendroflumethiazide prescribed 
OD.  
Suboptimal prescribing: timing 
problem.  
While thiazide diuretics should 
normally be taken in the morning, 
the panel did not feel there was a 
significant increased risk of harm 
from this once daily dosage 
instruction.  
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Oral corticosteroids prescribed 
without instructions that they 
should be taken in the morning.  
Suboptimal prescribing: timing 
problem.  
The BNF states that the 
suppressive action of a 
corticosteroid on cortisol secretion 
is least when it is given as a single 
dose in the morning. The panel 
felt that the risks of harm to 
patients from not stating that the 
drug should be taken in the 
morning were small in the 
majority of patients. Therefore 
this was classified as suboptimal 
prescribing rather than error.  
Simvastatin prescribed without 
instructions that it should be taken 
at night.  
Error: timing error.  Significant reduction in the 
probability of simvastatin being 
effective if not taken in the 
evening/at night.  
Benzodiazepines at low dose, e.g. 
2 mg, and small numbers of 
tablets, e.g. 10, prescribed, “as 
directed” for conditions such as 
flight phobia and muscle spasm.  
Suboptimal: information 
incomplete.  
The panel felt that in the majority 
of patients there would not be at 
significant increased risk of harm 
from this pattern of prescribing.  
Ear drops prescribed without 
indicating which ear they should 
be used in.  
Suboptimal prescribing: 
information incomplete.  
The panel felt that risks of harm to 
the patient would be low here as it 
is highly likely that the patient 
would know which ear to use the 
drops in.  
Eye drops (for non-serious 
symptomatic conditions such as 
conjunctivitis or dry eye) 
prescribed without indicating 
which eye the drop should be used 
in.  
Suboptimal prescribing: 
information incomplete.  
The panel felt that risks of harm to 
the patient would be low here as it 
is highly likely that the patient 
would know which eye to use the 
drops in.  
Eye drops for glaucoma 
prescribed as directed or without 
indicating which eye the drop 
should be used in.  
Prescribing error: information 
incomplete.  
Given that glaucoma is usually 
asymptomatic, and that there are 
serious risks to sight if treatment 
is not administered correctly, the 
panel felt that risk of harm would 
be significantly increased by not 
having clear dosage instructions.  
Eye drops containing steroids 
prescribed as directed or without 
indicating which eye the drop 
should be used in.  
Prescribing error: information 
incomplete.  
Given the risks of steroids in the 
eye, it is important to give clear 
instructions.  
GTN sublingual tablets/spray 
prescribed, “as directed”.  
Suboptimal  It was felt that patients would 
almost certainly have been 
informed about how to take GTN 
sublingual tablets/spray and that 
these products come with a Patient 
Information Leaflet that gives 
detailed unequivocal instructions 
on how to take the medicine.  
 
Inhaled corticosteroid prescribed 
without clear dosage instructions, 
e.g. PRN, BD.  
Error: information incomplete.  The panel felt that given that 
inhaled corticosteroids are 
normally prescribed regularly for 
asthma in order to prevent 
exacerbations, there was a 
significant increased risk of harm 
from not having clear dosage 
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instructions.  
Inhaled salbutamol prescribed 
PRN.  
Suboptimal prescribing: 
information incomplete.  
The panel felt that there was 
unlikely to be a significant 
increased risk of harm here 
because salbutamol inhalers come 
with clear dosage instructions on 
the PIL.  
Medication, with significant risk 
of harm if not taken according to 
precise dosage instructions, 
prescribed, “as directed” (e.g. 
Amiodarone, beta blockers, 
methotrexate, n.b. warfarin not 
included).  
Error: information incomplete.  Significant increased risk of harm 
if the patient does not know what 
is meant by “as directed”.  
Medication prescribed without 
stating the number of tablets to be 
taken each time, e.g. metformin 
500 mg tablets “twice daily” 
provided that the default dose of 
one tablet/capsule each time 
would be an appropriate dose (n.b. 
very high risk drugs not included 
in this scenario).  
Suboptimal: information 
incomplete.  
The panel felt that most 
community pharmacists and 
patients would interpret the 
instructions to mean one tablet to 
be taken at each dose, and that in 
most circumstances the inadequate 
dosage instructions would not 
present an increased risk to the 
patient.  
Oral corticosteroids prescribed, 
“as directed” without further 
instructions.  
Error.  Significant increased risk of harm 
if patients do not have clear 
instructions on how to take oral 
corticosteroids.  
Oral corticosteroids prescribed, 
“as directed by X” (where X is 
usually a secondary care 
clinician).  
Suboptimal.  The panel felt that while there was 
a potential increased risk of harm 
to patients, by specifying the 
patient was to follow directions 
given by another clinician it is 
likely that the patient had been 
given specific dosage instructions.  
Phosphodiesterase type-5 
inhibitors with “as directed” 
dosage instructions.  
Suboptimal prescribing: 
information incomplete.  
The panel felt the risks of harm in 
this situation were low.  
Prescription of a preparation for 
an adult that is available OTC and 
is prescribed with “as directed” 
dosage instructions (n.b. NSAIDs 
to be considered on a case-by-case 
basis).  
Sub optimal prescribing: 
information incomplete 
OTC preparations come with clear 
dosage instructions and so use of 
“as directed” is not likely to 
expose a patient to significant 
increased risk of harm. 
Prescription of a topical product 
which has very low potential for 
harm, e.g. emollient, antifungal, 
without clear dosage instructions.  
Sub optimal prescribing: 
information incomplete.  
Risk of harm not significant.  
Prescription of a topical product 
with significant potential for harm 
if dosage instructions are incorrect 
or not clear, e.g. moderate-potent 
corticosteroid in a child, or potent 
corticosteroid in an adult, or 
products containing antibacterial 
agents (includes lack of 
information on duration of use).  
Error: information incomplete.  Risk of harm significant.  
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Prescription of oral antibiotics 
without clear dosage instructions, 
e.g. PRN.  
Error: information incomplete.  The panel felt that there was a 
significant increased risk of harm 
from prescribing oral antibiotics 
without clear dosage instructions, 
e.g., due to risks of harm from 
underdosing, overdosing or 
prolonged treatment, and potential 
problems with development of 
antibiotic resistance.  
Prescription of hormone 
replacement therapy without 
detailed dosage instructions, e.g. 
“as directed”, for preparations 
where the PIL contains clear and 
unambiguous instructions.  
Suboptimal prescribing: 
information incomplete.  
For preparations where the PIL 
contains clear and unambiguous 
instructions the panel felt that 
there was not a significant 
increased risk of harm from “as 
directed” instructions.  
Prescription of hormone 
replacement therapy without 
detailed dosage instructions, e.g. 
“as directed”, for preparations 
where the PIL does not contain 
clear and unambiguous 
instructions.  
Error: information incomplete.  The panel felt that there was 
significant increased risk of harm 
from overdose if “as directed” 
instructions were given for a HRT 
preparation where the PIL did not 
give unambiguous dosage 
instructions.  
Prescription of the combined 
hormonal contraceptive pill/patch 
without detailed dosage 
instructions, e.g. “as directed”.  
Suboptimal prescribing: 
information incomplete.  
It was felt to be common practice 
for some GPs to use “as directed” 
instructions knowing that patients 
will have been informed about 
how to take the contraceptive pill 
and that all pill packets come with 
a Patient Information Leaflet that 
gives detailed instructions on how 
to take the medicine.  
Sofradex eye/ear drops prescribed 
without specifying whether they 
were to be used for eye or ear.  
Prescribing error: information 
incomplete.  
Given dangers of inadvertent use 
of steroids in the eye the panel 
judged this to be an error.  
Steroid eye drops prescribed as 
directed or without indicating 
which eye the drop should be used 
in.  
Prescribing error: information 
incomplete.  
Given the dangers of topical eye 
drops, clear dosage instructions 
are essential.  
Strong opioids with inadequate 
dosage instructions.  
Prescribing Error: information 
incomplete.  
Given legal requirements and risks 
from overdose, the panel felt that 
risk of harm to the patient was 
significantly increased if dosage 
instructions were not clear.  
Topical preparation prescribed 
with dosage instructions implying 
an oral route for administration, 
e.g. take one twice daily.  
Suboptimal: information 
incomplete.  
The panel judged that while these 
dosage instructions could be 
misinterpreted, it is almost certain 
that a community pharmacist 
would put the correct instructions 
on the dispensing label.  
Unclear dosage instructions on a 
corticosteroid inhaler for asthma 
in a patient with poorly controlled 
asthma.  
Error: information incomplete.  Significant increased risk of harm 
if the patient is not receiving an 
adequate dose.  
Varenicline starter pack with “as 
directed” instructions.  
Sub optimal prescribing: 
information incomplete.  
Instructions for use of the starter 
pack are complicated and these 
are clearly explained in the Patient 
Information Leaflet. The panel felt 
that it was not an error to write “as 
directed” as full and unequivocal 
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instructions are available in the 
PIL.  
Antiepileptic treatments (modified 
release preparations) prescribed 
generically for epilepsy where 
more than one brand is available.  
Error: generic/brand name error.  The panel felt there was a 
significant increased risk of 
patient harm from generic 
prescribing in these circumstances 
where there may be differences in 
bioavailability between brands.  
Failure to prescribe calcium and 
vitamins D to a patient who is 
receiving a bisphosphonate for 
osteoporosis or fracture 
prevention.  
Suboptimal: omission error.  The panel felt that while all trials 
of bisphosphonates had included 
calcium and vitamin D, some 
patients might be taking sufficient 
calcium and vitamin D through 
OTC supplementation or diet.  
Prescription of an NSAID to an 
older person (>65 yrs.) without an 
ulcer healing (younger patients to 
be judged on a case-by-case 
basis).  
Omission error related to failure to 
prescribe concomitant medication.  
Significant increased risk of harm 
(although judgement required in 
cases at the lower risk end of the 
spectrum, e.g. occasional use of 
low dose ibuprofen in a 65-year-
old with no other risk factors - 
such cases were discussed by the 
panel to reach a judgement).  
Prescription of a drug in 
circumstances where the 
pharmacist notes that a previous 
adverse drug reaction (ADR) has 
been recorded, but the details of 
that ADR have not been 
documented and the patient has 
used the drug since without 
apparent problems.  
Sub optimal prescribing: 
inadequate documentation in 
medical records.  
Risk of harm probably not 
significant given that patient has 
been taking the drug without 
apparent ill effects.  
Prescription of a drug with very 
high potential for harm (e.g. 
immunosuppressant, strong 
opioids) without documented 
evidence of an indication for the 
drug.  
Error: inadequate documentation 
in medical records.  
Significant increased risk of harm 
from prescribing high-risk 
medication without a recorded 
indication.  
Prescription of any medication 
(except those with very high 
potential to cause harm) without 
documentation of the indication in 
the medical records.  
Suboptimal prescribing: 
inadequate documentation in the 
medical records.  
Lack of documentation made it 
difficult to judge whether the 
prescription was associated with a 
significant increased risk of harm. 
Therefore sub-optimal prescribing 
classification used rather than 
error.  
Anthelminthic (for threadworms, 
head lice, scabies) prescribed on a 
single prescription with a quantity 
large enough to treat a whole 
family.  
Suboptimal prescribing: quantity 
issue.  
Even though the quantity is large, 
this does not necessarily imply an 
error and there is no legal issue 
unless the prescriber has explicitly 
suggested that someone other than 
the patient can use the medicine.  
Oral antibiotics prescribed with a 
quantity that is clearly below that 
normally recommended for 
successfully treating infection.  
Error: quantity issue.  Significant increased risk of harm 
if infection not treated adequately 
(or if infecting organism not fully 
eradicated, thus increasing the risk 
of resistant strains developing)  
Prescription of a very large 
quantity (e.g. greater than six 
months) of a drug that is not high-
Suboptimal: quantity issue.  The panel felt that there was 
probably not a significant 
increased risk of harm to patients.  
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risk and has low potential for 
misuse.  
Prescription of a large quantity 
(e.g. greater than three months) of 
a drug that is either high-risk or 
has significant potential for 
misuse.  
Error: quantity error.  The panel felt that there was a 
significant increased risk of harm.  
Oral Terbinafine prescribed (e.g. 
for fungal nail infection) for 3-6 
months without review.  
Suboptimal: duration problem.  The panel felt that in order to 
consider whether a prescription 
was still necessary, a patient 
should not go 3-6 months without 
a review. See further case below 
for prescribing beyond six months 
without review.  
Oral Terbinafine prescribed (e.g. 
for fungal nail infection) for 
greater than six months without 
review.  
Error: duration error.  Beyond 6 months without review, 
the panel felt that continuing 
prescribing might increase risks 
for patients when no assessment 
had been made as to whether 
further treatment was necessary.  
Not responding to a request from 
secondary care to undertake 
laboratory test monitoring where 
this request is justified in terms of 
risks from the medication the 
patient is taking.  
Error: monitoring not requested.  Significant increased risk of harm.  
Increasing the dose of an ACE 
inhibitor/AR II antagonist without 
checking U&E within three 
weeks.  
Error: monitoring not requested.  Increased risk of harm if adverse 
effects not picked up early.  
Dosage instructions given using 
decimals rather than words, e.g. 
0.5 tablets.  
Not a problem.  The panel felt that while the use of 
decimals may be dangerous in 
some circumstances, it is unlikely 
that they would be transmitted on 
to the dispensing label having 
gone through a community 
pharmacy or dispensary.  
Eye drops prescribed without 
indicating how many drops to use.  
Not a problem.  Eye drops designed so that one 
drop gives a sufficient volume; 
patient inadvertently using more 
than one drop are unlikely to come 
to harm as excess liquid spills out 
of the eye.  
Loop diuretics prescribed “twice 
daily” without stating “one to be 
taken in the morning and one at 
lunchtime”.  
Not a problem.  The panel felt that while the usual 
twice daily dosage for loop 
diuretics was in the morning and 
at lunchtime some patients might 
wish to take the doses at different 
times.  
Prescription of a broad spectrum 
oral antibiotic to a woman 
receiving the combined oral 
contraceptive pill (for 
contraception) without instruction 
(on the prescription, or 
documented in the patient's 
records) that extra contraceptive 
precautions should be taken.  
Not a problem.  In light of WHO and RCOG 
advice that risks of pregnancy are 
not increased by use of non-
enzyme inducing antibiotics, the 
panel judged this not to be a 
problem.  
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Scenario  Judgement  Rationale for judgement  
Prescription of a cephalosporin to 
a patient with previously recorded 
history of penicillin allergy (but 
no evidence of anaphylaxis).  
Not a problem.  Although cross sensitivity is a 
potential problem, the panel felt 
that it was not a significant risk 
unless the patient had previously 
had an anaphylactic reaction to 
penicillin.  
Prescription of a drug, e.g. an oral 
NSAID, at a frequency greater 
than that recommended in the 
BNF, but with the total daily dose 
no higher than the recommended 
maximum.  
Not a problem.  The panel felt there was no 
increased risk to patients from this 
pattern of prescribing.  
Prescription of mild opioids to 
patients with mild-moderate 
COPD.  
Not a problem.  The panel felt that the risk to 
patients was very low.  
Prescription of two or more 
antihypertensive drugs to a patient 
with blood pressure in the normal 
range (this also includes 
prescriptions of ACE inhibitors 
and non-potassium-sparing 
diuretics (or spironolactone in 
heart failure). 
Not a problem.  Risk of harm low and patients 
likely to receive benefit from 
having blood pressure in the 
normal range.  
Stating oral doses in milligrams, 
e.g. “amoxicillin 125mg/5mL, 
125mg three times a day” is 
acceptable practice, as is stating 
the volume per dose, e.g. 5mL 
three times a day.  
Not a problem.  Either way of stating the dose is 
acceptable practice.  
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Appendix 19: Framework for analysis of data from the retrospective review of patients' medical records 
The study’s aim was to determine the prevalence and nature of prescribing errors in older patients and in children in general practice.  
Description of general practices: the characteristics of the general practices, which will be described and compared, include their list size, number of GPs, 
age distribution of study age population, training status, Indices of Multiple Deprivation score (for 2010), Quality of Outcomes Framework (QoF) scores, and 
other relevant information. 
Description of patients: the study population will be characterised by the total number of patients in the study, and per practice, age distribution of younger 
and older patients, gender, and the months the patients have been registered with the practice. 
Description of prescribed drugs: the drugs prescribed to patients who are randomly selected will be grouped according to their British National Formulary 
(BNF) chapters. Analyses will include: the total number of drugs reviewed in each age group, median (and Interquartile Range, IQR) drugs per patient age 
group, total number (and percentage) of drugs on the monitoring list, numbers and percentages of acute and repeat prescription items, median and IQR of 
acute and repeat prescription items, topmost drugs and drug classes prescribed, medication formulation numbers and percentages, potential prescribing errors, 
the number and percentage of drugs with prescribing errors, potential monitoring errors, and the number and percentage of drugs with monitoring errors. 
Description of types of prescribers: the nature of prescribers will be loosely compared as the relationship between the type of prescriber and error is beyond 
the scope of this study. 
Description of the types of errors: number and percentages of potential errors for each error category, errors on acute and repeat prescription, topmost drugs 
and drug classes associated with potential prescribing and monitoring errors, medication forms associated with prescribing and monitoring errors, numbers 
and proportion of each type of prescribing and monitoring errors, most common categories of errors associated with topmost drugs and drug classes, and 
formulation type. These are summarised in the table below: 
Research Question   
What are the current rates and prevalence of 
medication error in primary healthcare? 
 
Identify the incidence of medication errors in 
elderly and children 
% Per patient 
% Per prescription 
Items 
% Acute medicines 
% Repeats 
 Explore characterises of patients with and without 
medicines-related problems 
 
 Report number of medicines per patient  
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 Identify the BNF categories of Medicines 
prescribed in the elderly and in children 
 
 Identify the types of formulations prescribed in the 
elderly and in children 
 
 Identify age and gender of elderly patients and 
children with MRP 
 
 Explore association between factors impact on 
MRP 
 Gender 
 Age  
 No of medications 
 No of co morbidities (based on medication 
type) 
 No of acute and repeat prescriptions 
 
Category of Errors Identify the incidence of different typology of 
errors in both patient groups 
 Monitoring 
o Not requested 
o Requested but not done 
o Requested but no results 
o Results no acted on 
% Per patient 
% Per prescription 
Items 
% Acute medicines 
% Repeats 
BNF categories 
High risk drugs 
  Prescribing 
o Unnecessary drug 
o Incorrect drug 
o Duplication 
o Allergy error 
o Contraindication 
o Interaction etc. 
% Per patient 
% Per prescription 
Items 
% Acute medicines 
% Repeats 
BNF categories 
High risk drugs 
 Factors, which may influence the typology of error 
 Age 
 Gender  
 Acute v repeats 
 No of drugs 
 
Severity Identify the range of severity of errors  
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 BNF drug categories 
 High risk medicines 
 Paediatrics versus elderly 
 Acute versus repeats 
 Number of medicines 
 Age 
 Gender 
 Formulation   
 Factors: 
 Practice list size 
 Safety culture 
 Prescriber type or category 
 Training status of practice 
 
Several Rating: Panel versus researcher  Inter-rater reliability  
   
MRP case vignettes to show data capture and 
analyses 
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Appendix 20: Summary of studies included in systematic review (Chapter 3) 
  349 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
A B C D E F G H I
Reference Year	of	study Country Study	setting Method	of	Identification Study	Design Type	of	error Definitions	used	for	data	collection Incidence/rate	reported
Abramson	et	al	(2011) 2005/2006 USA
78	Community-based	primary	
care	providers	across	two	
states	who	used	paper	
prescriptions
Prescription	and	medical	record	review
Non-randomised	
retrospective	study
Prescribing Errors	in	prescriptions	and	prescribing
36.7/100	prescriptions	(95%	CI	30.7-44.0),	excluding	
illegibility	errors
Al	Khaja	et	al	(2007) 2004 Bahrain 20	primary	health	care	centres Audit	of	paediatric	prescriptions
Retrospective	clinical	
prescription	review
Prescribing
Omission	(minor	and	major),	commission	(incorrect	information)	and	
integration	errors	(e.g.	Drug	interactions)
90.5%	prescriptions	(of	2,282	total	prescriptions,	excluding	
minor	errors	of	omission)
Al	Khaja	et	al	(2005) 2003 Bahrain 18	primary	health	care	centres
Pharmacy	staff	screened	prescriptions	
for	errors:	audit	of	prescriptions
Prospective	clinical	
prescription	review
Prescribing
Omission	(minor	and	major),	commission	(incorrect	information)	and	
integration	errors	(e.g.	Drug	interactions)
7.7%	prescriptions	(5,959/77,511	prescriptions,	excluding	
minor	errors	of	omission)
Ashcroft	et	al	(2005) 1995 UK 35	community	pharmacies Pharmacist-led	identification Prospective	study Dispensing
Near	miss’	-	incident	that	was	detected	up	to,	including	the	point	at	
which	medication	was	handed	over	to	patient	or	their	representative’
Incidents		detected	after	patients	had	taken	possession	of	medication	
were	recorded	as	‘dispensing	errors’
3.99	errors/10,000	dispensed	items	(95%	CI	2.96	-	5.26);	
'near	miss'	-	22.33	(95%	CI	19.79-25.10)
Avery	et	al	(2012) 2010 UK
15	general	practices	from	four	
Primary	Care	Trusts
Review	of	patient	clinical	or	medical	
records,	healthcare	professional	
interviews
Randomised	
retrospective	study
Prescribing,	
monitoring
Prescribing	error	occurs	when,	as	a	result	of	a	prescribing	decision	or	
prescription-writing	process,	there	is	an	unintentional,	significant	
reduction	in	the	probability	of	treatment	being	timely	and	effective,	or	
increase	in	the	risk	of	harm	when	compared	to	generally	accepted	
practice;	Monitoring	error	occurs	when	a	prescribed	medicine	is	not	
monitored	in	the	way	which	would	be	considered	acceptable	in	
routine	general	practice.
Percentage	of	prescriptions	with	prescribing	or	monitoring	
errors		=	4.9%	(95%	confidence	intervals	(CI)	4.4%-5.4%;	
n=1,200);	percentage	of	patients	with	errors	=	12%.
Barber	et	al	(2009) 2009 UK
256	residents	from	55	
nursing/residential	homes
Patient	interview,	note	review,	practice	
observation,	dispensed	items	
examination
Prospective	study	of	
random	sample	of	
residents	within	a	
purposive	sample	of	
homes
Prescribing,	
Dispensing,	
Administration	
Monitoring
Prescribing	error	-	deviations	from	prescribing	standards	in	decision	
and	writing	(Dean	et	al,	2000);	Monitoring	-	deviations	from	
monitoring	standards	(Alldred	et	al,	2008);	Dispensing	-	deviations	
from	prescriptions	and	orders	(Beso	et	al,	2005);	Administration	-	
variations	between	prescriptions	and	administrations	(Dean	and	
Barber,	2001)
Prescribing	-	8.3%	(95%	CI	7.1-9.5);	Dispensing	-	9.8%	(95%	
CI	8.5-11.2);	Medication	administration	error	-	8.4%	(95%	CI	
7.0-10.0);	Monitoring	-	14.7%	(95%	CI	10.3-20.1);	all	error	
rates	are	percentages	of	opportunity	for	error;	mean	
potential	harm	from	prescribing,	monitoring,	dispensing	
and	administration	errors=2.6,3.7,2.1,2.0	(0=no	harm,	
10=death).	69.5%	residents	had	one	or	more	errors;	Mean	
number	of	errors	per	resident	-	1.9	errors
Carruthers	et	al	(2008) 2006 UK
2,	480	residents	from	42	
primary	care-based	Regional	
aged-care	facilities	(RACFs)
Audit	of	the	accuracy	of	dose	
administration	aids	(DAA)
Prospective	observation	
(prior	to	patient	
administration)
Dispensing
Comparison	of	drug	charts	prepared	by	patients'	GPs	with	contents	of	
DAA	by	registered	nurses.	Discrepancies	were	recorded	as	incidents
4.3%	packs	or	12%	residents	corresponding	to	297	incidents	
in	6,972	packs.	Incidents	-	wrong	drug,	strength,	label	and	
instructions.
Chen	et	al	(2005) 1999/2000 UK
4	General	practices	with	an	
estimate	of	37,	940	patients
Review	of	computerised	patient	
medical	record
Retrospective	review	of	
identified	potential	drug-
drug	or	drug-disease	
interactions
Prescribing
Potential	for	serious	drug-drug	interactions	or	drug-disease	
interactions	(contraindications)
1.9	incidents/1,000	patient	years	(95%	CI	1.5-2.3)	or	
4.3/1,000	patients	on	2	or	more	medications	per	year	(95%	
CI	3.2-5.4);	2	adverse	drug	events
Chua	et	al	(2003) 2002 UK
4	conveniently-sampled	
community	pharmacies	within	
the	Hull	and	East	Riding	
Pharmacy	Research	Network,	
North	of	England
Review	and	analysis	of	self-recorded	
dispensing	errors	and	'near	misses'
Prospective	audit Dispensing
Near	miss'	-	dispensing	error	identified	by	pharmacy	prior	to	patient	
receipt	of	medication;	Dispensing	error	-	recorded	if	error	discovered	
following	patient	receipt
Dispensing	error	rate=0.08%	items;	'Near	miss'	rate=0.48%	
items;	56/10,000		items	or	0.56%	items	total	dispensing	
errors	or	'near	miss'	(95%	CI	49-62)
Dhabali	et	al.	(2011) 2010 Malaysia
Primary	care	setting	of	a	
University,	Universiti	Sains	
Malaysia	(USM)
Review	of	data	from	1	academic	year	
using	computerized	databases
Retrospective	study Prescribing Drug	contra-indications
5.3%	of	all	patients	over	a	1-year	period	or		5,339	DCIs	per	
100,000	patients	(923	patients	had	drug	contra-indications	
of	17,288	registered	patients);3.8%	patients	were	exposed	
to	5	or	more	contra-indications
Field	et	al	(2007) 2007 USA
Large	multi-specialty	group	
practice	with	30,000	enrolees
Electronic	tracking	of	administrative	
data;	clinician	reports;	hospital	
discharge	summary;	emergency	visit
Retrospective	review	of	
identified	potential	
adverse	events
Administration
Potential	adverse	drug	events	due	to	patient	errors	during	medication	
use
Incidence	difficult	to	interpret;	patient	errors	leading	to	
adverse	events	was	129	(of	1,299	patients	with	an	adverse	
event	in	original	study)
Flynn	et	al	(2009) 2009 USA
100	Community	chain	
pharmacies	in	large	
metropolitan	areas	of	four	
states
Unidentified	'shoppers	presented	non-
real	life	prescriptions	
Retrospective	
observation	of	dispensed	
items
Dispensing
Variation	between	prescription	and	dispensed	item	(accuracy	of	
dispensing)
22%	(%	errors	of	total	prescriptions	presented;	n=100)
Gagne	et	al	(2008) 2008 Italy
Outpatient	prescriptions	of	
residents	in	Regione	Emilia-
Romagna,	Italy
Review	of	all	outpatient	prescription	
claims	in	2004	in	the	region
Retrospective	review	of	
claims	data
Prescribing
Drug	interactions	-	presence	of	minimum	of	5-day	overlap	in	days	
supply	for	drugs	in	an	interacting	pair
211/100,000	items	prescribed	(0.2%);	8894	potential	drug	
interactions	detected
Gandhi	et	al	(2003) 2003 USA
1,202	patients	at	four	adult	
primary	care	practices	in	
Boston,	USA
Patient	survey,	chart	review Prospective	cohort	study
Prescribing,	
Administration,	
Monitoring	(adverse	
drug	reactions	from	
errors)
Preventable	adverse	drug	events	-	due	to	error	which	could	have	been	
avoided;	ameliorable	-	those	whose	severity	or	duration	could	have	
been	reduced
Adverse	drug	event	rate	=	25%	patients	or	27%	events	(of	
661	patients	responding	to	survey);	11%	and	28%	events	
were	preventable	and	ameliorable	respectively,	therefore	
medication	error	rate	=	39.2%	(i.e.	(51+20)/100x181)
Gandhi	et	al	(2005) 2003 USA
1,879	prescriptions	of	1,202	
patients	at	four	adult	primary	
care	practices	in	Boston,	USA
Prescription	review,	patient	survey,	
chart	review
Prospective	cohort	study Prescribing
A	medication	error	-	any	error	that	occurred	in	the	medication	use	
process.	The	subset	of	these	errors	related	to	prescribing		errors.	
Errors	causing	injury	were	preventable;	those	with	potential	to	cause	
injury	were	potential	ADEs
7.6%	prescriptions	(95%	confidence	interval	(CI)	6.4%	to	
8.8%)	contained	a	prescribing	error;	3%	prescriptions	had	
potential	for	patient	injury,	1%	was	life-threatening;	24%	
were	serious;	frequency	and	dosing	errors	most	common
Gurwitz	et	al	2003 1999/2000 USA
Medicare	enrolees	(30	397	
person-years	of	observation)	in	
a	multispecialty	group	practice	
>65	years
Review	of	provider	reports,	discharge	
summaries,		emergency	department	
notes,	computer-generated	signals,	
electronic	clinic	notes,	incident	reports
Retrospective	cohort	
study
Prescribing,	
monitoring,	
administration
Adverse	drug	event	-	injury	resulting	from	system	of	drug	use;	adverse	
drug	event	resulting	from	medication	error	was	defined	as	
preventable	adverse	drug	event
13.8	preventable	adverse	drug	events	per	1000	person-
years	or	27.6%	of	1,523	total	adverse	drug	events;	of	these,	
prescribing	errors	=	16.2%,	monitoring	=	16.8%,	
administration	=	5.8%	(all	of	total	events)
Hammerlein	et	al	
(2007)
2005 Germany
Nation-wide	study	in	1,146	
community	pharmacies	in	
Germany
Community	pharmacies	recorded	
identified	Drug-related	problems	
(DRPs)	during	any	1	week	period	per	
pharmacy	within	designated	study	
period
Prospective	study
Prescribing,	
administration	
('patient	level'),	
dispensing	('delivery	
level')
A	drug-related	problem	(DRP)	-	an	event	or	circumstance	that	actually	
or	potentially	interferes	with	desired	health	outcomes	with	potential	
for	ineffective	pharmacotherapy	and/or	drug-related	morbidity	and	
mortality.
Rate	was	difficult	to	interpret;	10,427	DRPs	identified	
representing	9.1	DRP	per	pharmacy	per	week;	drug-drug	
interactions	most	common
Kaushal	et	al	(2010) 2002/2003 USA
1,782	patients	from	six	
paediatric	(<21	years)	
outpatient	practice
Prescription	review,	telephone	survey,	
chart	review
Prospective	cohort	study
Prescribing,	
transcribing,	
administration,	
monitoring
Medication	errors	-	errors	in	medication	ordering,	transcribing,	
dispensing	administration	and	monitoring,	with	minimal	potential	for	
harm	and	near	misses;	Preventable	ADE	were	medication	errors	that	
caused	harm
Medication	errors	rate	=	74%	prescriptions	or	93.7%	
patients;	68%	patients	(53%	prescriptions)	had	minimal	
potential	for	error;	26%	patients	(21%	prescriptions)	had	
potential	for	harm	('near	misses').	Most	errors	were	at	
prescribing	stage
Kaushal	et	al	(2007) 2002/2003 USA
1,788	patients	from	six	
paediatric	(<21	years)	
outpatient	practice
Prescription	review,	telephone	survey,	
chart	review
Prospective	cohort	study
Prescribing,	
transcribing,	
administration,	
monitoring
Medication	errors	-	errors	in	medication	ordering,	transcribing,	
dispensing	administration	and	monitoring,	with	minimal	potential	for	
harm	and	near	misses;	Preventable	ADE	were	medication	errors	that	
caused	harm
Preventable	ADEs	=	3%	patients;	administration	errors	=	
2.24%	patients;	prescribing/ordering	=	26%	errors;	
dispensing	errors	=	3%	errors
Khoja	et	al	(2011) 2002 Saudi	Arabia
10		public	and	private	(5	each)	
primary	health	care	clinics	in	
Riyadh	City
Review	of	a	simple	random	selection	of	
patient	clinical	management	records	
(case	notes);	all	prescriptions	issued	on	
study	day
Retrospective	audit Prescribing
Prescription	error	-	any	preventable	event	that	may	cause	or	lead	to	
inappropriate	medication	or	patient	harm	when	medication	is	in	
control	of	the	healthcare	professional,	patient	or	consumer
Prescribing	error=18.7%	prescription	items	(990/5299	
items);	Type	A	or	potentially	serious	error	rate=0.15%	items	
(8/5299	items)
Knudsen	et	al	(2007) 2004 Denmark
40	randomly-selected	Danish	
community	pharmacies
Review	of	documented	self-reported	
incidents	by	community	pharmacies	
and	a	web-based	incident	reports	of	
ADEs	
Prospective	and	
retrospective	studies
Prescribing,	
dispensing,	
transcribing
Prescribing	error	-	administrative/clinical	prescription	interventions	by	
pharmacy;	dispensing	error	-	errors	in	dispensing	that	reached	the	
patient;	'near	miss'	-	internal	pharmacy	error	detected	prior	to	patient	
collection;	transcription	-	pharmacy	transfer	of	data	from	prescription	
to	label
Prescribing	error=23.1/10,000	prescriptions;	dispensing	
error=1.4/10,000	prescriptions;	'near	miss'=2.4/10,000	
prescriptions;	total	transcription	error	-	64.9%	of	total	
dispensing	errors
Kuo	et	al	(2008) 2000/2003 USA
52	family	practices	in	rural,	
urban	and	suburban	comprising	
private,	training	clinics	and	
community	health	centres
Analysis	of	data	from	two	error-
reporting	systems	(web-	and	paper-
based)
Retrospective	study
Prescribing,	
dispensing,	
monitoring,	
administration,	
documentation?
Medication	error	-	things	that	happened	in	the	practice	that	should	
not	have	happened,	which	staff	were	willing	to	prevent	and	those	that	
did	not	happen	but	should	have	(as	they	related	to	medication)
Medication	error	rate=14%	of	total	medical	errors	(of	1,265	
total	errors);	Of	these,	Prescribing	errors=70%,	
Documentation	error=10%,	Dispensing	errors=7%,	
Administration	errors=10%,	Monitoring	errors=3%
Lasser	et	al	(2006) 2002 USA
51	ambulatory	practices	in	
greater	Boston	area
Electronic	health	record	(EHR)	review	
of	patients	>18	years	who	received	a	
prescription	for	a	drug	containing	a	
'black	box'	warning	(as	defined)	during	
1	year
Retrospective	study
Prescribing,	
monitoring
Prescribing	error	-	drug-drug	interactions	and	drug-disease	
interactions	with	little	or	no	potential	for	harm;	Monitoring	error	-	
drug-laboratory	monitoring	interactions	with	little	or	no	potential	for	
harm	(violations	of	the	'black	box'	or	labelling	warnings	in	Physicians'	
Desk	Reference,	PDR)
2,354	patients	of	33,	778	received	prescription	in	violation	
of	warning	i.e.	70%	of	patients	prescribed	at	least	one	
medication	containing	warning	OR	0.7%	of	all	patients	
receiving	prescription	medication.	<1%	of	patients	had	an	
ADE	as	a	result	of	such	violations.	1	in	4	patients	(25%	
patients)	who	had	received	drug	in	violation	of	warning	had	
a	medication	error
Lynskey	et	al	(2007) 2004 UK
15	community	pharmacies	
within	Brighton	and	Hove	
Primary	Care	Trust	(PCT),	East	
Sussex
Pharmacist-detected	problems	(errors)	
as	reported	during	a	10-week	data	
collection	period
Prospective	study
Prescribing,	
dispensing,	
administration
An	incident'	was	as	any	preventable	event	that	may	lead	to	or	cause	
inappropriate	use	or	patient	harm.	'Near	miss'	was	any	incident	up	to	
and	including	the	point	at	which	the	medication	left	the	pharmacy.	
Actual	errors	were	error	discovered	once	the	medication	had	left	the	
pharmacy	following	dispensing
Near	miss'	prescribing	and	dispensing	error	rates	of	15.9%	
and	62.1%	of	total	errors	(n=23	and	90	of	145	errors	
reported	respectively);	'Actual	prescribing,	dispensing,	and	
administration	error	rates	of	2.1%,	19.3%	and	0.7%	of	total	
errors	(n=3,	28	and	1	of	145	errors	reported)	respectively
Martinez	Sanchez	and	
Campos	(2011)
2009 Spain 1	community	pharmacy
Pharmacist-detected	problems	(errors)	
reported	during	a	6-month	data	
collection	period
Prospective	study
Prescribing,	
Transcribing
Prescribing	errors	-	any	error	identified	in	the	process	of	dispensing	to	
interfere	with	initial	dispensing,	e.g.	incomplete	prescriptions/	
incorrect	information;	or	potentially	harmful	to		patients,	e.g.	
potentially	hazardous	drug-drug	interactions,	inappropriate	doses	or	
directions,	contraindications,	ADRs,	allergies,	and	duplications
Prescribing	error	rate	=	1.5%	of	total	prescriptions	(355	
errors	detected	of	23,995);		transcription	error	rate	=	0.44%	
of	total	prescriptions	
Marwaha	et	al	(2010) 2010 India
Handwritten	prescriptions	from	
seven	general	practice	
physicians	presented	to	
community	pharmacies
Retrospective	review	of	hand-written	
prescriptions	presented	to	community	
pharmacies	during	a	2-month	period
Retrospective	study Prescribing
An	error	is	defined	as	the	failure	of	a	planned	action	to	be	completed	
as	intended	or	the	use	of	a	wrong	plan	to	achieve	an	aim.	Prescription	
errors	-	defined	as	either	an	error	in	writing	the	prescription,	or	in	the	
prescribing	decision,	which	may	impair	effectiveness	of	treatment	
administration	or	have	potential	for	harming	a
patient
196	errors	from	3151	prescribed	items	collected	giving	an	
error	rate	of	6.09	per	100	items	(95%	CI	5.78-6.41).	Most	
common	errors	related	to	directions	with	an	error	rate	of	
2.8	per	100	items	(95%	CI	2.6-3)
Nanji	et	al	(2011) 2008 USA
Outpatient	computer-
generated	prescriptions	across	
three	states
Restrospective	review	of	computer-
generated	prescriptions	received	by	
commercial	outpatient	pharmacies	in	
three	states	over	4	weeks
Retrospective	cohort	
study
Prescribing
Prescriptions	errors	-	corrections	on	prescriptions	that	required	active	
interventions	by	pharmacists
Prescribing	error	rate	=	11.7%	of	prescriptions,	of	which	
35%	had	potential	for	harm.	(1	in	10	computer-generated	
prescriptions	included	at	least	one	error,	of	which	one-third	
had	potential	for	harm)	Error	rates	varied	by	computerized	
prescribing	system,	from	5.1%	to	37.5%	(denorminator	
uncertain)
Runciman	et	al	(2003) 2003 Australia
Representative	samples	of	
general	practices,	and	
community	pharmacies	patient	
records
Retrospective	review	of	national	data	
achives	on	1,000	GP	with	100,000	
annual	consultations	and	1,000	high-
risk	patients	from	pharmacists'	case	
notes	over	a	1	year	period
Retrospective	audit Prescribing
Medication	incident	-	an	event	or	circumstance	associated	with	
medication	use	that	could	have,	or	did	lead	to	unintended	and/or	
unnecessary	harm	to	a	person.
Adverse	event	rate	=	0.89%	of	'encounters'	(or	prescriber	
contact)	in	1999-2000;	of	these,	43%	were	ADR	(i.e.	Not	
solely	due	to	medication	errors).	Medication	error	rate	was	
not	reported,	and	was	difficult	to	calculate
Sayers	et	al	(2009) 2009 Ireland
28	general	practitioners	and	12	
community	pharmacies
Prospective	survey	of	prescriptions	
presented	to	community	pharmacies	
over	a	3-day	period
Prospective	study Prescribing
Prescription	errors	detected	by	community	pharmacies	requiring	
intervention	prior	to	dispensing	
Prescribing	error	rate	=	12.4%	prescriptions	(491	of	3,948)	
or	6.2%	items	(546	of	8,686);	2.4%	errors	were	serious
Shah	et	al	(2001) 2001 UK
3	community	pharmacies	and	3	
general	practices	located	near	
the	pharmacies	
Retrospective	analysis	prescriptions	
from	23	doctors	(three	general	
practices)	presented	to	three	
community	pharmacies	over	the	course	
of	two	months
Retrospective	study Prescribing
Prescription	errors	detected	by	community	pharmacies	requiring	
pharmacist	intervention	prior	to	dispensing	including	administrative	
and	legal	errors	(excluding	medicines	usually	used	'as	directed'	and	for	
unlicenced	indications)
Prescribing	error	rate	of	7.46	per	100	items	(95%	CI	7.2-
7.8);	Errors	were	found	on	140	of	the	1,373	handwritten	
items	presented	during	the	study	period	(10.2%)	compared	
with	1,233	of	the	33,772	computer-generated	items	(7.9%)	
(chi-square	15.65,	df	=	1,	P<0.0001)
O'Grady	and	Dean	
Franklin	(2007)
2007 UK 11	community	pharmacies
Direct	observation	of	dispensed	items	
awaiting	receipt	by	or	delivery	to	
patient
Prospective	study
Dispensing,	
Transcribing
Any	unintended	deviation	from	an	interpretable	written	prescription	
or	medication	order.	Both	content	and	labelling	errors	were	included.	
Any	unintended	deviation	from	professional	or	regulatory	references,	
or	guidelines	affecting	dispensing	procedures,	was	also	considered	a	
dispensing	error
Content	error	rate	=	1.7%;	Labelling	error	rate	=	1.6%	
(dispensed	items)
Szczepura	et	al	(2011) 2009/2010 UK
A	cohort	of	345	older	residents	
in	13	care	homes	(9	residential,	
4	nursing)
Disguised	observation	technique	using	
pharmacy-managed	barcode	
medication	administration	system,	
BCMA
Prospective	study Administration
Any	deviation	between	medication	as	prescribed	and	that	
administered
Medication	administration	error	rate=1.2%	of	total	barcode	
medication	administration	episodes;	90%	residents	were	
exposed	to	MAE	during	the	3-month	study	period;	each	
resident	was	exposed	to	6.6	potential	MAE
Warholak	et	al	(2009) 2006 US
Outpatient	computer-
generated	prescriptions	(e-
prescriptions)	in	five	states
Participating	pharmacists	documented	
active	interventions	on	e-prescriptions
Prospective	study Prescribing
Prescriptions	errors	-	corrections	on	prescriptions	that	required	active	
interventions	by	pharmacists
Error	rate	=	3.8%	prescriptions	(102	interventions	of	2,690	
e-prescriptions)
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Patient	ID ID	
number
Description	of	potential	prescribing/monitoring	problem Classification Panel:	
Classification:	
Error/Suboptim
al	prescribing:	A	
(A)
Panel:	
Classification:	
Error/Suboptim
al	prescribing:	B	
(N)
Panel:	
Classification:	
Error/Suboptima
l	prescribing:	C	
(M)
Panel	final	
decision	on	
Problem	type:	
subset	category
Problem	type:	
subset	category
Panel:	Problem	
type:	subset	
categoryA	(A)
Panel:	
Problem	
type:	subset	
category:	B	
(N)
Panel:	Problem	
type:	subset	
category	C	(M)
Panel	final	decision	on	
Problem	type:	subset	
category
Severity	rating	
NPSA	tool:	(no	
harm	-	impact	
prevented/impact	
not	prevented;	low	
harm;	moderate	
harm;	severe	
harm;	death)
Panel	rating:	NPSA	
tool:	(no	harm	-	
impact	
prevented/impact	
not	prevented;	low	
harm;	moderate	
harm;	severe	harm;	
death):	A	(A)
Panel	rating:	NPSA	
tool:	(no	harm	-	
impact	
prevented/impact	
not	prevented;	low	
harm;	moderate	
harm;	severe	
harm;	death):	B	(N)
Panel	rating:	NPSA	
tool:	(no	harm	-	
impact	
prevented/impact	
not	prevented;	
low	harm;	
moderate	harm;	
severe	harm;	
Final	panel	
rating:	NPSA	
tool:	(no	harm	-	
impact	
prevented/impa
ct	not	
prevented;	low	
harm;	moderate	
Severity	rating	-	
Dean	&	Barber's	
tool	(visual	
analoque	scale	0	
to	10;	0=no	harm;	
10=death)
Panel:	Severity	
rating	-	Dean	&	
Barber's	tool	(visual	
analoque	scale	0	to	
10;	0=no	harm;	
10=death):	A	(A)
Panel:	Severity	
rating	-	Dean	&	
Barber's	tool	
(visual	analoque	
scale	0	to	10;	0=no	
harm;	10=death):	
B	(N)
Panel:	Severity	
rating	-	Dean	&	
Barber's	tool	
(visual	
analoque	scale	
0	to	10;	0=no	
harm;	
10=death):	C	
Final	Panel:	
Severity	rating	-	
Dean	&	Barber's	
tool	(visual	
analoque	scale	0	
to	10;	0=no	
harm;	
10=death)_Mea
Final	Panel:	
Severity	rating	
Dean	&	Barber's	
tool	(visual	
analogue	scale	
0	to	10;	0=no	
harm;	
10=death)_Med
B1E89_724 1 This	error	describes	a	potential	omission	error	relating	to	failure	to	
prescribe	for	an	existing	clinical	condition.	86-year	old	female	who	was	
diagnosed	with	angina	and	hypertension	on	regular	repeat	prescriptions	
for	Furosemide	20mg	daily,	Bisoprolol	1.25mg	daily,	Aspirin	75mg	daily,	
Amlodipine	5mg	daily.	Patient	may	benefit	from	a	statin	for	secondary	
preventionof	coronary	heart	disease.	Also,	patient	may	benefit	from	
cardio-protection	with	ACE-I	-	patient	was	on	Ramipril	5mg,	which	was	
last	prescribed	in	Dec	2013	(record	reviewed	in	June	2014).	No	note	in	
patient's	record	as	to	why	Ramipril	has	since	not	been	prescribed
Omission	error	
relating	to	failure	
to	prescribe	for	an	
existing	clinical	
condition;	
Prescribing	error
Prescribing	error Omission	error	
relating	to	
failure	to	
prescribe	for	an	
existing	clinical	
condition;	
Prescribing	
error
Prescribing	error Omission	error	
relating	to	failure	
to	prescribe	for	
an	existing	
clinical	condition;	
Prescribing	error
Inadequate	review,	
inadequate	
documentation	in	
medical	records,	
omission	error	
relating	to	failure	to	
prescribe	for	an	
existing	clinical	
condition
Omission	error Omission	
error	relating	
to	failure	to	
prescribe	for	
an	existing	
clinical	
condition
Omission Omission	error	
relating	to	failure	to	
prescribe	for	an	
existing	clinical	
condition;	Prescribing	
error
Moderate Low	harm Moderate Moderate Moderate 5 4 5 4 4.5 4.5
B1E90_728 2 67-year	old	female	patient	on	Levothyroxine	75micrograms	daily	on	
repeat	prescription.	Levothyroxine	requires	12	monthly	TFT.	TFT	not	
ordered	in	the	past	2	years	-	last	ordered	and	recorded	in	May	2012	
(record	reviewed	in	June	2014)
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
Monitoring	not	
requested
Monitoring	not	
requested
Low No	harm Moderate Moderate Moderate 3 2 4 4 3.25 3.5
B1E91_729 3 82-year	old	female	on	Carbimazole	10mg	daily	"as	recommended	by	the	
hospital	consultant."	Carbimazole	requires	3	monthly	TFT;	6-monthly	if	
patient	has	been	stabilized	for	over	1	year.	Last	TFT	done	and	recorded	
in	Nov	2013,	over	6	months	ago.	Record	was	reviewed	in	June	2014
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
Monitoring	not	
requested
Monitoring	not	
requested
Moderate No	harm Moderate Low	harm Moderate 5 2 4 3 3.5 3.5
B1E95_774 4 79-year	old	male	prescribed	30gram	acute	Fucidin	H	cream	for	
application	two-three	times	daily.	Prescription	does	not	specify	duration	
of	use	and	no	advice	to	spread	thinly
Suboptimal	
prescribing	-	
Hydrocortisone	-	
mild	steroid
Prescribing	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Incomplete	
information
Incomplete	
information
Incomplete	
information
incomplete	
information
Incomplete	
information,	
inadequate	review
Low No	harm Low	harm Low	harm Low 2 2 3 2 2.25 2
B1E97_777 5 72-year	old	female	prescribed	Latanoprost	eye	drops	50mcg/ml	with	
directions	"one	drop	each	night."	Prescription	does	not	specify	which	
eye	is	being	treated	(eyedrop	for	Glaucoma)
Prescribing	error Prescribing	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Incomplete	
information
Incomplete	
information
Incomplete	
information
incomplete	
information
Incomplete	
information,	
inadequate	review
Moderate No	harm Moderate Low	harm Moderate 5 3 4 4 4 4
B1E103_831 6 This	error	describes	a	potential	omission	error	relating	to	failure	to	
prescribe	for	an	existing	clinical	condition.	71-year	old	female	on	
Losartan	25mg	daily	for	hypertension.	Last	BP	reading	recorded	was	
150/80mmHg	(Jan	2014).	There	may	be	indication	for	dose	optimization	
of	Losartan	or	for	co-prescription	of	a	different	antihypertensive	such	as	
a	diuretic	for	hypertension	not	controlled	on	one	drug	class
Omission	error	
relating	to	failure	
to	prescribe	for	an	
existing	clinical	
condition
No	error Not	decided	-	
no	error
Omission	error	
relating	to	failure	
to	prescribe	for	
an	existing	
clinical	condition
Omission	error	
relating	to	failure	
to	prescribe	for	
an	existing	
clinical	condition
Omission	error	
relating	to	failure	to	
prescribe	for	an	
existing	clinical	
condition
N/A Not	decided	-	
N/A
Omission	error	
relating	to	
failure	to	
prescribe	for	
an	existing	
clinical	
condition
Omission	error	
relating	to	failure	to	
prescribe	for	an	
existing	clinical	
condition
Moderate No	harm Not	decided	-	no	
harm
Low	harm Low 4 0 Not	decided	-	0 3s 1 2
B1E104_832 7 75-year	old	female	prescribed	28	Naproxen	tablets	250mg	three	times	
daily	on	acute	prescription	with	no	concomitant	gastro-protective	agent	
and	no	advice	to	take	with	or	after	meals
Prescribing	error Prescribing	error Prescribing	
error
Prescribing	error Prescribing	error Omission	error	
relating	to	failure	to	
prescribe	
concomitant	
medication
Omission	error Omission	
error	relating	
to	failure	to	
prescribe	
concomitant	
medication
Omission	error	
relating	to	
failure	to	
prescribe	
concomitant	
medication
Omission	error	
relating	to	failure	to	
prescribe	concomitant	
medication
Low	(in	view	of	the	
number	of	days'	
treatment;	in	this	
case	4)
Low	harm Moderate Moderate Moderate 3 4 5 4 4 4
B1E106_840 8 69-year	old	female	prescribed	Clobetasone	0.5%	ointment	(moderately-
potent	steroid)	on	acute	prescription	to	be	applied	1-2	times	daily.	
Duration	of	use	not	specified
Prescribing	error Prescribing	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Incomplete	
information
Incomplete	
information
Duration	
error
incomplete	
information
Incomplete	
information,	
inadequate	review
Low No	harm Low	harm Low	harm Low 2	-	based	on	
quantity	and	
potency
2 3 3 2 3
B1E107_852 9 This	error	describes	a	potential	omission	error	relating	to	failure	to	
prescribe	for	an	existing	clinical	condition.	66-year	old	female	with	on	
going	intervention	including	physiotherapy,	acupuncture	and	joint	
injections	for	joint	pains.	Patient	may	benefit	from	taking	a	
bisphosphonate	like	Alendronate	-	she	was	placed	on	Alendronate	
between	2010	and	2011,	but	this	was	stopped.	No	note	in	patient's	
record	suggest	this	was	purposively	discontinued	by	GP.	Patient	takes	
Adcal	D3	tablets
Prescribing	error,	
omission	error	
relating	to	failure	
to	prescribe	for	an	
existing	clinical	
condition
Prescribing	error Prescribing	
error,	omission	
error	relating	to	
failure	to	
prescribe	for	an	
existing	clinical	
condition
Sub-optimal	
prescribing
Prescribing	error,	
omission	error	
relating	to	failure	
to	prescribe	for	
an	existing	
clinical	condition
Inadequate	review,	
inadequate	
documentation	in	
medical	records,	
omission	error	
relating	to	failure	to	
prescribe	for	an	
existing	clinical	
condition
Incomplete	
information
Omission	
error	relating	
to	failure	to	
prescribe	for	
an	existing	
clinical	
condition
Omission	error	
relating	to	
failure	to	
prescribe	for	
an	existing	
clinical	
condition
Inadequate	review,	
inadequate	
documentation	in	
medical	records,	
omission	error	relating	
to	failure	to	prescribe	
for	an	existing	clinical	
condition
Low No	harm Moderate Low	harm Low 3 2 5 3 3.25 3
B1E114_918 10 74-year	old	female	on	Lisinopril	tablets	20mg	daily	as	a	regular	repeat	
medication.	ACE-I	(Lisniopril)	requires	12	monthly	U&E,	which	was	last	
done	and	recorded	in	May	2013	(review	date	-	09/06/2014).	The	last	
recorded	test	result	(	May	2013)	showed	elevated	serum	potassium	level	
(mmol/L)	at	5.3	(above	high	reference	limit	of	3.5-5.1)
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	acted	
upon
Monitoring	not	
requested
Monitoring	not	
requested
Moderate Low	harm Moderate Moderate Moderate 4 4 4 6 4.5 4
B1E120_964 11 82-year	old	male	prescribed	Losartan	tablets	50mg	daily	on	repeat	
prescription.	Angiotensin	II	receptor	antagonist	(Losartan)	requires	12-
monthly	U&E,	which	was	last	ordered	and	recorded	in	March	2013	
(patient's	record	was	reviewed	11/06/2014)
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
Monitoring	not	
requested
Monitoring	not	
requested
Low Low	harm Moderate Moderate Moderate 3 4 4 4 3.75 4
B1E120_964 12 82-year	old	male	prescribed	Bendroflumethiazide	2.5mg	daily	on	repeat	
prescription.	Diuretics	(Bendroflumethiazide)	requires	12-monthly	U&E	-	
last	ordered	and	recorded	in	March	2013	(record	review	date	-	
11/06/2014)
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
Monitoring	not	
requested
Monitoring	not	
requested
Low Low	harm Moderate Moderate Moderate 3 4 4 4 3.75 4
B1E126_1003 13 64-year	old	female	on	Ramipril	capsules	10mg	daily	on	repeat	
prescription.	ACE-I	(Ramipril)	require	12-monthly	U&E,	which	was	not	
ordered.	Patient	has	been	registered	with	practice	for	3	months,	and	
although	other	blood	tests	(haematology,	HbA1c	level,	endocrinology)	
have	since	been	ordered,	no	U&E	tests	have	been	ordered
Monitoring	error Monitoring	error Monitoring	
error
No	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
N/A Monitoring	not	
requested
Low Low	harm Moderate No	harm Low 2 4 4 0 2.5 3
B1E128_1025 14 68-year	old	male	prescribed	Co-codamol	20mg/500mg	twice	on	the	
same	prescription.	One	read	"100	capsules"	and	the	other	read	"1	pack	
of	100	capsules.	Prescriber's	intention	is	unclear
Prescribing	error Prescribing	error Prescribing	
error
Prescribing	error Prescribing	error Duplication Duplication Duplication Duplication Duplication No	harm Moderate	harm Low	harm Moderate Low 0 6 1 5 3 3
B1E129_1025 15 66-year	old	male	presented	with	"abdominal	discomfort	on	gong	for	a	
week."	He	was	diagnosed	with	indigestion	and	prescribed	28	capsules	of	
Omeprazole	gastro-resistant	20mg	daily	on	the	13th	of	May	(acute).	
Patient	was	issued	his	regular	repeat	prescription	of	56	Lansoprazole	
capules	15mg	daily	on	the	16th	of	May	leading	to	potential	duplication.	
Also,	it	is	not	certain	if	patient	was	taking	Lansoprazole	at	the	time	of	
reporting	the	symptoms	of	indigestion
Prescribing	error Prescribing	error Prescribing	
error
Prescribing	error Prescribing	error Duplication,	
inadequate	review
Duplication Duplication Duplication Duplication Low Low	harm Moderate Moderate Moderate 3 4 5 4 4 4
B1E131_1048 16 68-year	old	female	who	has	been	on	Citalopram	10mg	regularly	since	
Dec	2010	with	the	dosage	directions	‘one	daily.’		The	direction	was	then	
changed	to	‘one	alternate	days	for	next	8	weeks’	on	two	prescriptions	
issued	on	13	Jan	2014,	and	26	Feb	2014.	There	was	no	note	in	the	record	
to	indicate	why.	After	these	two	instances,	the	dose	reverted	to	‘one	
daily'	on	7	May	2014	(printed	by	a	receptionist).	It	was	not	clear	if	those	
changes	in	dosage	regime	was	intended
Suboptimal	
prescribing
Prescribing	error No	error Prescribing	error Prescribing	error Frequency	error,	
inadequate	
documentation	in	
medical	record
Inadequare	
documentation
N/A Frequency Frequency	error,	
inadequate	
documentation	in	
medical	record
No	harm Low	harm No	harm Moderate Low 0 4 0 5 2.25 2
B1E137_1101 17 80-year	old	male	on	Perindopril	8mg	daily,	Amlodipine	10mg	daily,	
Bendroflumethiazide	2.5mg	regular	repeat	prescriptions	for	blood	
presssure.	Also	on	Simvastatin	20mg	daily	at	night,	Metformin	MR	
500mg	daily,	NovoMix	30,	Tangina	XL	60mg	daily,	and	Fenofibrate	
160mg	daily.	Patient's	BP	was	recorded	as	124/67mmHg	(Jun	2014).	In	
view	of	patient's	age,	and	to	prevent	falls,	dose	optimization	(possibly	
reduction	of	Amlodipine	to	5mg)	of	antihypertensive	missed
Prescribing	error No	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Inadequate	review N/A Dose/strengt
h	error
Dose/strength	
error
Dose/strength	error Moderate No	harm Low	harm Low	harm Low 4 0 3 2 2.25 2.5
B1E137_1101 18 80-year	old	male	patient	prescribed	NovoMix	30	Flexpen	100	units/ml	
suspension	for	injection	with	the	directions	"use	as	directed."	Elderly	
patient	with	no	insulin	dose	specified	on	prescription.	Patient's	record	
documents	deteriorating	memory	and	provision	of	care	by	patient's	wife
Suboptimal	
prescribing
No	error No	error Prescribing	error No	error Incomplete	
information
N/A N/A incomplete	
information
Incomplete	
information
No	harm No	harm No	harm Moderate No	harm 0 0 0 5 1.25 0
B1E140_1120 19 77-year	old	female	prescribed	Zopiclone	7.5mg	at	night	until	June	2013.	
The	dose	was	changed	to	"take	half	a	tablet	at	night."	Based	on	patient’s	
age,	and	him	being	looked	after	by	a	carer,	the	3.75mg	tablet	should	
have	been	prescribed	instead	of	the	need	to	halve	the	7.5mg	tablet	–	
issues	around	manual	dexterity,	carer	not	present,	subject	to	
abuse/taking	more	than	prescribed,	memory	issues	(patient	also	takes	
20mg	Memantine	daily	on	regular	repeat)
Suboptimal	
prescribing
No	error Prescribing	
error
Prescribing	error Prescribing	error Inadequate	review N/A Formulation	
error
Dose/strength	
error
Dose/strength	error No	harm No	harm Moderate Low	harm Low 0 0 5 3 2 1.5
B1E140_1120 20 77-year	old	female	on	Levothyroxine	200mcg	daily	each	morning.	
Endocrinology	tests	done	in	Feb	2014	showed	Serum	free	T4	level	
(pmol/L)	=	20.4	(above	high	reference	limit	9.01-19.05)	and	Serum	TSH	
level	(miu/L)	=	0.03	(below	low	reference	limit	0.35-4.94.	A	note	in	the	
record	said	"NOT	ON	THYROID	THERAPY."	Patient	has	been	taking	
Levothyroxine	tablets	since	1980.	Missed	opportunity	for	intervention	
on	abnormal	test	results
Prescribing	error Monitoring	error Monitoring	
error
Prescribing	error Prescribing	error Results	not	acted	
upon,	inadequate	
review,	inadequate	
documentation	in	
medical	record
Results	not	
acted	upon
Monitoring	
not	acted	
upon
Dose/strength	
error
Results	not	acted	
upon
No	harm No	harm Moderate Moderate Moderate 0 3 4 5 3 3.5
B1E141_1123 21 81-year	old	patient	prescribed	Simvastatin	20mg	at	night,	which	was	
initiated	08	May	2013.	Statins	require	3	monthly	and	12	monthly	LFT	in	
the	first	year	following	initiation.	Pre-LFT	was	done	on	01	May	2013.	
Although	the	12	months	LFT	was	done	on	01	May	2014,	the	3-months	
test	following	initiated	was	not	ordered	nor	recorded
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
Monitoring	not	
requested
Monitoring	not	
requested
Low No	harm Moderate Low	harm Low 3 2 4 3 3 3
B1E142_1127 22 71-year	old	female	prescribed	Fluocinolone	Acetonide	gel	(0.025%)	on	
repeat	prescription	with	the	directions	"apply	at	night."	Duration	of	use	
not	specified.	Patient	has	chronic	allergic	skin	rash.	She	was	placed	on	
Fluocinolone	Acetonide	gel	by	hospital	consultant	in	Apr	2011,	and	
generally	has	2-3	repeats/year.	Between	mid	March	2014	and	July	2014	
however,	patient	had	ordered	4	repeat	prescriptions	for	30grams	each	
of	Fluocinolone	gel	suggesting	continuous	use	of	a	potent	steroid
Prescribing	error Prescribing	error No	error Sub-optimal	
prescribing
Prescribing	error Incomplete	
information,	
inadequate	review
Incomplete	
information
N/A incomplete	
information
Incomplete	
information,	
inadequate	review
Low No	harm No	harm Moderate Low 3 2 0 4 2.25 2.5
B1E143_1155 23 85-year	old	issued	acute	prescription	of	30grams	of	Clobetasone	0.05%	
cream	(moderately	potent	steroid)	with	the	directions	"apply	thinly	1-2	
times/day	to	hand."	No	advice	on	duration	of	use
Prescribing	error Prescribing	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Incomplete	
information,	
duration	error
Incomplete	
information
Duration	
error
incomplete	
information
Incomplete	
information,	duration	
error
Low No	harm Low	harm Low	harm Low 2 2 3 3 2.5 2.5
B1E145_1165 24 79-year	old	male	prescribed	30gram	acute	Fucibet	cream	for	twice	daily	
application.	Prescription	of	a	potent	steroid	+	antimicrobial	cream,	which	
did	not	specify	duration	of	use	and	carries	no	advice	to	spread	thinly
Prescribing	error Prescribing	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Duration	error Incomplete	
information
Incomplete	
information
incomplete	
information
Incomplete	
information
No	harm No	harm Low	harm Low	harm Low 0 2 3 3 2 2.5
B1E149_1184 25 69-year	old	female	prescribed	Prednisolone	5mg	at	the	following	
quantities	and	dosage	instructions:	13	Dec	2013	-	20	tablets	with	the	
dosage	"4	daily	for	5	days;"	17	Dec	2013	-	60	tablets	with	the	dosage	
"three	tablets	daily	days	1	and	2,	then	two	tablets	daily	day	3	and	4	then	
one	tablet	daily;"	and	lastly,	23	Dec	2013	-	28	tablets	with	a	daily	
reducing	dose.	As	patient	had	oesophagitis,	gastritis	and	bile	reflux	in	
2005,	enteric-coated	prednisolone	tablets	would	have	been	optimal	for	
the	repeated	courses	of	Prednisolone
Suboptimal	
prescribing
No	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Formulation	error N/A Formulation	
error
Formulation	
error
Formulation	error Low No	harm Moderate Moderate Low 2 0 4 5 2.75 3
B1E152_1220 26 65-year	old	female	prescribed	Bendroflumethiazide	2.5mg	daily	in	the	
morning,	which	requires	12	monthly	U&E	(diuretic).	Last	done	and	
recorded	in	May	2013	(record	was	reviewed	in	August	2014)
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
Monitoring	not	
requested
Monitoring	not	
requested
Low No	harm Moderate Moderate Moderate 2 4 4 4 3.5 4
B1E152_1220 27 65-year	old	female	prescribed	30grams	acute	Mometasone	ointment	
0.1%	(potent	steroid)	to	be	applied	daily.	Frequency	and	duration	of	use	
not	specified	on	prescription	of	a	potent	steroid
Prescribing	error Prescribing	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Incomplete	
information
Incomplete	
information
Incomplete	
information
incomplete	
information
Incomplete	
information
Low No	harm Low	harm Moderate Low 2 2 3 4 2.75 2.5
B1E152_1220 28 65-year	old	female	patient	prescribed	30gram	acute	Clobetasone	
ointment	0.05%	ointment	(moderately	potent	steroid)	to	be	applied	1-2	
times	daily	for	psoriatic	lesions.	Duration	of	use	not	specified.	
Furthermore,	GP's	consultation	notes	for	the	visit	noted	"red	cracked	
surface	of	skin."	The	prescription	did	not	contain	the	advice	to	avoid	
application	to	cracked	skin.
Prescribing	error Prescribing	error Prescribing	
error
Sub-optimal	
prescribing
Prescribing	error Incomplete	
information
Incomplete	
information
Incomplete	
information
incomplete	
information
Incomplete	
information
Low No	harm Moderate Low	harm Low 3 4 4 3 3.5 3.5
B1E153_1223 29 67-year	old	male	patient	reviewed	on	20	Jan	2014.	Patient	was	noted	as	
having	"irregular	chest,"	which	led	the	prescriber	to	increase	the	dose	of	
Bisoprolol	to	10mg	daily	as	documented	on	20	Jan	2014.	However,	
Bisoprolol	5mg	+	2.5mg	(patient's	normal	dose	prior	to	consulation	on	
20	Jan)	were	both	issued	on	22	Jan	&	31	Jan	respectively	(following	the	
increase	in	dose	to	10mg	daily).	It	was	not	until	10th	Feb	that	an	entry	
was	made	in	the	journal	to	stop	both	repeats	for	Bisoprolol	5mg	+	2.5mg
Prescribing	error Prescribing	error Prescribing	
error
Prescribing	error Prescribing	error Duplication,	
inadequate	review
Inadequate	
review
Duplication Duplication Duplication Moderate No	harm Moderate Moderate Moderate 6 2 5 5 4.5 5
B1E154_1227 30 75-year	old	female	on	repeat	Bendroflumethiazide	2.5mg	tablets	daily,	
which	requires	12	monthly	U&E.	U&E	last	done	in	May	2012.	Record	was	
reviewed	in	August	2014
Monitoring	error Monitoring	error Monitoring	
error
Monitoring	error Monitoring	error Monitoring	not	
requested
Monitoring	not	
requested
Monitoring	
not	
requested
Monitoring	not	
requested
Monitoring	not	
requested
Low No	harm Moderate Low	harm Low 3 4 4 3 3.5 3.5
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Appendix 22: Form for collecting data in community pharmacies 
Form for collecting demographic and prescription data on patients, and pharmacist’s 
intervention on prescription errors 
The SAFECaRE Study (Safety of Medication Use in Primary Care) 
Form 4: Community Pharmacy medicine-related problem (prescription errors) 
Date: ____________  Time: ___________  Origin: _________________ 
Patient’s Age (Years/Months): _______/_____   Gender: Male/Female (please circle) 
Prescription type (First dispense/repeat/Dental etc.): _____________________________  
Total No. of medicines: ___________   Prescription date: ________________ 
Name of medicine implicated: ________________________ 
Error category Intervention Comment 
 
 
 
 
  
 
 
Date: ____________  Time: ___________  Origin: _________________ 
Patient’s Age (Years/Months): _______/_____   Gender: Male/Female (please circle) 
Prescription type (First dispense/repeat/Dental etc.): _____________________________  
Total No. of medicines: ___________   Prescription date: ________________ 
Name of medicine implicated: ________________________ 
Error category Intervention Comment 
 
 
 
 
  
 
 
Date: ____________  Time: ___________  Origin: _________________ 
Patient’s Age (Years/Months): _______/_____   Gender: Male/Female (please circle) 
Prescription type (First dispense/repeat/Dental etc.): _____________________________  
Total No. of medicines: ___________   Prescription date: ________________ 
Name of medicine implicated: ________________________ 
Error category Intervention Comment 
 
 
 
 
  
 
